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1.1 Membrane Transport and ABC Transporters 
Biological membranes are selectively permeable structures, which form the interface between 
a cell or an organelle and its environment. Membrane transport constitutes one of the most 
fundamental processes in all living cells – it allows the maintenance of cellular homeostasis [1]. 
Due to the enormous chemical diversity of the molecules required by or expelled from the cell, 
it comes to no surprise that the transport mechanisms across biomembranes are multitudinous. 
In Escherichia coli, for example, about 10% of the entire genome encodes membrane-bound 
and soluble proteins involved in transport processes [2]. The simplest of all transport forms is 
passive diffusion. While some gases, water and other small polar molecules as well as unpolar 
compounds can freely permeate a lipid bilayer, ions and larger polar molecules like glucose 
cannot do so and require transport proteins, such as channel proteins or carriers/transporters, to 
mediate the passage [3-6]. This process is called passive transport or facilitated diffusion. In 
case a solute is to be moved against an electrochemical gradient, active transport under the 
consumption of energy is necessary [4,6]. Active transporters are either driven by an 
electrochemical potential difference at the biomembrane (secondary active transport) or by the 
hydrolysis of an energy-carrying molecule, mainly adenosine triphosphate (ATP) (primary 
active transport) [4,6]. Membrane ATPases are classified into four categories: F-ATPases are 
mitochondrial or chloroplast ATP synthases; P-ATPases, for instance sodium-potassium pumps 
or calcium pumps, build an electrochemical gradient; V-ATPases form a proton gradient and 
are found within many membranes of cell organelles, such as vacuoles in plant cells or 
endosomes [7]; and ATP-binding cassette (ABC) transporters translocate myriad substrates – 
inorganic and organic, charged and neutral – across cellular membranes [7-10]. The latter 
embody by far the largest and most diverse of the transporter families [7,8] and one of the 
largest protein families in general [11]. 
The substrates of ABC transporters are beyond number – and so are their functions. They are 
widespread in all three domains of life. In bacteria and archaea, ABC importers enable the 
uptake of various nutrients and ABC exporters sequester virulence factors or antibiotics [8,12]. 
The majority of eukaryotic family members function in the direction of export. On one hand, 
ABC transporters excrete endogenous metabolites from secretory epithelial cells, such as bile 
salts in the liver [9,10,13]. On the other hand, at physiological barriers, e.g. the intestinal barrier 
or the blood-brain barrier (BBB), they protect cells from the entry of diverse xenobiotics, 
including toxic and carcinogenic substances, but also a wide range of drugs such as cytostatics, 
antipsychotics or antiepileptic agents [9,10,14,15]. The diversity of the biological roles played 
by ABC transporters is reflected by their extensive involvement in diseases. A malfunction of 
ABC transporters is the cause of various severe genetic disorders, such as bile transport 
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disorders or cystic fibrosis [9,10,13]. Moreover, ABC transporters confer drug resistance 
(MDR) in cancer [16] or brain diseases [17,18] and they modulate the bioavailability of drugs 
[9,10,14,15]. 
Although ABC transporters deserve much attention because of their functions in the human 
body, they were first discovered and characterized in detail in bacteria, as early as in the 1970s 
[12,19-22]. Only later it was demonstrated that these proteins are not restricted to prokaryotes. 
In 1976, Juliano and Ling discovered a drug resistance-related glycoprotein in a mammalian 
cell line and called it P-glycoprotein (P-gp), because it appeared to confer drug resistance by 
making the cellular membrane less permeable [23]. It was not until 1986 that studies revealed 
a strong homology between the DNA sequence of P-gp and the bacterial transport proteins 
discovered before and it was suggested that P-gp functions as an energy-dependent export pump 
[24,25]. In the same year, it was recognized by Higgins et al. that highly conserved ATP-
binding subunits characterize a large superfamily of transport proteins [26]. The designation 
‘ABC transporters’ was first introduced in 1990 by Higgins’ group who named these proteins 
after their most characteristic feature – the aforementioned ATP-binding cassette [8,27]. 
Subsequent genome sequencing and phylogenetic analyses confirmed that the ABCs, or 
nucleotide binding domains (NBDs), are monophyletic, i.e. they have a common evolutionary 
origin [8,11,26,27]. The NBDs are characterized by highly conserved motifs including the 
Walker A and B motifs, common to many nucleotide binding proteins [28], and others like the 
signature motif, which is distinctive of ABC proteins [11,29]. Noteworthily, the ABC protein 
superfamily also comprises a second, smaller subfamily of cytosolic, non-transporter ABC 
proteins, which are dedicated to ‘housekeeping’ processes such as protein synthesis [11]. By 
contrast with the NBDs, the transmembrane domains (TMDs) of ABC transporters are variable 
and polyphyletic. Bioinformatic analyses showed that the TMDs of exporters have at least three 
different ancestors [30]. The archetypal ABC transporter comprises two TMDs, each composed 
of four to eleven (mostly six) transmembrane helices, and two cytosolic NBDs (Figure 1.1) 
[8,11,27,31-34]. In archaea and bacteria, these four domains often exist as distinct subunits, 
whereas in eukaryotes usually one NBD and one TMD are fused into half-transporters or all 
four domains reside in a single polypeptide chain and form a full-transporter [8,11,31-34]. ABC 
importers additionally comprise an extracytoplasmic solute-binding protein involved in the 




Figure 1.1. Cartoon of the structural organization of an archetypal ABC exporter composed of two TMDs and two NBDs. Two 
conformational states of the transporter – inward facing and outward facing – are depicted to demonstrate the alternating access 
mechanism of transport. Hydrolysis of ATP to ADP and inorganic phosphate (Pi) powers the transport. 
In the last two decades structural biology techniques – X-ray crystallography and cryogenic 
electron microscopy (cryo-EM) – have provided numerous structures of bacterial and human 
ABC transporters and enabled the visualization of conformational states at high resolutions. 
The structural organization and mechanism of ABC transporters is depicted in Figure 1.1. 
Generally, the two TMDs form a translocation pore across the membrane and feature the 
substrate binding site, whereas the NBDs bind and hydrolyze ATP [10,36-38]. In most ABC 
transporters the concomitant conformational changes in the NBDs induce a switching of the 
TMDs between an inward facing and outward facing conformation, thereby translocating the 
substrate [10,36-38]. It should be noted that there are mechanistic differences between 
individual ABC transporters, pre-eminently concerning the events at the TMDs, which reflects 
the variability in the TMDs and differing substrate specificities; even outward-only mechanisms 
have been proposed for some bacterial subtypes [39]. 
To date 51 human ABC proteins are known [40]. Due to the progress of the Human Genome 
Project and to other mass sequencing efforts in the 1990s, 30 human ABC proteins had been 
identified until 1999 [41]. They were divided into seven subfamilies based on similarity in gene 
structure (half- vs. full-transporter), on succession of domains, and on sequence homology in 
the NBDs and TMDs [34,42-45]. The Genome Nomenclature Committee of the Human 
Genome Organization (HUGO) developed a nomenclature system for the human ABC 
transporter family, which was implemented in 1999 [37,41]. The seven subfamilies were 
assigned the designations ABCA to ABCG. The A and C subfamilies are composed of full-
transporters, the D and G subfamily of half-transporters and the B subfamily contains both full- 
and half- transporters; the E and F subfamilies are non-transporter ABC proteins and have no 
TMDs [34,42-45]. The aforementioned transporter P-gp – the first eukaryotic ABC transporter 
to be discovered – was termed ABCB1. The human ABC transporter subtypes are of differing 
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medical relevance. The major drug transporters are ABCB1, ABCG2 and ABCC1 – this triad 
of efflux pumps seems to mostly account for MDR in cancer [16,46,47] and brain diseases [17], 
and they play a leading role in tissue defense and the bioavailability of drugs [14,15]. At the 
BBB, which is one of the most restrictive tissue barrier found within the human body, the 
predominant transporter was shown to be ABCG2 [48-50]. 
1.2 Structure and Mechanism of ABCG2 
In 1990, Chen et al. discovered a novel drug resistance-related membrane protein in a human, 
doxorubicin-resistant breast cancer cell line [51]. The gene encoding this protein was cloned by 
Doyle et al. in 1998, who identified the latter as an ABC transporter and named it breast cancer 
resistance protein (BCRP) [52]. Almost simultaneously, two further articles were published 
reporting on nearly identical genes expressed in the placenta [53] and in a mitoxantrone-
resistant colon carcinoma cell line [54], respectively. Accordingly, the genes were termed 
ABCP (for the expression in the placenta) and MXR (for mitoxantrone resistance). When the 
three sequences were eventually compared, they were recognized as essentially identical. 
Subsequently, the HUGO Genome Nomenclature Committee termed this transporter ABCG2 
[55]. 
The human ABCG subfamily comprises five half transporters [40] (as in all mammals, only 
rodents have one more) with an NBD at the N-terminus and a TMD at the C-terminus – this is 
the reverse configuration compared to other ABC subfamilies, where the NBD is at the 
C-terminus and the TMD at the N-terminus [34,42,44]. The ABCG2 gene spans over 66 kb and 
encodes a 75 kDa glycoprotein, composed of 655 amino acids [55,56]. Membrane topology 
analysis of the ABCG2 protein showed that the TMD consists of six transmembrane helices 
with the N- and C- termini located intracellularly (Figure 1.2A) [57]. As a half-transporter, 
ABCG2 must dimerize to form a functional transporter, with disulfide bridges contributing to 
homodimer stabilization [56]. 
The three-dimensional structure and the transport mechanism of ABCG2 remained a 
conundrum for almost three decades after its discovery. Generally, integral membrane proteins 
of mammalian origin are challenging targets for crystallographic studies, because they are often 
refractory to crystallization and/or difficult to express and purify in sufficient quantities for 
crystallization [58]. As a case in point, analyses of ABCG2 by electron crystallography 
provided only low resolution data, precluding insights into the structural details of the transport 
process [59-62]. In silico homology models did not provide a remedy, since they were not 
accurate, as demonstrated later by high-resolution techniques [63]. After years of speculations 
and hazy structural images, a new era was recently inaugurated with the ‘resolution revolution’ 
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in single-particle cryogenic electron microscopy (cryo-EM), mainly driven by direct electron 
detectors, better microscopes, and improved image processing software [38,58,62]. These novel 
technologies have made it possible to determine the atomic structure of ABCG2 as well as a 
broad range of biological macromolecules without crystallization [38,58,62]. In 2017, Locher’s 
group published the first, long-desired high-resolution structure of ABCG2, determined by 
cryo-EM [63]. One year later, the same group publicized the cryo-EM structures of ABCG2 in 
complex with two different inhibitors, one of them presented in the thesis in hand, providing a 
structural basis of small-molecule inhibition of ABCG2 [64]. Later that year, Locher’s 
laboratory provided cryo-EM structures of an ABCG2 mutant trapped in ATP-bound and 
substrate-bound states, further elucidating the transport mechanism of ABCG2 [65]. 
The aforementioned studies confirmed conjectures that ABCG2 exhibits an inward open 
conformation and functions according to the above-mentioned ‘switch model’ for ABC 
transport (Figure 1.1). The established membrane fold of the ABCG2 monomer with six 
transmembrane helices (TMs 1-6) was refined as depicted in Figure 1.2A. The NBD of each 
monomer is linked to TM1a via a highly charged amino acid sequence. The longest extracellular 
loop (EL3), between TM5c and TM6a, contains a single N-glycosylation site and three cysteine 
residues, two of which form an intramolecular disulfide bond and the third an intermolecular 
disulfide bridge to the second monomer. The two monomers form a homodimer with twofold 
symmetry (Figure 1.2B). The TMD interface is formed by TM2 and TM5 of opposing ABCG2 
monomers. At the interface, ABCG2 displays two cavities – the first of these (cavity 1) is 
accessible from the cytoplasmic side of the membrane and is separated from a second, 
extracellular site (cavity 2) by a plug formed by two leucine residues of opposing monomers. 
Cavity 1 was assigned the role of a multidrug binding pocket, accommodating both substrates 
and inhibitors of ABCG2, the slit-like shape of the cavity favoring flat, polycyclic and 
hydrophobic molecules. The NBDs are in functionally ‘open’ conformation in the absence of a 
substrate, with a gap between the catalytically relevant motifs, but they remain in contact. 
[63,65] 
Upon the binding of a substrate and ATP, conformational changes convert the transporter to an 
outward facing state (closed NBDs, rotated TMDs with collapsed cavity 1, open ‘leucine plug’ 
and cavity 2), the substrate being moved to cavity 2, from where it is expelled into the 
extracellular space (Figure 1.2B). The binding of two ATP molecules provides the power stroke 
for these conformational changes, which are induced via strict conformational coupling of the 
NBDs and TMDs. ATP hydrolysis to ADP and inorganic phosphate (Pi) resets the transporter 




Figure 1.2. Cartoon of the structure and mechanism of ABCG2. (A) Membrane topology of the ABCG2 monomer. Cystein 
residues forming intra- and intermolecular disulfide bonds are indicated, as is the N-glycosylation site. (B) Transport 
mechanism of the ABCG2 homodimer. The substrate enters cavity 1 from the cytoplasm or the inner leaflet of the membrane, 
the ‘leucine plug’ blocking the access to cavity 2. ATP binding induces the closing of the NMD interface, conversion of the 
homodimer from the inward to the outward facing state and the release of the substrate to the outside. Hydrolysis of ATP to 
ADP and Pi is accompanied by the return of the transporter to the inward facing state. 
Small-molecule inhibitors were shown to bind to the central multidrug binding site (cavity 1), 
just as substrates do. Either one or two molecules – depending on inhibitor size and shape – 
occupy almost the entire volume of cavity 1, thereby preventing the binding of other molecules, 
such as transporter substrates; in this sense, the inhibitors act competitively. Simultaneously, 
they lock the inward open conformation, and due to the conformational coupling of the TMBs 
to the NBDs, the closing of the NBDs and the ATPase activity, i.e. the ATP hydrolysis, are 
inhibited. The studies by Locher’s group also shed light on the question as to why certain 
compounds act as substrates, while others are inhibitors of ABCG2. The data corroborated the 
theory that the key determinant is the binding affinity. Whereas substrates appeared to bind 
deep in cavity 1, inhibitors were found to fill the cavity completely (one or two molecules) and 
immobilize the transporter like ‘wedges’, the numerous contacts to the TM helices explaining 































1.3 Functions and Substrates of ABCG2 
Soon after the discovery of ABCG2 in multidrug-resistant cancer cells, the expression of the 
protein in normal human tissue was researched in several studies, both on the RNA and on the 
protein level, the latter by using antibodies against ABCG2, such as 5D3 [66,67]. The tissue 
distribution pattern emerging from these reports – very similar to ABCB1 – implied that 
ABCG2 plays a role in the protection against xenobiotics and in the secretion/excretion of 
endobiotics, apart from conferring MDR to cancer cells [66,67]. Indeed, subsequent studies on 
abcg2-knockout mice and on loss-of-function polymorphisms of ABCG2 in humans confirmed 
these physiological functions [68,69]. 
Figure 1.3 shows a schematic overview of the ABCG2 localization in the human organism. The 
protein is expressed in the apical plasma membrane of epithelial cells throughout the body. It 
is located in the gastrointestinal tract, the liver and biliary tract, and the kidney, limiting the 
absorption and promoting the elimination of substrates. The highest expression was observed 
in the placenta, but also the testes and the brain are protected by ABCG2. The role of ABCG2 
in the (lactating) breast is still somewhat enigmatic. Besides epithelial cells, (hematopoietic) 
stem cells express ABCG2 in the plasma membrane. [66,67,70]. 
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1.3.1 Endogenous Functions 
Various studies suggest that transporters involved in drug resistance also have physiological 
functions: the secretion/excretion of metabolites, nutrients, antioxidants, microbiome products, 
bile salts, neurotransmitters, other neuro-active molecules, hormones, and signaling molecules 
[13]. In the case of ABCG2, several endogenous substrates (Figure 1.4) have been discovered. 
Studies identified sulfated conjugates of steroid hormones as ABCG2 substrates, suggesting an 
important role in the biliary and renal excretion of these hormones [71] (steroids are converted 
to water-soluble conjugates for excretion). Also the precursor of steroid hormones, cholesterol, 
and other sterols are extruded by ABCG2 [72]. Furthermore, it was discovered that ABCG2 is 
involved in the cellular export of porphyrins and hemes and their biliary excretion, possibly 
protecting the liver and other cells from an accumulation of these compounds, which is toxic 
and tends to occur under hypoxic conditions [73]. The abundant expression of ABCG2 in 
(hematopoietic) stem cells and the ability to survive under hypoxic conditions are thought to be 
related [73]. Moreover, ABCG2 is an important urate transporter, allowing excretion in the 
kidney and gastrointestinal tract, and its malfunction is associated with the gout disease [74]. 
On a final note, ABCG2 also secretes vitamin B2 (riboflavin) into the breast milk and bile [68]. 
This finding elucidates the presence of ABCG2 in the mammary gland a little, however it is 
still controversially discussed why a xenobiotic transporter is used to secrete vitamins into 
breast milk [68]. 
1.3.2 Barrier Functions 
Various lipophilic compounds rapidly pass through biological membranes. By recognizing and 
removing (often toxic) xenobiotics from the cell, ABC transporters – mainly ABCG2, ABCB1 
and ABCC1 – form our cellular defense system [14,75]. ABCG2 is a gatekeeper at all major 
physiological barriers [14,75]. The first hurdle after ingestion are the pre-systemic barriers, 
namely the intestinal barrier (gut-blood barrier) and the hepatic barrier (blood-bile barrier). 
Among the exogenous substrates of ABCG2 (Figure 1.4) are the following dietary toxins: 
pheophorbide A, a phototoxic chlorophyll metabolite structurally related to porphyrin, which 
occurs in plant-derived foods [76], PhIP (2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine), 
a carcinogen formed during the frying and cooking of meat [77], and aflatoxin B1, a carcinogen 
produced by certain molds [78]. Studies indicate that ABCG2 prevents or limits the absorption 
of the latter compounds in the gut, and mediates the efflux into the bile. Xeno-substrates that 
have managed to enter into the systemic circulation are excreted by ABCG2 at the renal barrier 
(blood-urine barrier). Also distribution to organs is limited by ABCG2 – it is highly expressed 
at the BBB and the blood-testis barrier, protecting these especially sensitive organs. Moreover, 
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at the blood-placental barrier (maternal-fetal barrier), ABCG2 defends the fetus against toxic 
materials ingested by the mother. [14,70,75] 
The flipside of the coin is that ABCG2, as well as ABCB1 and ABCC1, also accepts numerous 
drugs as substrates – with severe consequences. Firstly, the oral bioavailability of such drugs is 
often poor. For instance, the widely used anticancer drug topotecan exhibits low oral 
bioavailability of around 30%, which was attributed mainly to its property as an ABCG2 
substrate [79,80]. Therefore, intravenous application is standard for many ABCG2-transported 
drugs, which reduces a patient’s quality of life and increases hospital costs, in view of the fact 
that the patient cannot administer the drug at home [79]. Secondly, drugs that are ABCG2 
substrates have only very limited access to the brain – a major obstacle in the treatment of many 
brain disorders such as HIV infection of the brain or brain cancer, patients with a primary or 
metastatic brain tumor having a dismal prognosis [17,80]. And thirdly, eponymous for BCRP, 
expression of the protein in cancer cells confers MDR [70]. 
Drugs which are substrates of ABCG2 (Figure 1.4) comprise – but are not limited to – 
anticancer agents such as mitoxantrone, topotecan, methotrexate, and the tyrosine kinase 
inhibitors imatinib, gefitinib and nilotinib [70,81]; antibiotics like erythromycin [81]; antivirals 
including anti-HIV drugs such as lamivudine [81]; anti-inflammatory agents like sulfasalazine 
[81]; and the antiepileptic drug lamotrigine [82]. Noteworthily, also some fluorescent dyes are 
transported by ABCG2, for instance Hoechst 33342 and rhodamine 123 [81]. 
Taken together, over 200 transport substrates of ABCG2 have been identified, which 
considerably overlap with ABCB1 [83]. 
 































1.3.3 Function at the Blood-Brain Barrier 
The BBB is one of the most restrictive barriers found within the body [84], which comes to no 
surprise, considering that the brain is our most critical and most sensitive organ [85]. The BBB 
is formed primarily by a single monolayer of endothelial cells lining the brain capillaries 
(Figure 1.5), and represents a dual barrier: physical and biological [84,85]. In contrast to 
endothelia in peripheral capillaries, these endothelial cells are connected by tight junctions, 
making the BBB the densest physical barrier in the body (together with the urinary bladder) 
[17,84,85]. Therefore, paracellular transport of substances into the brain is negligible and the 
brain endothelium has to be penetrated via the transcellular route, which is restricted 
biologically by the expression of efflux pumps on the surface of the endothelial cells [17,18,84]. 
Quantitative (transcriptomic and proteomic) analyses of transporter expression in human brain 
microvessels revealed that ABCG2 is the most expressed efflux transporter at the BBB, 
followed by ABCB1 and, to a much lesser extent, by some members of the ABCC subfamily 
(Figure 1.5) [48-50]. It is worth mentioning that in mice, by contrast, ABCB1 was found to be 
predominant at the BBB, which led to the initial assumption that this is also the case at the 
human BBB. This interspecies difference questions the reliability of extrapolating animal data 
for predicting brain distribution of ABCG2 and ABCB1 substrates in humans [48-50]. 
 
Figure 1.5. Expression of ABC transporters (biological barrier) in brain capillary endothelial cells, which are connected by 
tight junctions (physical barrier) and constitute the principal cellular element of the BBB. 
The BBB is almost impermeable to drugs – approximately 98% of small molecule and all large 
molecule medications are normally excluded from the brain [84]. This is a key mechanism of 
drug resistance in brain diseases – a complex phenomenon, to which ABCG2 and ABCB1 
contribute in two ways: firstly, through their constitutive expression at the BBB and secondly 
by overexpression (at the BBB or in the target tissue) in some brain diseases, which can be 
triggered by the activation of nuclear receptors [17,18]. A detailed description of the ABC 
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In short, the expression of ABCG2 and ABCB1 has been shown to be the main reason for the 
difficulties in treating brain diseases [17]. Therefore, effective strategies to overcome the 
restrictions by the BBB, especially ABCG2 and ABCB1, have to be developed. 
1.3.4 Function in Multidrug Resistance in Cancer 
MDR in cancer is the ability of cancer cells to become simultaneously resistant to multiple, 
structurally and functionally unrelated drugs – a significant impediment to successful 
chemotherapy [16,87]. There are several mechanisms that cause drug resistance, including 
reduced drug uptake, e.g. by endocytosis, activation of detoxifying systems, such as DNA repair 
and cytochrome P450 oxidases, and defective apoptotic pathways [16]. The most commonly 
encountered mechanism is an increased efflux of cytostatics mediated by ABC transporters, 
mainly ABCG2 and its functional homologs ABCB1 and ABCC1 [46]. The notorious activity 
of ABCG2 in extruding anti-tumor drugs in a variety of cancer cell lines in vitro has been firmly 
established. By contrast, the clinical relevance of ABCG2 is still sketchy and there have been 
conflicting reports [70,83]. Studies on clinical samples usually examine the expression of 
ABCG2, either on the RNA or protein level, and correlate the latter with the outcome of a drug 
treatment regimen. Most of such studies were carried out for hematological malignancies. There 
is considerable evidence that ABCG2 (as well as ABCB1) is associated with a poor result in 
acute myeloid leukemia (AML) and diffuse large B-cell lymphoma, whereas for acute lymphoid 
leukemia the evidence is less convincing [70,83,88]. Yet, even for AML there exist 
contradictory studies [70]. Also (leukemic) cancer stem cells express high levels of ABCG2 
(and ABCB1), which has been found to correlate with a meager response to chemotherapy 
[70,83,88]. In solid tumors, the picture is mixed; some studies of solid tumors showed 
correlation between ABCG2 expression and prognosis, such as for lung or gastric cancer, while 
others did not. For many solid tumor types, there are not enough studies to draw compelling 
conclusions [70,83,88]. 
After almost half a century of research on drug transporters, launched with the discovery of 
ABCB1 in the 1970’s, the role of ABC transporters in clinical MDR has still not yet been 
clarified, especially that of ABCG2, the latest major drug transporter discovered. Several 
reasons have been invoked for this deficiency. A great problem is the detection of ABCG2 
expression. The detection is variable across laboratories and often not validated at all or 
validated with a cell line expressing extremely high levels of ABCG2, which one would not 
expect in clinical samples [70,89]. Besides, ABCG2 is often detected on the RNA level, which 
does not always directly correlate with the protein level [90]. In addition, ABCG2 has several 
polymorphic variants, which was not taken into consideration in all studies [90]. A second 
major challenge is the complexity of MDR mechanisms. Often, the expression of only one 
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transporter was examined, though the expression of multiple ABC transporters in a single tumor 
type is common [47,70]. In addition, studies indicate that several other survival factors, such as 
anti-apoptotic proteins, are up-regulated along with ABCG2, sometimes via the same regulatory 
machinery [90]. Thus it was suggested that ABCG2 expression by itself is not the sole 
mechanism behind MDR but rather a marker [90], which is supported by the intriguing 
observation that ABCG2 expression correlates positively with a resistant phenotype even if the 
drugs employed are not ABCG2 substrates [83,90]. 
Apart from chemotherapy, ABCG2 expression is also linked to the failure of photodynamic 
therapy, since some tumor-selective photosensitizers are substrates of ABCG2 [91]. 
All in all, studies have shown many correlative links between ABCG2 expression and clinical 
outcome, yet these have not proved causal. Despite this caveat, it is interesting that the tumor 
types most refractory to chemotherapy are among those with the highest levels of ABCB1 or 
ABCG2 expression [47], which suggests that overcoming these transporters may contribute to 
overcoming MDR in cancer. 
1.4 Applications of ABCG2 Inhibitors 
In parallel to mechanistic and functional studies, research has also focused on finding inhibitors 
of ABCG2. Given the wide distribution of the protein in the human body, its various functions 
including the involvement in diseases and drug response, and all the still open questions in these 
matters, several applications for ABCG2 inhibitors are obvious. On one hand, they are needed 
as molecular tools to gain further insight into the mechanism of ABCG2, its role in the human 
body, and its interaction with drugs. On the other hand, they may be of interest for improving 
the oral bioavailability of drugs and for overcoming drug resistance in brain diseases and in 
cancer. 
1.4.1 Applications as Molecular Tools 
1.4.1.1 Tools for Fundamental Research 
Comprehension of the molecular mechanism of ABC transporters is essential for understanding 
and modulating their function. High-resolution structural data offer an opportunity to model 
compounds into the binding pocket, which may facilitate a structure-based inhibitor and drug 
design or the identification of substrates [63]. ABC transporters are highly dynamic systems 
and a single structure is merely a snapshot of one conformational state of the protein as it moves 
its substrate through the membrane [38]. Thus, more than one structural image is necessary in 
order to understand the transport mechanism in detail, especially also with the protein trapped 
in a substrate-bound, ATP-bound or inhibitor-bound state. Therefore, inhibitors of ABC 
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transporters suitable for ‘complexing’ with the respective transporter in structural biology 
experiments are required. In the case of ABCG2, structures of the protein in complex with two 
different inhibitors have been published (see Section 1.2) [64], one of which will be presented 
in Chapter 2 of this thesis. 
Fundamental research into the functions of ABCG2 depends heavily on experiments with 
abcg2-knockout mice. The use of selective ABCG2 inhibitors, i.e. a chemical instead of a 
genetic disruption of the ABCG2 function, complements this approach. Moreover, the 
application of dual ABCB1/ABCG2 inhibitors is an alternative to double-knockout mice 
[90,92]. 
Although the results of animal studies are valuable, the extrapolation to humans is difficult due 
to interspecies differences. Experiments in humans are restricted to non-invasive methods, 
positron emission tomography (PET) being used most frequently [93]. For this purpose, a PET 
imaging probe that interacts with the ABC transporter is necessary: a substrate or inhibitor 
labeled e.g. with 11C or 18F [93]. Usually, transporter imaging probes used in PET studies are 
not molecules designed de novo, but are marketed drugs or natural food constituents (or 
metabolites thereof), which are repurposed for this application [93]. The first in vivo evidence 
for ABC transport activity at the human BBB was produced via PET imaging by Sasongko et 
al. in 2005. The distribution of the ABCB1-selective substrate [11C]verapamil (an 
antiarrhythmic drug) to the brain was increased during the inhibition of ABCB1 by cyclosporin 
A (an immunosuppressant drug) – a proof of ABCB1 activity at the human BBB [94]. This is 
an excellent example of how inhibition of an ABC transporter enabled pioneering fundamental 
research. 
The visualization of ABCG2 at the human BBB is hampered by the lack of an ABCG2-selective 
substrate probe. Langer’s group, who has conducted extensive research on imaging ABC 
transporter functions, developed a protocol in which they used a dual ABCB1/ABCG2 substrate 
probe and eliminated the influence of ABCB1 efflux by inhibiting this transporter with 
tariquidar (Figure 1.6) [95,96]. For lack of a clinical ABCG2 inhibitor, another obstacle, they 
performed experiments on subjects who were either non-carriers or heterozygous carriers of an 
ABCG2 polymorphism associated with a reduced function of the protein [96]. Indeed, the 
distribution of the substrate to the brain was increased in the carriers of the polymorphism – the 
first verification of ABCG2 activity at the human BBB in vivo, reported only four years ago 
[96]. To date, clinical ABCG2 inhibitors are still quite scarce and selective as well as dual 
ABCG2/ABCB2 inhibitors (depending on the experimental design) are urgently needed for the 
PET experiments with labeled substrate probes, as strikingly demonstrated by the elaborate 
workaround applied by Langer and co-workers. Furthermore, selective ABCG2 inhibitors 
amenable to PET labeling are of interest as PET imaging agents [97]. 
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1.4.1.2 Tools for Drug Discovery and Development 
During the discovery and development of new drugs, interactions of the latter with ABC 
transporters need to be assessed for several reasons. Firstly, it is likely that these drug efflux 
pumps limit the absorption and distribution of potential medications and promote their 
elimination; in case of anticancer agents, the uptake by cancer cells may be restrained. Thus, 
pharmaceutical companies include ABCB1 and ABCG2 transporter assays in early screens in 
drug discovery to eliminate drug candidates that are substrates of these proteins [98], which can 
be considered ‘antitargets’ in this respect [99]. Secondly, by contrast, compounds that do have 
substrate properties are selected in case drugs are not intended to enter the brain. Third 
generation antihistaminic agents, for example, were designed as substrates of ABC transporters 
and hence are devoid of central side effects like sleepiness [99,100]. And thirdly, relevant in 
(pre-) clinical drug development, substrate and inhibitor properties of drugs can cause drug-
drug interactions (DDIs). When two drugs which interact with the same ABC transporter are 
co-administered, one drug may induce transporter inhibition or saturation and thereby change 
the disposition of the other drug [101]. This phenomenon often causes severe adverse drug 
reactions in patients [102]. Therefore, the importance of assessing drug-transporter interactions 
was emphasized in a statement of the International Transporter Consortium in 2010 [102], on 
the basis of which regulatory authorities – the US Food and Drug Administration (FDA) and 
the European Medicines Agency (EMA) – recommend in their guidelines that all investigational 
drugs should be evaluated as substrates or inhibitors of ABCB1 and ABCG2 [103,104]. 
In the assessment of drug-transporter interactions, prototypical ABC inhibitors are important 
molecular tools. For instance, in vitro trans-epithelial transport assays, complemented with the 
use of selective inhibitors, allow probing for ABC transporter substrates [102]. On the 
examination of DDIs, in vivo studies may be recommended if a drug candidate turns out to be 
an ABC transporter substrate or inhibitor in vitro [102]. Regulators do not endorse animal 
studies due to pronounced interspecies differences [105] – DDI studies in humans are the ‘gold 
standard’ [106]. Healthy volunteers are treated with the drug of interest and an ABC inhibitor, 
in case the drug is a substrate. Vice versa, if the drug in question is an inhibitor, it is 
administered together with a substrate. Then, the drug concentration in the blood is assessed 
and compared to the results achieved when the drug is dosed alone [106]. Some DDIs may lead 
to changes in the organ distribution of drugs (e.g. brain, liver, kidneys) without affecting plasma 
concentrations. To elucidate potential DDIs on a tissue level, imaging techniques such as PET 
can be used. If the drug of interest is an inhibitor, it could be given in an unlabeled form to 
assess its influence on the distribution of a PET imaging substrate probe [107]. If the drug is a 
substrate, it may be radiolabeled and used in combination with a transporter inhibitor [107]. 
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As is the case in fundamental research, the shortage of clinically applicable, specific model 
inhibitors and substrates of ABC transporters as well as probes suitable for imaging studies is 
well recognized, and represents an area of research that warrants moving forward with drug-
transporter interaction and DDI studies [102]. 
1.4.1.3 Clinical Diagnostic Tools 
Though the role of ABCG2 expression in MDR has not yet been fully elucidated, ABCG2 has 
been identified as a tumor marker, which could be exploited in the diagnosis of cancer [108]. 
By analogy with ABCB1 [93], the detection of ABCG2 expression in tumors could be achieved 
by imaging techniques such as single-photon emission computed tomography (SPECT) or PET, 
using a labeled substrate probe and an ABCG2 inhibitor, which should increase the 
accumulation of the imaging probe in ABCG2 expressing tumors. Measuring ABCG2 
expression in tumors may also be useful for the prediction and assessment of MDR and response 
to chemotherapy [47]. This would be a valuable application of clinical ABCG2 inhibitors. 
1.4.2 Applications as Prospective Drugs 
To date, no inhibitor targeting an ABC transporter has received marketing authorization by 
regulatory agencies [47,99,109], though some marketed drugs addressing other targets show 
off-target, inhibitory activity at ABC transporters [109]. Nevertheless, several potential 
therapeutic applications of ABCG2 inhibitors have been and are still being explored. 
1.4.2.1 Drugs for Improving Oral Bioavailability 
In the light of ABCG2 expression at the intestinal and hepatic barrier, which was shown to limit 
the oral bioavailability of (anticancer) drugs, the idea of using ABCG2 inhibitors to improve 
oral bioavailability has been investigated [79,80,110,111]. Preceding preclinical and clinical 
studies on ABCB1 had already been successful, the most prominent example being the 
improvement of the oral bioavailability of the anticancer agent paclitaxel when combined with 
the ABCB1 inhibitor cyclosporin A [79,80,110,111]. Similarly, the oral bioavailability of 
topotecan was improved when co-administered with the dual ABCB1/ABCG2 inhibitor 
elacridar (Figure 1.6) in clinical research [112,113]. Since topotecan is a selective substrate for 
ABCG2, the results suggest that the interaction of the two compounds is due to inhibition of 
ABCG2 [112,113]. Given the co-expression of ABCB1 and ABCG2 at the intestinal and 
hepatic barrier and their overlapping substrate ‘specificities’, dual ABCB1/ABCG2 inhibition 
is of interest for dual substrates, as demonstrated in a clinical trial using the dual 
ABCB1/ABCG2 substrate irinotecan in combination with the tyrosine kinase inhibitor 
gefitinib, which also inhibits ABCB1 and ABCG2 [114]. Together, these findings encourage 
the application of ABCG2 inhibitors to improve oral bioavailability. The reservation must be 
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made, however, that ABCG2 inhibition can potentially increase brain uptake, which would be 
undesirable because of possible (neuro)toxic side effects, yet advantageous in case the tumor is 
located in the brain [111]. 
1.4.2.2 Drugs for Improving Brain Penetration 
Due to the restrictions by the BBB, the development of drugs targeting the brain shows the 
highest failure rates in phase I and II clinical trials: 93% to 98% [84]. Clinical strategies to 
overcome the BBB comprise physical methods such as the administration of drugs directly into 
the brain region of interest, requiring invasive surgery, and osmotic disruption, e.g. with a 
mannitol solution, implying increased and unwanted leaking of plasma material into the brain, 
which is severely toxic for the brain [84]. Neither method is ideal. An alternative in order to 
specifically increase the brain penetration by drugs which are substrates of ABC transporters is 
the inhibition of these efflux pumps by the use of inhibitors. In 2002 a first proof-of-concept 
study in mice demonstrated that the paclitaxel concentration in the brain, which is very low 
after an intravenous injection, was increased by co-administration with the ABCB1 inhibitor 
valspodar [115]. Whereas paclitaxel alone did not affect the volume of an implanted brain 
tumor, co-administration with valspodar reduced the tumor volume by 90% [115]. Several 
follow-up preclinical studies in mouse or rat models with different substrate/ inhibitor 
combinations confirmed the principle and showed that it is also applicable to ABCG2 
[111,116]. In most cases, however, ABCB1 and ABCG2 work in concert to transport a substrate 
drug from the brain back into the blood, which can be explained by their prominence and 
substrate overlap [111,116]. Studies with knockout mice showed that these two export pumps 
have a cooperative effect at the BBB: the removal of either transporter alone does not result in 
a significant increase in brain penetration of dual substrates, because it is compensated by the 
respective other transporter, whereas the complete removal of both efflux pumps has a 
disproportional effect on brain uptake [111,116]. Consequently, the largest increase in brain 
accumulation of dual substrate drugs should be achieved by the inhibition of both ABCB1 and 
ABCG2 [111,116]. This was verified in extensive preclinical research in rodents, mostly using 
the dual inhibitor elacridar in combination with various dual substrate drugs, not only 
cytostatics but also drugs for neurological disorders [111,116,117]. Because of interspecies 
differences, these results do not necessarily translate to humans. The confirmation that this 
principle – inhibition of ABC transporters to increase drug penetration – is applicable to humans 
was provided by PET imaging. The aforementioned PET studies, proving the activity of 
ABCB1 and ABCG2 at the human BBB, were recently followed by a couple of clinical trials 
focused on improving drug exposure to the brain. [11C]Erlotinib, a tyrosine kinase inhibitor, 
was used as a PET substrate probe. Its brain uptake is limited as it is a substrate of both ABCB1 
and ABCG2. The first such study, two years ago, was not successful, which was attributed to 
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the use of elacridar as a dual inhibitor, as practiced before in numerous preclinical trials [118]. 
Elacridar is a much more effective inhibitor of ABCB1 than it is of ABCG2, meeting the needs 
of the rodent BBB, where ABCB1 predominates over ABCG2. Since the situation is vice versa 
in humans, it was speculated that a better result could be achieved using a dual inhibitor with 
high potency at ABCG2. Indeed a proof-of-concept study carried out by Langer’s group only 
one year ago accomplished a much better outcome [119]. They found out that erlotinib is not 
only a dual substrate, but at a supratherapeutic dose it functions as an inhibitor of ABCB1 and 
ABCG2. Using erlotinib, they were able to achieve an increase in brain distribution of 
[11C]erlotinib [119]. However, the clinical application of supratherapeutic doses of erlotinib 
may be hampered by safety concerns [119], which is why further research on clinically 
applicable, potent dual ABCB1/ABCG2 inhibitors is desirable. 
Together, the preclinical and clinical data make a compelling case for the application of ABCG2 
and dual ABCB1/ABCG2 inhibitors as drugs to improve brain penetration. 
1.4.2.3 Drugs for Overcoming Multidrug Resistance in Cancer 
As the human ABC transporters were first discovered in cancer cells, where they extrude 
anticancer drugs, the use of ABC inhibitors to improve the response to chemotherapy stood to 
reason. Already in the 1980’s, less than 10 years after the discovery of ABCB1, the first clinical 
trials on combination chemotherapy – an anticancer drug together with an ABCB1 inhibitor – 
were carried out and dozens more followed [46]. Nevertheless, this is by far the most uncertain 
and most disputed potential application of ABC inhibitors – no wonder, considering that the 
role of ABC transporter expression in MDR is still unclear. 
Initially, drugs which had been approved for other indications and noted to inhibit ABCB1 (first 
generation inhibitors) were used in clinical trials, for instance verapamil or cyclosporin A 
[46,47,120,121]. Owing to their low inhibitory potency, higher doses than those required for 
their individual therapeutic activity were applied, which consequently led to unacceptable toxic 
side effects [46,47,120,121]. Second generation inhibitors were analogs of the initial agents 
developed solely for the purpose of altering drug resistance, the cyclosporin derivative 
valspodar being tested most frequently in clinical trials [46,47,120,121]. These inhibitors were 
more potent and less toxic, but induced pharmacokinetic interactions that limited the clearance 
and metabolism of anticancer drugs and thereby elevated their plasma concentrations beyond 
acceptable toxicity, for instance by inhibiting cytochrome P450 enzymes [46,47,120,121]. This 
usually prompted dose reductions of the anticancer agents down to ineffective levels 
[46,47,120,121]. Third generation inhibitors, such as elacridar and tariquidar, were designed 
with increased specificity to overcome these disadvantages [46,47,120,121]. Indeed, they 
displayed either no or only minor pharmacokinetic interactions with different anticancer agents, 
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yet several clinical studies failed to show a conclusive benefit of the addition of an ABCB1 
inhibitor to standard therapy and some were closed early owing to toxicity [46,47,120,121]. 
Therefore, the conduction of further trials was generally discouraged. However, the point must 
be made that the clinical trial designs were often flawed. Typically, ABCB1 was not assayed in 
tumors and there was no selection of patients whose tumors displayed overexpression of 
ABCB1 [46,120,122]. Furthermore, many studies enrolled patients following multiple lines of 
therapy, so that drug resistance was likely to be multifactorial, yet other drug efflux mechanisms 
or a lack of uptake mechanisms were not controlled [46,120,122]. Thus the idea of overcoming 
MDR by inhibiting ABCB1 was not adequately tested [46,120,122]. 
Given the lack of success with the preceding trials on ABCB1 inhibitors and the restricted 
knowledge about which cancers express ABCG2, only very few clinical trials aimed at 
overcoming ABCG2-mediated drug resistance have been carried through, and the picture is 
very similar to ABCB1. In the last decade, a couple of trials investigated the combination of 
topotecan with the tyrosine kinase inhibitor lapatinib, which also inhibits ABCG2 [88,123,124]. 
Unfortunately, the results did not demonstrate an advantage over the application of topotecan 
alone, although ABCG2 expression was detected [88,123-126]. This failure was attributed 
mainly to other mechanisms being involved in the resistance and also toxicity was a problem 
in some cases [88,123,124]. 
It is worth noting that an explanation for toxicity problems despite the lack of pharmacokinetic 
interactions could be the ABCB1/ABCG2 inhibition in cells, where these transporters are 
known to play a protective role, e.g. in bone marrow stem cells, yet in many cases there was no 
clear evidence for such an effect [120,123]. 
Taken together, there is still no definite answer to the question if inhibitors of ABC transporters 
can effectively reverse drug resistance in humans. It could be speculated, however, that in case 
proper patient populations were selected, whose tumors show ABC transporter-dominated 
resistance, successful reversal of drug resistance by ABC inhibitors might be feasible 
[46,47,120,124]. Given the expression of multiple ABC transporters in tumors, compounds that 
inhibit ABCB1 and ABCG2 (and ABCC1) may be advantageous [120]. 
Moreover, apart from chemotherapy, also photodynamic therapy (PDT) could profit from 
ABCG2 inhibition. As mentioned above, a couple of PDT agents were shown to be ABCG2 
substrates and high ABCG2 expression was correlated with decreased potency of the latter [91]. 
Thus, ABCG2 inhibitors may improve the response to PDT. 
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1.5 Reported ABCG2 Inhibitors and Problem 
Statement 
The research into inhibitors of ABC transporters began in 1981 with the serendipitous finding 
that the calcium channel blocker verapamil inhibited ABCB1-mediated drug efflux in resistant 
tumor cells [116,127]. Subsequently, numerous chemicals were screened for their potential to 
inhibit ABCB1 [116] and, as outlined in the previous section, a couple of ABCB1 inhibitors 
with higher potency were developed, in particular the two benzanilides elacridar (by Glaxo) 
[128] and tariquidar (by Xenova) [129] (Figure 1.6). Both are non-marketed, experimental 
compounds, which have been used in clinical trials. 
After the discovery of ABCG2, the ability of the hitherto developed ABCB1 inhibitors to 
impede also ABCG2-mediated drug efflux was investigated. Indeed, both elacridar [130] and 
tariquidar [131] happen to inhibit ABCG2, albeit less potently than ABCB1. The first selective 
inhibitor of ABCG2 reported was the fungal toxin fumitremorgin C (FTC) [132,133] 
(Figure 1.6), which, however, is precluded from the use in vivo due to its severe neurotoxic side 
effects. A number of other natural and dietary compounds were identified as ABCG2 inhibitors, 
primarily flavonoids [134,135]. Of these constituents, only curcumin (Figure 1.6) was evaluated 
clinically as an ABCG2 inhibitor [103,136]. This substance was also shown to inhibit ABCB1 
and ABCC1, yet with lower potency [136]. Disadvantageously, it shows poor absorption and 
extensive metabolic instability [137]. Furthermore, various drugs on the market were 
investigated for interaction with ABCG2. The immunosuppressant cyclosporin A (Figure 1.6) 
is a very unspecific ABCG2 inhibitor, since it also inhibits ABCB1 and other transporters, as 
well as cytochrome P enzymes [92,138]. With tyrosine kinase inhibitors emerging as anticancer 
drugs in the beginning of this century, they were evaluated in this regard and some turned out 
to be ABCG2 inhibitors, notably erlotinib [139] and lapatinib [103,140] (Figure 1.6), which 
were used in some of the clinical trials mentioned in Section 1.4. At higher concentrations, they 
inhibit ABCB1 as well [103,139,140]. Recently, the platelet-increasing agent eltrombopag 
(Figure 1.6) was demonstrated to be an ABCG2 inhibitor [92,141]. However, the use of drugs 
for in vivo experiments may cause safety problems due to the effects they were originally 
designated for. 
Of course, medicinal chemists did not remain idle and synthesized compounds designed solely 
for the purpose of inhibiting ABCG2. Soon after the discovery that the mycotoxin FTC is a 
selective ABCG2 inhibitor, analogs thereof, featuring lower toxicity and higher potency, were 
reported [142]. In particular Ko143 [142] (Figure 1.6), which is still among the most potent 
ABCG2 inhibitors published so far, has to be pointed out. Later it was shown that it is not 
entirely selective for ABCG2 and interacts with ABCB1 and ABCC1, but only at high 
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concentrations [143]. A drawback of Ko143 is its poor metabolic stability caused by the labile 
ester group [143,144]. Since the report on Ko143, many more ABCG2 inhibitors have been 
created, mostly derivatives of the aforementioned compounds. They were extensively reviewed 
elsewhere [135,145,146] and some prominent examples will be highlighted in Chapter 2. 
Nevertheless, to the best of the author’s knowledge, none of these have been developed for the 
use in humans. Hence, the aforementioned drugs and dietary compounds have to be repurposed, 
with all the detriments indicated above. For clinical DDI studies, for instance, the FDA 
recommends the use of cyclosporin A, eltrombopag and curcumin as ABCG2 inhibitors [147]. 
In some articles on the subject, the utilization of lapatinib is suggested [92,103]. 
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A thorough literature research by the author of this thesis brought to light a dilemma: 
researchers of many different disciplines lament the lack of clinically usable ABCG2 inhibitors, 
impeding their research into applications of the latter, while on the other hand, as many 
applications are not yet fully developed, medicinal chemists treat the discovery of ABCG2 
inhibitors as an end in itself, strikingly focusing on improved in vitro potency, thereby 
neglecting in vivo applicability. Therefore, in the author’s opinion, the research into novel 
ABCG2 inhibitors needs redirecting towards a more application-oriented design. More 
precisely, not only the pharmacodynamic but also the pharmacokinetic (i.e. absorption, 
distribution, the metabolism and excretion; ADME) and toxicity (Tox) properties should be 
optimized – only drug-like molecules, i.e. such ones with sufficiently favorable ADME-Tox 
properties, can be effective in vivo [148]. 
Two major shortcomings of ABCG2 inhibitors in terms of drug-like properties are particularly 
eminent. Firstly, ABCG2 inhibitors are typically very lipophilic compounds with high 
molecular weight, which generally entails low water solubility, compromising absorption and 
distribution. Considering that the inhibitors have to address the large and distinctly hydrophobic 
multidrug binding site of ABCG2 (see Section 1.2) [64], this is not surprising. Secondly, 
ABCG2 inhibitors often contain labile groups such as amide and ester moieties or Michael 
systems, which are susceptible to hydrolysis or other nucleophilic attack, thus causing 
metabolic instability. 
Consequently, the present thesis is devoted to the creation of ABCG2 inhibitors that are not 
only potent, but also drug-like, in particular water-soluble and stable. 
1.6 Scope and Objectives of the Thesis 
The ABCG2 transporter is involved in multidrug resistance of cancer and a functional 
component of the blood-brain-barrier. Inhibitors of this drug efflux pump are investigated to 
overcome the aforementioned obstacles. The research on ABCG2 inhibitors has concentrated 
on potency, while drug-like properties have been disregarded. Since the latter are an 
indispensable precondition for application in vivo and, ultimately, in humans, the present thesis 
is dedicated to the design, synthesis and characterization of novel, drug-like ABCG2 inhibitors, 
focusing on stability in blood plasma and water solubility. 
During preceding studies on the dual ABCB1/ABCG2 inhibitor tariquidar (Figure 1.6) by our 
working group, it had been found by serendipity that minimal structural modifications resulted 
in a drastic change in activity in favor of ABCG2 inhibition [149]. In contrast to tariquidar, 
which shows higher potency at the ABCB1 transporter, its analog UR-ME22-1 is selective for 
ABCG2. However, the aforementioned modifications rendered the molecule prone to 
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hydrolysis in blood plasma [150]. In cooperation with members of Prof. König’s group 
(Institute of Organic Chemistry, University of Regensburg), who provided the synthesis, the 
labile moieties in UR-ME22-1 were bioisosterically replaced by more stable groups. The key 
feature was a central triazole core. With the novel compounds in hand, our working group 
carried out biological assays. Furthermore, one of the inhibitors was forwarded to Prof. 
Locher’s group (Institute of Molecular Biology and Biophysics, ETH Zürich), which allowed 
the group to elucidate the structure of ABCG2 in an inhibitor-bound state in a cryo-EM 
experiment – a study they already published [64], which is outlined in Section 1.2. The first 
objective of the thesis in hand (Chapter 2) was the completion of the chemical and biological 
characterization of the new, tariquidar-related triazoles (among others the determination of the 
stability in blood plasma), the synthesis of known ABCG2 inhibitors as a reference, and the 
comparative analysis of the biological data collected in our as well as Prof. Locher’s working 
group, not least to gain deeper insight into the underlying transport inhibition mechanisms, 
which, heretofore, had still been an enigma. 
Subsequently, the focus of this thesis was directed on water solubility, which is a fundamental 
prerequisite for all bioactive compounds. The preceding, tariquidar-related triazoles acted as 
potent and effective ABCG2 inhibitors. Accordingly, they appeared to stay in solution at least 
for the short time span of the biological assays. Their equilibrium solubility, however, was very 
poor, a severe impediment for application, particularly in vivo. This is typical of ABCG2 
inhibitors, which are usually very large and lipophilic. Therefore, the second objective of the 
thesis in hand (Chapter 3) was the design and synthesis of novel potent and stable ABCG2 
inhibitors with improved equilibrium water solubility, using the previous inhibitors as a starting 
point. It was planned to pursue a fragment-based approach, which was considered suitable 
because ligands optimized in such an approach are more likely to be relatively small and 
hydrophilic [151,152]. On ‘growing’ the optimized fragments into potent and soluble inhibitors, 
it was devised to take advantage of a cryo-EM structure of ABCG2 [63] and to use molecular 
docking studies in order to optimize protein-ligand interactions. In addition to a thorough 
biological characterization, it was planned to establish solubility assays suitable for analyzing 
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2.1 Introduction 
In 1990, a novel drug resistance-related membrane protein was discovered in a doxorubicin 
resistant breast cancer cell line [1] and in 1998 it was identified as the most recent member of 
the human ABC transporter superfamily and named breast cancer resistance protein (BCRP) 
[2]. The Human Genome Nomenclature Committee termed the transporter ABCG2 [3]. ABCG2 
as well as other ABC transporter subtypes such as ABCB1 (P-gp) und ABCC1 (MRP1) are not 
only associated with the chemoresistance of malignant tumors [4-7], but they are also expressed 
at the blood-brain barrier (BBB), preventing the entry of a broad variety of xenobiotics, 
including numerous drugs, into the central nervous system [8-10]. Therefore, co-administration 
of an ABC inhibitor and a cytostatic drug represents an attractive strategy to overcome the BBB 
and multidrug resistance (MDR) of various malignancies. This has been demonstrated by 
several proof-of-concept studies, although ABC inhibitors are not in clinical use yet [11-16]. 
ABCG2 has come into focus since apart from being one of the three major subtypes conferring 
MDR in cancer cells (in addition to ABCB1 and ABCC1), it also appears to be the most 
abundant subtype at the human BBB [17,18]. 
Figure 2.1 shows a selection of ABCG2 inhibitors described so far. Among the first substances 
found to affect ABCG2 activity are inhibitors of the ABCB1 transporter, primarily the 
benzanilides elacridar (2.01) and tariquidar (2.02) [19-22]. Fumitremorgin C (FTC) (2.03), a 
fungal toxin from A. fumigatus Fresen. containing a tetrahydro-β-carboline backbone, was the 
first known specific inhibitor of the ABCG2 subtype [23]. Its neurotoxic effects, however, 
preclude its use in vivo. Its nontoxic analog Ko143 (2.04) was developed in 2002 and is still 
among the most potent known ABCG2 inhibitors [24]. It was recently reported, though, that it 
also interferes with both, ABCB1 and ABCC1 transport, but only at higher concentrations (low 
micromolar range) [25]. The suitability of Ko143 for in vivo studies is compromised by the 
poor metabolic stability of the ester moiety [26,27]. Lately, further derivatives of FTC have 
been prepared, e.g. compound 2.05 [28]. Besides the fungal toxin FTC, other natural 
compounds and derivatives thereof were reported to antagonize ABCG2, the main structural 
class being flavonoids such as flavones, chalcones and curcuminoids [29-34]. Chromone is a 
partial structure present in many active flavonoids and was derivatized to create novel, potent 
and nontoxic ABCG2 inhibitors such as compounds 2.06 and 2.07 [35]. The stability of these 
compounds still remains to be determined, though. In an ongoing search for potent, selective 
and stable inhibitors for ABCG2, further structure types have emerged, for instance the 
relatively small acrylonitrile YHO-13177 (2.08) [36,37]. 
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Figure 2.1. Structures of known ABCG2 inhibitors: elacridar (2.01), tariquidar (2.02), fumitremorgin C (2.03), Ko143 (2.04), 
the β-carboline derivative 2.05, the chromones 2.06 and 2.07 and the acrylonitrile YHO-13177 (2.08). 
Until recently, the mechanism of ABCG2 inhibition could only be speculated about, since there 
were no high-resolution structural data for ABCG2. The breakthrough came in 2017 with the 
high-resolution cryo-EM structure of ABCG2 [38]. One year later, we determined the structure 
of ABCG2 in complex with two different inhibitors, including UR-MB136 (2.59), a member of 
the series we present here [39]. The synthetic route to 2.59, the appertaining series of novel 
ABCG2 inhibitors and their biological characterization have not been published yet, and are 
subject of the present study. Heretofore, we modified the dual ABCB1/ABCG2 inhibitor 
tariquidar (2.02) to obtain the selective ABCG2 inhibitor UR-ME22-1 (2.09) (Figure 2.2) [40]. 
The main, selectivity-yielding modification was the shift of the hetarycarboxamido moiety from 
the ortho- to the meta-position of the central benzamide core. However, this shift rendered the 
central benzamide bond prone to hydrolysis in murine plasma, presumably due to inadequate 
steric hindrance, facilitating the attack of the amide bond by plasma hydrolases. In an attempt 
to gain stable tariquidar analogs, the labile amide moiety was replaced by an indole ring, 
yielding more stable inhibitors with higher efficacy than 2.09 [41]. However, it was shown that 
these compounds were still hydrolyzed to a certain extent, namely at the ester bond attached to 
the central, trisubstituted phenyl ring. Here we present the synthesis and pharmacological 
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evaluation of novel tariquidar derivatives. As shown in Figure 2.2, we introduced a triazole core 
as a bioisoster to the labile amide group in 2.09, which can be more conveniently synthesized 
than an indole moiety. Furthermore, we synthesized compounds in which the labile ester moiety 
was replaced by ketone groups. We aimed at ABCG2 inhibitors that are potent, effective, 
selective, and suitable for complexing with ABCG2 in cryo-EM experiments and, moreover, 
also stable in blood plasma, a prerequisite for in vivo studies. 
 
Figure 2.2. Structure of UR-ME22-1 (2.09) and general structure of the title compounds developed from 2.09. 
In order to rank our novel series we also purchased or prepared compounds 2.02-2.08 as 
reference substances and investigated them in our assays. 
2.2 Results and Discussion 
2.2.1 Synthesis 
“Key” step in the convergent synthesis of the title compounds was the production of the triazole 
core in a copper-catalyzed azide-alkyne cycloaddition (CuAAC), a stepwise variant of the 
Huisgen cycloaddition process, and the most often used “click” reaction [42]. Here we used the 
polytriazole TBTA as a copper(I)-stabilizing ligand [43]. The azides for the CuAAC were 
prepared in three steps (Scheme 2.1). In order to vary the linker length between the 
tetrahydroisoquinoline moiety and the phenyl ring, either 1-(bromomethyl)-4-nitrobenzene 
(2.10) or 1-(2-bromoethyl)-4-nitrobenzene (2.11) was combined with the respective 
tetrahydroisoquinoline derivative (2.12-2.14) in an N-alkylation reaction affording compounds 
2.15-2.19. In our previous studies on tariquidar analogs it proved to be advantageous in terms 
of efficacy to introduce a polyethylene glycol (PEG) chain at the tetrahydroisoquinoline moiety, 
which was explained by a solubilizing effect [41,44,45]. For this reason, we also synthesized 
the PEGylated tetrahydroisoquinoline derivative 2.14 according to our previous report [44] and 
alkylated the nitrogen. In the next two steps, the nitro group in compounds 2.15-2.19 was 
reduced to an amine group, resulting in compounds 2.20-2.24, and then converted into an azide 
moiety, affording compounds 2.25-2.29. 
Tariquidar-Related Triazoles as Potent, Selective and Stable Inhibitors of ABCG2 
37 
 
Scheme 2.1. Synthesis of the azides for the “click” reactions. Reagents and conditions: (a) K2CO3, MeCN, reflux, overnight; 
(b) Pd/C, H2 (40 bar), EtOH, rt, overnight or SnCl2, EtOH, reflux, 2 h; (c) (I) NaNO2, 6 M HCl aq, - 5 °C, 1 h; (II) NaN3, - 5 °C, 
1 h. 
The synthesis of the target compounds containing an ester group is shown in Scheme 2.2. 
Firstly, the alkyne 2.32 as the second reactant in the “click” reactions was prepared by 
Sonogashira coupling of methyl 2-amino-4-bromobenzoate (2.30) and trimethylsilylacetylene 
to 2.31 and subsequent TMS-deprotection (to compound 2.32). Then 2.32 was combined with 
the azides 2.25-2.29, affording the triazoles 2.33-2.37 and the quinoline moiety was introduced 
by amide coupling with quinoline-2-carboxylic acid, yielding the inhibitors 2.38-2.42. 
 
Scheme 2.2. Synthesis of the inhibitors 2.38-2.42 bearing an ester moiety. Reagents and conditions: (a) ethynyltrimethylsilane, 
Pd(PPh3)2Cl2, CuI, NEt3, THF, 60 °C, overnight; (b) TBAF, THF, 0 °C, 2 h;(c) CuSO4, sodium ascorbate, TBTA, DMF, rt, 
24 h; (d) quinoline-2-carboxylic acid, HBTU, DIPEA, DCM, 0 °C → rt, 24 h. 
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In the second subseries, the labile ester moiety was replaced by different ketone groups  
(Scheme 2.3). 3-Bromoaniline (2.43) was acylated in a Sugasawa reaction, a specific ortho-
acylation of anilines, to form the ketones 2.44-2.46. Compound 2.44 was first treated with 
quinoline-2-carboxylic acid to form the amide 2.47 and then submitted to a Sonogashira 
coupling with trimethylsilylacetylene (resulting in 2.48) and deprotected to 2.49. Precursors 
2.45 and 2.46 were first coupled with trimethylsilylacetylene under Sonogashira conditions 
(forming 2.50 and 2.51), deprotected (to 2.52 and 2.53), and then treated with quinoline-2-
carboxylic acid to form the amide bond (yielding 2.54 and 2.55). The final step was the “click” 
reaction of the alkynes 2.49, 2.54, and 2.55 with the azides 2.28 or 2.29 to form the inhibitors 
2.56-2.59. 
 
Scheme 2.3. Synthesis of the inhibitors 2.56-2.59 bearing a ketone moiety. Reagents and conditions: (a) (I) BCl3, DCM, 0 °C, 
20 min; (II) AlCl3, respective nitrile, reflux, 24 h; (III) 2 M HCl aq, 0 °C, 10 min → 80 °C, 1 h; (b) quinoline-2-carboxylic acid, 
HBTU, DIPEA, DCM, 0 °C → rt, 24 h; (c) ethynyltrimethylsilane, Pd(PPh3)2Cl2, CuI, NEt3, THF, 60 °C, overnight; (d) TBAF, 
THF, 0 °C, 2 h; (e) CuSO4, sodium ascorbate, TBTA, DMF or THF, rt, 24 h. 
The reference compounds 2.03 and 2.04 were commercially available; 2.02 [21], 2.05 [28], 2.06 
[35], 2.07 [35], and 2.08 [36,37] were synthesized according to literature. 
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2.2.2 Inhibition of the ABCG2, ABCB1 and ABCC1 Transport Activity 
The newly synthesized compounds (2.38-2.42 and 2.56-2.59), as well as our previous tariquidar 
analog 2.09 and the reference compounds 2.02-2.08, were analyzed for inhibition of the 
ABCG2 transport activity in a Hoechst 33342 microplate assay. The DNA stain Hoechst 33342, 
which emits blue fluorescence when bound to DNA, is a substrate of the ABCG2 transporter 
and therefore extruded from ABCG2-expressing cells such as the MCF-7/Topo cells utilized in 
this assay. When the ABCG2 transport function is inhibited, Hoechst 33342 accumulates in the 
cells and can be detected fluorometrically, which allows for determination of the inhibitory 
potency and efficacy of the target compounds. Examples of concentration-response curves are 
shown in Figure 2.3. In order to assess the selectivity of the inhibitors, they were also analyzed 
in a calcein-AM microplate assays with respect to inhibition of the ABCB1 and ABCC1 
transporter activity, using KB-V1 and MDCK.2-MRP1 cells, respectively. The assay principle 
is analogous to the Hoechst 33342 assay. The dual ABCB1 and ABCC1 substrate calcein-AM 
is added to the cells and exported by the respective transporter. Upon inhibition of the transport, 
calcein-AM accumulates in the cells, becomes cleaved to calcein by intracellular esterases and 
complexes Ca2+-ions, resulting in a strong green fluorescence. The fluorescence can be detected 
and correlated with the inhibitory potencies of the test compounds. The results of the transport 
assays are summarized in Table 2.1. 
 
Figure 2.3. Concentration-dependent inhibition of ABCG2-mediated Hoechst 33342 efflux in MCF-7/Topo cells by (A) the 
reference compounds FTC (2.03), Ko143 (2.04), 2.07 and 2.08 as well as (B) tariquidar (2.02) and its novel analogs 2.42, 2.57 
and 2.59. The inhibition is expressed relative to the maximal effect in the presence of 10 µM FTC set to 100%. 
FTC (2.03), its well-known analog Ko143 (2.04) and the more recent analog 2.05, which all 
comprise a tetrahydro-β-carboline moiety, were similarly effective at ABCG2 with an Imax 
value of 102%, 116% and 111%, respectively. However 2.04, with an IC50 value of 92 nM, was 
over ten times more potent than the other two tetrahydro-β-carboline derivatives in our assay. 
Whereas 2.04 is reported to be more potent than its precursor 2.03 [24], the IC50 value of 2.05 
determined here (1.1 µM) was about five times higher than reported in literature (lit. 233 nM 
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probably reflects differences in the assay set-up, for instance different concentrations of 
Hoechst 33342 were applied (it was higher in our assay). In accordance with previous reports 
[25], 2.04 was not entirely selective; in contrast to 2.03 and 2.05 it showed potency at the 
ABCB1 and ABCC1 transporter. The reference compounds 2.06-2.08 were almost 
equieffective with 2.04, but less potent. The chromone 2.07 inhibited ABCG2 with an IC50 
value of 707 nM (lit. 110 nM [35]), being almost three times more potent than the chromone 
2.06, which showed an IC50 value of 1.8 µM (lit. 170 nM [35]). Here again, the IC50 values 
determined by us were higher than those reported in literature. Furthermore, chromone 2.07, as 
opposed to chromone 2.06, showed very low inhibition of ABCB1 and ABCC1. The 
acrylonitrile 2.08 inhibited ABCG2 with a far higher IC50 value (3.3 µM) than 2.04. This 
compound is interesting insofar as it appears to be a triple ABCG2, ABCB1 and ABCC1 
inhibitor, which might have a different application than specific inhibitors. 
In accordance with previous publications [22], tariquidar (2.02) was a dual ABCG2 and ABCC1 
inhibitor, but showed much higher inhibitory potency and also higher efficacy at the ABCB1 
than at the ABCG2 transporter. Structural modifications at the benzamide core of 2.02 led to a 
drastic increase in selectivity for ABCG2 over ABCB1 (compound 2.09), confirming our 
previous results [40]. Compound 2.09 showed only very low inhibition of ABCB1, but inhibited 
ABCG2 with an IC50 value of 101 nM. The maximal response of 99% was higher than that 
determined in a flow cytometric mitoxantrone efflux assay we used before. The replacement of 
the labile amide moiety in 2.09 by a triazole ring resulted in the novel inhibitors 2.38-2.42. This 
replacement was well-tolerated, the efficacy of the new compounds being 85-95% and the 
potencies in the three-digit nanomolar range. Apparently the length of the linker between the 
tetrahydroisoquinoline moiety and the phenyl ring does not clearly correlate with the inhibitory 
potency. Compounds 2.38 and 2.41, as well as 2.39 and 2.42, only differ in the length of the 
linker (one vs. two methylene groups). Whereas compounds 2.39 and 2.42 were equipotent 
(IC50 values of about 150 nM), compound 2.38 (IC50 of 350 nM) was almost twice as potent as 
2.41. The introduction of a PEG chain increased the potency by a factor of two (2.38 vs. 2.39) 
or four (2.41 vs. 2.42). The replacement of the two methoxy groups at the 
tetrahydroisoquinoline moiety by hydrogen atoms (2.40) increased the potency slightly. Taken 
together, variations in the linker and the moieties attached to the tetrahydroisoquinoline ring 
seem to be well-tolerated. In terms of selectivity, compounds 2.38-2.42 showed great 
differences. While all of them were inactive at ABCC1, they showed very dissimilar effects on 
ABCB1. Here again, there was no correlation between the length of the linker and ABCB1 
inhibition. Both 2.38 and 2.39, with an identical linker (one methylene group), inhibited 
ABCB1 with a maximal response between 20% and 30% (up to 100 µM). 2.40, 2.41 and 2.42 
(two methylene groups) diverged very much depending on the substituents at the 
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tetrahydroisoquinoline moiety. 2.41 was inactive, 2.40 was 11% effective (up to 100 µM) and 
2.42, containing the PEG chain, was 80% effective and exhibited an IC50 value in the low 
micromolar range, making it a dual ABCG2 and ABCB1 inhibitor. It seems as if the PEG chain 
can confer potency at ABCB1. Since, however, this was not the case for 2.39, compared to 2.38, 
this effect appears to depend on the specific structure. 
Table 2.1. Inhibitory effect of the reference compounds 2.02-2.08, our previous tariquidar analog 2.09 and the new inhibitors 
2.38-2.42 and 2.56-2.59 on the transport activity of ABCG2, ABCB1 and ABCC1. 
 
 ABCG2a ABCB1b ABCC1c 
Compound IC50 [nM]d Imax [%]d,e IC50 [nM]d Imax [%]d,f IC50 [nM]d Imax [%]d,g 
2.02 (tariquidar) 6223 ± 707 72 ± 3 356 ± 3 100 ± 3 inactiveh,i – 
2.03 (FTC) 1483 ± 194 102 ± 3 inactive – inactive – 
2.04 (Ko143) 92 ± 9 116 ± 2 ≥ 25520j ≥ 11 6650 ± 2856 29 ± 8 
2.05 1115 ± 32 111 ± 3 inactive – inactive – 
2.06 1800 ± 300i 108 ± 5i inactivei – inactivei – 
2.07 707 ± 98 109 ± 12 6756 ± 946 10 ± 1 3599 ± 302 15 ± 1 
2.08 (YHO-13177) 3345 ± 342 106 ± 9 ≥ 65480 ≥ 53 ≥ 39750 ≥ 81 
2.09 (UR-ME22-1) 101 ± 17 99 ± 1 ≥ 12080 ≥ 14 inactive – 
2.38 (UR-MB86) 350 ± 53 87 ± 2 ≥ 10730 ≥ 25 inactive – 
2.39 (UR-MB84) 153 ± 12 85 ± 3 ≥ 25030 ≥ 21 inactive – 
2.40 (UR-MB81) 486 ± 5 95 ± 5 ≥ 38270 ≥ 11 inactive – 
2.41 (UR-MB19) 617 ± 179 90 ± 3 inactive – inactive – 
2.42 (UR-MB95) 144 ± 35 86 ± 3 1623 ± 405 80 ± 7 inactive – 
2.56 (UR-St1) 140 ± 40 97 ± 2 inactive – inactive – 
2.57 (UR-MB108) 79 ± 5 91 ± 2 inactive – inactive – 
2.58 (UR-St2) 295 ± 28 90 ± 0.4 ≥ 21830 ≥ 24 ≥ 19040 ≥ 14 
2.59 (UR-MB136) 81 ± 16 90 ± 3 ≥ 44460 ≥ 42 inactive – 
a Hoechst 33342 microplate assay using ABCG2-expressing MCF-7/Topo cells. 
b Calcein-AM microplate assay using ABCB1-expressing KB-V1 cells. 
c Calcein-AM microplate assay using ABCC1-expressing MDCK.2-MRP1 cells. 
d Mean values ± SEM from two to seven independent experiments, each performed in triplicate. 
e Maximal inhibitory effect (Imax) relative to the response to FTC at a concentration of 10 µM (100%). 
f Maximal inhibitory effect (Imax) relative to the response to tariquidar at a concentration of 10 µM (100%). 
g Maximal inhibitory effect (Imax) relative to the response to reversan at a concentration of 30 µM (100%). 
h Inactive: response ≤ 10% up to a concentration of 100 µM. 
i Data taken from our previous studies [46]. 
j No plateau was reached up to a concentration of 100 µM. In these cases, minimum IC50 values and Imax values were stated. 
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The second modification of 2.09 was the replacement of the labile ester moiety at the central, 
trisubstituted phenyl core by ketones, yielding the inhibitors 2.56-2.59. This alteration increased 
the efficacy at ABCG2 to 90-97%. The IC50 values were in the two- to low three-digit 
nanomolar range. The length of the acyl group attached to the benzamide core was varied. The 
propionyl group (in 2.57) proved to be superior to the smaller acetyl group (in 2.56) and also to 
the bulkier isobutyryl moiety (in 2.58) in terms of inhibitory potency and selectivity, 2.58 
showing moderate ABCB1 and ABCC1 activity. In this subseries, the introduction of a PEG 
chain (2.59) left the inhibitory potency at ABCG2 unchanged, but, here again, caused an 
inhibitory effect on ABCB1, with the maximal response being 42% (up to a concentration of 
100 µM). It is conceivable that the PEG chain confers affinity to the binding site in ABCB1. 
Except for 2.58, none of the ketone-containing inhibitors showed inhibition of ABCC1. 
2.2.3 Effect on the ABCG2 ATPase Activity 
On the basis of the results obtained from the functional transport assays, the two most potent 
novel inhibitors (2.57 and 2.59), their precursor 2.09 and the reference compounds 2.02-2.08 
were examined with regard to their effect on ABCG2 ATPase activity. The ATPase assay, 
requiring relatively high levels of transporter protein, was performed with ABCG2-expressing 
Sf9 membranes. ABC transporters gain the energy for the transport of their substrates from 
ATP hydrolysis to ADP and inorganic phosphate. The latter was determined in a colorimetric 
reaction after incubation of the membrane preparations with different concentrations of test 
compounds, resulting in concentration-response curves (examples depicted in Figure 2.4A+B). 
In a variant of this assay, the ABCG2 transporters in the membranes were additionally 
stimulated with the ABCG2 substrate sulfasalazine to investigate whether the test compounds 
reverse the activating effect caused by sulfasalazine, or not (Figure 2.4C+D). The results of the 
two assay variants are summarized in Table 2.2. 
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Figure 2.4. (A+B) Concentration-dependent stimulation or suppression of the ATPase activity in ABCG2-expressing Sf9 
membranes by (A) the reference compounds FTC (2.03), Ko143 (2.04), 2.06 and 2.08 as well as (B) tariquidar (2.02), its analog 
UR-ME22-1 (2.09) and its novel analogs 2.57 and 2.59. The effect is expressed relative to the basal ATPase activity (0%) and 
the maximal stimulatory effect in the presence of 30 µM sulfasalazine set to 100%. (C+D) Concentration-dependent inhibition 
of the sulfasalazine (3 µM) -stimulated ATPase activity in ABCG2-expressing Sf9 membranes by (C) the reference compounds 
FTC (2.03), Ko143 (2.04) and 7 as well as (D) tariquidar (2.02), its analog UR-ME22-1 (2.09) and its novel analogs 2.57 and 
2.59. The inhibition is expressed relative to the maximal inhibitory effect in the presence of 10 µM FTC set to 100%. 
In the absence of inhibitors, ABCG2 showed relatively high basal ATPase activity, which was 
set to zero in our assay. The test compounds, all being transport inhibitors, behaved in three 
different manners with respect to ABCG2 ATPase activity. Firstly, most of them decreased it 
to a level below the basal activity (below zero) or secondly, had no effect on it. In these two 
cases it can be assumed that the test compounds are not transported and the inhibition of the 
transport of other substrates may be, at least in part, attributed to the inhibition of the ATPase 
activity of the transporter. A reduction of the ATPase activity was evoked by FTC (2.03) and 
its analogs Ko143 (2.04) and 2.05, and the tariquidar analogs 2.09, 2.57 and 2.59, their maximal 
effects being between - 20% and - 37% and their potencies in the two-digit (2.04, 2.57 and 2.59) 
to three-digit (2.03, 2.05 and 2.09) nanomolar range. The compounds were also able to inhibit 
sulfasalazine-stimulated ATPase activity with an efficacy around 100% (2.03, 2.09, 2.57 and 
2.59) or more (2.04, 2.05) and potencies again in the two-digit (2.57 and 2.59) to three-digit 
(2.04, 2.05 and 2.09) nanomolar range. Only 2.03 showed a higher IC50 value of 1.8 µM. The 
chromone 2.07 exhibited no effect on the basal ATPase activity, but was able to reverse 
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Thirdly, some compounds increased the ATPase activity and can therefore be considered 
transporter substrates, although the coupling of ATP-hydrolysis to transport has been 
challenged [47]. It is conceivable that transport inhibitors that are strong ATPase activators at 
the same time compete with other substrates, e.g. Hoechst 33342, for transport by diffusing 
rapidly back into the cell (so-called “fast-diffusers”) [48]. To explore if they also compete for 
the same binding site, further interaction type analyses would be required. It seems probable, 
though, because we recently identified one central multidrug-binding site [39] (i.e. for 
substrates and inhibitors). The acrylonitrile 2.08 activated the ATPase activity as efficiently as 
the standard activator sulfasalazine (namely with 99%) and even exhibited a lower EC50 value 
(327 nM vs. 916 nM for sulfasalazine). Compound 2.08 might be such a “fast-diffuser”, an 
assumption also supported by its low molecular mass. 
Table 2.2. Effect of the reference compounds 2.02-2.08, our previous tariquidar analog 2.09 and the new inhibitors 2.57 and 
2.59 on the ATPase activity of ABCG2 with and without pre-stimulation with sulfasalazine. 
 
 Effect on ATPase activitya Inhibition on stimulated ATPase activityb 
Compound EC50 [nM]c,d Emax [%]c,e IC50 [nM]c Imax [%]c,f 
Sulfasalazine 916 ± 2 96 ± 4 – – 
2.02 (tariquidar) 211 ± 31 25 ± 3 ≥ 1180 ≥ 79 
2.03 (FTC) 412 ± 240 - 20 ± 2 1808 ± 203 104 ± 2 
2.04 (Ko143) 70 ± 17 - 31 ± 1 271 ± 44 124 ± 5 
2.05 134 ± 3 - 37 ± 2 226 ± 30 141 ± 8 
2.06 274 ± 86 45 ± 3 194 ± 128 19 ± 4 
2.07 – 0 ± 1 745 ± 74 113 ± 4 
2.08 (YHO-13177) 327 ± 34 99 ± 7 – – 
2.09 (UR-ME22-1) 105 ± 14 - 27 ± 7 294 ± 17 105 ± 3 
2.57 (UR-MB108) 70 ± 28 - 21 ± 4 96 ± 2 99 ± 3 
2.59 (UR-MB136) 52 ± 38 - 23 ± 0.1 93 ± 8 112 ± 1 
a ATPase microplate assay using ABCG2-expressing Sf9 membranes. 
b ATPase microplate assay using ABCG2-expressing Sf9 membranes; ABCG2 stimulated with sulfasalazine at a concentration 
of 3 µM. 
c Mean values ± SEM from two to four independent experiments, each performed in duplicate. 
d Half-maximal effective concentrations were termed EC50 (not IC50) values, even if the ATPase activity was reduced, in order 
to avoid confusion with the data from the ATPase assay with sulfasalazine stimulation. 
e Maximal effect (Emax) on the ATPase activity relative to the basal ATPase activity (0%) and to the response to sulfasalazine 
at a concentration of 30 µM (100%). 
f Maximal inhibitory effect (Imax) relative to the response to FTC at a concentration of 10 µM (100%). 
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Transport inhibitors that exert only a partially activating effect on the ATPase activity were 
tariquidar (2.02), showing a maximal effect of 25% and standing in contrast with its ATPase-
suppressing analogs (2.09, 2.57 and 2.59), and the chromone 2.06 (45%), as opposed to the 
chromone 2.07 with no effect. Nonetheless, both 2.02 and 2.07 were able to partly antagonize 
ATPase stimulation by sulfasalazine. 
The ATPase results from our novel tariquidar derivatives are consistent with the structural data 
on ABCG2 inhibition we published recently [39]. We showed that compound 2.59 and a 
derivative of 2.04 both bound to the multidrug-binding site identified in these experiments 
(cavity 1; located in the transmembrane domains) and locked the inward-facing conformation, 
thereby inhibiting the ATPase activity (of the cytoplasmic, nucleotide-binding domains) due to 
conformational coupling. 
Figure 2.5 shows the comportment of the reference compounds FTC (2.03) and its analogs 
Ko143 (2.04) and 2.05, in relation to our previous tariquidar analog 2.09 and our most potent 
novel analogs 2.57 and 2.59, all of which suppressed the ABCG2 ATPase activity. Depicted 
are half-maximal (effective or inhibitory) concentrations, determined in the three different 
functional assays performed, namely the Hoechst 33342 transport assay and the ATPase assay 
with and without pre-stimulation with sulfasalazine. Of course, it is expected that half-maximal 
concentrations differ when determined in different assays, depending on the experimental 
conditions. However, plotting the functional data obtained from different assays in a radar chart, 
we were able to show commonality and to identify outliers. Ko143 (2.04) and the tariquidar 
analogs 2.09, 2.57 and 2.59 showed similar behavior – their potencies in the three assays 
coincided fairly well. FTC (2.03) and its derivative 2.05, on the other hand, did not show 
comparable half-maximal concentrations. Their potencies determined in the Hoechst transport 
assay were much higher than those in the ATPase assay and compound 2.03 also showed a 
higher half-maximal concentration in the ATPase assay with sulfasalazine-stimulation than 
without. Our previous structural study [39] showed that one 2.59 molecule or two molecules of 
a derivative of 2.04 completely occupied the volume of cavity 1. We concluded that these 
inhibitors act competitively at the binding site with substrates, which was the second inhibition 
mechanism identified, apart from ATPase inhibition. So one could speculate that not only 2.59 
but also the other inhibitors compete for the binding site with substrates, and similar potencies 
in the three assays might suggest that the inhibitors 2.04, 2.09, 2.57 and 2.59 bind to ABCG2 
with higher affinities than the substrates Hoechst 33342 and sulfasalazine. Vice versa, higher 
potencies in assays in the presence of substrates might be taken as a hint to displaceability of 
2.03 and 2.05 by the respective substrates at the concentrations employed. 
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Figure 2.5. Comparison of half-maximal effective/ inhibitory concentrations produced by the compounds 2.03, 2.04, 2.05, 
2.07, 2.09, 2.57 and 2.59 in the Hoechst 33342 transport assay (black), the ATPase assay (orange) and the ATPase assay with 
pre-stimulation with sulfasalazine (blue). 
2.2.4 Thermostabilization of ABCG2 
We analyzed the thermostabilization of ABCG2 by our two most potent novel tariquidar 
analogs (2.57 and 2.59) and the reference compound Ko143 (2.04) in a size-exclusion 
chromatography-based thermostability assay (SEC-TS). For this purpose, purified ABCG2 was 
incubated with or without an inhibitor at increasing temperatures and subjected to SEC. The 
main peak heights were plotted against the temperature to obtain the “melting points” (Tm 
values) of ABCG2. The curves for ABCG2 in the presence and absence of compound 2.57 are 
depicted in Figure 2.6; the curves for ABCG2 in the presence and absence of compounds 2.04 
and 2.59 were included in our previous report [39] (on the cryo-EM structure of ABCG2 in 
complex with inhibitors). 
 
Figure 2.6. SEC-TS of ABCG2 before or after the addition of 2.57 at a concentration of 10 μM. The peak heights are expressed 
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The melting points determined in this assay are listed in Table 2.3. Compounds 2.04, 2.57 and 
2.59 showed approximately 7 °C thermostabilization of purified ABCG2. Since the three 
compounds stabilized ABCG2 to the same extent, it can be deduced that these compounds bind 
to ABCG2 with similar affinities. 
Table 2.3. Tm values of ABCG2 alone and in complex with 2.04, 2.57 or 2.59 determined in a SEC-TS. 
sample Tm [°C]a 
ABCG2 53.3 ± 0.3 
2.04 (Ko143) 60.0 ± 0.3 
2.57 (UR-MB108) 60.5 ± 0.3 
2.59 (UR-MB136) 59.0 ± 0.5 
a Best fit values ± SD. 
2.2.5 Cytotoxicity and Reversal of Drug Resistance 
The effect of the two most potent novel transport and ATPase inhibitors (2.57 and 2.59) and 
the most potent reference compound Ko143 (2.04) on the proliferation as well as the ability to 
overcome drug resistance of MCF-7/Topo cells were investigated in a kinetic chemosensitivity 
assay, using the inhibitors alone and in combination with the cytostatic topotecan, an ABCG2 
substrate. The results are shown in Figure 2.7. Incubation of the cells with 2.04 had no effect 
on cell proliferation up to a concentration of 3 µM. A slight cytotoxic effect was observed at a 
concentration of 10 µM. When incubated with topotecan alone at a concentration of 100 nM, 
the cells were not affected due to their resistance against the cytostatic. By contrast, the 
combination of 100 nM topotecan with a per se nontoxic concentration of 2.04 led to a complete 
reversal of resistance. Inhibitor 2.57 was nontoxic up to a concentration of 1 µM. At higher 
concentrations, however, it showed cytotoxicity, which might be an interesting property in view 
of addressing tumor stem cells [49]. By analogy with 2.04, 2.57 reversed topotecan resistance 
when administered at nontoxic concentrations in combination with the cytostatic (100 nM). The 
inhibitor 2.59, which only differs from 2.57 in the PEG chain attached to the 
tetrahydroisoquinoline moiety, was also able to reverse drug resistance in MCF-7/Topo cells 
and was superior to 2.57 in so far as it did not exhibit marked cytotoxicity at concentrations up 
to 10 µM. 
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Figure 2.7. (A-C) Antiproliferative activities of Ko143 (2.04) (A) and the novel tariquidar analogs 2.57 (B) and 2.59 (C) 
against MCF-7/Topo cells upon long-term incubation. (D-F) Reversal of ABCG2-mediated drug resistance against topotecan 
on proliferating MCF-7/Topo cells: effect of 100 nM topotecan (Topo) alone and in combination with different concentrations 
of 2.04 (D), 2.57 (E) or 2.59 (F). Antiproliferative effects correspond to the left y-axes. The growth curves of untreated control 
cells (open circles) correspond to the right y-axes. Data are mean values ± SEM of two to four independent experiments, each 
performed in octuplicate. 
In conclusion, the reversal of drug resistance in MCF-7/Topo cells by the compounds 2.04, 2.57 
and 2.59 is in good agreement with the data from the transport assays (Figure 2.3, Table 2.1) 
and confirms the three substances as inhibitors of ABCG2-mediated drug efflux. 
2.2.6 Stability in Blood Plasma 
A prerequisite for in vivo studies is the stability of the test compounds in blood plasma. We 
first replaced the labile benzamide bond in 2.09 by a triazole core (affording compounds 2.38-
2.42) and then introduced ketones at the central trisubstituted phenyl ring as alternatives to the 
labile ester moiety, resulting in the inhibitors 2.56-2.59. Exemplarily, the stability of 2.59 upon 
incubation in murine blood plasma at 37 °C was demonstrated by HPLC-analysis. As depicted 
in Figure 2.8, the peak area of 2.59 remains virtually unchanged over a period of 24 hours and 
no additional peaks were detected at 220 nm. This experiment demonstrates that the bioisosteric 
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Figure 2.8. Chromatograms illustrating the stability of compound 2.59 upon incubation in murine blood plasma at 37 °C over 
a period of 24 h. RP-HPLC analysis, UV detection at 220 nm. 
2.3 Conclusion 
The study presented is a continuation of our previous investigations on tariquidar analogs as 
ABCG2 inhibitors. Among the title compounds, UR-MB108 (2.57) and UR-MB136 (2.59) 
excelled in terms of inhibitory potency in the Hoechst 33342 transport assay. With IC50 values 
of around 80 nM, they are among the most potent ABCG2 inhibitors known so far. Reversal of 
drug resistance in MCF-7/Topo breast cancer cells confirmed their ability to inhibit drug efflux. 
The PEGylated compound 2.59 also showed low potency at ABCB1, whereas 2.57 was highly 
ABCG2-selective. Both compounds suppressed the basal ABCG2 ATPase activity and were 
able to antagonize the ATPase-activating effect of sulfasalazine. Furthermore, the two 
compounds thermostabilized ABCG2 to the same extent, suggesting comparable binding 
affinities. Compound 2.59 was already analyzed in our precedent cryo-EM study [39] of 
ABCG2 in complex with inhibitors, in which we showed that one 2.59 molecule occupied the 
cavity for multidrug binding (in the transmembrane domain), locked the inward-facing 
conformation and inhibited the cytosolic ATPase subunit via conformational coupling. 
Compounds 2.57 and 2.59 differ only in the PEG chain attached at the tetrahydroisoquinoline 
moiety in 2.59 and it is probable that they bind similarly to the central multidrug binding site, 
an assumption which is supported by their same behavior in the functional assays and the 
thermostability assay. 
Respecting future research, we expect compounds 2.57 and 2.59 to be of potential value as 
reference substances in mechanistic studies on ABCG2 regarding transport and inhibition. 
Compound 2.57 is beneficial, because it is more conveniently synthesized than 2.59. 
Furthermore, in the light of their stability in blood plasma, compounds 2.57 and 2.59 can be 
employed as pharmacological tools for in vivo investigations on the (patho-)physiological role 
of the ABCG2 transporter and as a means to overcome MDR and the BBB. The high specificity 
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of compound 2.57 towards ABCG2 makes it convenient, for instance, as PET tracer for imaging 
the ABCG2 transporter at the BBB, the two methoxy groups in 2.57 being suited for 11C-PET 
labeling. In addition, 2.57 could be used for in vivo studies with pharmacological interventions 
specifically on the ABCG2 subtype, for example to improve the efficacy of photodynamic 
therapy of non-melanoma skin cancer. 
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2.4 Experimental Section 
2.4.1 Chemistry 
2.4.1.1 General Experimental Conditions 
Chemicals and solvents were purchased from commercial suppliers (Sigma Aldrich, Munich, 
Germany; Merck, Darmstadt, Germany; VWR, Darmstadt, Germany; Thermo Fisher Scientific, 
Waltham, MA, USA; TCI, Eschborn, Germany) and used without further purification unless 
stated otherwise. The catalyst Pd(PPh3)2Cl2 [50] for the Sonogashira couplings and the ligand 
tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine) (TBTA) [43] for the CuAAC were 
synthesized according to published procedures. Per analysis grade solvents were used for 
reaction mixtures and technical grade solvents for chromatography (automated flash column 
chromatography and TLC). Reactions requiring anhydrous conditions were carried out in dried 
reaction vessels under an atmosphere of nitrogen and anhydrous solvents were used. Millipore 
water was used throughout for the preparation of buffers and HPLC eluents. Acetonitrile for 
analytical and preparative HPLC (gradient grade) was obtained from Merck (Darmstadt, 
Germany). 
Thin layer chromatography was performed on TLC Silica gel 60 F254 aluminium plates 
(Merck, Darmstadt, Germany). Visualization was accomplished by UV irradiation at 
wavelengths of 254 nm and 366 nm or by staining with potassium permanganate or Ehrlich’s 
reagent. 
Automated flash column chromatography was performed on an Isolera Spektra One device 
(Biotage, Uppsala, Sweden). Silica gel 60 (0.040-0.063 mm) for flash column chromatography 
(Merck, Darmstadt, Germany) was used. 
Melting points were determined in open capillaries on an OptiMelt MPA 100 apparatus 
(Stanford Research Systems, Sunnyvale, CA, USA) and are uncorrected. 
NMR spectra were recorded on an Avance 300 instrument (7.05 T, 1H: 300.1 MHz, 13C: 
75.5 MHz), an Avance 400 instrument (9.40 T, 1H: 400 MHz, 13C: 101 MHz) or an Avance 600 
instrument with cryogenic probe (14.1 T, 1H: 600 MHz, 13C: 151 MHz) (Bruker, Karlsruhe, 
Germany) with TMS as external standard. 
High-resolution mass spectrometry (HRMS) analysis was performed on an Agilent 6540 
UHD Accurate-Mass Q-TOF LC/MS system (Agilent Technologies, Santa Clara, CA, USA), 
using an ESI source. 
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IR spectra were recorded with a Golden Gate Single Reflection Diamond ATR System 
(Specac, Orpington, UK) in an Excalibur FTS 3000 FT-IR-Spectrometer (Bio-Rad, München, 
Germany). 
Preparative HPLC was performed on a system from Knauer (Berlin, Germany), consisting of 
two K-1800 pumps and a K-2001 detector. A Kinetex® XB-C18 (5 µm, 100 Å, 250 mm x 
21.2 mm; Phenomenex, Aschaffenburg, Germany) served as RP-column at a flow-rate of 
15 mL/min. Mixtures of acetonitrile and 0.1% aq TFA were used as mobile phase. The detection 
wavelength was set to 220 nm throughout. The solvent mixtures were removed by 
lyophilization, using an Alpha 2-4 LD lyophilization apparatus (Christ, Osterode am Harz, 
Germany) equipped with an RZ 6 rotary vane vacuum pump (Vacuubrand, Wertheim, 
Germany). 
Analytical HPLC was performed on a system from Agilent Technologies (Santa Clara, CA, 
USA) (Series 1100) composed of a G1312A binary pump equipped with a G1379A degasser, a 
G1329A ALS autosampler, a G1316A COLCOM thermostated column compartment and a 
G1314A VWD detector. A Kinetex® C8 (2.6 µm, 100 Å, 100 mm × 4.6 mm; Phenomenex, 
Aschaffenburg, Germany) served as RP-column at a flow rate of 1 mL/min. Oven temperature 
was set to 30 °C throughout. Mixtures of acetonitrile (A) and 0.05% aq TFA (B) were used as 
mobile phase. The detection wavelength was set to 220 nm throughout. Solutions for injection 
(40 µM) were prepared by diluting a stock solution in DMSO with a mixture of A and B 
corresponding to the mixture at the start of the gradient. The injection volume was 50 µL. The 
following linear gradient was applied: 0-12 min: A/B 30:70-95:5, 12-15 min: A/B 95:5. 
2.4.1.2 Synthesis Protocols and Analytical Data 
General Procedure for N-Alkylation 
The 1,2,3,4-tetrahydroisoquinoline derivative (1 eq), 1-(bromomethyl)-4-nitrobenzene (1 eq) 
or 1-(2-bromoethyl)-4-nitrobenzene (1 eq) and K2CO3 (3 eq) were refluxed in MeCN overnight. 
The reaction mixture was cooled to rt, filtered and the filtrate concentrated under reduced 
pressure. The residual solid was taken up in DCM and washed with H2O twice. The organic 
layer was dried over MgSO4, the solvent removed under reduced pressure and the residue 
purified by flash column chromatography. 
General Procedure for the Reduction of Nitro Compounds 
The nitrobenzene derivative (1 eq) was dissolved in EtOH, a 10% Pd/C catalyst (10 wt%) 
was added and the suspension was stirred rapidly in a hydrogen atmosphere (40 bar) at rt 
overnight. The catalyst was filtered off, the solvent was evaporated and the residue was 
subjected to flash column chromatography. 
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General Procedure for Azide Formation 
The amine (1 eq) was dissolved in 6 M HCl aq and cooled to - 5 °C. An aqueous solution of 
NaNO2 (1.0 eq) was added and the mixture was stirred for 1 h. The solution was neutralized 
with an aqueous solution of NaOAc while being cooled continuously. An aqueous solution of 
NaN3 (1.2 eq) was added dropwise. After another h of cooling, the mixture was slowly warmed 
to rt, and the product was extracted with EtOAc. The combined organic layers were washed 
with H2O and brine, dried over MgSO4 and concentrated. The product was used for subsequent 
conversion without further purification. 
General Procedure for the Ortho Acylation of 3-Bromoaniline 
To a cooled (0 °C) solution of BCl3 (1 M solution in heptane, 1.1 eq) in DCM 3-bromoaniline 
(1 eq) was added under a stream of nitrogen gas. The mixture was stirred for 20 min and AlCl3 
(1.1 eq) and the respective nitrile (1 eq) were added subsequently. Stirring continued for 24 h 
under reflux. After cooling to 0 °C, 2 M HCl aq was added. The mixture was stirred rapidly for 
10 min and heated again to 80 °C for 1 h. The product was extracted with DCM and the organic 
phase washed with 1 M NaOH aq, dried and concentrated. The residue was subjected to flash 
column chromatography. 
General Procedure for the Sonogashira Reaction 
The bromobenzene derivative (1 eq), CuI (0.1 eq) and Pd(PPh3)2Cl2 (0.05 eq) were placed in a 
sealed vial under nitrogen. A mixture of degassed THF and NEt3 (2:1) and 
ethynyltrimethylsilane (1.5 eq) was added. The solution was stirred at 60 °C overnight. H2O 
was added and the product was extracted with DCM. The organic phase was separated, 
concentrated and purified by flash column chromatography. 
General Procedure for TMS Deprotection 
A solution of the respective trimethylsilyl-protected alkyne (1 eq) in THF was cooled in an ice 
bath. Under stirring, TBAF (1.5 M in THF, 1.5 eq) was added and stirring was continued until 
TLC analysis revealed complete consumption of the starting material (approximately 2 h). The 
solvent was evaporated, saturated NH4Cl solution was added and the compound extracted with 
DCM. The organic layer was separated, dried over Mg2SO4 and the solvent was evaporated. In 
case of sufficient purity the product was used for subsequent reaction without further 
purification. Otherwise, flash column chromatography was used to remove traces of the starting 
material. 
General Procedure for Amide Formation 
DIPEA (10 eq), HBTU (3 eq) and quinoline-2-carboxylic acid (3 eq) were dissolved in 
anhydrous DCM under a nitrogen atmosphere and cooled to 0 °C. The amine derivative was 
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added in small portions and the mixture was allowed to reach rt and stirred for 24 h. The solution 
was washed with H2O and brine, twice each, dried and concentrated. The residue was subjected 
to flash column chromatography. 
General Procedure for the CuAAC 
The azide (1.0-1.5 eq), the alkyne (1.0-1.3 eq), CuSO4·6H2O (0.1 eq), sodium ascorbate 
(0.5 eq) and TBTA (0.1 eq) were dissolved in DMF or, in case of UR-St1 and UR-St2, in THF 
and stirred for 24 h under a nitrogen atmosphere. DCM was added and the organic layer was 
washed with H2O, dried over MgSO4 and concentrated. The crude mixture was purified by flash 
column chromatography. 
6-Methoxy-7-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-1,2,3,4-tetrahydro-
isoquinoline (2.14) [44] 
 
Compound 2.14 was prepared as described previously [44]. 
6,7-Dimethoxy-2-(4-nitrobenzyl)-1,2,3,4-tetrahydroisoquinoline (2.15) [51,52] 
 
Compound 2.15 was prepared according to the general procedure for N-alkylation and was 




Compound 2.16 was prepared from 2.14 (2.44 mmol) according to the general procedure for 
N-alkylation. Flash column chromatography (PE:EtOAc 1:1) afforded a brownish oil. Yield: 
843 mg (1.83 mmol, 75%). Rf (PE:EtOAc 1:1): 0.38. 1H NMR (400 MHz, CDCl3, δ): 2.72 (t, 
J=5.8 Hz, 2H), 2.82 (t, J=5.7 Hz, 2H), 3.35 (s, 3H), 3.49-3.55 (m, 4H), 3.60-3.67 (m, 4H), 3.68-
3.73 (m, 2H), 3.75 (s, 2H), 3.80 (s, 3H), 3.83 (t, J=5.2 Hz, 2H), 4.09 (t, J=5.2 Hz, 2H), 6.52 (s, 
1H), 6.60 (s, 1H), 7.57 (d, J=8.7 Hz, 2H), 8.18 (d, J=8.7 Hz, 2H). 13C NMR (101 MHz, CDCl3, 
δ): 28.7, 50.9, 55.7, 56.0, 59.0, 61.9, 68.7, 69.6, 70.5, 70.6, 70.8, 71.9, 112.1, 112.2, 123.6 (2C), 
126.3, 126.7, 126.9, 129.5 (2C), 146.6, 147.2, 148.3. IR [cm-1]: 2899.0 (m, br), 1602.8 (m), 
1516.0 (s), 1450.5 (m), 1342.5 (s), 1255.7 (m), 1226.7 (m), 1128.4 (s), 1105.2 (s), 854.5 (m), 
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632.7 (s), 536.2 (s), 497.6 (s), 414.7 (s). HRMS-ESI (m/z): [M + H]+ calcd. for C24H33N2O7
+ 
461.2282; found 461.2285. C24H32N2O7 (460.53). 
2-(4-Nitrophenethyl)-1,2,3,4-tetrahydroisoquinoline (2.17) [53] 
 
Compound 2.17 was prepared according to the general procedure for N-alkylation and was 
described elsewhere [53]. 
6,7-Dimethoxy-2-(4-nitrophenethyl)-1,2,3,4-tetrahydroisoquinoline (2.18) [53-55] 
 
Compound 2.18 was prepared according to the general procedure for N-alkylation and was 
described elsewhere [53-55]. 
6-Methoxy-7-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-2-(4-nitrophenethyl)-1,2,3,4-
tetrahydroisoquinoline (2.19) [44] 
 
Compound 2.19 was prepared from 2.14 according to the general procedure for N-alkylation 
and was described previously [44]. 
4-((6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)methyl)aniline (2.20) [52] 
 
Compound 2.20 was prepared from 2.15 according to the general procedure for the reduction 
of nitro compounds and was described elsewhere [52]. 
  





Compound 2.16 (1.58 mmol) was dissolved in EtOH before SnCl2 · 2H2O (6 eq) was added. 
The solution was refluxed under a nitrogen atmosphere for 2 h. The solvent was evaporated and 
EtOAc was added. The organic solution was washed with 1 M NaOH aq, H2O and brine, dried 
over MgSO4 and concentrated. The crude product was purified in two subsequent flash column 
chromatography runs (1st run: CHCl3:MeOH:NEt3 89:10:1, 2
nd run: EtOH) to obtain 2.21 as a 
yellow oil. Yield: 327 mg (0.76 mmol, 48%). Rf (CHCl3:MeOH:NEt3 89:10:1): 0.37, Rf 
(EtOH): 0.25. 1H NMR (400 MHz, CDCl3, δ): 2.68 (t, J=5.8 Hz, 2H), 2.79 (t, J=5.7 Hz, 2H), 
3.37 (s, 3H), 3.49 (s, 2H), 3.52-3.56 (m, 4H), 3.62-3.68 (m, 6H), 3.70-3.73 (m, 2H), 3.79 (s, 
3H), 3.83 (t, J=5.2 Hz, 2H), 4.10 (t, J=5.2 Hz, 2H), 6.53 (s, 1H), 6.58 (s, 1H), 6.65 (d, J=8.2 
Hz, 2H,), 7.15 (d, J=8.2 Hz, 2H). 13C NMR (101 MHz, CDCl3, δ): 28.8, 50.5, 55.5, 56.0, 59.0, 
62.3, 68.7, 69.7, 70.5, 70.6, 70.8, 72.0, 112.1, 112.4, 115.0 (2C), 127.0, 127.1, 128.1, 130.3 
(2C), 145.6, 146.4, 148.1. IR [cm-1]: 3450.6 (w, br), 3358.1 (w, br), 2887.4 (m, br), 2353.1 (w), 
2324.2 (w), 1734 (w), 1612.5 (m), 1516 (s), 1450.5 (m), 1363.7 (m), 1255.7 (m), 1224.8 (m), 
1122.6 (s), 833.2 (m), 632.7 (s), 536.2 (s), 497.6 (s), 403.1 (s). HRMS-ESI (m/z): [M + H]+ 
calcd. for C24H35N2O5
+ 431.2540; found 431.2542. C24H34N2O5 (430.55). 
4-(2-(3,4-Dihydroisoquinolin-2(1H)-yl)ethyl)aniline (2.22) [53] 
 
Compound 2.22 was prepared from 2.17 according to the general procedure for the reduction 
of nitro compounds and was described elsewhere [53]. 
4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)aniline (2.23) [53-55] 
 
Compound 2.23 was prepared from 2.18 according to the general procedure for the reduction 
of nitro compounds and was described elsewhere [53-55]. 
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4-(2-(6-Methoxy-7-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoquinolin-
2(1H)-yl)ethyl)aniline (2.24) [44] 
 
Compound 2.24 was prepared from 2.19 according to the general procedure for the reduction 
of nitro compounds and was described previously [44]. 
2-(4-azidobenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (2.25) 
 
Compound 2.25 was prepared from 2.20 (0.84 mmol) according to the general procedure for 
azide formation. Yield: 269 mg (0.83 mmol, 99%), brown oil. 1H NMR (400 MHz, CDCl3, δ): 
2.78-2.88 (m, 4H), 3.61 (s, 2H), 3.74 (s, 2H), 3.81 (s, 3H), 3.84 (s, 3H), 6.48 (s, 1H), 6.60 (s, 
1H), 7.01 (d, J=8.4 Hz, 2H), 7.39 (d, J=8.4 Hz, 2 H). 13C NMR (101 MHz, CDCl3, δ): 27.9, 
50.1, 54.7, 55.9 (2C), 61.1, 109.5, 111.4, 119.0 (2C), 125.5, 125.6, 130.9 (2C), 139.3, 147.4, 
147.7 (one quaternary carbon not apparent). IR [cm-1]: 2939.5 (w, br), 2117.8 (s), 1714.7 (m), 
1519.9 (m), 1363.7 (w), 1286.5 (m), 1261.4 (m), 1124.5 (m), 1055.1 (w), 1010.7 (w), 881.5 
(vw), 825.5 (vw), 632.7 (m), 536.2 (s), 495.7 (s), 405.1 (s). HRMS-ESI (m/z): [M + H]+ calcd. 
for C18H21N4O2




Compound 2.26 was prepared from 2.21 (0.53 mmol) according to the general procedure for 
azide formation. Yield: 242 mg (0.53 mmol, 100%), brownish oil. 1H NMR (400 MHz, CDCl3, 
δ): 2.90 (t, J=6.0 Hz, 2H), 3.06 (t, J=6.1 Hz, 2H), 3.36 (s, 3H), 3.51-3.56 (m, 2H), 3.61-3.67 
(m, 4 H), 3.69-3.73 (m, 2H), 3.78-3.82 (m, 5H), , 3.84 (t, J=5.1 Hz, 2H), 3.95 (s, 2H), 4.09 (t, 
J=5.1 Hz, 2H), 6.52 (s, 1H), 6.59 (s, 1H), 7.02 (d, J=8.4 Hz, 2H), 7.39 (d, J=8.4 Hz, 2H). 
13C NMR (101 MHz, CDCl3, δ): 25.9, 48.8, 52.6, 56.0, 58.8, 59.0, 68.6, 69.6, 70.5, 70.6, 70.8, 
71.9, 111.8, 112.0, 119.3 (2C), 122.7, 125.0, 130.3, 131.8 (2C), 140.3, 147.0, 148.8. IR [cm-1]: 
2910.6 (m, br), 2115.9 (s), 1708.9 (w), 1608.6 (w), 1516.0 (m, br), 1462.0 (w), 1363.7 (w), 
1286.5 (m, br), 1257.6 (w), 1228.7 (w), 1128.4 (m, br), 632.7 (s), 536.2 (s), 497.6 (s), 401.2 (s). 
Tariquidar-Related Triazoles as Potent, Selective and Stable Inhibitors of ABCG2 
58 
HRMS-ESI (m/z): [M + H]+ calcd. for C24H33N4O5




Compound 2.27 was prepared from 2.22 (1.19 mmol) according to the general procedure for 
azide formation. Yield: 292 mg (0.98 mmol, 82%), yellow oil. 1H NMR (400 MHz, CDCl3, δ): 
2.88-3.06 (m, 8H), 3.91 (s, 2H), 6.94-6.99 (m, 2H), 7.03-7.07 (m, 1H), 7.11-7.19 (m, 3H), 7.21-
7.24 (m, 2H). 13C NMR (101 MHz, CDCl3, δ): 27.3, 32.1, 49.9, 54.5, 58.4, 119.2 (2C), 126.2, 
126.77, 126.81, 128.7, 130.2 (2C), 132.3, 133.2, 136.0, 138.2. IR [cm-1]: 2939.5 (vw, br), 
2112.0 (m), 1714.7 (w), 1674.2 (w), 1506.4 (w), 1286.5 (w, br), 632.7 (m), 534.3 (s), 497.6 (s), 
405.1 (s). HRMS-ESI (m/z): [M + H]+ calcd. for C17H19N4
+ 279.1604; found 279.1604. 
C17H18N4 (278.36). 
2-(4-Azidophenethyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (2.28) [56] 
 
Compound 2.28 was prepared from 2.23 (1.28 mmol) according to the general procedure for 
azide formation. Yield: 260 mg (0.77 mmol, 60%), colorless solid. 1H NMR (400 MHz, 
[D6]DMSO, δ): 2.60-2.74 (m, 6H), 2.77-2.86 (m, 2H), 3.52 (s, 2H), 3.69 (s, 3H), 3.70 (s, 3H), 
6.62 (s, 1H), 6.65 (s, 1H), 7.02 (d, J=8.4 Hz, 2H), 7.30 (d, J=8.4 Hz, 2H). 13C NMR (101 MHz, 
[D6]DMSO, δ): 24.6, 29.0, 48.8, 51.4, 55.4, 55.5, 55.9, 109.6, 111.5, 119.3 (2C), 123.4, 130.2 
(2C), 134.2, 137.8, 147.5, 148.1 (one quaternary carbon not apparent). HRMS-ESI (m/z): [M 
+ H]+ calcd. for C19H23N4O2




Compound 2.29 was prepared from 2.24 (1.33 mmol) according to the general procedure for 
azide formation. Yield: 344 mg (0.73 mmol, 55%), brown oil. 1H NMR (400 MHz, CDCl3, δ): 
2.70-2.90 (m, 8H), 3.37 (s, 3H), 3.53-3.57 (m, 2H), 3.61 (s, 2H), 3.63-3.69 (m, 4H), 3.72-3.76 
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(m, 2H), 3.81 (s, 3H), 3.86 (t, J=5.2 Hz, 2H), 4.13 (t, J=5.2 Hz, 2H), 6.58 (s, 1H), 6.59 (s, 1H), 
6.96 (d, J=8.4 Hz, 2H), 7.22 (d, J=8.4 Hz, 2H). 13C NMR (101 MHz, CDCl3, δ): 28.7, 33.4, 
51.0, 55.7, 56.0, 59.1, 60.1, 68.8, 69.7, 70.6, 70.7, 70.8, 72.0, 112.0, 112.4, 119.0 (2C), 126.5, 
126.9, 130.1 (2C), 137.2, 137.8, 146.5, 148.3. IR [cm-1]: 2922.1 (w, br), 2110.1 (m), 1734.0 
(vw, br), 1510.3 (m), 1452.4 (w), 1371.4 (w), 1286.5 (w), 1257.6 (w), 1228.7 (w), 1126.4 (w), 
632.7 (m), 536.2(s), 497.6 (s), 403.1 (s). HRMS-ESI (m/z): [M + H]+ calcd. for C25H35N4O5
+ 
471.2602; found 471.2604. C25H34N4O5 (470.57). 
Methyl 2-amino-4-((trimethylsilyl)ethynyl)benzoate (2.31) [41] 
 
Compound 2.31 was prepared from methyl 2-amino-4-bromobenzoate according to the general 
procedure for the Sonogashira reaction and was described previously [41]. 
Methyl 2-amino-4-ethynylbenzoate (2.32) [41] 
 
Compound 2.32 was prepared from 2.31 according to the general procedure for TMS 




Compound 2.33 was prepared from 2.25 (0.86 mmol, 1.0 eq) and 2.32 (1.12 mmol, 1.3 eq) 
according to the general procedure for the CuAAC. The crude product was purified in two 
subsequent flash column chromatography runs (1st run: CHCl3:MeOH 49:1, 2
nd run: 
DCM:acetone 4:1). Yield: 255 mg, (0.51 mmol, 59%), colorless solid. Rf (CHCl3:MeOH 49:1): 
0.08, Rf (DCM:acetone 4:1): 0.09. MP: 197 °C. 1H NMR (400 MHz, CDCl3, δ): 2.77 (t, 
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J=5.7 Hz, 2H), 2.85 (t, J=5.7 Hz, 2H), 3.58 (s, 2H), 3.75 (s, 2H), 3.81 (s, 3H), 3.85 (s, 3H), 3.89 
(s, 3H), 5.86 (br s, 2H), 6.49 (s, 1H), 6.62 (s, 1H), 7.09 (dd, J=1.6, 8.3 Hz, 1H), 7.35 (d, 
J=1.6 Hz, 1H), 7.59 (d, J=8.5 Hz, 2H), 7.75 (d, J=8.5 Hz, 2H), 7.94 (d, J=8.3 Hz, 1H), 8.21 
(s, 1H). 13C NMR (101 MHz, CDCl3, δ): 28.7, 50.9, 51.6, 55.7, 56.0 (2C), 62.0, 109.5, 110.5, 
111.5, 113.4, 113.8, 118.5, 120.6 (2C), 126.1, 126.4, 130.3 (2C), 132.1, 135.4, 135.9, 139.9, 
147.3, 147.4, 147.6, 150.9, 168.3. IR [cm-1]: 3471.9 (m), 3361.9 (m), 3138.2 (w), 2941.4 (m), 
2912.5 (m), 2837.3 (w), 2787.1 (w), 2756.3 (w), 1680 (s), 1626 (m), 1593.2 (m), 1518 (s), 
1450.5 (m), 1431.2 (m), 1365.6 (m), 1298.1 (m), 1226.7 (s), 1186.2 (m), 1124.5 (m), 1099.4 
(m), 1039.6 (m), 887.3 (m), 850.6 (m), 812 (m), 781.2 (m), 700.2 (m), 555.5 (m), 403.1 (m). 
HRMS-ESI (m/z): [M + H]+ calcd. for C28H30N5O4





Compound 2.34 was prepared from 2.26 (0.40 mmol, 1.0 eq) and 2.32 (0.52 mmol, 1.3 eq) 
according to the general procedure for the CuAAC and purified by flash column 
chromatography (DCM:acetone:MeOH 13:6:1). For removal of residual TBTA, the mixture 
was subjected once more to column chromatography (CH3COOH:EtOAc 1:4 and then 
EtOAc:NEt3 4:1). The eluate was washed with H2O, dried over MgSO4 and concentrated. 
Yield: 0.25 mmol (63%), yellow solid. Rf (CH2CL2:acetone:MeOH 13:6:1): 0.60. MP: 111 °C. 
1H NMR (400 MHz, CDCl3, δ): 2.78 (m, 2H), 2.84 (m, 2H), 3.36 (s, 3H), 3.51-3.55 (m, 2H), 
3.57 (m, 2H), 3.61-3.68 (m, 4H), 3.68-3.74 (m, 2H), 3.76 (m, 2H), 3.81 (s, 3H), 3.84 (t, 
J=5.2 Hz, 2H), 3.89 (s, 3H), 4.11 (t, J=5.2 Hz, 2H), 5.87 (br s, 2H), 6.54 (s, 1H), 6.61 (s, 1H), 
7.09 (dd, J=1.6, 8.3 Hz, 1H), 7.35 (d, J=1.5 Hz, 1H), 7.59 (d, J=8.5 Hz, 2H), 7.75 (d, J=8.5 Hz, 
2H), 7.93 (d, J=8.3 Hz, 1H), 8.22 (s, 1H). 13C NMR (101 MHz, CDCl3, δ): 28.6, 50.7, 51.6, 
55.5, 56.0, 59.0, 61.8, 68.8, 69.6, 70.5, 70.6, 70.8, 71.9, 110.5, 112.1, 112.3, 113.4, 113.8, 
118.6, 120.6 (2C), 126.3 (HMBC), 126.7, 130.4 (2C), 132.1, 135.4, 136.0, 139.3 (HMBC), 
146.6, 147.4, 148.4, 150.9, 168.3. IR [cm-1]: 3481.5 (w), 3365.8 (w), 2922.1 (m, br), 2877.8 
(m, br), 1681.9 (m), 1624.1 (m), 1595.1 (m), 1560.4 (m), 1516.0 (s), 1448.5 (m), 1365.6 (m), 
1296.2 (m), 1234.4 (s), 1190.1 (m), 1097.5 (s), 1035.8 (m), 935.5 (w), 850.6 (m), 814.0 (m), 
Tariquidar-Related Triazoles as Potent, Selective and Stable Inhibitors of ABCG2 
61 
781.2 (m), 700.2 (m), 461.0 (w). HRMS-ESI (m/z): [M + H]+ calcd. for C34H42N5O7
+ 632.3079 




Compound 2.35 was prepared from 2.27 (1.56 mmol, 1.0 eq) and 2.32 (2.03 mmol, 1.3 eq) 
according to the general procedure for the CuAAC. The crude product was purified in three 
subsequent flash column chromatography runs (1st run: CHCl3:MeOH 19:1, 2
nd run: 
CHCl3:MeOH 49:1, 3
rd run: EtOAc:NEt3 49:1). Yield: 367 mg (0.81 mmol, 52%), colorless 
crystals. Rf (CHCl3:MeOH 19:1): 0.39, Rf (CHCl3:MeOH 49:1): 0.04, Rf (EtOAc:NEt3 49:1): 
0.23. MP: 191 °C. 1H NMR (400 MHz, CDCl3, δ): 2.78-2.86 (m, 4H), 2.91-3.02 (m, 4H), 3.74 
(s, 2H), 3.89 (s, 3H), 5.85 (br s, 2H), 7.01-7.17 (m, 5H), 7.34 (d, J=1.4 Hz, 1H), 7.42 (d, 
J=8.4 Hz, 2H), 7.69 (d, J=8.4 Hz, 2H), 7.93 (d, J=8.3 Hz, 1H), 8.17 (s, 1H). 13C NMR 
(101 MHz, CDCl3, δ): 29.1, 33.5, 51.0, 51.6, 56.1, 59.8, 110.5, 113.4, 113.8, 118.5, 120.6 (2C), 
125.7, 126.2, 126.6, 128.7, 130.1 (2C), 132.1, 134.2, 134.6, 135.2, 135.5, 141.7, 147.4, 150.9, 
168.3. IR [cm-1]: 3469.9 (m), 3363.8 (m), 3122.7 (w), 2922.1 (m), 2854.6 (w), 2802.6 (w), 
2347.4 (w), 2324.2 (w), 1683.9 (s), 1618.3 (m), 1583.6 (s), 1516 (m), 1448.5 (m), 1294.2 (m), 
1238.3 (s), 1193.9 (m), 1097.5 (s), 1037.7 (m), 889.2 (m), 829.4 (s), 785 (s), 742.6 (s), 698.2 
(s), 511.1 (s, br). HRMS-ESI (m/z): [M + H]+ calcd. for C27H28N5O2
+ 454.2238 found 




Compound 2.36 was prepared from 2.28 (0.24 mmol, 1.0 eq) and 2.32 (0.31 mmol, 1.3 eq) 
according to the general procedure for the CuAAC and purified by flash column 
chromatography (EtOAc:NEt3 99:1). Yield: 62 mg (0.12 mmol, 51%), yellowish solid. Rf 
(EtOAc:NEt3 99:1): 0.12. 1H NMR (400 MHz, CDCl3, δ): 2.73-2.87 (m, 6H), 2.92-3.00 (m, 
2H), 3.65 (s, 2H), 3.82 (s, 3H), 3.83 (s, 3H), 3.86 (s, 3H), 5.87 (br s, 2H), 6.53 (s, 1H), 6.59 (s, 
1H), 7.07 (dd, J=1.3, 8.3 Hz, 1H), 7.31 (d, J=1.1 Hz, 1H), 7.38 (d, J=8.3 Hz, 2H), 7.66 (d, 
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J=8.3 Hz, 2H), 7.90 (d, J=8.3 Hz, 1H), 8.17 (s, 1H). 13C NMR (101 MHz, CDCl3, δ): 28.7, 
33.6, 51.1, 51.6, 55.7, 55.97, 56.01, 59.7, 109.6, 110.5, 111.5, 113.4, 113.8, 118.6, 120.6 (2C), 
126.1, 126.4, 130.1 (2C), 132.1, 135.2, 135.5, 141.7, 147.3, 147.4, 147.7, 150.9, 168.3. MS-ESI 
(m/z): [M + H]+ calcd. for C29H32N5O4




Compound 2.37 was prepared from 2.29 (0.51 mmol, 1.0 eq) and 2.32 (0.66 mmol, 1.3 eq) 
according to the general procedure for the CuAAC and purified by flash column 
chromatography (DCM:acetone:MeOH 13:6:1). Yield: 220 mg (0.34 mmol, 67%), yellow 
solid. Rf (DCM:acetone:MeOH 13:6:1): 0.15. MP: 99 °C. 1H NMR (400 MHz, CDCl3, δ): 
2.77-2.88 (m, 6H), 2.94-3.02 (m, 2H), 3.37 (s, 3H), 3.53-3.56 (m, 2H), 3.63-3.69 (m, 6H), 3.71-
3.75 (m, 2H), 3.81 (s, 3H), 3.86 (t, J=5.2 Hz, 2H), 3.88 (s, 3H), 4.13 (t, J=5.2 Hz, 2H), 5.86 (br 
s, 2H), 6.59 (s, 1H), 6.60 (s, 1H), 7.09 (dd, J=1.5, 8.3 Hz, 1H), 7.34 (d, J=1.4 Hz, 1H), 7.41 (d, 
J=8.4 Hz, 2H), 7.69 (d, J=8.4 Hz, 2H), 7.93 (d, J=8.3 Hz, 1H), 8.19 (s, 1H). 13C NMR 
(101 MHz, CDCl3, δ): 28.7, 33.5, 51.0, 51.6, 55.6, 56.02, 59.05, 59.7, 68.8, 69.7, 70.6, 70.7, 
70.8, 72.0, 110.5, 112.0, 112.4, 113.4, 113.8, 118.6, 120.6 (2C), 126.4, 126.9, 130.1 (2C), 132.1, 
135.2, 135.5, 141.6, 146.5, 147.4, 148.3, 150.9, 168.3. IR [cm-1]: 3468.0 (w, br), 3361.9 (w, 
br), 2920.2 (m, br), 2873.9 (m), 2810.3 (w), 1732.1 (m), 1689.6 (s), 1622.1 (m), 1591.3 (m), 
1518.0 (s), 1448.5 (m), 1348.2 (w), 1301.9 (m), 1242.2 (s), 1224.8 (s), 1126.4 (s), 1097.5 (s), 
1033.8 (m), 987.6 (w), 943.2 (w), 891.1 (w), 842.9 (m), 815.9 (m), 777.3 (m), 700.2 (w), 528.5 
(w), 453.3 (w). HRMS-ESI (m/z): [M + H]+ calcd. for C35H44N5O7 646.3235; found 646.3237. 
C35H43N5O7 (645.76). 





Compound 2.38 was prepared from 2.33 (0.20 mmol) according to the general procedure for 
amide formation. It was purified by flash column chromatography (1st CHCl3:MeOH 20:1, 2
nd 
DCM:acetone:MeOH 12:7:1). Yield: 72 mg (0.11 mmol, 55%), yellowish solid. Rf 
(CHCl3:MeOH 20:1): 0.46; Rf (DCM:acetone:MeOH 12:7:1): 0.66. MP: 135 °C. 1H NMR 
(400 MHz, CD2Cl2, δ): 2.85 (s, 4H), 3.63 (s, 2H), 3.70-3.91 (m, 8H), 4.07 (s, 3H), 6.50 (s, 1H), 
6.62 (s, 1H), 7.55-8.01 (m, 8H), 8.14-8.54 (m, 5H), 9.51 (s, 1H), 13.28 (s, 1H). 13C NMR (101 
MHz, CD2Cl2, δ): 27.6, 50.1, 51.6, 54.5, 55.0 (2C), 60.8, 108.9, 110.9, 115.3, 116.3, 118.0, 
118.5, 119.1, 119.7 (2C), 125.1, 127.0, 127.5, 128.7, 129.2, 129.6, 129.7 (3C), 131.2, 135.2, 
135.3, 137.0, 140.6, 145.8, 146.4, 146.7, 147.1, 149.3, 162.8, 166.9 (one quaternary carbon not 
apparent). HRMS-ESI (m/z): [M + H]+ calcd. for C38H35N6O5
+ 655.2663; found 655.2661. 
C38H34N6O5 (654.73). 






Compound 2.39 was prepared from 2.34 (0.15 mmol) according to the general procedure for 
amide formation. It was purified with flash column chromatography (CHCl3:MeOH 100:7). 
Yield: 73 mg (0.09 mmol, 59%). Rf (CHCl3:MeOH 100:7): 0.40. MP: 138 °C. 1H NMR 
(400 MHz, CDCl3, δ): 2.74-2.81 (m, 2H), 2.82-2.88 (m, 2H), 3.36 (s, 3H), 3.51-3.55 (m, 2H), 
3.59 (s, 2H), 3.62-3.68 (m, 4H), 3.70-3.74 (m, 2H), 3.76 (s, 2H), 3.82 (s, 3H), 3.85 (t, J=5.2 Hz, 
2H), 4.09 (s, 3H), 4.12 (t, J=5.2 Hz, 2H), 6.56 (s, 1H), 6.62 (s, 1H), 7.61 (d, J=8.4 Hz, 2H), 
7.64-7.69 (m, 1H), 7.80 (d, J=8.5 Hz, 2H), 7.82-7.86 (m, 1H), 7.90-7.94 (m, 1H), 7.99 (dd, 
J=1.7, 8.3 Hz, 1H), 8.25 (d, J=8.3 Hz, 1H), 8.36 (d, J=8.5 Hz, 1H), 8.38 (s, 2H), 8.45 (s, 1H), 
9.46 (d, J=1.6 Hz, 1H), 13.41 (s, 1H). 13C NMR (101 MHz, CDCl3, δ): 28.6, 50.8, 52.5, 55.6, 
56.1, 59.0, 62.0, 68.8, 69.7, 70.6, 70.7, 70.8, 72.0, 112.1, 112.3, 116.0, 117.3, 118.8, 119.1, 
120.2, 120.5 (2C), 126.8, 127.7, 128.4, 129.4, 130.3 (4C), 132.2, 136.0, 137.8, 141.3, 146.6, 
146.7, 147.4, 148.3, 150.0, 163.9, 167.8 (three quaternary carbons not apparent). HRMS-ESI 
(m/z): [M + H]+ calcd. for C44H47N6O8
+ 787.3450; found 787.3436. C44H46N6O8 (786.89). 





Compound 2.40 was prepared from 2.35 (0.22 mmol) according to the general procedure for 
amide formation. It was purified by flash column chromatography (EtOAc:MeOH 19:1). Yield: 
81 mg (0.13 mmol, 59%), yellowish solid. Rf (EtOAc:MeOH 19:1): 0.42. MP: 131 °C. 
1H NMR (400 MHz, CDCl3, δ): 2.81-2.89 (m, 4H), 2.93-3.05 (m, 4H), 3.77 (s, 2H), 4.09 (s, 
3H), 7.03-7.08 (m, 1H), 7.10-7.16 (m, 3H), 7.44 (d, J=8.4 Hz, 2H), 7.65-7.70 (m, 1H), 7.75 (d, 
J=8.4 Hz, 2H), 7.82-7.87 (m, 1H), 7.91-7.95 (m, 1H), 7.99 (dd, J=1.6, 8.3 Hz, 1H), 8.25 (d, 
J=8.3 Hz, 1H), 8.34-8.44 (m, 4H), 9.45 (d, J=1.6 Hz, 1H), 13.42 (s, 1H). 13C NMR (101 MHz, 
CDCl3, δ): 29.0, 33.5, 51.0, 52.5, 56.1, 59.8, 116.0, 117.3, 118.8, 119.1, 120.2, 120.6 (2C), 
125.7, 126.3, 126.6, 127.7, 128.4, 128.7, 129.4, 130.1 (2C), 130.31, 130.34, 132.2, 134.2, 135.2, 
136.0, 137.8, 141.3, 141.6, 146.7, 147.4, 150.0, 163.9, 167.8 (one quaternary carbon not 
apparent). HRMS-ESI (m/z): [M + H]+ calcd. for C37H33N6O3





Compound 2.41 was prepared from 2.36 (0.12 mmol) according to the general procedure for 
amide formation. It was purified by flash column chromatography (EtOAc:NEt3 99:1). Yield: 
60 mg (0.09 mmol, 75%), yellowish solid. Rf (EA: NEt3 99:1): 0.34. MP: 129 °C. 1H NMR 
(400 MHz, CDCl3, δ): 2.80-2.89 (m, 6H), 2.97-3.04 (m, 2H), 3.69 (s, 2H), 3.82-3.88 (m, 6H), 
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4.06 (s, 3H), 6.55 (s, 1H), 6.61 (s, 1H), 7.43 (d, J=8.4 Hz, 2H), 7.66 (t, J=7.5 Hz, 1H), 7.75 (d, 
J=8.4 Hz, 2H), 7.80-7.86 (m, 1H), 7.91 (d, J=8.0 Hz, 1H), 7.98 (dd, J=1.6, 8.3 Hz, 1H), 8.24 
(d, J=8.3 Hz, 1H), 8.33-8.40 (m, 3H), 8.43 (s, 1H), 9.44 (d, J=1.5 Hz, 1H), 13.40 (s, 1H). 
13C NMR (101 MHz, CDCl3, δ): 28.5, 33.4, 51.0, 52.5, 55.6, 55.9, 56.0, 59.6, 109.5, 111.4, 
116.0, 117.3, 118.8, 119.1, 120.1, 120.6 (2C), 126.0, 126.1, 127.7, 128.3, 129.4, 130.1 (2C), 
130.29, 130.32, 132.1, 135.2, 136.0, 137.7, 141.3, 141.4, 146.6, 147.3, 147.4, 147.7, 150.0, 
163.9, 167.8. IR [cm-1]: 3130.5 (vw), 2922.1 (m, br), 2852.7 (w), 1691.6 (s), 1612.5 (w), 1568.1 
(m), 1500.6 (s), 1427.3 (m), 1230.6 (s), 1126.4 (m), 1103.3 (m), 1037.7 (m), 819.7 (w), 767.7 
(s), 696.3 (m), 528.5 (m), 478.3 (m), 457.1 (m). MS-ESI (m/z): [M + H]+ calcd. for 
C39H37N6O5





Compound 2.42 was prepared from 2.37 (25 mmol) according to the general procedure for 
amide formation. It was purified by flash column chromatography (CHCl3:MeOH 100:7). 
Yield: 120 mg (15 mmol, 60%), colorless solid. MP: 129 °C. 1H NMR (600 MHz, CDCl3, δ): 
2.79-2.89 (m, 6H), 2.99-3.04 (m, 2H), 3.37 (s, 3H), 3.53-3.56 (m, 2H), 3.64-3.70 (m, 6H), 3.72-
3.75 (m, 2H), 3.82 (s, 3H), 3.86 (t, J=5.3 Hz, 2H), 4.08 (s, 3H), 4.15 (t, J=5.3 Hz, 2H), 6.61 (s, 
2H), 7.43 (d, J=8.5 Hz, 2H), 7.63-7.69 (m, 1H), 7.75 (d, J=8.5 Hz, 2H), 7.82-7.85 (m, 1H), 
7.90-7.93 (m, 1H), 7.98 (dd, J=1.7, 8.3 Hz, 1H), 8.24 (d, J=8.3 Hz, 1H), 8.36 (d, J=8.6 Hz, 1H), 
8.38 (s, 2H), 8.42 (s, 1H), 9.45 (d, J=1.6 Hz, 1H), 13.40 (s, 1H). 13C NMR (151 MHz, CDCl3, 
δ): 28.6, 33.5, 51.0, 52.4, 55.5, 56.0, 59.0, 59.6, 68.8, 69.6, 70.5, 70.6, 70.8, 71.9, 112.0, 112.4, 
116.0, 117.3, 118.8, 119.0, 120.2, 120.6 (2C), 126.8 (2C), 127.6, 128.3, 129.4, 130.1 (2C), 
130.26, 130.29, 132.1, 135.1, 136.0, 137.7, 141.3, 141.5, 146.5, 146.6, 147.3, 148.3, 150.0, 
163.9, 167.8. HRMS-ESI (m/z): [M + H]+ calcd. for C45H49N6O8
+ 801.3606; found 801.3640. 
C45H48N6O8 (800.91). 




Compound 2.44 was synthesized according to the general procedure for the ortho acylation of 
3-bromoaniline (15.64 mmol) and purified by flash column chromatography. Yield: 569 mg 
(2.66 mmol, 17%). 1H NMR (400 MHz, CDCl3, δ): 2.54 (s, 3H), 6.32 (br s, 2H), 6.76 (dd, 
J=1.9, 8.6 Hz, 1H), 6.83 (d, J=1.9 Hz, 1H), 7.55 (d, J=8.6 Hz, 1H). 13C NMR (101 MHz, 
CDCl3, δ): 27.9, 117.1, 119.0, 119.5, 129.0, 133.3, 151.0, 200.1. HRMS-ESI (m/z): [M + H]
+ 
calcd. for C8H9BrNO
+ 213.9862; found 213.9860. C8H8BrNO (214.06). 
1-(2-Amino-4-bromophenyl)propan-1-one (2.45) [57] 
 
Compound 2.45 was synthesized according to the general procedure for the ortho acylation of 
3-bromoaniline (46.3 mmol) and purified with by column chromatography (PE:EtOAc 4:5). 
Yield: 550 mg (11.6 mmol, 25%). Rf (PE:EtOAc 4:5): 0.58. 1H NMR (400 MHz, CD3OD, δ): 
1.14 (t, J=7.3 Hz, 3H), 2.92 (q, J=7.3 Hz, 2H), 6.68 (dd, J=2.0, 8.7 Hz, 1H), 6.93 (d, J=2.0 Hz, 
1H), 7.65 (d, J=8.7 Hz, 1H). 13C NMR (101 MHz, CD3OD, δ): 9.2, 33.2, 117.2, 119.0, 120.4, 
129.7, 133.9, 153.6, 204.4. HRMS-ESI (m/z): [M + H]+ calcd. for C9H11BrNO
+ 228.0019; 
found 228.0018. C9H10BrNO (228.09). 
1-(2-Amino-4-bromophenyl)-2-methylpropan-1-one (2.46) (CAS 1598834-65-1) 
 
Compound 2.46 was synthesized according to the general procedure for the ortho acylation of 
3-bromoaniline (45.5 mmol) and purified by flash column chromatography (DCM). Yield: 
1.20 g (5.0 mmol, 11%). 1H NMR (400 MHz, CDCl3, δ): 1.18 (d, J=6.8 Hz, 6H), 3.50 (m, 1H), 
6.37 (br s, 2H), 6.75 (dd, J=1.9, 8.6 Hz, 1H), 6.83 (d, J=1.9 Hz, 1H), 7.59 (d, J=8.7 Hz, 1H). 
13C NMR (101 MHz, CDCl3, δ): 19.6 (2C), 35.5, 115.6, 119.0, 119.8, 128.7, 132.3, 151.7, 
206.5. C10H12BrNO (242.12). 




Compound 2.47 was prepared from 2.44 (2.57 mmol) according to the general procedure for 
amide formation. It was purified by flash column chromatography (DCM). Yield: 417 mg 
(1.13 mmol, 44%). Rf (DCM): 0.55. 1H NMR (400 MHz, CDCl3, δ): 2.73 (s, 3H), 7.32 (dd, 
J=2.0, 8.5 Hz, 1H), 7.63-7.69 (m, 1H), 7.78-7.85 (m, 2H), 7.88-7.93 (m, 1H), 8.34-8.37 (m, 
2H), 8.38-8.42 (m, 1H), 9.33 (d, J=2.0 Hz, 1H), 13.84 (s, 1H). 13C NMR (101 MHz, CDCl3, 
δ): 28.7, 118.9, 121.8, 123.9, 125.9, 127.6, 128.4, 129.4, 129.8, 130.3, 130.5, 132.7, 137.7, 
141.2, 146.7, 149.7, 164.3, 201.1. HRMS-ESI (m/z): [M + H]+; calcd. for C18H14BrN2O2
+ 
369.0233; found 369.0230. C18H13BrN2O2 (369.22). 
N-(2-Acetyl-5-((trimethylsilyl)ethynyl)phenyl)quinoline-2-carboxamide (2.48) 
 
Compound 2.48 was prepared from 2.47 (1.14 mmol) according to the general procedure for 
the Sonogashira reaction. It was purified by flash column chromatography (PE:DCM 1:1). 
Yield: 336 mg (0.87 mmol, 76%). Rf (PE:DCM 1:1): 0.33. 1H NMR (400 MHz, CDCl3, δ): 
0.28 (s, 9H), 2.73 (s, 3H), 7.24 (dd, J=1.6, 8.3 Hz, 1H), 7.62-7.68 (m, 1H), 7.79-7.85 (m, 1H), 
7.87-7.92 (m, 2H), 8.36 (s, 2H), 8.40 (d, J=8.4 Hz, 1H), 9.18 (d, J=1.5 Hz, 1H), 13.79 (s, 1H). 
13C NMR (101 MHz, CDCl3, δ): 0.0 (3C), 28.8, 98.6, 104.1, 119.1, 122.8, 124.4, 126.0, 127.8, 
128.5, 129.6, 129.8, 130.4, 130.6, 131.6, 137.8, 140.3, 146.8, 150.1, 164.3, 201.5. MS-ESI 
(m/z): [M + H]+; calcd. for C23H23N2O2Si
+ 387.1523; found 387.1523. C23H22N2O2Si (386.15). 




Compound 2.49 was prepared from 2.48 (0.85 mmol) according to the general procedure for 
TMS deprotection and purified by flash column chromatography (DCM). Yield: 200 mg 
(0.64 mmol, 75%). Rf (DCM): 0.57. MP: 187 °C. 1H NMR (300 MHz, CDCl3, δ): 2.74 (s, 3H), 
3.27 (s, 1H), 7.25-7.30 (m, 1H, signals interfering with the solvent signal), 7.62-7.68 (m, 1H), 
7.77-7.86 (m, 1H), 7.87-7.95 (m, 2H), 8.35 (s, 2H), 8.40 (d, J=8.6 Hz, 1H), 9.22 (d, J=1.5 Hz, 
1H), 13.78 (s, 1H). 13C NMR (75 MHz, CDCl3, δ): 28.7, 80.6, 82.8, 118.9, 122.9, 124.4, 126.1, 
127.6, 128.3, 128.5, 129.4, 130.2, 130.5, 131.5, 137.6, 140.2, 146.7, 149.9, 164.2, 201.3. 
HRMS-ESI (m/z): [M + H]+ calcd. for C20H15N2O2




Compound 2.50 was synthesized from 2.45 (3.9 mmol) according to the general procedure for 
the Sonogashira reaction and purified by flash column chromatography (PE:EtOAc 7:1). Yield: 
850 mg (3.5 mmol, 89%). Rf (PE:EtOAc 7:1): 0.38. 1H NMR (400 MHz, CDCl3, δ): 0.25 (s, 
9H), 1.19 (t, J=7.3 Hz, 3H), 2.95 (q, J=7.3 Hz, 2H), 6.25 (br s, 2H), 6.71 (dd, J=1.5, 8.3 Hz, 
1H), 6.76 (d, J=1.4 Hz, 1H), 7.67 (d, J=8.3 Hz, 1H). 13C NMR (101 MHz, CDCl3, δ): 0.0 (3C), 
8.8, 32.5, 96.9, 104.4, 117.7, 119.3, 120.6, 128.6, 131.0, 149.9, 203.0. HRMS-ESI (m/z): [M + 
H]+ calcd. for C14H20NOSi
+ 246.1309; found 246.1313. C14H19NOSi (245.40). 
  




Compound 2.51 was prepared from 2.46 (4.80 mmol) according to the general procedure for 
the Sonogashira reaction. It was purified by flash column chromatography (PE:EtOAc 9:1). 
Yield: 510 mg (1.97 mmol, 41%). Rf (PE:EtOAc 9:1): 0.55. 1H NMR (400 MHz, CDCl3, δ): 
0.25 (s, 9H), 1.19 (d, J=6.8 Hz, 6H), 3.54 (m, 1H), 6.21 (br s, 2H), 6.73 (dd, J=1.5, 8.3 Hz, 1H), 
6.80 (d, J=1.4 Hz, 1H), 7.68 (d, J=8.4 Hz, 1H). 13C NMR (101 MHz, CDCl3, δ): 0.0 (3C), 19.7 
(2C), 35.6, 97.1, 104.3, 116.9, 119.6, 121.1, 128.7, 131.0, 150.1, 206.7. HRMS-ESI (m/z): [M 
+ H]+; calcd. for C15H22NOSi
+ 260.1465; found 260.1467. C15H21NOSi (259.42). 
1-(2-amino-4-ethynylphenyl)propan-1-one (2.52) 
 
Compound 2.52 was prepared from 2.50 (3.1 mmol) according to the general procedure for 
TMS deprotection. It was purified by flash column chromatography (0-20% EtOAc in PE). 
Yield: 359 mg (2.1 mmol, 68%). Rf (PE:EtOAc 7:1): 0.31. 1H NMR (400 MHz, CDCl3, δ): 
1.20 (t, J=7.3 Hz, 3H), 2.95 (q, J=7.3 Hz, 2H), 3.14 (s, 1H), 6.27 (s, 2H), 6.74 (dd, J=1.6, 
8.3 Hz, 1H), 6.78 (d, J=1.5 Hz, 1H), 7.69 (d, J=8.3 Hz, 1H). 13C NMR (101 MHz, CDCl3, δ): 
8.7, 32.4, 79.2, 83.0, 117.8, 119.2, 120.8, 127.5, 131.0, 149.8, 202.9. HRMS-ESI (m/z): [M + 
H]+ calcd. for C11H12NO
+ 174.0913; found 174.0915. C11H11NO (173.22). 
1-(2-Amino-4-ethynylphenyl)-2-methylpropan-1-one (2.53) 
 
Compound 2.53 was prepared from 2.51 (1.34 mmol) according to the general procedure for 
TMS deprotection. It was purified by flash column chromatography (PE:EtOAc 9:1). Yield: 
238 mg (1.27 mmol, 95%). Rf (PE:EtOAc 9:1): 0.45. 1H NMR (400 MHz, CDCl3, δ): 1.19 (d, 
J=6.8 Hz, 6H), 3.14 (s, 1H), 3.54 (m, 1H), 5.99 (br s, 2H), 6.75 (dd, J=1.6, 8.3 Hz, 1H), 6.81 
(d, J=1.6 Hz, 1H), 7.70 (d, J=8.3 Hz, 1H). 13C NMR (101 MHz, CDCl3, δ): 19.5 (2C), 35.5, 
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79.2, 83.0, 116.9, 119.3, 121.1, 127.5, 131.0, 150.2, 206.6. HRMS-ESI (m/z): [M + H]+; calcd. 
for C12H14NO
+ 188.1070; found 188.1073. C12H13NO (187.24). 
N-(5-Ethynyl-2-propionylphenyl)quinoline-2-carboxamide (2.54) 
 
Compound 2.54 was prepared from 2.52 (1.2 mmol) according to the general procedure for 
amide formation and was purified by flash column chromatography (PE:EtOAc 7:1). Yield: 
379 mg (1.2 mmol, 100%). Rf (PE:EtOAc 7:1): 0.2. 1H NMR (400 MHz, CDCl3, δ): 1.31 (t, 
J=7.2 Hz, 3H), 3.09 (q, J=7.2 Hz, 2H), 3.26 (s, 1H), 7.24-7.28 (m, 1H, signals interfering with 
the solvent signal), 7.61-7.68 (m, 1H), 7.79-7.85 (m, 1H,), 7.89 (d, J=8.2 Hz, 1H), 7.92 (d, 
J=8.2 Hz, 1H), 8.35 (s, 2H), 8.40 (d, J=8.5 Hz, 1H), 9.21 (d, J=1.5 Hz, 1H), 13.79 (s, 1H). 
13C NMR (101 MHz, CDCl3, δ): 8.7, 33.5, 80.4, 82.8, 118.9, 122.7, 124.6, 126.1, 127.6, 128.1, 
128.3, 129.4, 130.2, 130.5, 130.6, 137.6, 140.1, 146.7, 150.0, 164.1, 203.8. HRMS-ESI (m/z): 
[M + H]+ calcd. for C21H17N2O2
+ 329.1285; found 329.1287. C21H16N2O2 (328.37). 
N-(5-Ethynyl-2-isobutyrylphenyl)quinoline-2-carboxamide (2.55) 
 
Compound 2.55 was prepared from 2.53 (0.58 mmol) according to the general procedure for 
amide formation. It was purified by flash column chromatography (PE:EtOAc 8:2). Yield: 
171 mg (0.50 mmol, 86%). MP: 196 °C. Rf (PE:EtOAc 8:2): 0.52. 1H NMR (300 MHz, CDCl3, 
δ): 1.30 (d, J=6.8 Hz, 6H), 3.26 (s, 1H), 3.66 (m, 1H), 7.29 (dd, J=8.2, 1.6 Hz, 1H), 7.64-7.70 
(m, 1H), 7.81-7.88 (m, 1H), 7.89-7.96 (m, 2H), 8.37 (s, 2H), 8.44 (d, J=8.4 Hz, 1H), 9.20 (d, 
J=1.6 Hz, 1H), 13.72 (s, 1H). 13C NMR (75 MHz, CDCl3, δ): 19.6 (2C), 36.8, 80.5, 82.9, 119.1, 
122.3, 124.9, 126.2, 127.7, 128.1, 128.4, 129.5, 130.3, 130.5, 130.6, 137.8, 140.6, 146.8, 150.1, 
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164.2, 207.5. HRMS-ESI (m/z): [M + H]+ calcd. for C22H19N2O2





Compound 2.56 was synthesized from 2.28 (0.33 mmol, 1.5 eq) and 2.49 (0.22 mmol, 1.0 eq) 
according to the general procedure for the CuAAC. It was purified in two subsequent flash 
column chromatography runs (1st run: DCM:MeOH 95:5, 2nd run: PE:acetone 1:1). Yield: 
24 mg (0.04 mmol, 18%), dark yellowish solid. Rf (DCM:MeOH 95:5): 0.32. 1H NMR 
(300 MHz, CDCl3, δ): 2.80 (s, 3H), 2.81-2.91 (m, 6H), 2.97-3.07 (m, 2H), 3.69 (m, 2H), 3.83-
3.88 (m, 6H), 6.55 (s, 1H), 6.62 (s, 1H), 7.44 (d, J=8.4 Hz, 2H), 7.64-7.71 (m, 1H), 7.76 (d, 
J=8.4 Hz, 2H), 7.81-7.88 (m, 1H), 7.89-7.95 (m, 1H), 8.03 (dd, J=1.6, 8.3 Hz, 1H), 8.11 (d, 
J=8.4 Hz, 1H), 8.37 (m, 2H), 8.41-8.48 (m, 2H), 9.48 (d, J=1.5 Hz, 1H), 13.98 (s, 1H). 
13C NMR (75 MHz, CDCl3, δ): 28.8, 28.9, 33.7, 51.2, 55.8, 56.0, 56.1, 59.9, 109.5, 111.4, 
117.7, 118.9, 119.4, 120.1, 120.7 (2C), 122.8, 126.2, 126.4, 127.7, 128.5, 129.5, 130.2 (2C), 
130.4, 130.7, 132.8, 135.2, 136.4, 137.8, 141.0, 141.8, 146.8, 147.3, 147.4, 147.7, 150.1, 164.7, 
201.7. HRMS-ESI (m/z): [M + H]+ calcd. for C39H37N6O4
+ 653.2871; found 653.2874. 
C39H36N6O4 (652.76). 






Compound 2.57 was prepared from 2.28 (0.38 mmol, 1.0 eq) and 2.54 (0.49 mmol, 1.3 eq) 
according to the general procedure for the CuAAC. It was purified by flash column 
chromatography (CHCl3:MeOH 100:7) and recrystallization (CHCl3). Yield: 118 mg 
(0.18 mmol, 48%), colorless solid. Rf (CHCl3:MeOH 100:7): 0.38. MP: 170 °C. For further 
purification, the substance was subjected to preparative HPLC (gradient: 0-30 min: MeCN/ 
0.1% aq TFA 51:49-87:13, tR = 12.5 min). Analytical and pharmacological characterization 
was performed with the HPLC purified substance. 1H NMR (600 MHz, [D6]DMSO, δ): 1.22 
(t, J=7.1 Hz, 3H), 2.99-3.14 (m, 2H), 3.19-3.28 (m, 4H), 3.38 (m, 1H), 3.55 (m, 2H), 3.75 (s, 
3H), 3.76 (s, 3H), 3.81 (m, 1H), 4.33 (m, 1H), 4.56 (m, 1H), 6.81 (s, 1H), 6.86 (s, 1H), 7.61 (d, 
J=8.5 Hz, 2H), 7.79-7.84 (m, 2H), 7.96-8.01 (m, 1H), 8.04 (d, J=8.4 Hz, 2H), 8.17 (d, J=8.0 Hz, 
1H), 8.27 (d, J=8.3 Hz, 1H), 8.31-8.36 (m, 2H), 8.70 (d, J=8.5 Hz, 1H), 9.50 (s, 1H), 9.57 (d, 
J=1.6 Hz, 1H), 10.07 (br s, 1H), 13.76 (s, 1H). 13C NMR (151 MHz, [D6]DMSO, δ): 8.5, 24.6, 
29.2, 32.9, 49.3, 51.9, 55.5, 55.6, 55.6, 109.6, 111.5, 116.6, 118.6, 119.8, 120.0, 120.4 (2C), 
121.1, 122.5, 123.1, 128.2, 128.7, 129.1, 129.4, 130.3 (2C), 131.0, 132.4, 135.4, 135.5, 137.7, 
138.5, 139.8, 145.9, 146.3, 147.8, 148.5, 149.5, 163.3, 204.2. HRMS-ESI (m/z): [M + H]+ 
calcd. for C40H39N6O4
+ 667.3027; found 667.3029. C40H38N6O4 · C2HF3O2 (666.78 + 114.02). 





Compound 2.58 was prepared from 2.28 (0.38 mmol, 1.5 eq) and 2.55 (0.25 mmol, 1.0 eq) 
according to the general procedure for the CuAAC. It was purified in three subsequent flash 
column chromatography runs (1st run: DCM:MeOH 95:5, 2nd run: PE:acetone 1:1). Yield: 
16 mg (0.02 mmol, 8%), beige solid. Rf (DCM:MeOH 95:5): 0.29. 1H NMR (300 MHz, CDCl3, 
δ) 1.34 (d, J=6.8 Hz, 6H), 2.79-2.91 (m, 6H), 2.98-3.06 (m. 2H), 3.69 (s, 2H), 3.72-3.81 (m. 
1H), 3.84-3.87 (m, 6H), 6.56 (s, 1H), 6.62 (s, 1H), 7.45 (d, J=8.5 Hz, 2H), 7.64-7.72 (m, 1H), 
7.76 (d, J=8.5 Hz, 2H), 7.82-7.90 (m, 1H), 7.91-7.95 (m, 1H), 8.05 (dd, J=1.7, 8.3 Hz, 1H), 
8.14 (d, J=8.6 Hz, 1H), 8.38 (m, 2H), 8.43-8.48 (m, 2H), 9.47 (d, J=1.6 Hz, 1H), 13.97 (s, 1H). 
HRMS-ESI (m/z): [M + H]+ calcd. for C41H41N6O4






We described compound 2.59 recently [39]. For clarity it is also included here. 2.59 was 
prepared from 2.29 (0.37 mmol, 1.0 eq) and 2.54 (0.48 mmol, 1.3 eq) according to the general 
procedure for the CuAAC. It was purified by column chromatography (DCM:MeOH 95:5). 
Yield: 160 mg (0.20 mmol, 54%). MP: 168 °C. 1H NMR (600 MHz, CDCl3, δ): 1.34 (t, 
J=7.2 Hz, 3H), 2.79-2.88 (m, 6H), 2.96-3.01 (m, 2H), 3.14 (q, J=7.2 Hz, 2H), 3.36 (s, 3H), 
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3.53-3.55 (m, 2H), 3.63-3.69 (m, 6H), 3.71-3.75 (m, 2H), 3.81 (s, 3H), 3.86 (t, J=5.2 Hz, 2H), 
4.14 (t, J=5.2 Hz, 2H), 6.60 (m, 2H), 7.42 (d, J=8.3 Hz, 2H), 7.63-7.67 (m, 1H), 7.74 (d, 
J=8.4 Hz, 2H), 7.81-7.85 (m, 1H), 7.89 (d, J=8.0 Hz, 1H), 7.98 (dd, J=1.6, 8.3 Hz, 1H), 8.09 
(d, J=8.3 Hz, 1H), 8.33-8.35 (m, 2H), 8.41-8.44 (m, 2H), 9.44 (d, J=1.6 Hz, 1H), 13.96 (s, 1H). 
13C NMR (151 MHz, CDCl3, δ): 8.7, 28.6, 33.3, 33.5, 50.9, 55.5, 55.9, 59.0, 59.6, 68.7, 69.6, 
70.5, 70.6, 70.7, 71.9, 111.9, 112.3, 117.6, 118.7, 119.1, 119.9, 120.5 (2C), 122.3, 126.3, 126.8, 
127.5, 128.3, 129.3, 130.0 (2C), 130.2, 130.5, 131.6, 135.1, 135.9, 137.6, 140.7, 141.5, 146.5, 
146.7, 147.1, 148.3, 150.0, 164.4, 203.9. HRMS-ESI (m/z): [M + H]+ calcd. for C46H51N6O7
+ 
799.3814; found 799.3823. C46H50N6O7 · C2HF3O2 (798.94 + 114.02). 
2.4.2 Biology 
2.4.2.1 General Experimental Conditions 
Materials. Commodity chemicals and solvents were purchased from commercial suppliers 
(Sigma Aldrich, Munich, Germany; Merck, Darmstadt, Germany; VWR, Darmstadt, Germany; 
Thermo Fisher Scientific, Waltham, MA, USA; Invitrogen, Karlsruhe, Germany). Topotecan 
and vinblastine were obtained from Sigma Aldrich. Hoechst 33342 and calcein-AM were 
procured from Biotium (Fremont, CA, USA). FTC was from Merck. Tariquidar was 
synthesized in our laboratory according to literature [21] with slight modifications [58]. 
Reversan was obtained from Tocris (Wiesbaden-Nordenstadt, Germany). Cholesterol/RAMEB, 
a complex of 5.4% cholesterol and randomly methylated β-cyclodextrin, was acquired from 
CycloLab (Cyclodextrin Research and Development Laboratory, Budapest, Hungary). 
Millipore water was used throughout for the preparation of buffers, aqueous reagent solutions 
and HPLC eluents. The pH of buffers and aqueous reagent solutions was adjusted with NaOH 
aq or HCl aq unless stated otherwise. Acetonitrile for HPLC (gradient grade) was obtained from 
Merck. Mammalian cell lines were purchased from the ATCC (American Type Culture 
Collection; Manassas, VA, USA), Sf9 cells were obtained from CLS (Eppelheim, Germany). 
Tissue culture flasks were procured from Sarstedt (Nümbrecht, Germany). Dulbecco’s 
Modified Eagle’s Medium - high glucose (DMEM/High; with 4500 mg/L glucose, sodium 
pyruvate and sodium bicarbonate, without L-glutamine, liquid, sterile-filtered, suitable for cell 
culture) and L-glutamine solution (200 mM, sterile-filtered, BioXtra, suitable for cell culture) 
were from Sigma Aldrich. Insect-Xpress Medium was obtained from Lonza (Verviers, 
Belgium). Fetal calf serum (FCS) and trypsin/EDTA and were from Biochrom (Berlin, 
Germany). For all assays in microplate format, 96-well plates (PS, clear, F-bottom, with lid, 
sterile) from Greiner Bio-One (Frickenhausen, Germany) were used. The BaculoGold 
transfection kit was bought from BD Biosciences (San Jose, CA, USA). The Bio-Rad protein 
assay kit was purchased from Bio-Rad Laboratories (Munich, Germany). Syringe filters 
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(Phenex-RC, 4 mm, 0.2 µm) used in the chemical stability assay were from Phenomenex 
(Aschaffenburg, Germany). 
Stock solutions. Topotecan and vinblastine were dissolved in 70% EtOH to give 100 µM stock 
solutions. Hoechst 33342 stock solution (0.8 mM) was prepared in water and calcein-AM stock 
solution (100 µM) in DMSO. The test compounds and the reference compounds 
fumitremorgin C, tariquidar, reversan and sulfasalazine were dissolved in DMSO at 100 times 
the final concentrations in the transport assays and the ATPase assay and at 1000 times the final 
concentrations in the chemosensitivity assay. A 1.5 mM stock solution of sulfasalazine in 
DMSO was prepared for stimulating ABCG2 in the inhibition mode of the ATPase Assay. 
Furthermore, 3 mM stock solutions of the test compounds in DMSO were prepared for the 
stability assay in blood plasma. If not stated otherwise, water served as solvent for other assay 
reagents. 
Instruments. Fluorescence and absorbance measurements in microplates were carried out with 
a GENios Pro microplate reader (equipped with a Xenon arc lamp; Tecan, Grödig, Austria). 
Analytical HPLC of compound 2.59 after incubation in murine plasma was performed on a 
system from Agilent described in Section 2.4.1.1. The HPLC conditions were as described, yet 
with two alterations. The following linear gradient was applied: 0-12 min: A/B 20:80-95:5, 12-
15 min: A/B 95:5. The injection volume was 100 µL. 
Software. All biological data were analyzed with GraphPad Prism 5 (GraphPad Software, San 
Diego, CA, USA). 
2.4.2.2 Cell Culture 
All mammalian cells were cultured in DMEM/High supplemented with 2% (v/v) of a 200 mM 
L-glutamine solution and 10% (v/v) FCS at 37 °C in a water-saturated atmosphere containing 
5% CO2. 
MCF-7/Topo cells, an ABCG2-overexpressing variant of the MCF-7 cell line (ATCC® HTB-
22), were obtained by passaging the MCF-7 cells with increasing amounts of topotecan in the 
culture medium to achieve a maximum concentration of 550 nM within a period of about 40 d; 
after 3 passages at the maximum concentration the treated cells expressed sufficient quantities 
of ABCG2 [40,59]. They were cultured with 550 nM topotecan to maintain overexpression of 
the ABCG2 transporter. 
KB-V1 cells, an ABCB1-overexpressing variant of the KB cell line (ATCC® CCL-17), were 
obtained by passaging the KB cells with increasing amounts of vinblastine in the culture 
medium to achieve a maximum concentration of 330 nM within a period of about 90 d; after 3 
passages at the maximum concentration the treated cells expressed sufficient quantities of 
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ABCB1 transporter [58,60]. They were cultured with 330 nM vinblastine to maintain 
overexpression of the ABCB1 transporter. 
MDCK.2-MRP1 cells were a kind gift from Prof. Dr. P. Borst from the Netherland Cancer 
Institute (Amsterdam, NL). They were obtained by transfecting MDCK.2 cells (ATCC® CRL-
2936) with human ABCC1 [61,62]. Due to the strong adherence of this cell line, trypsinization 
was performed using 2X trypsin/EDTA (0.1%./0.04%) for 30 min. 
Sf9 cells (CLS 604328) were cultured in Insect Xpress medium supplemented with 5% (v/v) 
FCS in 250 or 500 mL disposable Erlenmeyer flasks at 28 °C and under rotation at 150 rpm. 
All cells were routinely monitored for mycoplasma contamination by PCR using the 
Venor®GeM mycoplasma detection kit (Minerva Biolabs, Berlin, Germany) and were negative. 
2.4.2.3 Inhibition of ABCG2: Hoechst 33342 Transport Assay [44] 
MCF-7/Topo cells were seeded into 96-well plates at a density of 20,000 cells per well 
(100 μL/well) and allowed to attach to the surface of the microplates at 37 °C in a water-
saturated atmosphere containing 5% CO2 overnight. The next day, the culture medium was 
removed and the cells were incubated with loading suspension (DMEM, supplemented as 
described above, 8 μM Hoechst 33342 and the test compounds at increasing concentrations; 
100 µL/well) for 2 h (37 °C, water-saturated atmosphere containing 5% CO2). FTC at a final 
concentration of 10 μM served as reference compound (positive control); the vehicle DMSO 
(1%) served as negative control. Each concentration was measured in triplicate, positive and 
negative control 12-fold each. The supernatants were drained and the cells were fixed with 4% 
(w/w) PFA in PBS (100 μL/well) under light protection for 20 min. Afterwards, the MCF-
7/Topo cells were washed with PBS twice (250 μL/well each time) to remove residual dye and 
overlaid with PBS (100 μL/well). The relative fluorescence intensities (λexc=340 nm, 
λem=485 nm) were determined using a GENios Pro microplate reader. On each plate, the 
optimal gain was calculated by the determination of the fluorescence intensities in the presence 
of the reference substance FTC. 
The data were normalized relative to the fluorescence intensity in the absence of an ABCG2 
inhibitor (negative control) and the response elicited by the FTC (positive) control, which was 
defined as 100% inhibition of the Hoechst 33342 efflux. IC50 values were calculated using four 
parameter sigmoidal fits. Errors were expressed as standard error of the mean (SEM). 
2.4.2.4 Inhibition of ABCB1: Calcein-AM Transport Assay [44] 
KB-V1 cells were seeded into 96-well plates at a density of 20,000 cells per well (100 μL/well) 
and allowed to attach to the surface of the microplates at 37 °C in a water-saturated atmosphere 
containing 5% CO2 overnight. The next day, the culture medium was removed and the cells 
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were washed with loading buffer (120 mM NaCl, 5 mM KCl, 2 mM MgCl2, 1.5 mM CaCl2, 
25 mM HEPES, 10 mM glucose, pH 7.4) in order to remove unspecific serum esterases. 
Afterwards, the cells were incubated with loading suspension (loading buffer, 5 mg/mL BSA, 
1.25 μL/mL 20% (w/w) Pluronic® F-127 in DMSO, 0.5 μM calcein-AM and the test 
compounds at increasing concentrations; 100 µL/well) for 10 min (37 °C, water-saturated 
atmosphere containing 5% CO2). Tariquidar at a final concentration of 10 μM served as 
reference compound (positive control); the vehicle DMSO (1%) served as negative control. 
Each concentration was measured in triplicate, positive and negative control 12-fold each. The 
supernatants were drained and the cells were fixed with 4% (w/w) PFA in PBS (100 μL/well) 
under light protection for 20 min. Afterwards, the KB-V1 cells were washed with PBS twice 
(250 μL/well each time) to remove residual dye and overlaid with PBS (100 μL/well). The 
relative fluorescence intensities (λexc=485 nm, λem=535 nm) were determined using a GENios 
Pro microplate reader. On each plate, the optimal gain was calculated by the determination of 
the fluorescence intensities in the presence of the reference substance tariquidar. 
The data were normalized relative to the fluorescence intensity in the absence of an ABCB1 
inhibitor (negative control) and the response elicited by the tariquidar (positive) control, which 
was defined as 100% inhibition of the calcein-AM efflux. IC50 values were calculated using 
four parameter sigmoidal fits. Errors were expressed as standard error of the mean (SEM). 
2.4.2.5 Inhibition of ABCC1: Calcein-AM Transport Assay [41] 
MDCK.2-MRP1 cells were seeded into 96-well plates at a density of 20,000 cells per well 
(100 μL/well) and allowed to attach to the surface of the microplates in a water-saturated 
atmosphere containing 5% CO2 at 37 °C overnight. The assay was performed and the data 
evaluated as described for the calcein-AM transport assay for analyzing ABCB1 inhibition with 
two exceptions: reversan at a final concentration of 30 µM served as positive control and the 
incubation time was 1 h. 
2.4.2.6 ABCG2 ATPase Assay 
Generation of recombinant baculoviruses encoding the ABCG2 protein (in the pVL1392 
vector) was performed in Sf9 insect cells using the BD BaculoGold transfection kit according 
to the manufacturer’s protocol. High-titer virus stock solutions were generated by 2-3 sequential 
amplifications. The supernatant fluid from the last amplification was stored at 4 °C under light 
protection. 
Membrane preparation. The protocol is based on the work of Sarkadi et al. [63]. Sf9 cells 
with a density of 3 x 106 cells/mL (100 mL) were infected 1:500 with a high-titer ABCG2 
baculovirus stock, incubated for 48 h and harvested by centrifugation at 4 °C and 500 g for 
10 min. The cell pellet was re-suspended in Tris mannitol buffer (50 mM Tris, 300 mM 
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mannitol, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), pH 7; 100 mL) and centrifuged 
again. Then the pellet was lysed and homogenized in TMEP buffer (50 mM Tris, 50 mM 
mannitol, 1 mM EDTA, 10 µg/mL leupeptin, 10 µg/mL benzamidine, 0.5 mM PMSF, 2 mM 
DTT, pH 7; 60 mL) by a Potter Elvehjem tissue homogenizer. Undisrupted cells and cellular 
debris were pelleted by centrifugation at 4 °C and 500 g for 10 min and the supernatant, 
containing the membranes, was removed carefully. For cholesterol loading [64,65], 2.5 mg/mL 
Cholesterol/RAMEB complex (cholesterol content 5.4%) was added (150 mg total) and the 
membranes were incubated at 4 °C for 20 min. After centrifugation at 4 °C and 100,000 g for 
1 h the pellet (containing the membranes) was re-suspended in TMEP buffer (30 mL), giving a 
protein concentration of 2.0-3.0 mg/mL, and homogenized with a Potter Elvehjem tissue 
homogenizer. All procedures during the membrane preparation were performed at 4 °C and 
aliquots (500-1000 µL) were stored at - 80 °C until use. 
Protein quantification was performed by the method of Bradford using the Bio-Rad protein 
assay kit according to the manual. 
Assay procedure. The assay was performed by analogy with the ABCB1 ATPase assay 
procedure described by Sarkadi et al. [63]. The ATPase activity of the ABCG2 transporter was 
estimated by measuring inorganic phosphate liberation. It was determined as orthovanadate-
sensitive ATPase activity in the presence of inhibitors in ABCG2 Sf9 membrane preparations. 
The assay was carried out in the activation mode, i.e. without stimulation of ABCG2, and in 
the inhibition mode, where the ABCG2 transporters in the membranes were stimulated with 
sulfasalazine. 
Membranes containing 2.0-2.5 mg total protein were thawed on ice and pelleted by 
centrifugation at 4 °C and 16,200 g for 10 min. Then they were suspended in assay buffer 
(50 mM MOPS-Tris (100 mM MOPS, pH adjusted to 7.0 with 1.7 M Tris), 50 mM KCl, 5 mM 
NaN3, 2 mM EGTA, 2 mM DTT, 1 mM ouabain; 4.2 mL), mixed with 10% (w/w) CHAPS 
(42 µL; decreases the high basal ABCG2 ATPase activity) and homogenized using a syringe 
and a needle (27G). When the assay was performed in the inhibition mode, 1.5 mM 
sulfasalazine (10.5 µL; final conc. 3 µM) was added to the suspension to activate ABCG2. The 
suspension was split into 2 portions (2.0 mL each) and one portion was supplemented with 
orthovanadate (100 mM Na3VO4, pH 10; 50 µL; final conc. 2 mM), the other with the same 
amount of purified water. The two suspensions (w. and wo. orthovanadate) were transferred 
into a 96-well plate on ice (40 µL/well; 20-25 µg protein/well) and pre-incubated at 37 °C for 
3 min. 
The ATPase reaction was started by adding the reference and test compounds in assay buffer 
containing 20 mM ATP (10 µL/well, giving a final volume of 50 µL/well; final conc. 4 mM) 
with a multichannel pipette and the plate was incubated at 37 °C in a microplate shaker for 1 h. 
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For this purpose, an ATP solution (200 mM MgxATP, 400 mM MgCl2, pH adjusted to 7.0 with 
1.7 M Tris) was diluted 1:10 (v/v) with assay buffer and the test and reference compounds were 
added 5-fold concentrated. Sulfasalazine at a final concentration of 30 µM served as reference 
activator (positive control) in the activation mode; FTC at a final concentration of 10 μM served 
as reference inhibitor (positive control) in the inhibition mode; the vehicle DMSO (1% final 
content) served as negative control. Each concentration (w. and wo. orthovanadate) was 
measured in duplicate, positive and negative control in quadruplicate each. 
The reaction was stopped by the addition of 10% (w/w) SDS (30 µL/well); background control 
(phosphate stemming from the assay buffer) (w. and wo. orthovanadate) was stopped before 
starting the reaction with MgATP and was measured in duplicate. 
Phosphate standards (0, 0.05, 0.1, 0.25, 1.5 and 2.0 mM NaH2PO4 in assay buffer; 50 µL/well; 
each concentration measured in duplicate) were included on each plate for calibration. 
The amount of phosphate was determined by adding a colorimetric reagent (1 part of reagent A 
(35 mM ammonium molybdate, 15 mM zinc acetate) mixed with 4 parts of reagent B (5% 
(w/w) ascorbic acid, pH 5.0; freshly prepared); 200 µL/well) and by incubating at 37 °C for 
further 20 min. The absorbance (820 nm) as a parameter proportional to the phosphate amount 
was measured, using a GENios Pro microplate reader. 
The data obtained under the treatment with orthovanadate were subtracted from the data without 
orthovanadate to obtain phosphate liberation resulting from ABCG2 activity. The ensuing data 
were normalized relative to the absorbance in the absence of an ABCG2 activator/inhibitor 
(negative control) and the response elicited by the sulfasalazine (positive) control, which was 
defined as 100% ATPase activity in the activation mode, or the response elicited by the FTC 
(positive) control, which was defined as 100% ATPase inhibition in the inhibition mode of the 
assay, where the membranes were activated with sulfasalazine. IC50 values were calculated 
using four parameter sigmoidal fits. Errors were expressed as standard error of the mean (SEM). 
2.4.2.7 Size-Exclusion Chromatography-Based Thermostability Assay (SEC-TS) 
Expression and purification of human ABCG2 was performed as described in our previous 
report [39]. 
Assay procedure. The assay was carried out as described in our previous study [39]. In short: 
Detergent-purified ABCG2 was incubated with or without the test compound at a concentration 
of 10 µM for 10 min at room temperature. Samples were aliquoted (100 µL each) and heated at 
one temperature, ranging from 30-75 °C, for 10 min in a Bio-Rad Thermocycler. Then the 
samples were cooled on ice, centrifuged at 4 °C and 100,000 g for 20 min and subjected to 
HP-SEC, using a TSKgel G3000SWxl column (Tosoh Biosciences) as stationary phase and a 
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detection wavelength of 280 nm. Tm values were calculated using four parameter sigmoidal fits. 
Errors were expressed as standard deviation (SD) of the best fit values. 
2.4.2.8 Chemosensitivity Assay [66] 
MCF-7/Topo cells were seeded into 96-well plates at a density of 1500 cells per well 
(100 μL/well) and allowed to attach to the surface of the microplates in a water-saturated 
atmosphere containing 5% CO2 at 37 °C overnight. The next day, fresh medium containing the 
test compounds at 2-fold final concentrations was added (100 µL/well; giving a final volume 
of 200 µL/well). On each plate, vinblastine at a final concentration of 300 nM served as 
reference cytostatic (positive control); the vehicle DMSO (0.1%) served as negative control to 
monitor cell growth in the absence of a drug. Each concentration was measured 8-fold, positive 
and negative control 16-fold each. Growth of the cells was stopped after different periods of 
time by removal of medium and fixation with 2% (v/v) glutardialdehyde in PBS. All the plates 
were stored at 4 °C until the end of the experiment and afterwards stained with 0.02% crystal 
violet (100 µL/well) for 20 min. Excess dye was removed by rinsing the plates with water three 
times. Crystal violet bound by the fixed cells was re-dissolved in 70% EtOH (180 µL/well) 
while shaking the microplates for 2-3 h. The absorbance (580 nm) as a parameter proportional 
to the cell mass was measured using a GENios Pro microplate reader. 









CT corr  
where T is the mean absorbance of the treated cells, C the mean absorbance of the negative 
controls and C0 the mean absorbance of the cells at the time of compound addition (t0). When 
the absorbance of treated cells T was lower than at the beginning of the experiment (C0), the 









2.4.2.9 Chemical Stability Assay (in Blood Plasma) [41] 
The blood from NMRI (nu/nu) mice was collected by cardiac puncture in deep anesthesia using 
heparinized syringes. To remove cellular components, the samples were immediately 
centrifuged at 4 °C and 4500 g for 7 min and the supernatant was carefully removed. The 
plasma samples were stored at - 80 °C. 
Stock solutions of the test compounds (3 mM in DMSO) were diluted 1:50 with murine plasma 
giving a concentration of 60 µM. The samples were vortexed shortly and incubated at 37 °C. 
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After different periods of time, aliquots were taken and deproteinated by adding two parts of 
ice-cold MeCN, vortexing and storing at 4 °C for 30 min. Samples were centrifuged at 4 °C and 
14,000 g for 5 min and the supernatants were filtered with syringe filters, diluted 1:1 with 
MeCN and stored at - 80 °C until analyzed. They were thawed at room temperature and 
analyzed with HPLC. 
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2.5 Supplementary Material 
2.5.1 NMR-Spectra of Key Compounds 
1H NMR spectrum (600 MHz, DMSO-d6) of compound 2.57. 
13C NMR spectrum (151 MHz, DMSO-d6) of compound 2.57. 
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1H NMR spectrum (600 MHz, CDCl3) of compound 2.59. 
13C NMR spectrum (151 MHz, CDCl3) of compound 2.59.  
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2.5.2 Chromatograms (Purity Control) of Key Compounds 
 
Chromatogram (purity control) of 2.07 (RP-HPLC). 
 
Chromatogram (purity control) of 2.08 (RP-HPLC). 
 
Chromatogram (purity control) of 2.41 (RP-HPLC). 
Tariquidar-Related Triazoles as Potent, Selective and Stable Inhibitors of ABCG2 
86 
 
Chromatogram (purity control) of 2.42 (RP-HPLC). 
 
Chromatogram (purity control) of 2.56 (RP-HPLC). 
 
Chromatogram (purity control) of 2.57 (RP-HPLC). 
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Chromatogram (purity control) of 2.59 (RP-HPLC). 
  
Tariquidar-Related Triazoles as Potent, Selective and Stable Inhibitors of ABCG2 
88 
2.6 References 
[1] Y.N. Chen, L.A. Mickley, A.M. Schwartz, E.M. Acton, J. Hwang, A.T. Fojo, 
Characterization of adriamycin-resistant human breast cancer cells which display 
overexpression of a novel resistance-related membrane protein, J. Biol. Chem., 265 (1990) 
10073-10080. 
[2] L.A. Doyle, W. Yang, L.V. Abruzzo, T. Krogmann, Y. Gao, A.K. Rishi, D.D. Ross, A 
multidrug resistance transporter from human MCF-7 breast cancer cells, Proc. Natl. Acad. Sci. 
U. S. A., 96 (1999) 2569. 
[3] F. Staud, P. Pavek, Breast cancer resistance protein (BCRP/ABCG2), Int. J. Biochem. Cell 
Biol., 37 (2005) 720-725. 
[4] M.M. Gottesman, T. Fojo, S.E. Bates, Multidrug resistance in cancer: role of ATP-
dependent transporters, Nat. Rev. Cancer, 2 (2002) 48-58. 
[5] H.R. Mellor, R. Callaghan, Resistance to Chemotherapy in Cancer: A Complex and 
Integrated Cellular Response, Pharmacology, 81 (2008) 275-300. 
[6] B.C. Baguley, Multiple Drug Resistance Mechanisms in Cancer, Mol. Biotechnol., 46 
(2010) 308-316. 
[7] R.W. Robey, K.M. Pluchino, M.D. Hall, A.T. Fojo, S.E. Bates, M.M. Gottesman, Revisiting 
the role of ABC transporters in multidrug-resistant cancer, Nat. Rev. Cancer, 18 (2018) 452-
464. 
[8] D.J. Begley, ABC transporters and the blood-brain barrier, Curr. Pharm. Des., 10 (2004) 
1295-1312. 
[9] C. Ghosh, V. Puvenna, J. Gonzalez-Martinez, D. Janigro, N. Marchi, Blood-brain barrier 
P450 enzymes and multidrug transporters in drug resistance: a synergistic role in neurological 
diseases, Curr. Drug Metab., 12 (2011) 742-749. 
[10] A. Mahringer, G. Fricker, ABC transporters at the blood-brain barrier, Expert Opin. Drug 
Metab. Toxicol., 12 (2016) 499-508. 
[11] M. Hubensack, C. Mueller, P. Hoecherl, S. Fellner, T. Spruss, G. Bernhardt, A. Buschauer, 
Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in 
nude mice, J. Cancer Res. Clin. Oncol., 134 (2008) 597-607. 
[12] M.H. Hasanabady, F. Kalalinia, ABCG2 inhibition as a therapeutic approach for 
overcoming multidrug resistance in cancer, J. Biosci., 41 (2016) 313-324. 
[13] J.W. Ricci, D.M. Lovato, V. Severns, L.A. Sklar, R.S. Larson, Novel ABCG2 Antagonists 
Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts, 
Mol. Cancer Ther., 15 (2016) 2853-2862. 
[14] M.C. de Gooijer, N.A. de Vries, T. Buckle, L.C.M. Buil, J.H. Beijnen, W. Boogerd, O. van 
Tellingen, Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition 
of ABCB1 and ABCG2, Neoplasia, 20 (2018) 710-720. 
[15] A. Karbownik, K. Sobańska, W. Płotek, T. Grabowski, A. Klupczynska, S. Plewa, E. 
Grześkowiak, E. Szałek, The influence of the coadministration of the p-glycoprotein modulator 
elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal 
fluid, Invest. New Drugs, (2019) Ahead of Print. 
[16] M. Bauer, R. Karch, B. Wulkersdorfer, C. Philippe, L. Nics, E.-M. Klebermass, M. Weber, 
S. Poschner, H. Haslacher, W. Jaeger, N. Tournier, W. Wadsak, M. Hacker, M. Zeitlinger, O. 
Langer, A proof-of-concept study to inhibit ABCG2- and ABCB1- mediated efflux transport at 
the human blood-brain barrier, J. Nucl. Med., 60 (2019) 486-491. 
[17] S. Dauchy, F. Dutheil, R.J. Weaver, F. Chassoux, C. Daumas-Duport, P.-O. Couraud, J.-
M. Scherrmann, I. De Waziers, X. Decleves, ABC transporters, cytochromes P450 and their 
main transcription factors: expression at the human blood-brain barrier, J. Neurochem., 107 
(2008) 1518-1528. 
Tariquidar-Related Triazoles as Potent, Selective and Stable Inhibitors of ABCG2 
89 
[18] R. Shawahna, Y. Uchida, X. Decleves, S. Ohtsuki, S. Yousif, S. Dauchy, A. Jacob, F. 
Chassoux, C. Daumas-Duport, P.-O. Couraud, T. Terasaki, J.-M. Scherrmann, Transcriptomic 
and Quantitative Proteomic Analysis of Transporters and Drug Metabolizing Enzymes in 
Freshly Isolated Human Brain Microvessels, Mol. Pharmaceutics, 8 (2011) 1332-1341. 
[19] F. Hyafil, C. Vergely, P. Du Vignaud, T. Grand-Perret, In vitro and in vivo reversal of 
multidrug resistance by GF120918, an acridonecarboxamide derivative, Cancer Res., 53 (1993) 
4595-4602. 
[20] M. de Bruin, K. Miyake, T. Litman, R. Robey, S.E. Bates, Reversal of resistance by 
GF120918 in cell lines expressing the ABC half-transporter, MXR, Cancer Lett., 146 (1999) 
117-126. 
[21] M. Roe, A. Folkes, P. Ashworth, J. Brumwell, L. Chima, S. Hunjan, I. Pretswell, W. 
Dangerfield, H. Ryder, P. Charlton, Reversal of P-glycoprotein mediated multidrug resistance 
by novel anthranilamide derivatives, Bioorg. Med. Chem. Lett., 9 (1999) 595-600. 
[22] R.W. Robey, K. Steadman, O. Polgar, K. Morisaki, M. Blayney, P. Mistry, S.E. Bates, 
Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition, Cancer Res., 64 (2004) 
1242-1246. 
[23] S.K. Rabindran, H. He, M. Singh, E. Brown, K.I. Collins, T. Annable, L.M. Greenberger, 
Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by 
fumitremorgin C, Cancer Res., 58 (1998) 5850-5858. 
[24] J.D. Allen, A. Van Loevezijn, J.M. Lakhai, M. Van der Valk, O. Van Tellingen, G. Reid, 
J.H.M. Schellens, G.-J. Koomen, A.H. Schinkel, Potent and specific inhibition of the breast 
cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel 
analogue of fumitremorgin C, Mol. Cancer Ther., 1 (2002) 417-425. 
[25] L.D. Weidner, S.S. Zoghbi, S. Lu, S. Shukla, S.V. Ambudkar, V.W. Pike, J. Mulder, M.M. 
Gottesman, R.B. Innis, M.D. Hall, The inhibitor Ko143 is not specific for ABCG2, J. 
Pharmacol. Exp. Ther., 354 (2015) 384-393. 
[26] S.A.L. Zander, J.H. Beijnen, O. van Tellingen, Sensitive method for plasma and tumor 
Ko143 quantification using reversed-phase high-performance liquid chromatography and 
fluorescence detection, J. Chromatogr. B: Anal. Technol. Biomed. Life Sci., 913-914 (2013) 
129-136. 
[27] K. Liu, J. Zhu, Y. Huang, C. Li, J. Lu, M. Sachar, S. Li, X. Ma, Metabolism of Ko143, an 
ABCG2 inhibitor, Drug Metab. Pharmacokinet., 32 (2017) 193-200. 
[28] A. Spindler, K. Stefan, M. Wiese, Synthesis and Investigation of Tetrahydro-β-carboline 
Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2), J. Med. Chem., 59 
(2016) 6121-6135. 
[29] W. Chearwae, S. Shukla, P. Limtrakul, S.V. Ambudkar, Modulation of the function of the 
multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer 
chemopreventive agent curcumin, Mol. Cancer Ther., 5 (2006) 1995-2006. 
[30] E. Nicolle, J. Boccard, D. Guilet, M.-G. Dijoux-Franca, F. Zelefac, S. Macalou, J. 
Grosselin, J. Schmidt, P.-A. Carrupt, A. Di Pietro, A. Boumendjel, Breast cancer resistance 
protein (BCRP/ABCG2): New inhibitors and QSAR studies by a 3D linear solvation energy 
approach, Eur. J. Pharm. Sci., 38 (2009) 39-46. 
[31] K. Takada, N. Imamura, K.R. Gustafson, C.J. Henrich, Synthesis and structure-activity 
relationship of botryllamides that block the ABCG2 multidrug transporter, Bioorg. Med. Chem. 
Lett., 20 (2010) 1330-1333. 
[32] J. Gallus, K. Juvale, M. Wiese, Characterization of 3-methoxy flavones for their interaction 
with ABCG2 as suggested by ATPase activity, Biochim. Biophys. Acta, Biomembr., 1838 
(2014) 2929-2938. 
[33] N. Sjostedt, K. Holvikari, P. Tammela, H. Kidron, Inhibition of Breast Cancer Resistance 
Protein and Multidrug Resistance Associated Protein 2 by Natural Compounds and Their 
Derivatives, Mol. Pharmaceutics, 14 (2017) 135-146. 
Tariquidar-Related Triazoles as Potent, Selective and Stable Inhibitors of ABCG2 
90 
[34] K. Silbermann, C.P. Shah, N.U. Sahu, K. Juvale, S.M. Stefan, P.S. Kharkar, M. Wiese, 
Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins 
ABCB1 and ABCG2, Eur. J. Med. Chem., 164 (2019) 193-213. 
[35] G. Valdameri, E. Genoux-Bastide, B. Peres, C. Gauthier, J. Guitton, R. Terreux, S.M.B. 
Winnischofer, M.E.M. Rocha, A. Boumendjel, A. Di Pietro, Substituted Chromones as Highly 
Potent Nontoxic Inhibitors, Specific for the Breast Cancer Resistance Protein, J. Med. Chem., 
55 (2012) 966-970. 
[36] R. Yamazaki, H. Hatano, T. Yaegashi, Y. Igarashi, O. Yoshida, Y. Sugimoto, Preparation 
of 3-[4-(4-hydroxypiperidin-1-yl)thiophen-2-yl]-2-phenylacrylonitrile 2-(cyclic amino)acetyl 
esters as breast cancer resistance protein (ABCG2) inhibitors, WO2009072267A1, 2009. 
[37] R. Yamazaki, Y. Nishiyama, T. Furuta, H. Hatano, Y. Igarashi, N. Asakawa, H. Kodaira, 
H. Takahashi, R. Aiyama, T. Matsuzaki, N. Yagi, Y. Sugimoto, Novel Acrylonitrile 
Derivatives, YHO-13177 and YHO-13351, Reverse BCRP/ABCG2-Mediated Drug Resistance 
In Vitro and In Vivo, Mol. Cancer Ther., 10 (2011) 1252-1263. 
[38] N.M.I. Taylor, I. Manolaridis, S.M. Jackson, J. Kowal, H. Stahlberg, K.P. Locher, 
Structure of the human multidrug transporter ABCG2, Nature, 546 (2017) 504-509. 
[39] S.M. Jackson, I. Manolaridis, J. Kowal, M. Zechner, N.M.I. Taylor, M. Bause, S. Bauer, 
R. Bartholomaeus, G. Bernhardt, B. Koenig, A. Buschauer, H. Stahlberg, K.-H. Altmann, K.P. 
Locher, Structural basis of small-molecule inhibition of human multidrug transporter ABCG2, 
Nat. Struct. Mol. Biol., 25 (2018) 333-340. 
[40] M. Kühnle, M. Egger, C. Müller, A. Mahringer, G. Bernhardt, G. Fricker, B. König, A. 
Buschauer, Potent and Selective Inhibitors of Breast Cancer Resistance Protein (ABCG2) 
Derived from the p-Glycoprotein (ABCB1) Modulator Tariquidar, J. Med. Chem., 52 (2009) 
1190-1197. 
[41] S. Bauer, C. Ochoa-Puentes, Q. Sun, M. Bause, G. Bernhardt, B. Koenig, A. Buschauer, 
Quinoline Carboxamide-Type ABCG2 Modulators: Indole and Quinoline Moieties as Anilide 
Replacements, ChemMedChem, 8 (2013) 1773-1778. 
[42] L. Liang, D. Astruc, The copper(I)-catalyzed alkyne-azide cycloaddition (CuAAC) “click” 
reaction and its applications. An overview, Coord. Chem. Rev., 255 (2011) 2933-2945. 
[43] T.R. Chan, R. Hilgraf, K.B. Sharpless, V.V. Fokin, Polytriazoles as Copper(I)-Stabilizing 
Ligands in Catalysis, Org. Lett., 6 (2004) 2853-2855. 
[44] C.O. Puentes, P. Höcherl, M. Kühnle, S. Bauer, K. Bürger, G. Bernhardt, A. Buschauer, 
B. König, Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring 
breast cancer resistance protein (ABCG2), Bioorg. Med. Chem. Lett., 21 (2011) 3654-3657. 
[45] C. Ochoa-Puentes, S. Bauer, M. Kühnle, G. Bernhardt, A. Buschauer, B. König, 
Benzanilide–Biphenyl Replacement: A Bioisosteric Approach to Quinoline Carboxamide-Type 
ABCG2 Modulators, ACS Med. Chem. Lett., 4 (2013) 393-396. 
[46] J.E. Obreque-Balboa, Q. Sun, G. Bernhardt, B. König, A. Buschauer, Flavonoid 
derivatives as selective ABCC1 modulators: Synthesis and functional characterization, Eur. J. 
Med. Chem., 109 (2016) 124-133. 
[47] S. Kraege, K. Stefan, K. Juvale, T. Ross, T. Willmes, M. Wiese, The combination of 
quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast 
cancer resistance protein (BCRP/ABCG2), Eur. J. Med. Chem., 117 (2016) 212-229. 
[48] T. Litman, T.E. Druley, W.D. Stein, S.E. Bates, From MDR to MXR: new understanding 
of multidrug resistance systems, their properties and clinical significance, Cell. Mol. Life Sci., 
58 (2001) 931-959. 
[49] T. Reya, S.J. Morrison, M.F. Clarke, I.L. Weissman, Stem cells, cancer, and cancer stem 
cells, Nature, 414 (2001) 105-111. 
[50] H. Itatani, J.C. Bailar, Homogenous catalysis in the reactions of olefinic substances. V. 
Hydrogenation of soybean oil methyl ester with triphenylphosphine and triphenylarsine 
palladium catalysts, J. Am. Oil Chem. Soc., 44 (1967) 147-151. 
Tariquidar-Related Triazoles as Potent, Selective and Stable Inhibitors of ABCG2 
91 
[51] G. Palmisano, G. Lesma, M. Nali, B. Rindone, S. Tollari, A mild and chemoselective 
reduction of cyclic iminium salts, Synthesis, (1985) 1072-1074. 
[52] A. Heckel, R. Walter, W. Grell, J.C.A. Van Meel, N. Redemann, 
Aminomethyleneindolinones with antitumor activity, WO9962882A1, 1999. 
[53] W. Klinkhammer, H. Mueller, C. Globisch, I.K. Pajeva, M. Wiese, Synthesis and 
biological evaluation of a small molecule library of 3rd generation multidrug resistance 
modulators, Bioorg. Med. Chem., 17 (2009) 2524-2535. 
[54] T.A. Davidson, R.C. Griffith, N-[Amino(or hydroxy)phenethyl]-1,2,3,4-
tetrahydroisoquinolines and precursors, EP51190A2, 1982. 
[55] N. Dodic, B. Dumaitre, A. Daugan, P. Pianetti, Synthesis and Activity against Multidrug 
Resistance in Chinese Hamster Ovary Cells of New Acridone-4-carboxamides, J. Med. Chem., 
38 (1995) 2418-2426. 
[56] B. Liu, Q. Qiu, T. Zhao, L. Jiao, J. Hou, Y. Li, H. Qian, W. Huang, Discovery of Novel P-
Glycoprotein-Mediated Multidrug Resistance Inhibitors Bearing Triazole Core via Click 
Chemistry, Chem. Biol. Drug Des., 84 (2014) 182-191. 
[57] G.A. Gazzaeva, M.I. Khasanov, S.S. Mochalov, N.S. Zefirov, 4H-3,1-Benzoxazines from 
ortho-aminoacylbenzenes, Chem. Heterocycl. Compd., 43 (2007) 799-810. 
[58] M. Hubensack, Approaches to Overcome the Blood-Brain Barrier in the Chemotherapy of 
Primary and Secondary Brain Tumors: Modulation of P-glycoprotein 170 and Targeting of the 
Transferrin Receptor, Dissertation, University of Regensburg, 2005, https://epub.uni-
regensburg.de/10297/. 
[59] C.-H. Yang, E. Schneider, M.-L. Kuo, E.L. Volk, E. Rocchi, Y.-C. Chen, 
BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells, Biochem. 
Pharmacol., 60 (2000) 831-837. 
[60] K. Kohno, J. Kikuchi, S. Sato, H. Takano, Y. Saburi, K. Asoh, M. Kuwano, Vincristine-
resistant human cancer KB cell line and increased expression of multidrug-resistance gene, Jpn. 
J. Cancer Res., 79 (1988) 1238-1246. 
[61] R. Evers, M. Kool, L. van Deemter, H. Janssen, J. Calafat, L.C. Oomen, C.C. Paulusma, 
R.P. Oude Elferink, F. Baas, A.H. Schinkel, P. Borst, Drug export activity of the human 
canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing 
cMOAT (MRP2) cDNA, J. Clin. Invest., 101 (1998) 1310-1319. 
[62] E. Bakos, R. Evers, G. Szakacs, G.E. Tusnady, E. Welker, K. Szabo, M. De Haas, L. Van 
Deemter, P. Borst, A. Varadi, B. Sarkadi, Functional multidrug resistance protein (MRP1) 
lacking the N-terminal transmembrane domain, J. Biol. Chem., 273 (1998) 32167-32175. 
[63] B. Sarkadi, E.M. Price, R.C. Boucher, U.A. Germann, G.A. Scarborough, Expression of 
the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated 
membrane ATPase, J. Biol. Chem., 267 (1992) 4854-4858. 
[64] A. Telbisz, M. Mueller, C. Ozvegy-Laczka, L. Homolya, L. Szente, A. Varadi, B. Sarkadi, 
Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug 
transporter, Biochim. Biophys. Acta, Biomembr., 1768 (2007) 2698-2713. 
[65] A. Pal, D. Mehn, E. Molnar, S. Gedey, P. Meszaros, T. Nagy, H. Glavinas, T. Janaky, O. 
von Richter, G. Bathori, L. Szente, P. Krajcsi, Cholesterol potentiates ABCG2 activity in a 
heterologous expression system: improved in vitro model to study function of human ABCG2, 
J. Pharmacol. Exp. Ther., 321 (2007) 1085-1094. 
[66] G. Bernhardt, H. Reile, H. Birnböck, T. Spruß, H. Schönenberger, Standardized kinetic 
microassay to quantify differential chemosensitivity on the basis of proliferative activity, J. 








3 Water-Soluble Inhibitors of ABCG2 





Prior to the submission of this thesis, this chapter was submitted slightly modified for 
publication: 
F. Antoni*, D. Wifling, G. Bernhardt, Water-soluble inhibitors of ABCG2 (BCRP) – a 




F.A. conceived the project with input from the co-authors. F.A. designed the target structures; 
3.48, 3.49 and 3.50 were designed by F.A. and D.W. together. D.W. performed the molecular 
docking studies. F.A. performed the synthesis, the biological assays, the solubility assays and 




Water-Soluble Inhibitors of ABCG2 – A Fragment-Based and Computational Approach 
94 
3.1 Introduction 
Water solubility of a compound is indispensable for its biological activity: undissolved, a 
molecule cannot reach its target. This is a simple fact, however often undervalued. There is a 
general tendency in drug discovery towards large and lipophilic molecules – such compounds 
are more likely to be identified as ‘hits’ in high-throughput screenings (in which the compounds 
are added ‘pre-dissolved’ in DMSO) [1,2], and during the optimization of the ‘hits’ often 
additional lipophilic substituents are attached [3]. The dilemma is that higher lipophilicity is 
strongly connected with increased in vitro activity [2,4], because hydrophobic interactions are 
the dominant driving forces in small-molecule ligand-protein binding processes [5,6]. 
Frequently, drug discovery strategies lead to a substance with high activity and selectivity but 
very poor aqueous solubility [1,2]. 
This phenomenon causes immense problems, because aqueous solubility plays an essential role 
in virtually every phase of the discovery and development of pharmacological tools and drugs 
[3,7]. It already begins in the purification process, where RP-HPLC is commonly the method 
of choice, for which the substance needs to be dissolved in a water-containing eluent. In 
biological in vitro studies, low solubility leads to erratic and erroneous assay results [3]. If 
precipitation occurs before the compound can reach its target, the actual concentration is lower 
than intended and the substance appears less active [3,8]. Hence, structure-activity relationship 
analyses are compromised [9] and off-target activities may become undetectable [3]. In vivo, 
after oral administration, poor water solubility results in inadequate resorption [1-3,8,10]. Self-
evidently, the compound needs to be dissolved in the aqueous gastrointestinal fluids in order to 
cross the intestinal membranes, and the flux (passive diffusion) is directly proportional to the 
concentration gradient of the agent between the intestinal lumen and the blood [1]. Poorly 
soluble compounds are particularly susceptible to food effects (on drug absorption) and often 
special excipients are required, which can impair the results of in vivo studies [3]. Not only oral 
drug forms, but also parenteral formulations depend heavily on sufficient aqueous solubility, 
water being the solvent of choice for intravenous administration [10]. Furthermore, in 
organisms, poorly soluble drugs may precipitate at high concentrations and cause adverse 
effects such as phlebitis [11]. Taken together, sufficient aqueous solubility is of major 
importance for both drugs and pharmacological tools and low solubility of drug candidates has 
been the cause of numerous failures in drug development [12]. 
When addressing solubility problems, formulation technology can help, but this approach is 
expensive and there is no guarantee of success [1-3,9]. Therefore, the primary strategy should 
be to improve solubility by adequate alterations of the chemical structure of the molecule 
[2,9,13]. Such structural changes fall into three categories: they aim either at (I) decreasing the 
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crystal packing energy, e.g. by disrupting planarity, [2,7,13-15] (II) increasing the solvation 
energy, for example by attaching polar or ionizable groups [2,7,13,15] or at (III) reducing the 
cavitation energy [16] – required to form a cavity in the water structure in order to host the 
solute molecule, which results in a concomitant decrease in entropy – for instance by reducing 
the size of the molecule [2,15]. Whether these structural changes actually enhance the solubility 
is hard to predict, also when in silico methods are applied [2]. In 1997, Lipinski et al. published 
their seminal article on the well-known ‘rule of five’ (Ro5) [1]. Using a library of drugs with 
‘good’ resorption properties (i.e. drugs that passed clinical Phase II selection), the group 
identified four calculable parameters to estimate resorption by free diffusion, a process which 
is dependent on sufficient solubility and permeability. The authors concluded that resorption 
problems are more likely to occur, when there are more than five H-bond donors, ten H-bond 
acceptors, the molecular weight (MWT) is higher than 500 Da and the calculated logP (clogP) 
is higher than five (all values are five or multiples thereof) [1]. Since then, a couple of drugs 
that are Ro5-outliers have emerged (e.g. the anticancer drug Navitoclax [17]), but the bottom 
line of articles on the subject is mostly the same: the development of ‘beyond-Ro5’ drugs is 
feasible and for some targets necessary, but extremely difficult, and there is a high probability 
of failure [18-20]. Therefore, medicinal chemists are well-advised to take the Ro5 into 
consideration when designing novel chemical entities. 
Ultimately, with the designed compound in hand, solubility can be assessed experimentally to 
find out if the solubility-optimization process was successful. Usually a distinction is made 
between the kinetic and the thermodynamic (equilibrium) solubility of a compound (c.f. 
Section 3.2.4). What levels of equilibrium solubility are required for pharmacological tools and 
drugs is debated, but a range between 1 µM to 0.1 M may be considered as a drug solubility 
window [21]. As a rule of thumb, the solubility of a compound should be at least three times its 
IC50 value [22]. 
The target we address in this study – ABCG2 – is a member of the ATP-binding cassette (ABC) 
transporter superfamily [23]. It functions as an exporter and is predominantly expressed in the 
plasma membrane [24]. Inhibitors of ABCG2 have been developed as pharmacological tools to 
study the patho(physiological) role of this transporter and as a means to overcome the blood-
brain barrier (BBB) [25] or multidrug resistance (MDR) in cancer [26]. During the development 
of ABCG2 inhibitors the focus has been on optimizing their potency and selectivity. In a few 
cases [27,28], efforts have been made to improve some of their drug-like (i.e. ADME-Tox) 
properties, mainly to increase their stability or decrease their toxicity. But their physicochemical 
properties, especially their water solubility, have been neglected so far. Aqueous solubility has 
not been a parameter much taken into consideration and up to now no solubility-driven 
optimization of ABCG2 inhibitors has been reported. The outcome is that most ABCG2 
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inhibitors described so far are relatively large and lipophilic molecules. Increasing the aqueous 
solubility of ABCG2 inhibitors is a great challenge, because ABCG2, much more than many 
other targets, requires ligands that show high lipophilicity and size. In contrast to ligands of 
membrane-spanning receptors, an ABCG2 inhibitor must permeate through the cell membrane 
to reach its target, i.e. the multidrug binding site, which was recently identified by cryo-EM 
studies [29,30]. Moreover, as revealed in the aforementioned structural studies, the binding site 
is comparatively large and markedly hydrophobic. 
 
Figure 3.1. Our previous tariquidar-related ABCG2 inhibitors UR-MB108 (3.01) and UR-MB19 (3.02) and rationale of our 
fragment-based approach: deconstruction of 3.02 to the fragments 3.03 and 3.04. 
Previously we reported on tariquidar-related triazoles (such as UR-MB108 (3.01); Figure 3.1 
as selective and stable inhibitors of ABCG2 [28]. Inhibitor 3.01 acted as a potent and effective 
ABCG2 transport and ATPase inhibitor. Accordingly, it appeared to stay in solution at least for 
the short time span of the transport and ATPase assay. Unfortunately – preempting one result 
of the present study – the equilibrium solubility of inhibitor 3.01 was as low as 78 nM, neither 
reaching the level of at least 1 µM mentioned above, nor fulfilling the rule of thumb, the IC50 
value of 3.01 also being around 80 nM. In the present study, we set out to design and prepare 
potent and stable ABCG2 inhibitors with improved equilibrium water solubility, using our 
previous inhibitors (3.01 and UR-MB19 (3.02); Figure 3.1) as a starting point. To this end, we 
pursued a fragment-based approach, which we considered suitable for our predicament because 
of the following reasons: high-affinity ligands that are small have been shown to bind with 
favorable enthalpy, dominated by optimal polar interactions [31,32], whereas for larger ligands 
entropy changes become increasingly important (coming mainly from the desolvation; water 
molecules from the solvation shell are released and join bulk water) [31,32]. Therefore, ligands 
optimized in a fragment-based approach are more likely to be relatively low in hydrophobicity 
and small in size [31,32]. Moreover, fragments are easier to prepare synthetically, so this 
strategy is also time-saving. Figure 3.1 shows the rationale of our fragment-based approach: 
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compound 3.02 was ‘deconstructed’ to the fragments 3.03 and 3.04 for analysis and 
optimization. When ‘enlarging’ the new fragments to obtain potent and soluble inhibitors, we 
took advantage of the recently published cryo-EM structure of ABCG2 in complex with 
inhibitors [29], too, and used molecular docking studies to optimize protein-ligand interactions. 
In addition, we considered Lipinski’s Ro5 when designing our novel inhibitors. Furthermore, 
we established thermodynamic and kinetic solubility assays suitable for analyzing compounds 
in the comparatively low solubility range of ABCG2 inhibitors. 
3.2 Results and Discussion 
3.2.1 Design and Synthesis 
We designed fragment 3.04 in a way that it contains a more readily accessible ester moiety (like 
in 3.02), instead of a more stable ketone function (as in 3.01), because stability was not an issue 
in case of the fragments; they merely served as a starting point for structural optimizations and 
‘enlarging’ or merging/linking with other fragments to obtain potent inhibitors. The 
introduction of a ketone group only gave very low yields, whereas the building block 
comprising the ester was commercially available. 
The synthesis of the fragments 3.03 and 3.04 is shown in Scheme 3.1. Compound 3.03 was 
prepared in a copper-catalyzed azide-alkyne cycloaddition (CuAAC), belonging to a set of 
synthetic procedures termed ‘click’ reactions due to their convenience, versatility and 
achievement of high yields [33]. The azide for the ‘click’ reaction was synthesized according 
to our previous report [28]. 1-(2-bromoethyl)-4-nitrobenzene (3.05) was treated with 6,7-
dimethoxy-1,2,3,4-tetrahydroisoquinoline (3.06) in an N-alkylation reaction to give compound 
3.07, then the nitro group was hydrogenated to an amine group (yielding 3.08) and converted 
to an azide, resulting in compound 3.09, which was introduced into a ‘click’ reaction with 
phenylacetylene (3.10). In this variant of the CuAAC we used the polytriazole TBTA as a 
copper(I)-stabilizing ligand. 
Fragment 3.04 was synthesized by amide bond formation from methyl 2-amino-4-
bromobenzoate (3.11) and quinoline-2-carboxylic acid, using TBTU as a coupling reagent. 
Compound 3.11 is a building block of our previous inhibitor 3.02 and was therefore abundantly 
available in our laboratory. In pursuit of convenient, fast and economic procedures, we used 
3.11 for synthesizing compound 3.04 (and further fragments), which is the reason for the 
presence of bromine in the respective substructure. 
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Scheme 3.1. (A) Synthesis of fragment 3.03. Reagents and conditions: (a) K2CO3, MeCN, 130 °C (microwave), 70 min; (b) 
Pd/C, H2 (10 bar), EtOH, rt, overnight; (c) (I) NaNO2, 6 M HCl aq, 0 °C, 1 h; (II) NaN3, 0 °C → rt, 2 h; (d) CuSO4, sodium 
ascorbate, TBTA, CHCl3, reflux, 1 d. (B) Synthesis of the fragments 3.04 and 3.12-3.28. Reagents and conditions: (a) respective 
carboxylic acid, TBTU, DIPEA, DMF, 80 °C (microwave), 30 min; or respective carboxylic acid chloride (carboxylic acid, 
SOCl2, pyridine, toluene, reflux, 2 h), DIPEA, DCM, 0 °C, overnight; (b) HSiCl3, DIPEA, DCM, 0 °C → rt, overnight. 
Based on the inhibitory potency and efficacy of the two fragments 3.03 and 3.04, fragment 3.04 
was selected for further optimization and study. We replaced the quinoline moiety by 17 
different groups, yielding the novel fragments 3.12-3.28 (Scheme 3.1B). Our strategy for 
designing the fragment library derived from compound 3.04 was as follows: we performed 
structural changes aiming at improved solubility and/or introduced substructures known to 
confer inhibitory potency at ABCG2. In order to gain structural information, we performed an 
X-ray analysis of a crystal of 3.04 (Figure 3.2). This showed that the molecule was present in a 
flat conformation and that there was a hydrogen bond between the ester carbonyl oxygen and 
the amide hydrogen. The quinoline nitrogen faced the amide hydrogen, probably due to dipole-
dipole interaction. As a trend, the higher the planarity the more π-π stacking is possible, 
contributing to crystal lattice stability [4]. The solubility can be increased by disrupting 
planarity, thus decreasing the crystal lattice energy. We implemented this idea by substituting 
the quinoline nitrogen by a carbon (3.12) (in the hope of decreasing the dipole-dipole 
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interactions with the amide hydrogen, thereby allowing rotation), by increasing the fraction of 
sp3-hybridized carbon (3.13, 3.14) and by omitting one aromatic ring (3.15). Destabilizing the 
crystal lattice is a useful approach, when high lipophilicity is required by targets such as 
ABCG2. We also made efforts to decrease the logP value by introducing polar groups 
(substituting one aromatic ring) (3.16-3.23) or by substituting the quinoline nitrogen by oxygen 
(more electronegative), hence increasing polarity (3.24-3.26). Fragments 3.18 and 3.19 bear 
methoxy groups, which are present in many known ABCG2 inhibitors [35-37], and compound 
3.21 contains a nitro group, also found in a number of ABCG2 inhibitors [38,39]. Furthermore, 
chromone is a very prominent substructure of numerous ABCG2 inhibitors reported [40-42] 
and is a structural element of the fragments 3.27 and 3.28. 
 
Figure 3.2. Structure of compound 3.04, determined by X-ray analysis. 
Like their precursor 3.04, the fragments 3.12-3.21 and 3.24-3.28 were synthesized from 3.11 
and the respective carboxylic acid by amide bond formation (Scheme 3.1B). The carboxylic 
acids employed were all commercially available, except the corresponding acid for fragment 
3.13. The acid was synthesized according to literature [34]. 5,6,7,8-Tetrahydroquinoline was 
oxidized at the nitrogen with 3-chlorobenzoperoxoic acid, yielding 5,6,7,8-tetrahydroquinoline 
1-oxide (3.29), then treated with trimethylsilyl cyanide and dimethylcarbamoyl chloride to form 
5,6,7,8-tetrahydroquinoline-2-carbonitrile (3.30) and afterwards hydrolyzed with hydrochloric acid 
to 5,6,7,8-tetrahydroquinoline-2-carboxylic acid (3.31). The fragments 3.22 and 3.23 were 
obtained by reduction of the nitro group in compound 3.21 to an amino group (in 3.22) and a 
hydroxyl amino group (in 3.23), using trichlorosilane. 
According to the biological results of the novel fragments, we chose compound 3.27, containing 
a chromone moiety, for further optimization and ‘decorating’, yielding a chromone-based series 
of inhibitors (comprising two subsets; Scheme 3.2) Aiming at increased solubility, we 
introduced solubilizing groups such as basic, acidic and hydroxyl moieties. 
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In a first chromone subset, we introduced solubilizing groups via ‘click’ chemistry in meta-
position to the amide moiety (replacing the bromine), analogous to our previous inhibitors 3.01 
and 3.02, which bear a triazole ring in an equivalent position. For this purpose, we converted 
protonatable 2-morpholinoethyl chloride (3.32) and 2-pyrrolidoethyl chloride (3.33) into the 
corresponding azides (3.34 and 3.35) (Scheme 3.2A). Besides, we employed the azide 3.09 and 
commercially available azides containing a hydroxyl group or a carboxylic acid. For stability 
reasons, we also substituted the ester moiety by a ketone. The latter was synthesized by 
acylating 3-ethynylaniline (3.36) in ortho-position to the amine group in a variant of the 
Sugasawa reaction, using GaCl3 as a Lewis acid (forming 3.37). Then the chromone-2-
carboxylic acid was introduced by amide bond formation, giving compound 3.38, which was 
treated with the respective azide in a ‘click’ reaction to form the inhibitors 3.39-3.43 
(Scheme 3.2B). 
We performed molecular docking experiments with fragment 3.27, using the recently published 
cryo-EM structure of ABCG2 (see Section 3.2.2). Based on these experiments, we created a 
second chromone subset, in which we introduced solubilizing groups (also via ‘click’) in ortho-
position to the amide moiety, substituting the ester group, and a methyl group meta to the amide 
group (substituting the bromine). The synthesis started from 2-iodo-5-methylaniline (3.44), 
which was coupled with trimethylsilysacetylene in a Sonogashira reaction (yielding the alkyne 
3.45), deprotected with potassium carbonate to 3.46, treated with chromone-2-carboxylic acid 
to form the amide 3.47 and then submitted to CuAAC with the respective azide, resulting in the 
inhibitors 3.48-3.50 (Scheme 3.2C). 
  
Water-Soluble Inhibitors of ABCG2 – A Fragment-Based and Computational Approach 
101 
 
Scheme 3.2. (A) Synthesis of the azide building blocks 3.34 and 3.35. Reagents and conditions: NaN3, H2O, 130 °C 
(microwave), 1 h. (B+C) Synthesis of the inhibitors 3.39-3.43 (B) and 3.48-3.50 (C), bearing a chromone moiety. Reagents 
and conditions: (a) (I) propionitrile, BCl3, CHCl3, 0 °C; (II) GaCl3, 0 °C, 10 min → rt → reflux, overnight; (III) 2 M HCl aq, 
0 °C → 70 °C, 2 h; (b) 4-oxo-4H-chromene-2-carboxylic acid, TBTU, DIPEA, DMF, 80 °C (microwave), 30 min; (c) 
respective azide, CuSO4, sodium ascorbate, TBTA, CHCl3, reflux, 2-3 d; (d) trimethylsilylacetylene, Pd(PPh3)2Cl2, CuI, NEt3, 
THF, rt, 90 min; (e) K2CO3, MeOH, rt, 2 h. 
In addition to the compounds derived from fragment 3.27, we prepared a second series 
(Scheme 3.3), in which we merged fragments showing activity similar to their precursor 3.04, 
with fragment 3.03. By analogy with our previous inhibitor 3.01, we also replaced the ester 
moiety by a ketone group in order to provide for chemical stability. This series was synthesized 
from compound 3.37, which was treated with the corresponding carboxylic acids to form the 
amides 3.51-3.58 and then introduced into a ‘click’ reaction with the azide 3.09, yielding the 
inhibitors 3.59-3.64, 3.66 and 3.58. Compound 3.65 could not be synthesized in this way – the 
CuAAC failed – so 3.65 was formed by treating 3.37 with 3.09 under ‘click’ conditions first 
(resulting in 3.69) and then introducing the corresponding carboxylic acid to form the amide 
bond. By analogy with the corresponding fragment 3.22, compound 3.67 was synthesized from 
3.66 by reducing the nitro group with ammonium formate, using palladium on charcoal as a 
catalyst. 
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Scheme 3.3. Synthesis of the inhibitors 3.59-3.68. Reagents and conditions: (a) corresponding carboxylic acid, TBTU, DIPEA, 
DMF, 80 °C (microwave), 30 min; or corresponding carboxylic acid chloride (carboxylic acid, SOCl2, pyridine, toluene, reflux, 
2 h), DIPEA, DCM, 0 °C, overnight; (b) CuSO4, sodium ascorbate, TBTA, CHCl3 or THF or DMSO/2-propanol, reflux, 1-3 d; 
(c) ammonium formate, Pd/C, THF/MeOH, reflux, overnight. 
3.2.2 Molecular Docking 
We performed molecular (induced-fit) docking experiments with our most potent fragment 3.27 
(see Table 3.1), using the recently reported cryo-EM structure of the ABCG2 transporter (PDB 
ID: 5NJ3 [30]). Based on our calculations, the most probable binding site is located between 
the two ABCG2 monomers in the center of the transmembrane domain (Figure 3.3A), which is 
in agreement with a cryo-EM structure of ABCG2 in complex with small molecule inhibitors 
[29]. Within this cavity, the carbonyl oxygen in the ester moiety of 3.27 formed a hydrogen 
bond with N436 of the first monomer, and the chromone ring structure established π-π contacts 
with the phenyl ring of F439 belonging to the second monomer (Figure 3.3B). Noteworthily, 
one molecule of compound 3.27 bound to both ABCG2 monomers and connected them with 
each other (as did our much larger previous inhibitor UR-MB136 in the cryo-EM structure 
[29]). In contrast, two molecules of MZ29, also rather a small inhibitor, proved [29] to bind to 
the ABCG2 transporter. Fragment 3.27 served as a starting point for structural optimization. 
Retaining the N-phenyl-chromone-2-carboxamide scaffold, we varied both, the nature and the 
position of the substituents at the central phenyl ring. Thereby we considered stability as well 
as solubility aspects, e.g. by substituting the labile ester moiety and introducing polar groups 
such as heterocycles and hydroxyl groups. Guided by a low XP Gscore, visual inspection of the 
binding poses and synthetic feasibility, we selected compound 3.48 (Figure 3.3C) for synthesis 
and characterization. Compounds 3.49 and 3.50 were derived from 3.48. Compound 3.48 
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seemed favorable because it showed interactions similar to those of 3.27, which had already 
been proven very potent in the biological assays: there was a hydrogen bond between the 
triazole ring and N436 (first monomer) and π-π stacking between the chromone ring and the 
phenyl ring of F439 (second monomer). We chose a methyl group in para position to the triazole 
ring to optimally occupy the hydrophobic pocket formed by F431, F432 and two other residues 
not depicted in the figure (M549 and L555). The position of the triazole ring was chosen not 
only because of the favorable hydrogen bond, but also because the rather spacious morpholine 
ring, which is attached to the triazole ring via an ethylene linker, is directed towards the wide, 
intracellular part of the pore between the two ABCG2 monomers. 
 
Figure 3.3. Binding poses of 3.27 and 3.48 obtained from induced-fit docking to the ABCG2 transporter. (A) Ribbon 
illustration of the ABCG2 homodimer, with individual G2 monomers colored blue and yellow. Bound ligand (3.27 and 3.48) 
molecules are colored orange and violet, respectively. (B+C) Specific interactions between 3.27 (B) or 3.48 (C) and ABCG2 
residues within the binding pocket are highlighted: the respective residues are labelled, hydrogen bonds are indicated as yellow, 
and π-π stacking as green, dashed lines. 
3.2.3 Biological Characterization 
3.2.3.1 Inhibition of the ABCG2, ABCB1 and ABCC1 Transport Activity 
In order to investigate an inhibition of ABCG2-mediated transport activity by our compounds, 
we performed a Hoechst 33342 microplate assay, using ABCG2-expressing MCF-7/Topo cells. 
Hoechst 33342 is a substrate of ABCG2, which accumulates in the cells upon ABCG2 
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inhibition and can be detected fluorometrically (after DNA-intercalation). In addition, we 
analyzed the effect on the transport activity of ABCB1 and ABCC1 in a calcein-AM microplate 
assay, using KB-V1 and MDCK.2-MRP1 cells, respectively. By analogy with the Hoechst 
33342 assay, the accumulation of the dual ABCB1/C1 substrate calcein-AM is determined by 
measuring the fluorescence after intracellular cleavage to calcein, which fluoresces in complex 
with Ca2+-ions. 
The fragments 3.03 and 3.04, representing partial structures of our previous, tariquidar-related 
ABCG2 inhibitors (3.01 and 3.02), showed distinct behavior in the Hoechst 33342 assay. 
Whereas compound 3.03 was only 41% effective, fragment 3.04 was as effective as 3.01 and 
3.02, namely 86%, and showed a moderate IC50 value of 1.9 µM (Figure 3.4A and Table 3.1). 
Therefore, we considered 3.04 as a starting point for optimization. The novel fragments derived 
from 3.04 (compounds 3.12-3.28), in which the quinoline moiety was replaced by other groups, 
were analyzed for inhibition of ABCG2, ABCB1 and ABCC1 at a concentration of 10 µM 
(Figure 3.4B-D). The highest signal in the Hoechst 33342 assay at this concentration was 
detected in the case of the chromone-bearing fragment 3.27. When analyzed in a concentration-
dependent manner in the Hoechst 33342 assay, 3.27 proved to be as potent as inhibitor 3.01 
(Figure 3.4A and Table 3.1). This is astonishing in so far, as it is a variant of only a part of 
compound 3.01; it has a much lower MWT than 3.01, hence a much higher ligand efficiency 
[43]. Therefore, we prepared a series of ABCG2 inhibitors derived from 3.27 (chromone series, 
compounds 3.39-3.43 and 3.48-3.50). Fragments 3.12, 3.16, 3.18, 3.19, 3.20, 3.22 and 3.25 
inhibited ABCG2 to the same extent as fragment 3.04 (at 10 µM), namely by more than 50%. 
These fragments, as well as 3.13, 3.14 and 3.21, were selected as a basis for our second series 
of ABCG2 inhibitors (compounds 3.59-3.68). Fragments 3.13, 3.14 and 3.21, although they 
inhibited ABCG2 by less than 50% (at 10 µM), were considered interesting: the inhibitors 
derived from 3.13 and 3.14 were likely to show higher solubilities (increase in the fraction of 
sp3-hybridized carbon, disrupting planarity) and 3.21 bears a nitro group, reportedly conferring 
activity at ABCG2, which we hoped would influence larger molecules more than the fragments. 
Fragment 3.28, differing from 3.27 only in the position of the carboxamido substituent at the 
chromone moiety, turned out to be instable in aqueous solution (data not shown), which is most 
probably the reason for its inactivity. All fragments were selective towards ABCG2. They did 
not show inhibition of ABCB1 and ABCC1 at 10 µM. 
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Figure 3.4. (A, B) Inhibition of ABCG2-mediated Hoechst 33342 efflux in MCF-7/Topo cells (A) by our previous tariquidar-
related inhibitor 3.01, the two substructures 3.03 and 3.04 and the novel fragment 3.27 (derived from 3.04) in a concentration-
dependent manner as well as (B) by compounds 3.04 and 3.12-3.28 at a concentration of 10 µM. The inhibition is expressed 
relative to the maximal effect in the presence of 10 µM FTC set to 100%. (C, D) Inhibition of ABCB1 (C) and ABCC1 (D) 
-mediated calcein-AM efflux in KB-V1 (C) and MDCK.2-MRP1 (D) cells by the fragments 3.04 and 3.12-3.28 at a 
concentration of 10 µM. The inhibition is expressed relative to the maximal effect in the presence of 10 µM tariquidar (C) and 
30 µM reversan (D) set to 100%. Presented are mean values ± SEM from at least three independent experiments, each 
performed in triplicate. 
The results of the transport assays for two series of inhibitors are depicted in Figure 3.5 and 
Figure 3.6, showing exemplary concentration-response curves, and are summarized in 
Table 3.1. The introduction of polar groups into the structure of 3.27 via ‘click’ chemistry and 
the substitution of the methoxycarbonyl moiety by a propionyl group yielded the first subset 
(compounds 3.39-3.43) of a chromone series. Compound 3.39, which contains a 
6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline moiety connected to the triazole ring with a 
phenylethyl linker (analogous to 3.01 and 3.02), was only 65% effective. The comparison with 
fragment 3.27 (91% effective), as well as solubility considerations, suggested the introduction 
of much smaller moieties. Therefore, we conceived structures with only an ethylene or 
methylene linker between a polar group and the triazole ring. Compound UR-Ant116 (3.40), 
containing a morpholine ring, proved to be very effective (95%) and potent, showing an IC50 
value of 312 nM (Figure 3.5). Compound UR-Ant121 (3.41), bearing a pyrrolidine ring, was 
even a bit more potent (IC50 value of 158 nM), but less effective (70%) (Figure 3.5). The 
introduction of a hydroxyl group (compound 3.42) decreased potency to an IC50 value above 
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was abolished. It is very probable that the acid moiety, which on the one hand should increase 
solubility, on the other hand prevents the compound from entering the cell membrane. 
 
Figure 3.5. Concentration-dependent inhibition of ABCG2-mediated Hoechst 33342 efflux in MCF-7/Topo cells by (A) the 
chromones 3.40, 3.41, 3.48 and 3.49 as well as (B) the compounds 3.62, 3.63, 3.66 and 3.67. The inhibition is expressed relative 
to the maximal effect in the presence of 10 µM FTC set to 100%. Presented are mean values ± SEM from at least three 
independent experiments, each performed in triplicate. 
With respect to selectivity, the first subset of the chromone series showed interesting results. 
Compound 3.39 was selective for ABCG2. The smaller compounds 3.40-3.43, though 
structurally extremely similar, behaved very differently. Whereas 3.41, bearing a pyrrolidine 
ring, was selective for ABCG2, compound 3.40, differing from 3.41 in the morpholine ring, 
was a triple ABCG2, ABCB1 and ABCG2 inhibitor (Figure 3.6). These two compounds could 
have different applications. For pharmacological tools selectivity is usually a necessity. For 
some clinical uses, however, inhibition of the three transporter subtypes may be advantageous. 
Especially ABCG2 and ABCB1 often have a concerted effect. Their expression overlaps at 
many physiological barriers (e.g. the GBB and the BBB), they share a number of clinically 
relevant substrates (such as topotecan), and a loss of function of one of these transporter 
subtypes can be compensated by an increase in the function of the respective other subtype 
[44,45]. Therefore a dual ABCB1/ABCG2 inhibitor may be necessary to overcome 
physiological barriers and MDR. Compound 3.42 showed low inhibition of ABCB1 and 
ABCC1. 3.43 was not only inactive at ABCG2, but also at ABCB1 and ABCC1. This is in 
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Figure 3.6. Concentration-dependent inhibition of ABCG2-mediated Hoechst 33342 efflux in MCF-7/Topo cells and of 
ABCB1 and ABCC1 -mediated calcein-AM efflux in KB-V1 and MDCK.2-MRP1 cells, respectively, by compound 3.40. The 
inhibition is expressed relative to the maximal effect in the presence of 10 µM FTC, 10 µM tariquidar and 30 µM reversan, 
respectively, all set to 100%. Presented are mean values ± SEM from at least three independent experiments, each performed 
in triplicate. 
The second subset (compounds 3.48-3.50) of the chromone series features different substitution 
at the central phenyl ring and results from molecular docking studies with fragment 3.27. 
Compounds UR-Ant131 (3.48), containing a morpholine ring, and UR-Ant132 (3.49) with a 
poyrrolidine ring were highly effective (over 100%) and highly potent in the Hoechst 33342 
assay (IC50 values of 188 nM for 3.48 and 109 nM for 3.49) (Figure 3.5); as was compound 
3.50 (bearing a hydroxyl group), though a bit less so than the other two inhibitors (Imax 91%, 
IC50 447 nM). Also these three compounds showed different selectivities. Contrary to 3.49 and 
3.50, which were specific ABCG2 inhibitors, compound 3.48 also inhibited ABCB1 and 
ABCC1, though only to a small extent (13% and 22%, respectively). It seems as if a morpholine 
ring can confer inhibitory potency at ABCB1 and ABCC1, since we observed the same effect 
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Table 3.1. Inhibitory effects of our previous, tariquidar-related inhibitors 3.01 and 3.02, the two substructures 3.03 and 3.04 
and the novel fragment 3.27 (derived from 3.04), as well as of the novel inhibitors 3.39-3.43, 3.48-3.50 and 3.59-3.68 on the 
transport activity of ABCG2, ABCB1 and ABCC1. 
 
 ABCG2a ABCB1b ABCC1c 
Compound IC50 [nM]d Imax [%]d,e IC50 [nM]d Imax [%]d,f IC50 [nM]d Imax [%]d,g 
3.01 (UR-MB108)h 79 ± 5 91 ± 2 inactivei – inactive – 
3.02 (UR-MB19)h 617 ± 179 90 ± 3 inactive – inactive – 
3.03 (UR-Ant74) 3606 ± 271 41 ± 5 inactive – inactive – 
3.04 (UR-Ant31) 1918 ± 482 86 ± 5 inactive – inactive – 
3.27 (UR-Ant56) 140 ± 14 91 ± 3 inactive – inactive – 
3.39 (UR-Ant71) 80 ± 25 65 ± 4 inactive – inactive – 
3.40 (UR-Ant116) 312 ± 14 95 ± 2 1342 ± 176 92 ± 3 2076 ± 163 66 ± 2 
3.41 (UR-Ant121) 158 ± 22 70 ± 4 inactive – inactive – 
3.42 (UR-Ant127) ≥ 1102j ≥ 71j ≥ 2285j ≥ 41j ≥ 1963j ≥ 33j 
3.43 (UR-Ant122) inactive – inactive – inactive – 
3.48 (UR-Ant131) 188 ± 21 108 ± 3 ≥ 1601j ≥ 13j ≥ 1469j ≥ 22j 
3.49 (UR-Ant132) 109 ± 6 103 ± 4 inactive – inactive – 
3.50 (UR-Ant133) 447 ± 27 91 ± 4 inactive – inactive – 
3.59 (UR-Ant124) 249 ± 20 70 ± 2 inactive – inactive – 
3.60 (UR-Ant115) 180 ± 15 63 ± 3 inactive – inactive – 
3.61 (UR-Ant110) 166 ± 24 81 ± 6 ≥ 9972k ≥ 19k inactive – 
3.62 (UR-Ant68) 116 ± 9 95 ± 2 inactive – inactive – 
3.63 (UR-Ant105) 322 ± 32 92 ± 2 inactive – inactive – 
3.64 (UR-Ant108) 116 ± 21 68 ± 5 ≥ 2775k ≥ 13k inactive – 
3.65 (UR-Ant112) 328 ± 48 75 ± 1 ≥ 18450k ≥ 14k inactive – 
3.66 (UR-Ant111) 70 ± 7 91 ± 2 inactive – inactive – 
3.67 (UR-Ant113) 82 ± 10 75 ± 3 inactive – inactive – 
3.68 (UR-Ant62) 120 ± 8 78 ± 1 inactive – inactive – 
a Hoechst 33342 microplate assay, using ABCG2-expressing MCF-7/Topo cells. 
b Calcein-AM microplate assay, using ABCB1-expressing KB-V1 cells. 
c Calcein-AM microplate assay, using ABCC1-expressing MDCK.2-MRP1 cells. 
d Mean values ± SEM from at least three independent experiments, each performed in triplicate. 
e Maximal inhibitory effect (Imax) relative to the response to FTC at a concentration of 10 µM (100%). 
f Maximal inhibitory effect (Imax) relative to the response to tariquidar at a concentration of 10 µM (100%). 
g Maximal inhibitory effect (Imax) relative to the response to reversan at a concentration of 30 µM (100%). 
h Data taken from our previous study [28]. 
i Inactive: response ≤ 10% up to a concentration of 100 µM. 
j No plateau was reached at the kinetic solubility limit; minimum IC50 values and Imax values were stated. 
k No plateau was reached up to a concentration of 100 µM; minimum IC50 values and Imax values were stated. 
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The second series (compounds 3.59-3.68) originating from the fragment screening, are analogs 
of compound 3.01, the quinoline group being substituted with aryl moieties that compared 
favorably in the fragment analysis. They all showed IC50 values in the two- to low three-digit 
nM range. The most effective substances from this series, with an Imax value of over 90%, were 
compound 3.62, with a 2-chloropyridine moiety, compound 3.63, containing a 
2-methoxypyridine group, and compound 3.66, featuring 2-nitropyridine, which was the most 
potent substance of this series with an I50 value of 70 nM (Figure 3.5). Compound 3.61, 
comprising a 2-methylpyridine moiety, was with 81% only a little less effective. Compounds 
3.59, 3.60, 3.64, 3.65, 3.67 and 3.68 showed efficacies somewhat below 80%. Compound 3.67, 
with a 2-aminopyridine group, was the most potent among the latter substances, showing an 
IC50 value of 82 nM (and an Imax value of 75%) (Figure 3.5). All members of this series were 
highly selective for ABCG2, except for compounds 3.61, 3.64 and 3.65. The latter also inhibited 
ABCB1, but only by less than 20% and only at very high concentrations (100 µM). They 
showed a clear preference for ABCG2 and thus are rather selective. 
3.2.3.2 Cytotoxicity and Reversal of Drug Resistance 
The cytotoxicity and the ability to reverse the resistance of MCF-7/Topo cells toward the 
cytostatic drug topotecan was investigated exemplarily in a kinetic chemosensitivity assay for 
the inhibitors 3.40 and 3.48 as representatives of the two subsets of the chromone series and 
compound 3.63, a member of the second series. As shown in Figure 3.7, against MCF-7/Topo 
cells, compound 3.40 was nontoxic up to a concentration of 1 µM and exhibited a cytotoxic 
effect only at higher concentrations. Upon incubation with topotecan at a concentration of 
100 nM, the cells were not affected due to their resistance, whereas the addition of 3.40 at per 
se nontoxic concentrations entirely reversed the resistance. Inhibitor 3.48 did not show any 
cytotoxicity, even at a concentration as high as 10 µM. Analogous to 3.40, 3.48 was able to 
reverse topotecan resistance; the same was true of inhibitor 3.63, when administered at a 
nontoxic concentration, which was up to 1 µM. At higher concentrations 3.63 displays a 
cytotoxic effect. In sum, this assay disclosed that the compounds analyzed prevented the 
topotecan efflux, which is in accordance with the results of the Hoechst 33342 transport assay. 
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Figure 3.7. (A-C) Antiproliferative activities of the inhibitors 3.40 (A), 3.48 (B) and 3.63 (C) against MCF-7/Topo cells upon 
long-term incubation. (D-F) Reversal of ABCG2-mediated drug resistance against topotecan on proliferating MCF-7/Topo 
cells: effect of 100 nM topotecan (Topo) alone and in combination with different concentrations of 3.40 (D), 3.48 (E) or 3.63 
(F). Antiproliferative effects correspond to the left y-axes. The growth curves of untreated control cells (open circles) 
correspond to the right y-axes. Data are mean values ± SEM of two to three independent experiments, each performed in 
octuplicate. 
3.2.3.3 Effect on the ATPase Activity 
For comprehensive biological characterization, we investigated our most advantageous 
transport inhibitors in terms of potency and solubility, UR-Ant116 (3.40), UR-Ant121 (3.41), 
UR-Ant131 (3.48) and UR-Ant132 (3.49), in an ATPase assay, which gives information on the 
type of inhibition. We performed the assay with membrane preparations of human ABCG2 
overexpressing MCF-7/Topo breast cancer cells in order to provide a membrane environment 
for native protein structure and function. Transport of substrates by ABCG2 is an alternating 
process, whereby the substrate-bound, inward-open conformation is converted to an outward 
facing state that can release the substrate to the outside [30]. ABCG2 gains the energy for this 
process by ATP-hydrolysis to ADP and inorganic phosphate. The latter was determined by a 
molybdenum blue reaction after incubation of the membranes for a certain period of time (with 
and without a transport inhibitor) as an estimate for the ABCG2-associated ATPase activity, 
thereby assessing the influence of test compounds on the ATPase activity of ABCG2. In the 
absence of an ATPase stimulating agent, ABCG2 typically displays basal ATPase activity, 
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preparations, which was set to zero in our assay. As depicted in Figure 3.8A, both compounds 
3.40 and 3.41, belonging to the first subset of the chromone series, at concentrations of 1 µM 
and 10 µM, suppressed the ATPase activity to a level even below the basal ATPase activity. 
This led to the conclusion that these two compounds are not substrates of ABCG2. It has been 
shown that the inhibition of the ATPase and of the transport activity are closely connected. A 
recent cryo-EM study [29] suggested that ABCG2 transport inhibitors, including one member 
of our preceding tariquidar analogs (UR-MB136), bind to a central multidrug binding site 
located in the transmembrane domain, lock the inward-facing conformation of ABCG2 and 
inhibit the ATPase activity through conformational coupling with the cytoplasmic nucleotide-
binding domain. Based on these results, it can be assumed that the inhibition of the ATPase 
activity by compounds 3.40 and 3.41 contributes to the overall inhibition of ABCG2 transport. 
In contrast to the compounds 3.40 and 3.41, the transport inhibitors 3.48 and 3.49, members of 
the second subset of the chromone series displaying different substitution at the central phenyl 
ring, showed a very distinct behavior in the ATPase assay – they did not suppress, but stimulate 
the ATPase activity of ABCG2 (at concentrations of 1 µM and 10 µM) and therefore are most 
likely substrates of the transporter rather than ATPase inhibitors. In order to find out to which 
degree they activate the ABCG2 ATPase activity, we determined concentration-response 
curves of the two compounds. As shown in Figure 3.8B, 3.48 and 3.49 exhibited Imax values of 
46% and 29%, respectively, and potencies of 96 nM and 62 nM, respectively. It is conceivable 
that they compete with other substrates, such as Hoechst 33342, for transport and thereby reduce 
their transport. However, they do not fully activate the ATPase activity; it can also be supposed 
that by being transported more slowly, they occupy the multidrug binding site of the transporter, 
so that it is not at disposal for other substrates. 
 
Figure 3.8. Stimulation or suppression of the ATPase activity in ABCG2-expressing MCF-7/Topo membrane preparations by 
the compounds 3.40, 3.41, 3.48 and 3.49 at a concentration of 1 µM and 10 µM (A) and concentration-dependent stimulation 
of the ATPase activity by the compounds 3.48 and 3.49 (B). The effect is expressed relative to the basal ATPase activity (0%) 
and the maximal stimulatory effect in the presence of 30 µM sulfasalazine set to 100%. Presented are mean values ± SEM from 
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It is interesting that minor structural changes have such an impact on the type of inhibition. This 
shows that it is possible to modulate the inhibition type according to the needs of the desired 
application. ATPase activators and suppressors may have different applications. Whereas 
ATPase activators deplete the cell of ATP, a compelling effect when addressing resistant tumor 
cells [47], ATPase suppressors do not interfere with the ATP balance of the cell. 
3.2.3.4 Stability in Blood Plasma 
Having analyzed the biological activity and selectivity of our inhibitors, investigations on their 
drug-like properties were pending. After studying cytotoxicity we determined the stability in 
blood plasma, which is a precondition for in vivo studies. Chromone is a structural element 
quite common in natural products and drugs and can be considered a privileged scaffold [48,49] 
in drug discovery, not least due to its synthetic availability, structural diversity and low toxicity 
(confirmed in our cytotoxicity assay, using MCF-7/Topo cells, see Figure 3.7). However, 
chromones may be susceptible to hydrolysis, depending on the substitution pattern. 
3-Substituted chromones are very reactive towards the attack of nucleophiles, such as water 
[50]. We observed this behavior with fragment 3.28, a 3-substituted chromone, which 
hydrolyzed rapidly in aqueous solution, explaining the lack of biological activity. By contrast, 
fragment 3.27, a chromone substituted in 2-position, exhibited excellent inhibition of ABCG2 
and was the foundation of our chromone series. Exemplarily of this series, compound 3.49 was 
incubated in human plasma and analyzed via HPLC with UV detection at 220 nm (Figure 3.9A). 
The peak area of 3.49 decreased by about 58% over a period of 24 hours, yet no additional 
peaks were detected. On the off chance that a possible degradation product may not be 
detectable by this method (due to lacking UV-absorption or retention), the samples were also 
analyzed by HPLC-MS coupling (0 h and 24 h). Also with this hyphenated technique, applying 
a different gradient, no additional peaks were detected (data not shown). Therefore, we 
attributed the decrease in the peak area to adsorption, either to the vial surface or to plasma 
proteins, and concluded that 3.49 is in fact stable in blood plasma. Moreover, the main decrease 
in peak height occurred in the first five hours and after that, the peak area remained almost 
unchanged, which supports our assumption that the decrease is due to adsorption, not to 
hydrolysis. 
Furthermore, as a representative of the second series, inhibitor 3.65 was studied in the same 
manner (Figure 3.9B). The situation was the same as with compound 3.49 – the peak area of 
3.65 decreased but no additional peaks were detected, also upon HRMS analysis (data not 
shown). Hence, we again concluded that the compound was adsorbed to a certain extent. 
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Figure 3.9. Chromatograms illustrating the stability of the compounds 3.49 (A) and 3.65 (B) upon incubation in human blood 
plasma at 37 °C over a period of 24 h. RP-HPLC analysis, UV detection at 220 nm. 
3.2.4 Aqueous Solubility 
When determining the solubility of chemical entities, it is fundamental to understand the 
distinction between thermodynamic and kinetic solubility. Thermodynamic – or equilibrium – 
solubility is defined as the maximum concentration of a solute in a solvent in a state of complete 
thermodynamic equilibrium, i.e. a saturated solution at equilibrium with an excess of 
undissolved solid and at a fixed temperature and pressure [51,52]. It is usually determined by 
the classical shake-flask method (using a solid in a buffer) with subsequent HPLC-analysis 
[1,8,13,53]. By contrast, in kinetic solubility assays no equilibrium is reached. Most often the 
compound, ‘pre-dissolved’ in DMSO, is added into an aqueous buffer and precipitation is 
measured turbidimetrically or nephelometrically after a short period of time [54-56]. The 
concentration of the compound in the buffer at which a precipitate appears is termed kinetic 
solubility [1,8,13]. Unlike thermodynamic solubility assays, kinetic assays can be performed in 
microplates in high throughput and they are useful to verify concentration-response data – 
making sure that precipitation does not occur on the time scale of the biological assay. They are 
also used as an early estimate of solubility in drug discovery [1,8,55]. However, the apparent 
solubility in a kinetic assay is always – sometimes dramatically – higher than the 
thermodynamic ‘true’ solubility and therefore should not be used for decision-making, 
otherwise the optimization process may be driven towards the synthesis of compounds with the 
slowest precipitation rather than the highest solubility [1,2,8,57]. 
Here, we established both a kinetic solubility assay mainly to verify our biological data and a 
thermodynamic solubility assay in order to rank our ABCG2 inhibitors in terms of solubility 
and thereby to assess if our efforts met our objective – potent ABCG2 inhibitors with improved 
solubility. 
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3.2.4.1 Kinetic Solubility 
Assay Adaptation. We conducted the kinetic solubility assay in microplates under conditions 
identical to those in the biological assays. Inhibitor solutions in DMSO at increasing 
concentrations were diluted 1:100 in the respective aqueous buffer, resulting in a uniform 
DMSO concentration (1%) in each well. The plates were incubated at 37 °C for two hours – the 
time span of the Hoechst 33342 assay, which is the most time-consuming assay among the 
ATPase and transport assays. While handling the plates, attention was paid to avoiding 
scratches on the plates that might have interfered with the readouts. Then the extinction was 
measured as a function of the inhibitor concentration. The extinction of electromagnetic 
radiation, when passed through a suspension, is due to the processes of absorption, scattering, 
diffraction and reflection. When the extinction is measured at a wavelength at which the test 
compound does not absorb any light, a sharp increase in the extinction values at a certain 
concentration arises from scattering due to precipitation, corresponding to the solubility limit 
of the respective compound [54]. At that point, the clear solution turns into a turbid suspension 
containing solid particles. 
Since ABCG2 inhibitors show poor solubility, we strove for a detection limit as low as possible, 
thus a signal intensity as high as possible. Therefore, we needed to adjust the changeable assay 
parameters, namely sample volume and measurement wavelength, accordingly. In order to get 
an estimate for the detection limit we required a substance with extremely low aqueous 
solubility as a reference. We chose coronene, a polycyclic aromatic compound comprising six 
peri-fused benzene rings, which shows an aqueous solubility as low as 0.5 nM [58] (detected 
fluorometrically). When performing the assay with this compound, it can be assumed that the 
concentration at which the sharp increase in extinction occurs indicates the detection limit of 
the assay rather than the solubility limit of coronene, because coronene is practically insoluble 
in water and experiments showed that precipitation takes place quickly – after the addition of 
the DMSO stock solution to the buffer the concentration-extinction curve was measured 
repeatedly and remained almost constant for 24 hours (data not shown). Using coronene, we 
explored the effects of the sample volume and of the wavelength on the signal intensity, thus 
the detection limit of the assay. As expected, the signal intensity increased with the sample 
volume (data not shown). Therefore, we employed the highest volume possible per microplate 
well in the assay, namely 300 µL. For analyzing the dependence of the signal intensity on the 
wavelength, we considered the spectral properties of coronene, DMSO and polystyrene 
(microplate material). The latter shows absorption between 200 nm and 290 nm, which 
decreases rapidly above 290 nm [59]. DMSO exhibits a sharp absorption maximum at a 
wavelength of around 250 nm and practically no absorption above 265 nm [61]. The main 
absorption bands of coronene are located between 300 nm and 350 nm and there is only very 
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low absorption above 350 nm [60]. Therefore, we performed the experiment at different 
wavelengths ranging from 380 nm to 830 nm, where the aforementioned compounds do not 
absorb radiation (Figure 3.10A). Light scattering drastically decreases with increasing 
wavelength, though this effect depends on the particle size and is more pronounced for small 
particles [62]. Accordingly, when measuring the extinction as a function of the coronene 
concentration, we found the highest signal intensity at a wavelength of 380 nm and the lowest 
at 830 nm. To find the lowest wavelength compatible, we measured the UV/VIS absorption 
spectra of our inhibitors (examples thereof depicted in Figure 3.10B) and found that they have 
a cut-off wavelength of 380 nm, which we chose as measurement wavelength for our assay. 
 
Figure 3.10. (A) Effect of the wavelength on the signal intensity in a kinetic solubility assay: extinction (mainly due to 
scattering) as a function of the concentration of the ‘insoluble’ standard coronene at different wavelengths. The data were 
normalized to the blank value. Presented are mean values ± SEM from one experiment performed in octuplicate. (B) UV/VIS 
absorption spectra of the inhibitors 3.01, 3.40 and 3.66, revealing a shared cut-off wavelength of 380 nm. 
By analogy with a recently published study [63] covering the solubility of a detergent (sodium 
lauroyl isethionate), we estimated the kinetic solubility of the test compounds as the highest 
concentration at which more than 95% of the radiation is transmitted, i.e. the extinction is lower 
than 0.0223, the data having been normalized to the blank value (1% DMSO in buffer). The 
threshold is indicated as a dashed line in Figure 3.10A and Figure 3.11. In the case of coronene, 
the highest concentration below the threshold was 1 µM, which we identified as the detection 
limit. It should be noted that the detection limit determined in this assay is only applicable under 
the assumption that the inhibitors precipitate with particle size and form similar to coronene. 
Assay Results. We examined our previous inhibitor UR-MB108 (3.01), fragment 3.27, and all 
our novel inhibitors (3.39-3.43, 3.48-3.50 and 3.59-3.68) in the kinetic solubility assay, using 
PBS (pH 7.4) as a solvent. We included coronene in every batch of assays as a control for 
precipitation. Exemplary concentration-extinction curves are depicted in Figure 3.11. The 
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Figure 3.11. Concentration-dependent extinction (at 380 nm) due to scattering in a kinetic solubility assay in PBS caused by 
(A) the chromone inhibitors 3.40, 3.41, 3.48 and 3.49 as well as (B) the inhibitors 3.62, 3.63, 3.66 and 3.67. The data were 
normalized to the blank value. Presented are mean values ± SEM from two to three independent experiments, each performed 
in triplicate. 
We compared the concentration-dependent curves in the functional assays with the kinetic 
solubility limits in order to decide if the biological data were compromised by precipitation (c.f. 
Figure 3.13 in the supplementary material, Section 3.5.1). If a curve reached a plateau before 
the solubility limit was achieved, we concluded that the curve was unaffected by solubility 
constraints and that the values derived from the curve (Imax and IC50) are valid. Our previous 
inhibitor 3.01 and fragment 3.27 showed a solubility limit of 3 µM and 10 µM, respectively. 
The curves of both compounds reached a plateau in the Hoechst 33342 transport assay at around 
1 µM, meaning that the biological data are reliable. The chromone inhibitors exhibited 
solubility limits between 3 µM and 30 µM and all of them, except for one, achieved a plateau 
in the Hoechst 33342 assay before the solubility limit was reached. Only the curve of compound 
3.42, which was less potent than the other chromones, did not reach a plateau; the values 
increased up to a concentration of 3 µM and then suddenly dropped. This reflects the results of 
the kinetic solubility assay, according to which the solubility limit was reached at 3 µM. This 
consistency indicates that the kinetic solubility assay is reliable. We marked insufficient 
solubility as the cause for the incomplete curve in a footnote to Table 3.1. We also investigated 
some of our chromone inhibitors – compounds 3.40, 3.41, 3.48 and 3.49 – in the ATPase assay. 
Since the highest concentration employed there was 10 µM, the ATPase data are largely not 
compromised by insufficient solubility. 
Our second series of inhibitors, compounds 3.59-3.68, showed kinetic solubilities up to 10 µM. 
The curves of compounds 3.60, 3.63 and 3.65-3.68 all reached a plateau in the Hoechst 33342 
assay at concentrations lower than the respective kinetic solubility limit. The curves of 
compounds 3.59, 3.61 and 3.64 also reached a plateau, although this was at concentrations that 
slightly exceeded their respective kinetic solubility limit. It is possible that with higher 












































Water-Soluble Inhibitors of ABCG2 – A Fragment-Based and Computational Approach 
117 
plateau at about 3 µM and this inhibitor exhibited a solubility limit of 1 µM, which is around 
the detection limit. The first values of the concentration-extinction curve coincided with the 
ones from the control coronene but a strong increase occurred only at higher concentrations, at 
around 10 µM. Therefore it is improbable that the biological data of compound 3.62 are 
impaired. 
We did not only test our substances for interaction with ABCG2, but we also assessed their 
selectivity and therefore examined them for inhibition of ABCB1 and ABCC1 in the calcein-
AM assay. Most of the inhibitors analyzed were selective towards ABCG2 or just exhibited 
very low inhibitory potency at the other two transporters. At concentrations higher than their 
solubility limits – we studied the inhibitors at concentrations up to 100 µM – they might appear 
more selective than they actually are. Since this concerns only quite high concentrations, 
however, we considered this not very relevant. Three compounds were not selective, namely 
the chromones 3.40, 3.42 and 3.48. Regarding compound 3.42, the situation is the same as with 
the Hoechst 33342 assay; no plateau was reached at the solubility limit (as we indicated in the 
footnote to Table 3.1). The curves of compound 3.40, which is a triple 
ABCB1/ABCC1/ABCG2 inhibitor, plateaued in both calcein-AM assays before the solubility 
limit of 10 µM was reached. Compound 3.48 also showed some potency at ABCB1 and 
ABCC1, but did not reach a plateau in the calcein-AM assays at concentrations below the 
solubility limit of 10 µM, which we indicated in Table 3.1. 
Altogether, with a few exceptions, the biological data were not affected much by kinetic 
solubility limits. 
Table 3.2: Estimated kinetic solubility limits of our previous tariquidar analog 3.01, fragment 3.27, and the chromone inhibitors 
(3.39-3.43, 3.48-3.50) as well as the second series of inhibitors (3.59-3.68). 
Compound Kinetic Solubility [µM]a  Compound Kinetic Solubility [µM] a 
3.01 (UR-MB108)h 3  3.59 (UR-Ant124) 3 
3.27 (UR-Ant56) 10  3.60 (UR-Ant115) 7 
3.39 (UR-Ant71) 7  3.61 (UR-Ant110) 3 
3.40 (UR-Ant116) 10  3.62 (UR-Ant68) 1 
3.41 (UR-Ant121) 30  3.63 (UR-Ant105) 7 
3.42 (UR-Ant127) 3  3.64 (UR-Ant108) 3 
3.43 (UR-Ant122) 10  3.65 (UR-Ant112) 7 
3.48 (UR-Ant131) 10  3.66 (UR-Ant111) 10 
3.49 (UR-Ant132) 7  3.67 (UR-Ant113) 10 
3.50 (UR-Ant133) 3  3.68 (UR-Ant62) 7 
a Highest concentration in the kinetic solubility assay in PBS (data normalized to the blank value), at which transmission was 
higher than 95%, i.e. the extinction was lower than 0.0223. 
The buffer used in the transport assays also contained serum albumin. Since this can influence 
precipitation, we also performed kinetic solubility assays in a buffer containing bovine serum 
albumin (BSA). We found that the addition of BSA did not change the data significantly, which 
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is shown exemplarily for compound 3.01 in Figure 3.14 in the supplementary material 
(Section 3.5.1). 
3.2.4.2 Thermodynamic Solubility 
Assay Adaption. To determine thermodynamic solubility the traditional shake-flask technique 
was modified. In the course of the optimization of the assay, we repeatedly faced major 
challenges due to the high lipophilicity and low solubility range of ABCG2 inhibitors. 
We scaled the procedure down in order to facilitate handling and to minimize the amount of 
substance required. On downscaling it should be borne in mind that the surface to volume ratio 
is larger the smaller the flask. Therefore adsorption of the solute to the vial surface may have a 
greater effect on the thermodynamic equilibrium between the saturated solution and the 
undissolved solid. To minimize adsorption we tested different vial materials regarding the 
ability to adsorb compounds such as 3.01. Indeed there were distinct differences. We found the 
most pronounced adsorption with untreated glass vials (maybe due to ionic interactions between 
the negatively charged silanol glass surface and the positively charged, protonated heterocycle 
in 3.01), followed by untreated polypropylene (PP), ‘siliconized’ PP (i.e. PP treated with a 
siliconizing agent) and the least with ‘siliconized’ glass, which we chose for the assay (graph 
see Figure 3.15 in the supplementary material, Section 3.5.1). 
With respect to in vitro as well as in vivo studies we used PBS at a pH value of 7.4 as a solvent. 
This is the usual pH value in the biological assays and the pH value in the small intestine as 
well as many other body fluids, such as blood plasma, lymph, cerebrospinal fluid and 
cytoplasm. It is common practice to use an aqueous buffer as a simplistic surrogate of the 
intestinal content in solubility studies [2,64]. Typically, the sample is prepared by adding solid 
to the buffer. This turned out to be practically impossible with our substances – they showed 
very poor wettability and tended to float on the surface, even after shaking, making it impossible 
to take out a homogeneous aliquot for HPLC analysis without some of the solid adhering to the 
pipette tip. This behavior may be attributed to their lipophilicity. Unfortunately, the lipophilicity 
also made it impossible to remove floating substance by filtration – adsorption to the filter 
(different materials tested) was so pronounced that not only the floating substance, but also the 
dissolved compound was removed from the solution and after filtration there was no signal 
detectable by HPLC. We solved this problem by adding a stock solution in DMSO to the buffer 
instead of adding solid. Of course, the presence of DMSO influences the solubility of a 
compound. It has been shown that a DMSO content over 5‰ can distort the results of 
thermodynamic solubility assays [65]. So we kept the DMSO content at only 1‰. 
After the sample preparation, we incubated it in a shaker at 25 °C. Studies showed that a 
thermodynamic equilibrium is usually established after 24 hours of stirring [66]. We shook our 
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samples for 36-40 hours to make sure an equilibrium had been reached and then allowed 
sedimentation for another 24 hours. In case a compound did not sediment properly, we 
centrifuged the sample. 
Another challenge associated with the low solubility and high lipophilicity of the inhibitors was 
the transfer of the samples into the HPLC vials. After transferring compound 3.01, we did not 
detect any peak and found out that the reason was adsorption of 3.01 to the pipette tip. After 
pipetting the sample into an HPLC vial containing acetonitrile and rinsing the tip, a peak was 
detectable. 
Having established a procedure for the thermodynamic solubility assay, we validated it with 
haloperidol as a reference substance. The solubility of the latter is referred to as 37 µM in 
literature [67]. We determined a solubility of 40 ± 1 µM. 
Assay Results. We investigated fragment 3.27, our novel inhibitors (3.39-3.42, 3.48-3.50 and 
3.59-3.68) as well as our previous tariquidar analog 3.01 in the thermodynamic solubility assay 
(Table 3.3). As already stated in the introduction, compound 3.01 exhibited an equilibrium 
solubility of only 78 nM. Furthermore it violates two of the Ro5 due to its size and high clogP. 
The first series of inhibitors is based on fragment 3.27, a substructure of 3.01, containing a 
chromone instead of a quinoline moiety. Though much smaller, 3.27 was equipotent with 3.01. 
Its solubility, however, with 109 nM, was not much higher than the solubility of 3.01, despite 
its low molecular weight and conformity with the Ro5. This can probably be attributed to the 
lack of a protonatable nitrogen. The inhibitors derived from fragment 3.27 all contain a polar 
or ionizable moiety. Compounds 3.39-3.42, the first subset of the chromone inhibitors, display 
very different solubilities. Merging 3.27 with fragment 3.03 led to the inhibitor 3.39, which was 
only slightly more soluble than 3.01 (149 nM). However, when far smaller polar moieties were 
introduced (compounds 3.40-3.42), the solubility could be enhanced markedly and in contrast 
to 3.39 the compounds complied with the Ro5, or in case of 3.40, almost complied (only the 
MWT was slightly higher than 500 g/mol). Compounds 3.41 and 3.42 both contain a 
heterocycle (morpholine in 3.40 and pyrrolidine in 3.41) and exhibit solubilities of ca. 1 and 
1.5 µM, respectively – 13-fold and 19-fold the solubility of inhibitor 3.01. The introduction of 
a hydroxyl group into compound 3.42 increased the solubility to 575 nM. Compound 3.43, 
containing a carboxyl group, was not measured because it did not inhibit ABCG2. The second 
subset of the chromone inhibitors, compounds 3.48-3.50, differs structurally from the first 
subset, the main difference being the absence of an acyl moiety. The inhibitors obey the Ro5 
and, here again, the compounds containing an ionizable ring – 3.48 and 3.49 – showed high 
solubilities (1.1 and 1.3 µM, respectively) compared to 3.01. The introduction of a hydroxyl 
group (in compound 3.50) did not increase the solubility. 
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The second series of inhibitors (3.59-3.68) is structurally more similar to compound 3.01. The 
compounds are analogs of 3.01, the quinoline moiety being replaced by other ring structures. 
They have MWTs similar to 3.01 and, therefore, violate at least one Ro5. However, we were 
able to increase the fraction of sp3-hybridized carbon or decrease the clogP values compared to 
3.01, i.a. by introducing polar groups. The latter strategy, of course, also led to an increase in 
the number of H-donors or H-acceptors and in some cases to Ro5 violations. 
Compound 3.59, containing a naphthalene ring and designed with regard to improved rotation 
around the amide bond and reduced planarity, did not show improved solubility. Compound 
3.60 contains a tetrahydroquinoline ring to reduce aromaticity, thus planarity and π-π stacking 
and ultimately crystal packing. This substitution did not increase the solubility, either. However, 
when the phenyl ring in the quinoline moiety was replaced by a smaller group containing sp3-
hybridized carbon, namely a methyl group (compound 3.61), the solubility was six-fold 
increased to 445 nM. The introduction of polar moieties, replacing the phenyl ring, yielded 
different results. Compound 3.62, an organic chloride, did not display increased solubility. 
Though electronegative, chlorine confers lipophilicity due to its size. Also the introduction of 
a methoxy group, attached in different positions in compounds 3.63 and 3.64, did not solve the 
solubility problem; neither did the attachment of a nitro (in 3.66) or an amino (in 3.67) group. 
Here, a general problem of increasing solubility by introducing polar groups becomes apparent 
– on one hand, polarity will indeed be increased by this approach and the heteroatoms can form 
stabilizing H-bonds with water, but on the other hand also polar intermolecular interactions may 
be increased. This could lead to enhanced crystal packing, counteracting the solubilizing effect 
of the polar groups. Fortunately, this strategy proved successful, nevertheless. Compound 3.65, 
displaying a hydroxyl group, is over ten times more soluble than 3.01 (855 nM). We find it 
surprising that the introduction of an amino group did not have the same effect. Lastly, the 
replacement of the quinoline moiety by a slightly smaller and less lipophilic benzofuran ring 
(in 3.68) did not improve the solubility. 
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Table 3.3. Ro5 compliance and thermodynamic solubilities of our previous tariquidar analog 3.01, fragment 3.27, and the 
chromone inhibitors (3.39-3.43, 3.48-3.50) as well as the second series of inhibitors (3.59-3.68). 




3.01 (UR-MB108) 666.77 5.42 1 10 2 78 ± 5 
3.27 (UR-Ant56) 402.20 3.23 1 6 0 109 ± 18 
3.39 (UR-Ant71) 683.75 3.64 1 11 2 149 ± 36 
3.40 (UR-Ant116) 501.53 1.75 1 10 (1) 999 ± 189 
3.41 (UR-Ant121) 485.53 2.81 1 9 0 1483 ± 383 
3.42 (UR-Ant127) 432.43 1.51 2 9 0 575 ± 144 
3.43 (UR-Ant122) 446.41 1.85 2 10 0 n. d.c 
3.48 (UR-Ant131) 459.50 1.71 1 9 0 1144 ± 203 
3.49 (UR-Ant132) 443.50 2.76 1 8 0 1228 ± 106 
3.50 (UR-Ant133) 390.39 1.47 2 8 0 < 100 
3.59 (UR-Ant124) 665.78 5.63 1 9 2 < 100 
3.60 (UR-Ant115) 670.80 5.41 1 10 2 < 100 
3.61 (UR-Ant110) 630.74 4.46 1 10 1 445 ± 48 
3.62 (UR-Ant68) 651.15 4.47 1 10 1 < 100 
3.63 (UR-Ant105) 646.73 5.25 1 11 3 < 100 
3.64 (UR-Ant108) 646.73 4.21 1 11 2 119 ± 29 
3.65 (UR-Ant112) 632.71 4.30 2 11 2 855 ± 242 
3.66 (UR-Ant111) 661.71 4.05 1 13 2 < 100 
3.67 (UR-Ant113) 631.72 3.60 3 11 2 < 100 
3.68 (UR-Ant62) 655.74 5.04 1 10 2 < 100 
a Calculated LogP values, using ACD/Structure Designer. 
b Thermodynamic solubility assay: shake-flask experiment in PBS with subsequent HPLC analysis. Mean values ± SEM from 
at least six independent experiments, each performed in duplicate. 
c n. d.: not determined. 
When comparing the two series of inhibitors it becomes obvious that the chromone inhibitors, 
which are smaller and structurally more different from 3.01, are superior to the members of the 
second series in terms of solubility and Ro5 compliance. The fragment-based approach led to 
the discovery of fragment 3.27, which is a very potent and effective ABCG2 inhibitor on its 
own. Thus it was possible to obtain much smaller and more polar inhibitors, which exhibited 
up to 19-fold increased solubility. Furthermore, it became apparent that if a compound complies 
with the Ro5 plus contains a protonatable nitrogen, it is a good predictor for improved 
solubility. 
As a side note it should be mentioned that in silico methods (we used the ACD/Structure 
Designer) failed to predict the solubility of our substances. Another common approach to 
estimate solubility is to use experimentally easily accessible parameters for guidance. For 
instance, the retention time in RP-HPLC analysis is linked to the lipophilicity of a compound 
[68] and the crystal lattice energy can be estimated from the melting point [2]. This approach 
turned out to be rather productive. For example, when comparing compound 3.49 with 
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compound 3.01, marked decreases in retention time (3.8 min vs. 7.2 min) and melting point (ca. 
180 °C vs. 219 °C) were observed, in parallel with the increase in solubility (1.2 µM vs. 
78 nM). Another operating experience worth disclosing is that adsorption of the substances to 
the vial surface can be critical. A case in point is compound 3.65, which showed a 3-fold higher 
solubility when ‘siliconized’ PP vials (higher adsorption) were used instead of ‘siliconized’ 
glass vials (2.9 µM vs. 855 nM). Apparently, the presence of a layer of molecules adhering to 
the vial surface can influence the equilibrium in favor of higher solubility values. 
Figure 3.12 summarizes the properties of the novel inhibitors that are most promising in terms 
of potency and solubility, specifically 3.40, 3.41, 3.48, 3.49 and 3.65, in comparison to our 
previous inhibitor 3.01 and fragment 3.27. Depicted are IC50 values in the Hoechst 33342 assay 
and kinetic and thermodynamic solubility limits. As mentioned before, medicinal chemists 
often face the dilemma of improving solubility at the expense of diminished biological activity, 
due to the positive correlation of lipophilicity and affinity to hydrophobic binding pockets in 
drug targets [31]. The chart shows that by virtue of a fragment-based and rational approach we 
were able to circumvent this predicament and increase the equilibrium solubility of our 
compounds while maintaining inhibitory potency. Whereas compound 3.01 and fragment 3.27 
exhibited equilibrium solubilities in the range of their potencies, the chromone inhibitors 3.40, 
3.41, 3.48, and 3.49 showed equilibrium solubilities that were three to nine times higher than 
their IC50 values. Compound 3.65, the most soluble compound of the second series, showed an 
equilibrium solubility 2.5 times higher than its IC50 value. 
As expected, the kinetic solubilities were considerably higher than the thermodynamic 
equilibrium solubilities. This means that by adding a DMSO stock solution to the buffer, a 
supersaturated solution was produced in the concentration range between the thermodynamic 
and the kinetic solubility limit. Here it becomes obvious that time is a critical factor. On the 
time scale of the biological assays performed in this study, namely up to two hours, the 
precipitation of our previous inhibitor 3.01 was slow enough to allow for reliable results. 
However, since the thermodynamic (equilibrium) solubility of 3.01 was in the range of its IC50 
value, compound 3.01 is not suited for in vitro assays requiring long time-periods of incubation 
and especially in vivo studies can be impaired. By contrast, the novel inhibitors with improved 
equilibrium solubility qualify for such examinations. 
Lastly, there was no clear correlation between the thermodynamic and kinetic solubility, but as 
a tendency, higher kinetic solubility can be taken as a hint to increased equilibrium solubility. 
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Figure 3.12. Comparison of the IC50 values in the Hoechst 33342 assay and kinetic and thermodynamic solubility limits of our 
previous tariquidar analog 3.01, fragment 3.27, the novel chromone inhibitors 3.40, 3.41, 3.48 and 3.49 as well as the novel, 
3.01-related inhibitor 3.65. 
3.3 Conclusion 
Poor aqueous solubility has been reported to cause major problems with purification as well as 
in vitro and in vivo studies of biologically active compounds [3]. ABCG2 inhibitors are 
especially prone to solubility issues due to their size and lipophilic nature. Our previous, 
tariquidar-related inhibitor UR-MB108 (3.01) [28] shows high potency (79 nM), but extremely 
low equilibrium solubility (78 nM). This study comprises a solubility-driven discovery of novel 
ABCG2 inhibitors based on 3.01. In a fragment-based approach, we synthesized and tested 
substructures of 3.01 for inhibitory potency, optimized them and included molecular docking 
experiments to grow the most promising fragments into inhibitors. The novel compounds 
inhibited ABCG2 with IC50 values in the two- to low three-digit nanomolar range, categorizing 
them among the most potent known ABCG2 inhibitors. Their ability to inhibit ABCG2 
transport was not only assessed in a Hoechst 33342 transport assay, but also confirmed by their 
ability to reverse the drug resistance in MCF7-Topo cells. The most promising compounds in 
terms of potency and solubility were the inhibitors UR-Ant116 (3.40), UR-Ant121 (3.41), 
UR-Ant131 (3.48) and UR-Ant132 (3.49), all of which displayed an N-phenyl-chromone-2-
carboxamide scaffold. Their equilibrium solubility ranged between 1 µM and 1.5 µM, which 
puts them at the lower edge of the drug solubility window. Compared to 3.01, this is an up to 
19-fold improvement of equilibrium solubility. As a rule of thumb, the solubility of a potential 
drug should be at least three times its IC50 value. Compounds 3.40, 3.41, 3.48 and 3.49 exhibit 
solubilities of three to nine times their IC50 value – sufficient to exert their maximal effect. 
Moreover they do not or, in case of 3.40 only slightly, violate Lipinski’s Ro5, which predicts 
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Whereas 3.41 was a triple ABCB1/ABCC1/ACBG2 inhibitor, compounds 3.42 and 3.49 were 
selective for ABCG2 and 3.48 was almost selective – it inhibited the other two subtypes only 
with very low potency and efficacy. Besides, the substances showed different modes of 
inhibition. An ATPase assay revealed that compounds 3.40 and 3.41 decreased the ATPase 
activity, whereas 3.48 and 3.49, both differing structurally from the aforementioned two 
inhibitors, were partial ATPase activators. As a prerequisite for in vivo studies, we 
demonstrated the stability of the compounds in blood plasma and their non-toxicity. 
Taken together, we offer scientists investigating ABCG2 a set of potent, selective and non-
selective inhibitors that are stable, non-toxic and water-soluble (> 1 µM). To the best of our 
knowledge, this is the first study on ABCG2 inhibitors focusing on improved aqueous solubility 
and the first report providing not only biological, but also solubility information on the 
compounds. We expect them to be of great value for in vitro examinations requiring long time-
periods of incubation such as structural biology studies on protein-ligand interactions using 
X-ray crystallography or NMR. Such studies depend on sufficient equilibrium solubility of the 
ligands; insufficient solubility has been identified as the cause of crystallography failures and 
as limitation to the method [69]. In the light of their stability in blood plasma and low toxicity, 
our substances are promising candidates for in vivo investigations, their aqueous solubility 
increasing the chances of success. For instance, due to their high selectivity, UR-Ant121 (3.41) 
and UR-Ant132 (3.49) should be well-suited as pharmacological tools for PET studies of 
ABCG2, e.g. at the BBB, provided that appropriate radioactive labeling can be achieved. Up to 
now, inhibitors of ABCG2 are not in clinical use yet [70]. Potential therapeutic applications 
were explored in several in vivo studies [70,71], for instance as a means to overcome the BBB 
and MDR. Since ABCB1 and ABCG2 (and to a lesser extent ABCC1) act in concert at many 
physiological barriers [72], the triple ABCB1/ABCC1/ABCG2 inhibitor UR-Ant116 (3.40) is 
an attractive candidate for therapeutic studies. 
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3.4 Experimental Section 
3.4.1 Chemistry 
3.4.1.1 General Experimental Conditions 
Chemicals and solvents were purchased from commercial suppliers (Sigma Aldrich, Munich, 
Germany; Merck, Darmstadt, Germany; VWR, Darmstadt, Germany; Thermo Fisher Scientific, 
Waltham, MA, USA; TCI, Eschborn, Germany) and used without further purification unless 
stated otherwise. Reactions requiring anhydrous conditions were carried out in dry reaction 
vessels under an atmosphere of argon and anhydrous solvents were used. Millipore water was 
used throughout for the preparation of buffers and HPLC eluents. Acetonitrile for HPLC 
(gradient grade) was obtained from Merck. 
Microwave reactions were carried out in an Initiator 8 microwave reactor (Biotage, Uppsala, 
Sweden). 
Thin layer chromatography was performed on TLC Silica gel 60 F254 aluminium plates 
(Merck, Darmstadt, Germany). Visualization was accomplished by UV irradiation at 
wavelengths of 254 nm and 366 nm or by staining with ninhydrin (1.5 g ninhydrin, 5 mL acetic 
acid, 500 mL 95% ethanol). 
For column chromatography Geduran® Silica 60 gel (0.040-0.063 mm; Merck, Darmstadt, 
Germany) was used. 
Automated flash column chromatography was performed on a 971-FP Flash Purification 
System (Agilent Technologies, Santa Clara, CA, USA) using pre-packed SuperFlash Silica 50 
columns (Agilent Technologies). The crude products were dissolved in a suitable solvent, 
mixed with Geduran® Silica 60 gel (0.040-0.063 mm; Merck, Darmstadt, Germany), 
concentrated under reduced pressure and placed in a load cartridge prior to the run. 
Melting points were determined with a Büchi B-540 apparatus (Büchi Labortechnik, Essen, 
Germany) and are uncorrected. 
NMR spectra were recorded on an Avance 300 instrument (7.05 T, 1H: 300.1 MHz, 13C: 
75.5 MHz), an Avance 400 instrument (9.40 T, 1H: 400 MHz, 13C: 101 MHz) or an Avance 600 
instrument with cryogenic probe (14.1 T, 1H: 600 MHz, 13C: 151 MHz) (Bruker, Karlsruhe, 
Germany) with TMS as external standard. 
High-resolution mass spectrometry (HRMS) analysis was performed on an Agilent 6540 
UHD Accurate-Mass Q-TOF LC/MS system (Agilent Technologies, Santa Clara, CA, USA) 
using an ESI source. 
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Low-resolution mass spectrometry (MS) was performed on a Finnigan MAT SSQ 710 A 
GC/MS system (Finnigan MAT, now Thermo Fisher Scientific, Waltham, MA, USA). 
Preparative HPLC was performed on a system from Knauer (Berlin, Germany) consisting of 
two K-1800 pumps and a K-2001 detector. A Kinetex® XB-C18 (5 µm, 100 Å, 250 mm x 
21.2 mm; Phenomenex, Aschaffenburg, Germany) served as RP-column at a flow-rate of 
15 mL/min. Mixtures of acetonitrile and 0.1% aq TFA were used as mobile phase. The detection 
wavelength was set to 220 nm throughout. The solvent mixtures were removed by 
lyophilization using an Alpha 2-4 LD lyophilization apparatus (Christ, Osterode am Harz, 
Germany) equipped with an RZ 6 rotary vane vacuum pump (Vacuubrand, Wertheim, 
Germany). 
Analytical HPLC was performed on a system from Agilent Technologies (Santa Clara, CA, 
USA) (Series 1100) composed of a G1312A binary pump equipped with a G1379A degasser, a 
G1329A ALS autosampler, a G1316A COLCOM thermostated column compartment and a 
G1314A VWD detector. A Kinetex® C8 (2.6 µm, 100 Å, 100 mm × 4.6 mm; Phenomenex, 
Aschaffenburg, Germany) served as RP-column at a flow rate of 1 mL/min. Oven temperature 
was set to 30 °C throughout. Mixtures of acetonitrile (A) and 0.05% aq TFA (B) were used as 
mobile phase. The detection wavelength was set to 220 nm throughout. Solutions for injection 
(40 µM) were prepared by diluting a stock solution in DMSO with a mixture of A and B 
corresponding to the composition of the eluent at the start of the gradient. The following linear 
gradient was applied: 0-12 min: A/B 30:70-95:5, 12-15 min: A/B 95:5. Retention (capacity) 
factors were calculated from retention times (tR) according to k = (tR - t0)/t0 (t0 = dead time). 
X-Ray analysis. Single clear colorless prism-shaped crystals of compound 3.04 were obtained 
by recrystallization from CHCl3. A crystal (0.35×0.21×0.20) was selected and mounted on a 
MITIGEN holder oil on a SuperNova, Single source at offset, Atlas diffractometer. The crystal 
was kept at T = 123.00(10) K during data collection. Using Olex2 (Dolomanov et al., 2009), 
the structure was solved with the ShelXT (Sheldrick, 2015) structure solution program, using 
the Direct Methods solution method. The model was refined with olex2.refine (Bourhis et al., 
2015) using Gauss-Newton minimization. 
3.4.1.2 Synthesis Protocols and Analytical Data 
All compounds were characterized by 1H and 13C NMR spectroscopy, (HR)MS, and melting 
point (if applicable). In addition, final compounds were characterized by RP-HPLC (purity 
control). The purity of the final compounds was ≥ 95% throughout. 
General Procedure for N-Acylation of Anilines 1 
Under dry conditions the carboxylic acid (1.0-1.5 eq) was dissolved in anhydrous DMF (0.5 M) 
in a microwave reaction vessel. DIPEA (2.0-3.0 eq) and the coupling reagent TBTU (1.0-
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1.5 eq) were added and the solution was stirred at rt for 5 min. The aniline (1.0-1.1 eq) was 
added and stirring was continued at 80 °C for another 30 min in a microwave reactor. The 
mixture was diluted either with DCM or EtOAc and washed with H2O, saturated NH4Cl-
solution and brine. The organic layer was dried over Na2SO4, and the volatiles were removed 
under reduced pressure. The residue was subjected to column chromatography (eluent: 
PE/EtOAc) and/ or to recrystallization in EtOAc or CHCl3. 
General Procedure for N-acylation of Anilines 2 
Under dry conditions the carboxylic acid (1.0 eq) was dissolved in anhydrous toluene (0.5 M) 
and treated with SOCl2 (2.0 eq) and pyridine (2.0 eq). After 2 h of refluxing, the volatiles were 
removed under reduced pressure. The residue was redissolved in DCM and added dropwise to 
a stirred solution of the aniline (1.0 eq) and DIPEA (4.0 eq) in DCM at 0 °C. Stirring was 
continued at rt overnight. The mixture was diluted with DCM and washed with H2O and 
saturated NH4Cl-solution. The organic layer was dried over Na2SO4, and the solvent was 
evaporated. The residue was subjected to recrystallization in EtOAc or to flash column 
chromatography (eluent: PE/EtOAc). 
General Procedure for CuAAC [73,74] 
The alkyne (1.0 eq), the azide (1.2 - 1.5 eq), CuSO4∙5H2O (0.15 eq), sodium ascorbate (0.7 eq) 
and TBTA (0.15 eq) were dissolved/suspended in CHCl3, THF or DMSO/isopropanol and 
refluxed for 1 to 3 d. In a few cases a washing step followed. After removal of the solvent under 
reduced pressure the remaining crude material was purified by (flash) column chromatography 




Compound 3.03 was prepared according to the general procedure for the CuAAC. The reaction 
was carried out using ethynylbenzene (21.5 µL, 0.196 mmol, 1.0 eq), 2-(4-azidophenethyl)-6,7-
dimethoxy-1,2,3,4-tetrahydroisoquinoline (3.09) (99.4 mg, 0.294 mmol, 1.5 eq), CuSO4∙5H2O 
(7.3 mg, 0.029 mmol, 0.15 eq), sodium ascorbate (27.2 mg, 0.137 mmol, 0.7 eq) and TBTA 
(15.6 mg, 0.029 mmol, 0.15 eq) in CHCl3 (2 mL). Refluxing lasted for 1 d. Column 
chromatography (eluent: DCM/MeOH 19:1, Rf = 0.2) followed by preparative HPLC (gradient: 
0-30 min: MeCN/ 0.1% aq TFA 33:67-69:31, tR = 11.0 min) afforded the product as a yellowish 
solid (71.8 mg, 0.129 mmol, 66%), mp 193-195 °C. 1H NMR (600 MHz, CDCl3) δ (ppm) 
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12.96 (br s, 1H), 8.19 (s, 1H), 7.88 (m, 2H), 7.74 (d, J = 8.2 Hz, 2H), 7.45 (m, 2H), 7.41 (d, J 
= 8.2 Hz, 2H), 7.37 (m, 1H), 6.64 (s, 1H), 6.54 (s, 1H), 4.65 (d, J = 14.5 Hz, 1H), 4.07 (d, J = 
14.5 Hz, 1H), 3.86 (s, 3H), 3.83 (s, 3H), 3.76 (m, 1H), 3.51-3.21 (m, 6H), 2.97 (m, 1H). 
13C NMR (151 MHz, CDCl3) δ (ppm) 162.0 (TFA), 161.8 (TFA), 149.5, 148.9, 148.7, 136.8, 
136.4, 130.4 (2C), 130.1, 129.1 (2C), 128.7, 126.0 (2C), 122.4, 121.2 (2C), 118.1, 117.8, 117.1 
(TFA), 115.2 (TFA), 111.3, 109.3, 56.2, 56.1, 55.7, 52.5, 49.5, 30.5, 24.1. RP-HPLC (220 nm): 
99% (tR = 4.5 min, k = 3.3). HRMS (ESI): m/z [M+H]
+ calcd. for C27H29N4O2
+: 441.2285, 
found: 441.2310. C27H28N4O2 · C2HF3O2 (440.54 + 114.02). 
Methyl 4-bromo-2-(quinoline-2-carboxamido)benzoate (3.04) 
 
3.04 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using quinoline-2-carboxylic acid (113 mg, 0.652 mmol, 1.5 eq), TBTU 
(209 mg, 0.652 mmol, 1.5 eq), DIPEA (222 µL, 1.30 mmol, 3.0 eq) and methyl 2-amino-4-
bromobenzoate (100 mg, 0.435 mmol, 1.0 eq) and DMF (1 mL). Dilution with EtOAc preceded 
the washing steps. Purification by column chromatography (eluent: PE/EtOAc = 4:1, Rf = 0.3) 
and recrystallization in EtOAc afforded 3.04 as slightly yellowish crystals (144 mg, 
0.374 mmol, 86%), mp 184-186 °C. 1H NMR (300 MHz, CDCl3) δ (ppm) 13.26 (s, 1H), 9.26 
(d, J = 2.0 Hz, 1H), 8.33 (s, 2H), 8.29 (d, J = 8.5 Hz, 1H), 7.92 (d, J = 8.6 Hz, 1H), 7.87 (dd, J 
= 0.9, 8.2 Hz, 1H), 7.80 (m, 1H), 7.63 (m, 1H), 7.29-7.22 (m, 1H, signals interfering with the 
solvent signal), 4.03 (s, 3H). 13C NMR (75 MHz, CDCl3) δ (ppm) 167.6, 163.7, 149.7, 146.6, 
141.7, 137.8, 132.4, 130.4, 130.3, 129.5, 129.4, 128.5, 127.8, 126.1, 123.5, 119.0, 115.2, 52.7. 
RP-HPLC (220 nm): 98% (tR = 10.1 min, k = 8.7). HRMS (ESI): m/z [M+H]
+ calcd. for 
C18H14BrN2O3
+: 385.0182, found: 385.0189. C18H13BrN2O3 (385.21). 
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6,7-Dimethoxy-2-(4-nitrophenethyl)-1,2,3,4-tetrahydroisoquinoline (3.07) [75,76] 
 
1-(2-Bromoethyl)-4-nitrobenzene (300 mg, 1.30 mmol, 1.0 eq), 6,7-dimethoxy-1,2,3,4-
tetrahydroisoquinoline hydrochloride (330.8 mg, 1.43 mmol, 1.1 eq) and K2CO3 (721 mg, 
5.22 mmol, 4.0 eq) were suspended in MeCN (10 mL) in a microwave vessel and kept in a 
microwave reactor at 130 °C for 70 min. The suspension was filtered, and the filtrate 
concentrated under reduced pressure. The residue was subjected to flash column 
chromatography (4 g column, gradient: 0-20 min: DCM/MeOH 100:0-96:4, Rf = 0.3 in 
DCM/MeOH 96:4), yielding 3.07 as an orange solid (276 mg, 0.806 mmol, 62%), mp 102-
108 °C (lit. [76,77] mp 118 °C). 1H NMR (300 MHz, CDCl3) δ (ppm) 8.14 (d, J = 8.8 Hz, 2H), 
7.40 (d, J = 8.7 Hz, 2H), 6.60 (s, 1H), 6.52 (s, 1H), 3.84 (s, 3H), 3.83 (s, 3H), 3.68 (s, 2H), 3.08-
2.99 (m, 2H), 2.90-2.78 (m, 6H). 13C NMR (75 MHz, CDCl3) δ 148.2, 147.8, 147.5, 146.7, 
129.7 (2C), 125.8, 125.7, 123.8 (2C), 111.4, 109.5, 59.0, 56.1, 56.0, 55.5, 51.0, 33.7, 28.4. 
HRMS (ESI): m/z [M+H]+ calcd. for C19H23N2O4
+: 343.1652, found: 343.1654. C19H22N2O4 
(342.39). 
4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)aniline (3.08) [75-77] 
 
6,7-Dimethoxy-2-(4-nitrophenethyl)-1,2,3,4-tetrahydroisoquinoline (3.07) (894 mg, 
2.61 mmol, 1.0 eq) was dissolved in EtOH (18 mL) and a 10% Pd/C catalyst (100 mg) was 
added. The suspension was stirred under a hydrogen atmosphere (10 bar) overnight and 
the catalyst was filtered off. Column chromatography (eluent: DCM/MeOH = 14:1, Rf = 
0.2) yielded 3.08 as a yellow solid (577 mg, 1.85 mmol, 71%), mp 120-122 °C (lit. [77] mp 
120 °C). 1H NMR (300 MHz, CDCl3) δ (ppm) 7.02 (d, J = 8.3 Hz, 2H), 6.66-6.58 (m, 3H), 
6.53 (s, 1H), 3.84 (s, 3H), 3.83 (s, 3H), 3.68 (s, 2H), 3.62 (br s, 2H), 2.92-2.69 (m, 8H). 
13C NMR (75 MHz, CDCl3) δ (ppm) 147.7, 147.3, 144.7, 130.0, 129.6 (2C), 126.4, 126.0, 
115.4 (2C), 111.4, 109.5, 60.4, 56.0, 56.0, 55.6, 51.0, 33.0, 28.4. HRMS (ESI): m/z [M+H]+ 
calcd. for C19H25N2O2
+: 313.1911, found: 313.1912. C19H24N2O2 (312.41). 
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2-(4-Azidophenethyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (3.09) [78] 
 
4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)aniline (3.08) (560 mg, 
1.79 mmol, 1.0 eq) was dissolved in 6 M HCl aq (10 mL) and cooled to 0 °C using an ice bath. 
A solution of NaNO2 (148 mg, 2.15 mmol, 1.2 eq) in H2O (2 mL) was added dropwise, and 
stirring was continued for 1 h. Thereafter, a solution of NaN3 (233 mg, 3.59 mmol, 2.0 eq) was 
added dropwise, and the mixture was brought to rt and stirred for another 2 h. Then, the mixture 
was diluted with H2O, and the product was extracted with DCM (3 x 100 mL). The combined 
organic layers were dried over Na2SO4 and the volatiles were removed under reduced pressure, 
affording 3.09 as a yellow solid (556 mg, 1.64 mmol, 92%), mp 168-175 °C (lit. [78] mp 68-
70°C). 1H NMR (300 MHz, CDCl3) δ (ppm) 7.23 (d, J = 8.5 Hz, 2H), 6.93 (d, J = 8.5 Hz, 2H), 
6.61 (s, 1H), 6.53 (s, 1H), 4.64-4.51 (m, 1H), 4.07-3.96 (m, 1H), 3.83 (s, 3H), 3.81 (s, 3H), 
3.72-3.56 (m, 1H), 3.47-3.19 (m, 6H), 2.98-2.84 (m, 1H). 13C NMR (75 MHz, CDCl3) δ (ppm) 
149.3, 148.7, 139.3, 132.7, 130.3 (2C), 122.5, 119.6 (2C), 118.0, 111.2, 109.3, 56.1, 56.1, 55.8, 
52.2, 49.3, 30.1, 24.0. HRMS (ESI): m/z [M+H]+ calcd. for C19H23N4O2
+: 339.1816, found: 
339.1818. C19H22N4O2 (338.41). 
Methyl 2-(2-naphthamido)-4-bromobenzoate (3.12) 
 
3.12 was prepared according to the general procedure 2 for N-acylation of anilines. The reaction 
was carried out using 2-naphthoic acid (100 mg, 0.581 mmol, 1.0 eq), thionyl chloride (84 µL, 
1.162 mmol, 2.0 eq), pyridine (94 µL, 1.162 mmol, 2.0 eq), methyl 2-amino-4-bromobenzoate 
(134 mg, 0.581 mmol, 1.0 eq), DIPEA (405 µL, 2.323 mmol, 4.0 eq), and toluene (1 mL). After 
the washing steps, recrystallization in EtOAc afforded 3.12 as a beige-colored solid (104 mg, 
0.271 mmol, 47%), mp 145-146 °C. 1H NMR (400 MHz, CDCl3) δ (ppm) 12.21 (s, 1H), 9.26 
(d, J = 1.9 Hz, 1H), 8.57 (s, 1H), 8.11-7.87 (m, 5H), 7.64-7.54 (m, 2H), 7.29-7.24 (m, 1H, 
signals interfering with the solvent signal), 3.99 (s, 3H). 13C NMR (101 MHz, CDCl3) δ (ppm) 
168.8, 165.9, 142.8, 135.2, 132.9, 132.1, 131.7, 130.0, 129.6, 128.9, 128.6, 128.2, 127.9, 127.0, 
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126.0, 123.6, 123.5, 113.9, 52.8. RP-HPLC (220 nm): 97% (tR = 10.4 min, k = 8.9). HRMS 
(ESI): m/z [M+H]+ calcd. for C19H15BrNO3
+: 384.0230, found: 384.0236. C19H14BrNO3 
(384.23). 
Methyl 4-bromo-2-(5,6,7,8-tetrahydroquinoline-2-carboxamido)benzoate (3.13) 
 
3.13 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using 5,6,7,8-tetrahydroquinoline-2-carboxylic acid (3.31) (100 mg, 
0.564 mmol, 1.0 eq), TBTU (181 mg, 0.564 mmol, 1.0 eq), DIPEA (197 µL, 1.129 mmol, 
2.0 eq) and methyl 2-amino-4-bromobenzoate (143 mg, 0.621 mmol, 1.1 eq) and DMF (2 mL). 
Dilution with DCM preceded the washing steps. Recrystallization in EtOAc afforded 3.13 as 
beige-colored crystals (30 mg, 0.077 mmol, 14%), mp 142-143 °C. 1H NMR (400 MHz, 
CDCl3) δ (ppm) 12.92 (s, 1H), 9.24 (d, J = 1.9 Hz, 1H), 7.99 (d, J = 7.8 Hz, 1H), 7.93 (d, J = 
8.6 Hz, 1H), 7.55 (d, J = 7.8 Hz, 1H), 7.28-7.22 (m, 1H, signals interfering with the solvent 
signal), 4.00 (s, 3H), 3.08 (t, J = 6.3 Hz, 2H), 2.86 (t, J = 6.2 Hz, 2H), 1.92 (m, 4H). 13C NMR 
(101 MHz, CDCl3) δ (ppm) 167.6, 164.1, 156.7, 147.1, 141.8, 138.2, 136.5, 132.4, 129.4, 126.0, 
123.6, 120.2, 115.3, 52.6, 32.7, 29.1, 23.0, 22.7. RP-HPLC (220 nm): 97% (tR = 10.5 min, k = 
9.0). HRMS (ESI): m/z [M+H]+ calcd. for C18H18BrN2O3
+: 389.0495, found: 389.0498. 
C18H17BrN2O3 (386.15). 
Methyl 4-bromo-2-(6-methylpicolinamido)benzoate (3.14) 
 
3.14 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using 6-methylpicolinic acid (100 mg, 0.729 mmol, 1.0 eq), TBTU (234 mg, 
0.729 mmol, 1.0 eq), DIPEA (254 µL, 1.458 mmol, 2.0 eq) and methyl 2-amino-4-
bromobenzoate (185 mg, 0.802 mmol, 1.1 eq) and DMF (2 mL). Dilution with DCM preceded 
the washing steps. Purification by column chromatography (eluent: PE/EtOAc = 10:1, Rf = 0.3) 
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afforded 3.14 as a yellowish solid (198 mg, 0.567 mmol, 78%), mp 157-158 °C. 1H NMR 
(300 MHz, CDCl3) δ (ppm) 13.02 (s, 1H), 9.24 (d, J = 2.0 Hz, 1H), 8.09 (d, J = 7.7 Hz, 1H), 
7.94 (d, J = 8.6 Hz, 1H), 7.80 (t, J = 7.7 Hz, 1H), 7.36 (d, J = 7.7 Hz, 1H), 7.30-7.23 (m, 1H, 
signals interfering with the solvent signal), 4.00 (s, 3H), 2.73 (s, 3H). 13C NMR (75 MHz, 
CDCl3) δ (ppm) 167.6, 163.7, 157.7, 149.3, 141.7, 138.0, 132.4, 129.4, 126.6, 126.2, 123.7, 
120.1, 115.3, 52.7, 24.5. RP-HPLC (220 nm): 98% (tR = 9.1 min, k = 7.7). HRMS (ESI): m/z 
[M+H]+ calcd. for C15H14BrN2O3
+: 349.0182, found: 349.0195. C15H13BrN2O3 (349.18). 
Methyl 4-bromo-2-(picolinamido)benzoate (3.15) 
 
3.15 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using picolinic acid (80 mg, 0652 mmol, 1.5 eq), TBTU (209 mg, 0.652 mmol, 
1.5 eq), DIPEA (122 µL, 1.30 mmol, 3.0 eq) and methyl 2-amino-4-bromobenzoate (100 mg, 
0.435 mmol, 1.0 eq) and DMF (1 mL). Dilution with EtOAc preceded the washing steps. 
Purification by column chromatography (eluent: PE/EtOAc = 4:1, Rf = 0.3) afforded 3.15 as a 
white, fluffy solid (109 mg, 0.325 mmol, 75%), mp 179-181 °C. 1H NMR (300 MHz, CDCl3) 
δ (ppm) 13.05 (s, 1H), 9.26 (d, J = 1.9 Hz, 1H), 8.78 (d, J = 4.3 Hz, 1H), 8.29 (d, J = 7.8 Hz, 
1H), 7.98-7.87 (m, 2H), 7.55-7.46 (m, 1H), 7.31-7.26 (m, 1H, signals interfering with the 
solvent signal), 4.00 (s, 3H). 13C NMR (75 MHz, CDCl3) δ (ppm) 167.8, 163.6, 150.1, 148.8, 
141.9, 137.7, 132.4, 129.6, 126.8, 126.3, 123.7, 123.0, 115.0, 52.8. RP-HPLC (220 nm): 98% 
(tR = 8.2 min, k = 6.9). HRMS (ESI): m/z [M+H]
+ calcd. for C14H12BrN2O3
+: 335.0031, found: 
335.0031. C14H11BrN2O3 (335.15). 
Methyl 4-bromo-2-(6-chloropicolinamido)benzoate (3.16) 
 
3.16 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using 6-chloropicolinic acid (500 mg, 3.174 mmol, 1.0 eq), TBTU (1019 mg, 
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3.174 mmol, 1.0 eq), DIPEA (1106 µL, 6.347 mmol, 2.0 eq) and methyl 2-amino-4-
bromobenzoate (803 mg, 3.491 mmol, 1.1 eq) and DMF (8 mL). Dilution with EtOAc preceded 
the washing steps. Recrystallization in CHCl3 afforded 3.16 as a white solid (272 mg, 
0.736 mmol, 23%), mp 167-169 °C. 1H NMR (300 MHz, CDCl3) δ (ppm) 12.82 (s, 1H), 9.18 
(d, J = 1.9 Hz, 1H), 8.20 (s, 1H), 7.98-8.16 (m, 2H), 7.53 (d, J = 7.9 Hz, 1H), 7.29 (dd, J = 2.0, 
8.6 Hz, 1H), 4.05 (s, 3H). 13C NMR (75 MHz, CDCl3) δ (ppm) 167.4, 162.0, 150.6, 150.5, 
141.1, 140.4, 132.6, 129.4, 127.7, 126.6, 123.6, 121.6, 115.5, 52.9. RP-HPLC (220 nm): 99% 
(tR = 9.1 min, k = 7.7). HRMS (ESI): m/z [M+H]
+ calcd. for C14H11BrClN2O3
+: 368.9636, 
found: 368.9639. C14H10BrClN2O3 (369.60). 
Methyl 4-bromo-2-(5-chloropicolinamido)benzoate (3.17) 
 
3.17 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using 5-chloropicolinic acid (500 mg, 3.174 mmol, 1.0 eq), TBTU (1019 mg, 
3.174 mmol, 1.0 eq), DIPEA (1106 µL, 6.347 mmol, 2.0 eq) and methyl 2-amino-4-
bromobenzoate (803 mg, 3.491 mmol, 1.1 eq) and DMF (8 mL). Dilution with EtOAc preceded 
the washing steps. Recrystallization in CHCl3 afforded 3.17 as a white solid (178 mg, 
0.482 mmol, 15%), mp 195-199 °C. 1H NMR (400 MHz, CDCl3) δ (ppm) 12.94 (s, 1H), 9.21 
(d, J = 1.7 Hz, 1H), 8.71 (d, J = 2.2 Hz, 1H), 8.23 (d, J = 8.4 Hz, 1H), 7.94 (d, J = 8.6 Hz, 1H), 
7.88 (dd, J = 2.3, 8.4 Hz, 1H), 7.28 (dd, J = 1.8, 8.6 Hz, 1H), 3.99 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ (ppm) 167.8, 162.7, 148.3, 147.9, 141.7, 137.4, 135.7, 132.4, 129.6, 126.4, 124.0, 
123.7, 115.0, 52.8. RP-HPLC (220 nm): 98% (tR = 9.3 min, k = 7.9). HRMS (ESI): m/z 
[M+H]+ calcd. for C14H11BrClN2O3
+: 368.9636, found: 368.9640. C14H10BrClN2O3 (369.60). 
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Methyl 4-bromo-2-(6-methoxypicolinamido)benzoate (3.18) 
 
3.18 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using 6-methoxypicolinic acid (100 mg, 0.653 mmol, 1.0 eq), TBTU (210 mg, 
0.653 mmol, 1.0 eq), DIPEA (228 µL, 1.306 mmol, 2.0 eq) and methyl 2-amino-4-
bromobenzoate (165 mg, 0.718 mmol, 1.1 eq) and DMF (1.5 mL). Dilution with DCM 
preceded the washing steps. Recrystallization in EtOAc afforded 3.18 as a white solid (77 mg, 
0.211 mmol, 32%), mp 177-179 °C. 1H NMR (300 MHz, CDCl3) δ (ppm) 13.03 (s, 1H), 9.26 
(d, J = 2.0 Hz, 1H), 7.95-7.83 (m, 2H), 7.80-7.72 (m, 1H), 7.29-7.22 (m, 1H, signals interfering 
with the solvent signal), 6.95 (dd, J = 0.8, 8.2 Hz, 1H), 4.19 (s, 3H), 3.92 (s, 3H). 13C NMR 
(75 MHz, CDCl3) δ (ppm) 167.6, 163.6, 163.2, 147.4, 142.0, 139.9, 132.1, 129.5, 126.1, 123.6, 
116.1, 115.1, 115.0, 54.4, 52.4. RP-HPLC (220 nm): 98% (tR = 9.4 min, k = 8.0). HRMS (ESI): 
m/z [M+H]+ calcd. for C15H14BrN2O4
+: 365.0131, found: 365.0147. C15H13BrN2O4 (365.18). 
Methyl 4-bromo-2-(5-methoxypicolinamido)benzoate (3.19) 
 
3.19 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using 5-methoxypicolinic acid (100 mg, 0.653 mmol, 1.0 eq), TBTU (210 mg, 
0.653 mmol, 1.0 eq), DIPEA (228 µL, 1.306 mmol, 2.0 eq) and methyl 2-amino-4-
bromobenzoate (165 mg, 0.718 mmol, 1.1 eq) and DMF (1 mL). Dilution with EtOAc preceded 
the washing steps. Purification by column chromatography (eluent: PE/EtOAc = 4:1, Rf = 0.2) 
afforded 3.19 as a white solid (70 mg, 0.192 mmol, 29%), mp 162-164 °C. 1H NMR 
(300 MHz, CDCl3) δ (ppm) 12.89 (s, 1H), 9.24 (d, J = 2.0 Hz, 1H), 8.42 (d, J = 2.3 Hz, 1H), 
8.23 (d, J = 8.6 Hz, 1H), 7.92 (d, J = 8.6 Hz, 1H), 7.33 (dd, J = 2.4, 8.6 Hz, 1H), 7.26-7.20 (m, 
1H, signals interfering with the solvent signal), 3.98 (s, 3H), 3.93 (s, 3H). 13C NMR (75 MHz, 
CDCl3) δ (ppm) 167.9, 163.5, 158.3, 142.7, 142.1, 136.9, 132.3, 129.5, 125.9, 124.3, 123.5, 
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120.8, 114.8, 56.0, 52.7. RP-HPLC (220 nm): 100% (tR = 8.5 min, k = 7.2). HRMS (ESI): m/z 
[M+H]+ calcd. for C15H14BrN2O4
+: 365.0131, found: 365.0138. C15H13BrN2O4 (365.18). 
Methyl 4-bromo-2-(6-hydroxypicolinamido)benzoate (3.20) 
 
3.20 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using 6-hydroxypicolinic acid (100 mg, 0.719 mmol, 1.0 eq), TBTU (230 mg, 
0.719 mmol, 1.0 eq), DIPEA (250 µL, 1.438 mmol, 2.0 eq) and methyl 2-amino-4-
bromobenzoate (182 mg, 0.797 mmol, 1.1 eq) and DMF (2 mL). Dilution with DCM preceded 
the washing steps. The crude product was subjected to column chromatography (eluent: 
DCM/MeOH = 50:1, Rf = 0.3) and for further purification to preparative HPLC (gradient: 0-
30 min: MeCN/ 0.1% aq TFA 55:45-90:10, tR = 12.0 min). Removal of the solvent from the 
eluate through evaporation and lyophilization afforded 3.20 as a white solid (94 mg, 
0.268 mmol, 37%), mp 182-184 °C. 1H NMR (400 MHz, DMSO-d6) δ 12.43 (s, 1H), 11.22 (s, 
1H), 9.02 (d, J = 1.6 Hz, 1H), 7.97 (d, J = 8.6 Hz, 1H), 7.88 (t, J = 7.8 Hz, 1H), 7.65 (d, J = 
6.9 Hz, 1H), 7.45 (dd, J = 2.0, 8.5 Hz, 1H), 6.98 (d, J = 8.2 Hz, 1H), 3.96 (s, 3H). 13C NMR 
(151 MHz, DMSO-d6) δ (ppm) 166.5, 162.9, 162.7, 147.2, 140.8 (2C), 132.8, 127.9, 126.2, 
122.7, 115.6, 114.6, 114.4, 52.9. RP-HPLC (220 nm): 100% (tR = 6.8 min, k = 5.5). HRMS 
(ESI): m/z [M+H]+ calcd. for C14H12BrN2O4
+: 350.9975, found: 350.9976. C14H11BrN2O4 
(351.16). 
Methyl 4-bromo-2-(6-nitropicolinamido)benzoate (3.21) 
 
3.21 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using 6-nitropicolinic acid (100 mg, 0.595 mmol, 1.0 eq), TBTU (191 mg, 
0.595 mmol, 1.0 eq), DIPEA (207 µL, 1.190 mmol, 2.0 eq) and methyl 2-amino-4-
bromobenzoate (151 mg, 0.654 mmol, 1.1 eq) and DMF (2 mL). Dilution with DCM preceded 
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the washing steps. Recrystallization in EtOAc afforded 3.21 as a yellowish solid (82 mg, 
0.216 mmol, 36%), mp 222-223 °C. 1H NMR (300 MHz, CDCl3) δ (ppm) 13.02 (s, 1H), 9.19 
(d, J = 2.0 Hz, 1H), 8.67 (dd, J = 0.8, 7.7 Hz, 1H), 8.47 (dd, J = 0.8, 8.0 Hz, 1H), 8.30 (t, J = 
7.9 Hz, 1H), 7.99 (d, J = 8.6 Hz, 1H), 7.34 (dd, J = 2.0, 8.6 Hz, 1H), 4.07 (s, 3H). 13C NMR 
(75 MHz, CDCl3) δ (ppm) 167.8, 161.1, 155.4, 149.9, 142.0, 141.0, 132.6, 129.5, 128.2, 127.1, 
123.7, 120.8, 115.6, 53.1. RP-HPLC (220 nm): 100% (tR = 8.1 min, k = 6.8). HRMS (ESI): 
m/z [M+H]+ calcd. for C14H11BrN3O5
+: 379.9877, found: 379.9879. C14H10BrN3O5 (386.15). 
Methyl 2-(6-aminopicolinamido)-4-bromobenzoate (3.22) 
 
Methyl 4-bromo-2-(6-nitropicolinamido)benzoate (3.21) (30 mg, 0.079 mmol, 1.0 eq) was 
dissolved in anhydrous DCM (1 mL) and DIPEA (69 µL. 0.395 mmol, 5.0 eq) was added. The 
stirred solution was cooled down to 0 °C using an ice bath, HSiCl3 was added dropwise and 
stirring was continued at rt overnight. The reaction was quenched with H2O followed by 
extraction with DCM. The combined organic layers were dried over Na2SO4 and the volatiles 
were removed under reduced pressure. Purification by column chromatography (eluent: 
DCM/MeOH = 100:1, Rf = 0.2) was not sufficient to separate the product entirely from the 
byproduct methyl 4-bromo-2-(6-(hydroxyamino)picolinamido)benzoate (3.23) (Rf = 0.1). 
Therefore the mixture was subjected to preparative HPLC (gradient: 0-30 min: MeCN/ 0.1% 
aq TFA 46:54-82:18, tR = 12.8 min). Removal of the solvent from the eluate through 
evaporation and lyophilization afforded 3.22 as a brownish solid (8.3 mg, 0.024 mmol, 30%), 
mp 186-188 °C. 1H NMR (400 MHz, CDCl3) δ (ppm) 12.88 (s, 1H), 9.23 (d, J = 2.0 Hz, 1H), 
7.92 (d, J = 8.6 Hz, 1H), 7.66-7.59 (m, 2H), 7.27-7.23 (m, 1H, signals interfering with the 
solvent signal), 6.74-6.67 (m, 1H), 3.97 (s, 3H), 3.66 (2H). 13C NMR (101 MHz, CDCl3) δ 
(ppm) 167.7, 163.8, 157.3, 148.2, 142.0, 139.3, 132.3, 129.5, 126.0, 123.6, 115.0, 113.4, 112.4, 
52.6. RP-HPLC (220 nm): 97% (tR = 6.1 min, k = 4.8). HRMS (ESI): m/z [M+H]
+ calcd. for 
C14H13BrN3O3
+: 350.0135, found: 350.0164. C14H12BrN3O3 (350.17). 
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Methyl 4-bromo-2-(6-(hydroxyamino)picolinamido)benzoate (3.23) 
 
3.23 is a side product of the synthesis of 3.22. Preparative HPLC (gradient: 0-30 min: MeCN/ 
0.1% aq TFA 46:54-82:18, tR = 14.5 min) and removal of the solvent from the eluate through 
evaporation and lyophilization afforded 3.23 as a white solid (3.9 mg, 0.011 mmol, 13%), mp 
252-255 °C. Due to a slow rotation around the amide group on the NMR time scale, two isomers 
(ratio ca 1:0.3) were evident in the NMR spectra. 1H NMR (600 MHz, DMSO-d6) δ (ppm) 
12.48 (s, 0.3H), 12.40 (s, 1H), 9.05 (d, J = 2.0 Hz, 0.3H), 9.04 (d, J = 2.0 Hz, 1H), 8.99 (s, 1H), 
8.82 (d, J = 1.5 Hz, 1H), 7.96 (d, J = 8.5 Hz, 1.3H), 7.87 (t, J = 7.8 Hz, 1H), 7.63 (m, 0.3H), 
7.55 (m, 1H), 7.45 (m, 1.3H), 7.33 (m, 0.3H), 7.14 (d, J = 8.2 Hz, 1H), 6.75 (dd, J = 0.7, 8.3 Hz, 
0.3H), 6.18 (s, 0.5H), 3.98 (s, 3H), 3.97 (s, 0.9H). 13C NMR (151 MHz, DMSO-d6) δ (ppm) 
166.3, 163.2, 162.3, 146.9, 140.6, 139.4, 132.9, 127.9, 126.1, 122.6, 115.7, 113.6, 110.9, 52.9. 
RP-HPLC (220 nm): 96% (tR = 6.4 min, k = 5.1). HRMS (ESI): m/z [M+H]
+ calcd. for 
C14H13BrN3O4
+: 366.0084, found: 366.0087. C14H12BrN3O4 (366.17). 
Methyl 4-bromo-2-(furan-2-carboxamido)benzoate (3.24) 
 
3.24 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using furan-2-carboxylic acid (73 mg, 0.652 mmol, 1.5 eq), TBTU (209 mg, 
0.652 mmol, 1.5 eq), DIPEA (122 µL, 1.30 mmol, 3.0 eq) and methyl 2-amino-4-
bromobenzoate (100 mg, 0.435 mmol, 1.0 eq) and DMF (1 mL). Dilution with EtOAc preceded 
the washing steps. The crude product was subjected to column chromatography (eluent: 
PE/EtOAc = 6:1, Rf = 0.2) and for further purification to preparative HPLC (gradient: 0-20 min: 
MeCN/0.1% aq TFA 50:50-95:5, tR = 14.3 min). Removal of the solvent from the eluate 
through evaporation and lyophilization afforded 3.24 as a white, fluffy solid (4.63 mg, 
0.014 mmol, 3%), mp 142-144 °C. 1H NMR (300 MHz, DMSO-d6) δ (ppm) 11.85 (s, 1H), 
8.88 (d, J = 2.0 Hz, 1H), 8.06 (m, 1H), 7.95 (d, J = 8.6 Hz, 1H), 7.44 (dd, J = 2.0, 8.6 Hz, 1H), 
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7.34 (dd, J = 0.5, 3.5 Hz, 1H), 6.77 (dd, J = 1.7, 3.5 Hz, 1H), 3.91 (s, 3H). 13C NMR (101 MHz, 
DMSO-d6) δ (ppm) 167.4, 155.8, 146.9, 146.6, 141.1, 132.5, 128.0, 126.1, 122.4, 116.2, 114.9, 
112.9, 52.9. RP-HPLC (220 nm): 97% (tR = 7.9 min, k = 6.6). HRMS (ESI): m/z [M+H]
+ calcd. 
for C13H11BrNO4
+: 323.9866, found: 323.9868. C13H10BrNO4 (324.13). 
Methyl 2-(benzofuran-2-carboxamido)-4-bromobenzoate (3.25) 
 
3.25 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using benzofuran-2-carboxylic acid (106 mg, 0.652 mmol, 1.5 eq), TBTU 
(209 mg, 0.652 mmol, 1.5 eq), DIPEA (122 µL, 1.30 mmol, 3.0 eq) and methyl 2-amino-4-
bromobenzoate (100 mg, 0.435 mmol, 1.0 eq) and DMF (1 mL). Dilution with EtOAc preceded 
the washing steps. Purification by column chromatography (eluent: PE/EtOAc = 4:1, Rf = 0.3) 
and recrystallization in EtOAc afforded 3.25 as white crystals (63 mg, 0.168 mmol, 39%), mp 
163-165 °C. 1H NMR (300 MHz, CDCl3) δ (ppm) 12.26 (s, 1H), 9.17 (d, J = 1.9 Hz, 1H), 7.94 
(d, J = 8.6 Hz, 1H), 7.73-7.64 (m, 2H), 7.62 (d, J = 1.0 Hz, 1H), 7.50-7.43 (m, 1H), 7.36-7.26 
(m, 2H, signals interfering with the solvent signal), 4.01 (s, 3H). 13C NMR (75 MHz, CDCl3) 
δ (ppm) 168.3, 157.5, 155.3, 148.7, 141.9, 132.2, 129.8, 127.7, 127.5, 126.4, 124.0, 123.7, 
122.9, 114.3, 112.5, 112.0, 52.9. RP-HPLC (220 nm): 96% (tR = 9.6 min, k = 8.2). HRMS 
(ESI): m/z [M+H]+ calcd. for C17H13BrNO4
+: 374.0028, found: 374.0029. C17H12BrNO4 
(374.19). 
Methyl 4-bromo-2-(2-oxo-2-phenylacetamido)benzoate (3.26) 
 
3.26 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using 2-oxo-2-phenylacetic acid (326 mg, 2.173 mmol, 1.0 eq), TBTU 
(698 mg, 2.173 mmol, 1.0 eq), DIPEA (757 µL, 4.347 mmol, 2.0 eq) and methyl 2-amino-4-
bromobenzoate (500 mg, 2.391 mmol, 1.1 eq) and DMF (5 mL). Dilution with EtOAc preceded 
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the washing steps. Recrystallization in CHCl3 afforded 3.26 as a yellow solid (326 mg, 
0.900 mmol, 41%), mp 171-173 °C. 1H NMR (300 MHz, CDCl3) δ (ppm) 12.54 (s, 1H), 9.09 
(d, J = 1.9 Hz, 1H), 8.45-8.36 (m, 2H), 7.95 (d, J = 8.6 Hz, 1H), 7.71-7.61 (m, 1H), 7.57-4.47 
(m, 2H), 7.33 (dd, J = 1.9, 8.6 Hz, 1H), 3.98 (s, 3H). 13C NMR (75 MHz, CDCl3) δ (ppm) 
186.8, 167.8, 160.1, 140.9, 134.8, 133.1, 132.4, 131.5 (2C), 129.6, 128.7 (2C), 127.1, 123.5, 
115.2, 53.0. RP-HPLC (220 nm): 97% (tR = 9.5 min, k = 8.1). HRMS (ESI): m/z [M+H]
+ calcd. 
for C16H13BrNO4
+: 362.0022, found: 362.0022. C16H12BrNO4 (362.17). 
Methyl 4-bromo-2-(4-oxo-4H-chromene-2-carboxamido)benzoate (3.27) 
 
3.27 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using 4-oxo-4H-chromene-2-carboxylic acid (500 mg, 2.63 mmol, 1.0 eq), 
TBTU (844 mg, 6.63 mmol, 1.0 eq), DIPEA (916 µL, 5.26 mmol, 2.0 eq) and methyl 2-amino-
4-bromobenzoate (665 mg, 2.89 mmol, 1.1 eq) and DMF (5 mL). Dilution with DCM preceded 
the washing steps. Recrystallization in CHCl3 afforded 3.27 as a white solid (490 mg, 
1.22 mmol, 46%), mp 257-260 °C. 1H NMR (300 MHz, CDCl3) δ (ppm) 12.83 (s, 1H), 9.12 
(d, J = 1.9 Hz, 1H), 8.23 (dd, J = 1.4, 8.0 Hz, 1H), 7.97 (d, J = 8.6 Hz, 1H), 7.84-7.70 (m, 2H), 
7.49 (m, 1H), 7.35 (dd, J = 1.9, 8.6 Hz, 1H), 7.27-7.24 (m, 1H, signals interfering with the 
solvent signal), 4.03 (s, 3H). 13C NMR (75 MHz, CDCl3) δ (ppm) 178.4, 168.3, 157.9, 155.4, 
154.6, 141.0, 134.9, 132.3, 130.0, 127.4, 126.3, 126.1, 124.4, 123.7, 118.7, 114.8, 112.7, 53.0. 
RP-HPLC (220 nm): 99% (tR = 8.5 min, k = 7.1). HRMS (ESI): m/z [M+H]
+ calcd. for 
C18H13BrNO5
+: 401.9972, found: 401.9972. C18H12BrNO5 (402.20). 
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Methyl 4-bromo-2-(4-oxo-4H-chromene-3-carboxamido)benzoate (3.28) 
 
3.28 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using 4-oxo-4H-chromene-3-carboxylic acid (500 mg, 2.63 mmol, 1.0 eq), 
TBTU (844 mg, 6.63 mmol, 1.0 eq), DIPEA (916 µL, 5.26 mmol, 2.0 eq) and methyl 2-amino-
4-bromobenzoate (665 mg, 2.89 mmol, 1.1 eq) and DMF (5 mL). Dilution with DCM preceded 
the washing steps. Recrystallization in CHCl3 afforded 3.28 as a yellow solid (393 mg, 
0.98 mmol, 37%), mp 215-217 °C. Due to a slow rotation around the amide group on the NMR 
time scale, two isomers (ratio ca 1:0.4) were evident in the NMR spectra. 1H NMR (300 MHz, 
CDCl3) δ (ppm) 14.78-14.44 (m, 1H), 13.68-13.48 (m, 0.3H), 9.09-8.99 (m, 0.4H), 8.95-8.85 
(m, 1H), 8.24-8.16 (m, 1H), 8.15-8.09 (m, 0.4H), 8.05-7.95 (m, 1.4H), 7.84-7.77 (m, 1.4H), 
7.66-7.55 (m, 1.4H), 7.49-7.41 (m, 1.4H), 7.33-7.21 (m, 2.8H, signals interfering with the 
solvent signal), 4.07 (m, 3H), 4.05 (m, 1.1H). 13C NMR (75 MHz, CDCl3) δ (ppm) 181.3, 
166.2, 164.0, 155.0, 152.9, 151.9, 141.0, 135.2, 133.7, 133.5, 129.7, 129.2, 126.9, 126.8, 124.6, 
124.4, 120.5, 119.9, 117.7, 117.5, 117.4, 101.2, 53.4. RP-HPLC (220 nm): 77% (tR = 7.4 min, 
k = 6.1). HRMS (ESI): m/z [M+H]+ calcd. for C18H13BrNO5
+: 401.9972, found: 401.9974. 
C18H12BrNO5 (402.20). 
5,6,7,8-Tetrahydroquinoline 1-oxide (3.29) [79,80] 
 
5,6,7,8-Tetrahydroquinoline (300 mg, 2.252 mmol, 1.0 eq) and 3-chlorobenzoperoxoic acid 
(466 mg, 2.703 mmol, 1.2 eq) were dissolved in DCM (10 mL) and stirred at rt overnight. The 
reaction was quenched with 1 M NaOH aq (15 mL) and the product extracted with DCM. The 
combined organic layers were dried over Na2SO4 and the solvent was evaporated. Purification 
by column chromatography (eluent: DCM/MeOH = 19:1, Rf = 0.3) afforded 3.29 as a yellowish 
solid (271 mg, 1.816 mmol, 81%), mp 52-53 °C (lit. [79] mp 77-79 °C). 1H NMR (300 MHz, 
CDCl3) δ (ppm) 8.14-8.04 (m, 1H), 7.06-6.91 (m, 2H), 2.90 (t, J = 6.4 Hz, 2H), 2.74 (t, J = 
6.0 Hz, 2H), 1.93-1.66 (m, 4H). 13C NMR (75 MHz, CDCl3) δ (ppm) 148.8, 136.9, 136.5, 
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126.4, 122.1, 28.7, 24.8, 21.9, 21.7. GC-MS (EI+): m/z (%) 149.08310 (4) [M]•+, 133.08776 
(74) [M-O]•+, 132.08048 (100) [M-O-H]+. C9H11NO (149.19). 
5,6,7,8-Tetrahydroquinoline-2-carbonitrile (3.30) [81,82] 
 
5,6,7,8-Tetrahydroquinoline-1-oxide (3.29) (714 mg, 4.79 mmol, 1.0 eq), trimethylsilyl 
cyanide (1317 µl, 10.53 mmol, 2.2 eq) and dimethylcarbamoyl chloride (1132 mg, 
10.53 mmol, 2.2 eq) were dissolved in DCM (7 ml) and stirred at rt overnight. The reaction was 
quenched with 3 M NaOH aq (10 ml) and stirring was continued for 10 min. After extraction 
with DCM, the combined organic layers were dried over Na2SO4 and concentrated under 
reduced pressure. Purification by column chromatography (eluent: DCM (Rf = 0.35) to 
DCM/MeOH 19:1) yielded 3.30 as a white solid (589 mg, 3.72 mmol, 78%), mp 75-76 °C (lit. 
mp 79-80 °C). 1H NMR (400 MHz, CDCl3) δ (ppm) 7.44 (m, 2H), 2.94 (t, J = 6.5 Hz, 2H), 
2.84 (t, J = 6.3 Hz, 2H), 1.87 (m, 4H). 13C NMR (101 MHz, CDCl3) δ (ppm) 160.1, 137.4, 
137.3, 130.7, 125.7, 117.8, 32.5, 29.2, 22.6, 22.2. GC-MS (EI+): m/z (%) 158.08320 (94) [M]•+, 
157.07600 (100) [M-H]+,143.06009 (36) [M-CH3]
+, 130.05276 (63) [M-C2H4]
•+. C10H10N2 
(158.20). 
5,6,7,8-Tetrahydroquinoline-2-carboxylic acid (3.31) [34,83] 
 
5,6,7,8-Tetrahydroquinoline-2-carbonitrile (3.30) (569 mg, 3.597 mmol, 1.0 eq) was dissolved 
in 6 M HCl aq (15 mL) and refluxed for 2 d. The product was extracted with DCM, the 
combined organic layers dried over Na2SO4 and the solvent evaporated to give 3.31 as a beige-
colored solid (543 mg, 3.06 mmol, 85%), which was used in the next step without further 
purification, mp 131-132 °C. 1H NMR (400 MHz, CDCl3) δ 7.95 (d, J = 7.8 Hz, 1H), 7.62 (d, 
J = 7.8 Hz, 1H), 6.64 (s, 1H), 2.98 (t, J = 6.4 Hz, 2H), 2.88 (t, J = 6.3 Hz, 2H), 1.99-1.80 (m, 
4H). 13C NMR (101 MHz, CDCl3) δ (ppm) 164.5, 156.7, 143.2, 139.4, 138.3, 121.1, 31.9, 29.0, 
22.6, 22.3. HRMS (ESI): m/z [M+H]+ calcd. for C10H12NO2
+: 178.0863, found: 178,0864. 
C10H11NO2 (177.20). 
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4-(2-Azidoethyl)morpholine (3.34) [84,85] 
 
4-(2-Chloroethyl)morpholine hydrochloride (1000 mg, 5.37 mmol, 1 eq) and NaN3 (524 mg, 
8.06 mmol, 1.5 eq) were dissolved in H2O (10 mL) in a microwave vessel and kept in a 
microwave reactor at 130 °C for 1 h. The solution was basicified with 0.1 M NaOH aq (1 mL) 
and the product was extracted with ether (100 mL) several times. The combined organic 
layers were dried over Na2SO4 and the volatiles were removed under reduced pressure, 
affording 3.34 as a yellowish oil (240 mg, 1.54 mmol, 29%). 1H NMR (300 MHz, CDCl3) δ 
(ppm) 3.73-3.64 (m, 4H), 3.36-3.27 (m, 2H), 2.60-2.51 (m, 2H), 2.50-2.41 (m, 4H). 13C NMR 
(75 MHz, CDCl3) δ (ppm) 66.8 (2C), 57.6, 53.6 (2C), 47.8. HRMS (ESI): m/z [M+H]
+ calcd. 
for C6H13N4O
+: 157.1084, found: 157.1088. C6H12N4O (156.19). 
1-(2-Azidoethyl)pyrrolidine (3.35) [85,86] 
 
1-(2-Chloroethyl)pyrrolidine (1000 mg, 5.88 mmol, 1.0 eq) and NaN3 (573 mg, 8.82 mmol, 
1.5 eq) were dissolved in H2O (10 mL) in a microwave vessel and kept in a microwave reactor 
at 130 °C for 1 h. The solution was basicified with 1 M NaOH aq (1 mL) and the product 
extracted with DCM (3 x 150 mL). The combined organic layers were dried over Na2SO4 
and the volatiles removed under reduced pressure, affording 3.35 as a brown oil (174 mg, 
1.24 mmol, 21%). 1H NMR (300 MHz, CDCl3) δ (ppm) 4.09-3.99 (m, 2H), 3.92-3.74 (m, 2H), 
3.27-3.15 (m, 2H), 2.97-2.78 (m, 2H), 2.30-1.98 (m, 4H). 13C NMR (75 MHz, CDCl3) δ 54.5 
(2C), 53.7, 47.0, 23.4 (2C). HRMS (ESI): m/z [M+H]+ calcd. for C6H12N4
+: 141.1135, found: 
141.1138. C6H12N4 (140.19). 
1-(2-Amino-4-ethynylphenyl)propan-1-one (3.37) [28] (Sugasawa [87] reaction) 
 
Under dry conditions 3-ethynylaniline (5.00 g, 42.7 mmol, 1.0 eq) and propionitrile (6.10 ml, 
85.4 mmol, 2.0 eq) were dissolved in CHCl3 (40 ml) and cooled down to 0 °C using an ice bath. 
1 M heptane solution of BCl3 (46.9 ml, 46.9 mmol, 1.1 eq) was added very slowly (with a drip 
rate of 1-2 drops per second) in order to avoid aggregation. A white, milky suspension was 
formed. With stirring at 0 °C, GaCl3 (8.27 g, 46.9 mmol, 1.1 eq) was added and the milky 
Water-Soluble Inhibitors of ABCG2 – A Fragment-Based and Computational Approach 
143 
suspension turned into an emulsion of a dark brown oil in a yellow solution. The mixture was 
stirred for 10 min at 0 °C, brought to rt and then refluxed overnight, the color turning from pale 
yellow to orange. After cooling to rt 2 M HCl aq (55 ml) was added very slowly (extremely 
exothermic reaction) and the mixture was stirred for 2 h at 70 °C, cooled to rt and transferred 
into a separation funnel with DCM and H2O. The two phases were separated and rests of the 
product extracted from the aqueous layer with DCM. The combined organic layers were dried 
over Na2SO4 and the volatiles were removed under reduced pressure. Transfer and extraction 
were hampered by the dark brown, viscid oil formed in the reaction. After purification by 
column chromatography (eluent: PE/EA 10:1, Rf = 0.2), an orange solid (1.05 g, 6.09 mmol, 
14%) was obtained, mp 64-69 °C. 1H NMR (300 MHz, CDCl3) δ (ppm) 7.68 (d, J = 8.3 Hz, 
1H), 6.79 (d, J = 1.4 Hz, 1H), 6.74 (dd, J = 1.5, 8.3 Hz, 1H), 6.25 (br s, 2H), 3.14 (s, 1H), 2.95 
(q, J = 7.3 Hz, 2H), 1.19 (t, J = 7.3 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ (ppm) 203.0, 149.6, 
131.1, 127.5, 121.0, 119.4, 118.0, 83.1, 79.3, 32.5, 8.7. HRMS (ESI): m/z [M+H]+ calcd. for 
C11H12NO
+: 174.0913, found: 174.0914. C11H11NO (173.22). 
N-(5-Ethynyl-2-propionylphenyl)-4-oxo-4H-chromene-2-carboxamide (3.38) 
 
3.38 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using 4-oxo-4H-chromene-2-carboxylic acid (494 mg, 2.60 mmol, 1.5 eq), 
TBTU (834 mg, 2.60 mmol, 1.5 eq), DIPEA (905 µL, 5.20 mmol, 3.0 eq) and 1-(2-amino-4-
ethynylphenyl)propan-1-one (37) (300 mg, 1.73 mmol, 1.0 eq) and DMF (6 mL). Dilution with 
DCM preceded the washing steps. Purification by column chromatography (eluent: 
DCM/MeOH = 100:1, Rf = 0.4) and recrystallization in CHCl3 afforded 3.38 as a yellow solid 
(181 mg, 0.52 mmol, 30%), mp 262-266 °C (decomp.). 1H NMR (600 MHz, CDCl3) δ (ppm) 
13.45 (s, 1H), 9.07 (d, J = 1.3 Hz, 1H), 8.25 (dd, J = 1.5, 7.8 Hz, 1H), 7.98 (d, J = 8.3 Hz, 1H), 
7.87-7.81 (m, 2H), 7.52-7.48 (m, 1H), 7.34 (dd, J = 1.4, 8.2 Hz, 1H), 7.27 (s, 1H), 3.30 (s, 1H), 
3.13 (q, J = 7.2 Hz, 2H), 1.31 (t, J = 7.2 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ (ppm) 205.0, 
178.6, 158.2, 155.6, 155.0, 139.6, 135.0, 130.9, 129.1, 127.3, 126.3, 126.1, 124.7, 124.4, 122.1, 
118.8, 112.6, 82.5, 81.4, 33.5, 8.7. HRMS (ESI): m/z [M+H]+ calcd. for C21H16NO4
+: 346.1074, 
found: 346.1072. C21H15NO4 (345.35). 






3.39 was prepared according to the general procedure for the click reaction. The reaction was 
carried out using N-(5-ethynyl-2-propionylphenyl)-4-oxo-4H-chromene-2-carboxamide (3.38) 
(45.0 mg, 0.130 mmol, 1.0 eq), 2-(4-azidophenethyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-
isoquinoline (3.09) (66.1 mg, 0.195 mmol, 1.5 eq), CuSO4∙5H2O (4.9 mg, 0.020 mmol, 
0.15 eq), sodium ascorbate (18.1 mg, 0.091 mmol, 0.7 eq) and TBTA (10.4 mg, 0.020 mmol, 
0.15 eq) in CHCl3 (10 mL). Refluxing lasted for 3 d. Flash column chromatography (4 g 
column, gradient: 0-20 min: DCM/MeOH 100:0-95:5, Rf = 0.3 in DCM/MeOH 95:5) followed 
by preparative HPLC (gradient: 0-30 min: MeCN/ 0.1% aq TFA 42:58-78:22, tR = 16.0 min) 
afforded the product as a yellowish solid (14.9 mg, 0.019 mmol, 14%), mp 221-225 °C 
(decomp.). 1H NMR (600 MHz, DMSO-d6) δ (ppm) 13.30 (s, 1H), 10.11 (s, 1H), 9.51 (s, 1H), 
9.33 (d, J = 1.6 Hz, 1H), 8.35 (d, J = 8.4 Hz, 1H), 8.11 (dd, J = 1.6, 7.9 Hz, 1H), 8.01 (m, 3H), 
7.87 (dd, J = 1.6, 8.2 Hz, 1H), 7.81 (d, J = 8.3 Hz, 1H), 7.61 (m, 3H), 7.01 (s, 1H), 6.86 (s, 1H), 
6.81 (s, 1H), 4.56 (d, J = 15.1 Hz, 1H), 4.32 (dd, J = 7.8, 14.9 Hz, 1H), 3.81 (m, 1H), 3.76 (s, 
3H), 3.75 (s, 3H), 3.54 (m, 2H), 3.38 (m, 1H), 3.26 (q, J = 7.1 Hz, 2H), 3.21 (t, J = 8.3 Hz, 2H), 
3.14-2.98 (m, 2H), 1.21 (t, J = 7.1 Hz, 3H). 13C NMR (151 MHz, DMSO-d6) δ (ppm) 205.2, 
177.3, 158.2 (TFA), 158.0 (TFA), 157.7, 154.9, 154.9, 148.5, 147.8, 146.0, 139.0, 137.8, 135.8, 
135.5, 135.4, 132.6, 130.3 (2C), 126.4, 125.2, 123.7, 123.1, 122.5, 121.2, 120.9, 120.4 (2C), 
119.8, 118.4, 116.7, 111.5, 111.2, 109.6, 55.6, 55.6, 55.5, 51.8, 49.3, 32.9, 29.2, 24.6, 8.4. 
RP-HPLC (220 nm): 99% (tR = 6.4 min, k = 5.2). HRMS (ESI): m/z [M+H]
+ calcd. for 
C40H38N5O6
+: 684.2817, found: 684.2829. C40H37N5O6 · C2HF3O2 (683.75 + 114.02). 
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N-(5-(1-(2-Morpholinoethyl)-1H-1,2,3-triazol-4-yl)-2-propionylphenyl)-4-oxo-4H-
chromene-2-carboxamide hydrotrifluoroacetate (3.40) 
 
3.40 was prepared according to the general procedure for the click reaction. The reaction was 
carried out using N-(5-ethynyl-2-propionylphenyl)-4-oxo-4H-chromene-2-carboxamide (3.38) 
(37.0 mg, 0.107 mmol, 1.0 eq), 4-(2-azidoethyl)morpholine (3.34) (25.1 mg, 0.161 mmol, 
1.5 eq), CuSO4∙5H2O (4.0 mg, 0.016 mmol, 0.15 eq), sodium ascorbate (14.9 mg, 0.075 mmol, 
0.7 eq) and TBTA (8.5 mg, 0.016 mmol, 0.15 eq) in CHCl3 (7 mL). Refluxing lasted for 3 d. 
Flash column chromatography (4 g column, gradient: 0-20 min: DCM/MeOH 100:0-95:5, 
Rf = 0.2 in DCM/MeOH 95:5) followed by preparative HPLC (gradient: 0-30 min: MeCN/ 
0.1% aq TFA 33:67-69:31, tR = 12.0 min) afforded the product as a white solid (50.3 mg, 
0.082 mmol, 76%), mp 232-234 °C (decomp.). 1H NMR (600 MHz, DMSO-d6, D2O 10%) δ 
(ppm) 9.19 (d, J = 1.6 Hz, 1H), 8.77 (s, 1H), 8.26 (d, J = 8.4 Hz, 1H), 8.06 (dd, J = 1.5, 7.9 Hz, 
1H), 7.96 (m, 1H), 7.74 (m, 2H), 7.57 (m, 1H), 6.95 (s, 1H), 4.89 (t, J = 6.4 Hz, 2H), 3.82 (m, 
4H), 3.73 (m, 2H), 3.29 (m, 4H), 3.18 (q, J = 7.1 Hz, 2H), 1.16 (t, J = 7.1 Hz, 3H) (the NH 
protons are not apparent because of the addition of D2O). 13C NMR (151 MHz, DMSO-d6, D2O 
10%) δ (ppm) 205.5, 177.8, 158.7 (TFA), 158.5 (TFA), 157.8, 155.1, 155.1, 145.6, 139.2, 
136.3, 135.8, 132.9, 126.8, 125.5, 124.1, 123.8, 122.3, 120.9, 118.7, 116.7, 111.4, 63.7 (2C), 
55.0, 51.8 (2C), 44.3, 33.1, 8.6. RP-HPLC (220 nm): 99% (tR = 4.1 min, k = 3.0). HRMS 
(ESI): m/z [M+H]+ calcd. for C27H28N5O5
+: 502.2085, found: 502.2090. C27H27N5O5 · 
C2HF3O2 (501.54 + 114.02). 
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4-Oxo-N-(2-propionyl-5-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)phenyl)-
4H-chromene-2-carboxamide hydrotrifluoroacetate (3.41) 
 
3.41 was prepared according to the general procedure for the click reaction. The reaction was 
carried out using N-(5-ethynyl-2-propionylphenyl)-4-oxo-4H-chromene-2-carboxamide (3.38) 
(40.0 mg, 0.116 mmol, 1.0 eq), 1-(2-azidoethyl)pyrrolidine (3.35) (24.4 mg, 0.174 mmol, 
1.5 eq), CuSO4∙5H2O (4.3 mg, 0.017 mmol, 0.15 eq), sodium ascorbate (16.1 mg, 0.081 mmol, 
0.7 eq) and TBTA (9.2 mg, 0.017 mmol, 0.15 eq) in CHCl3 (10 mL). Refluxing lasted for 2 d. 
Flash column chromatography (4 g column, gradient: 0-20 min: DCM/MeOH 100:0-90:10, 20-
30 min: DCM/MeOH 90:10, Rf = 0.3 in DCM/MeOH 90:10) followed by preparative HPLC 
(gradient: 0-30 min: MeCN/ 0.1% aq TFA 33:67-69:31, tR = 11.5 min) afforded the product as 
a white solid (58.3 mg, 0.097 mmol, 84%), mp 228-234 °C (decomp.). 1H NMR (600 MHz, 
DMSO-d6) δ (ppm) 13.32 (s, 1H), 9.86 (s, 1H), 9.24 (m, 1H), 8.87 (m, 1H), 8.32 (m, 1H), 8.10 
(m, 1H), 8.00 (m, 1H), 7.79 (m, 2H), 7.60 (m, 1H), 6.99 (m, 1H), 4.88 (t, J = 6.2 Hz, 2H), 3.83 
(m, 2H), 3.59 (m, 2H), 3.23 (q, J = 7.1 Hz, 2H), 3.11 (m, 2H), 2.09-1.82 (m, 4H), 1.20 (t, J = 
7.1 Hz, 3H). 13C NMR (151 MHz, DMSO-d6) δ (ppm) 205.2, 177.3, 158.1 (TFA), 157.9 (TFA), 
157.7, 154.8 (2C), 145.3, 139.1, 136.1, 135.5, 132.7, 126.4, 125.2, 123.9, 123.7, 122.1, 120.5, 
118.4, 116.4, 111.2, 53.7 (2C), 52.8, 45.9, 32.8, 22.6 (2C), 8.4. RP-HPLC (220 nm): 97% (tR 
= 4.3 min, k = 3.1). HRMS (ESI): m/z [M+H]+ calcd. for C27H28N5O4
+: 486.2136, found: 
486.2139. C27H27N5O4 · C2HF3O2 (485.54 + 114.02). 





3.42 was prepared according to the general procedure for the click reaction. The reaction was 
carried out using N-(5-ethynyl-2-propionylphenyl)-4-oxo-4H-chromene-2-carboxamide (3.38) 
(40.0 mg, 0.116 mmol, 1.0 eq), 2-azidoethan-1-ol (15.1 mg, 0.174 mmol, 1.5 eq), CuSO4∙5H2O 
(4.3 mg, 0.017 mmol, 0.15 eq), sodium ascorbate (16.1 mg, 0.081 mmol, 0.7 eq) and TBTA 
(9.2 mg, 0.017 mmol, 0.15 eq) in CHCl3 (6 mL). Refluxing lasted for 2 d. Flash column 
chromatography (4 g column, gradient: 0-20 min: DCM/MeOH 100:0-95:5, 20-25 min: 
DCM/MeOH 95:5, Rf = 0.3 in DCM/MeOH 95:5) followed by preparative HPLC (gradient: 0-
30 min: MeCN/ 0.1% aq TFA 44:56-80:20, tR = 11.0 min) afforded the product as a slightly 
yellow solid (30.3 mg, 0.070 mmol, 60%), mp 273-275 °C (decomp.). 1H NMR (600 MHz, 
DMSO-d6) δ (ppm) 13.30 (s, 1H), 9.24 (d, J = 1.6 Hz, 1H), 8.75 (s, 1H), 8.30 (d, J = 8.4 Hz, 
1H), 8.12 (dd, J = 1.6, 8.0 Hz, 1H), 8.01 (m, 1H), 7.81 (m, 2H), 7.61 (m, 1H), 7.01 (s, 1H), 5.10 
(t, J = 5.4 Hz, 1H), 4.49 (t, J = 5.3 Hz, 2H), 3.86 (m, 2H), 3.24 (q, J = 7.1 Hz, 2H), 1.20 (t, J = 
7.1 Hz, 3H). 13C NMR (151 MHz, DMSO-d6) δ (ppm) 205.2, 177.3, 157.7, 154.9, 154.9, 144.8, 
139.0, 136.6, 135.5, 132.5, 126.4, 125.2, 123.7, 123.6, 122.1, 120.6, 118.4, 116.4, 111.2, 59.7, 
52.6, 32.8, 8.4. RP-HPLC (220 nm): 100% (tR = 5.1 min, k = 3.9). HRMS (ESI): m/z [M+H]
+ 
calcd. for C23H21N4O5
+: 433.1506, found: 433.1508. C23H20N4O5 (432.44). 
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2-(4-(3-(4-Oxo-4H-chromene-2-carboxamido)-4-propionylphenyl)-1H-1,2,3-triazol-1-
yl)acetic acid (3.43) 
 
3.43 was prepared according to the general procedure for the click reaction. The reaction was 
carried out using N-(5-ethynyl-2-propionylphenyl)-4-oxo-4H-chromene-2-carboxamide (3.38) 
(40.0 mg, 0.116 mmol, 1.0 eq), 2-azidoacetic acid (130 µL, 0.174 mmol, 1.5 eq), CuSO4∙5H2O 
(4.3 mg, 0.017 mmol, 0.15 eq), sodium ascorbate (16.1 mg, 0.081 mmol, 0.7 eq) and TBTA 
(9.2 mg, 0.017 mmol, 0.15 eq) in CHCl3 (10 mL). Refluxing lasted for 3 d. Flash column 
chromatography (4 g column, gradient: 0-20 min: DCM/MeOH 95:5-75:25, 20-30 min: 
DCM/MeOH 75:25, Rf = 0.2 in DCM/MeOH 75:25) followed by preparative HPLC (gradient: 
0-30 min: MeCN/ 0.1% aq TFA 45:55-75:25, tR = 14.0 min) afforded the product as a white 
solid (16.7 mg, 0.037 mmol, 32%), mp 295-297 °C (decomp.). 1H NMR (600 MHz, DMSO-
d6) δ (ppm) 13.51 (s, 1H), 13.30 (s, 1H), 9.24 (d, J = 1.6 Hz, 1H), 8.78 (s, 1H), 8.31 (d, J = 
8.5 Hz, 1H), 8.11 (dd, J = 1.6, 7.9 Hz, 1H), 8.00 (m, 1H), 7.80 (m, 2H), 7.61 (m, 1H), 7.00 (s, 
1H), 5.38 (s, 2H), 3.24 (q, J = 7.1 Hz, 2H), 1.20 (t, J = 7.1 Hz, 3H). 13C NMR (151 MHz, 
DMSO-d6) δ (ppm) 205.2, 177.3, 168.5, 157.7, 154.9, 154.9, 145.0, 139.1, 136.3, 135.5, 132.6, 
126.4, 125.2, 124.5, 123.7, 122.2, 120.6, 118.4, 116.5, 111.2, 50.8, 32.8, 8.4. RP-HPLC 
(220 nm): 98% (tR = 5.4 min, k = 4.2). HRMS (ESI): m/z [M+H]
+ calcd. for C23H19N4O6
+: 
447.1299, found: 447.1298. C23H18N4O6 (446.42). 
5-Methyl-2-((trimethylsilyl)ethynyl)aniline (3.45) [88] (Sonogashira [89] coupling) 
 
The liquids used in this reaction (THF, NEt3 and trimethylsilylacetylene) were deoxygenated 
by bubbling with argon for 30 min. Under an atmosphere of argon, 2-Iodo-5-methylaniline 
(907 mg, 3.89 mmol, 1 eq), Pd(PPh3)2Cl2 (137 mg, 0.195 mmol, 0.05 eq) and CuI (37.1 mg, 
0.195 mmol, 0.05 eq) were placed in a dried Schlenk flask and dissolved THF. NEt3 (1085 µL, 
7.784 mmol, 2 eq) was added and the mixture was deoxygenated again by bubbling with argon. 
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Trimethylsilylacetylene (825 µL, 5.84 mmol, 1.5 eq) was added dropwise, resulting in a color 
change from yellow over red to green. After 1.5 h of stirring at rt the volatiles were removed 
under reduced pressure and the residue subjected to flash column chromatography (15 g 
column, gradient: 0-20 min: PE/EtOAc 100:0-90:10, Rf = 0.3 in DCM/MeOH 90:10), which 
afforded 3.45 as a yellow oil (720 mg, 3.54 mmol, 91%). 1H NMR (400 MHz, CH2Cl2) δ (ppm) 
7.18 (d, J = 7.7 Hz, 1H), 6.52-6.47 (m, 2H), 4.27 (br s, 2H), 2.25 (s, 3H), 0.27 (s, 9H). 13C NMR 
(101 MHz, CH2Cl2) δ (ppm) 148.3, 140.4, 132.2, 119.0, 114.9, 105.2, 102.2, 99.1, 21.8, 0.3 
(3C). GC-MS (EI+): m/z (%) 203.11332 (65) [M]•+, 188.09008 (100) [M-CH3]
+. C12H17NSi 
(203.36). 
2-Ethynyl-5-methylaniline (3.46) [90] 
 
5-Methyl-2-((trimethylsilyl)ethynyl)aniline (3.45) (684 mg, 3.36 mmol, 1.0 eq) was dissolved 
in MeOH (10 mL) and K2CO3 (697 mg, 5.05 mmol, 1.5 eq) was added. The suspension was 
stirred at rt for 2 h, diluted with H2O and the product was extracted with DCM (3x). The 
combined organic layers were dried over Na2SO4 and the solvent evaporated to give 3.46 as a 
brown solid (331 mg, 2.52 mmol, 75%), which was used for the subsequent reaction without 
further purification, mp 44-47 °C. 1H NMR (400 MHz, CDCl3) δ (ppm) 7.21 (d, J = 7.7 Hz, 
1H), 6.54-6.48 (m, 2H), 4.18 (br s, 2H), 3.34 (s, 1H), 2.26 (s, 3H). 13C NMR (101 MHz, CDCl3) 
δ (ppm) 148.6, 140.7, 132.6, 119.1, 115.1, 104.0, 81.9, 81.0, 21.8. GC-MS (EI+): m/z (%) 
131.06984 (100) [M]•+, 130.06257 (89) [M-H]+. C9H9N (131.18). 
N-(2-Ethynyl-5-methylphenyl)-4-oxo-4H-chromene-2-carboxamide (3.47) 
 
3.47 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using 4-oxo-4H-chromene-2-carboxylic acid (544 mg, 2.86 mmol, 1.5 eq), 
TBTU (918 mg, 2.86 mmol, 1.5 eq), DIPEA (996 µL, 5.72 mmol, 3.0 eq) and 2-ethynyl-5-
methylaniline (3.46) (250 mg, 1.91 mmol, 1.0 eq) and DMF (4 mL). Dilution with DCM 
preceded the washing steps. Purification by flash column chromatography (8 g column, 
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gradient: 0-20 min: DCM/MeOH 100:0-99:1, Rf = 0.4 in DCM/MeOH 99:1) and 
recrystallization in CHCl3 afforded 3.47 as yellow crystals (331 mg, 1.09 mmol, 57%). mp 260-
277 °C (decomp.). 1H NMR (400 MHz, CDCl3) δ (ppm) 9.55 (s, 1H), 8.43 (s, 1H), 8.26 (dd, J 
= 1.3, 7.9 Hz, 1H), 7.81-7.74 (m, 1H), 7.54-7.47 (m, 2H), 7.44 (d, J = 7.9 Hz, 1H), 7.28 (s, 1H), 
7.01-6.96 (m, 1H), 3.67 (s, 1H), 2.42 (s, 3H). 13C NMR (101 MHz, CDCl3) δ (ppm) 178.2, 
156.9, 155.3, 154.6, 141.5, 138.3, 134.9, 132.3, 126.4, 126.4, 125.8, 124.5, 120.3, 118.1, 112.8, 
108.9, 84.4, 79.4, 22.2. HRMS (ESI): m/z [M+H]+ calcd. for C19H14NO3
+: 304.0968, found: 
304.0974. C19H13NO3 (303.32). 
N-(5-Methyl-2-(1-(2-morpholinoethyl)-1H-1,2,3-triazol-4-yl)phenyl)-4-oxo-4H-
chromene-2-carboxamide hydrotrifluoroacetate (3.48) 
 
3.48 was prepared according to the general procedure for the click reaction. The reaction was 
carried out using N-(2-ethynyl-5-methylphenyl)-4-oxo-4H-chromene-2-carboxamide (3.47) 
(40.0 mg, 0.132 mmol, 1.0 eq), 4-(2-azidoethyl)morpholine (3.34) (30.9 mg, 0.198 mmol, 
1.5 eq), CuSO4∙5H2O (4.9 mg, 0.020 mmol, 0.15 eq), sodium ascorbate (18.3 mg, 0.092 mmol, 
0.7 eq) and TBTA (10.5 mg, 0.020 mmol, 0.15 eq) in CHCl3 (9 mL). Refluxing lasted for 3 d. 
Flash column chromatography (4 g column, gradient: 0-40 min: DCM/MeOH 100:0-95:5, 
Rf = 0.3 in DCM/MeOH 95:5), followed by preparative HPLC (gradient: 0-30 min: MeCN/ 
0.1% aq TFA 28:72-64:36, tR = 11.0 min), afforded the product as a slightly yellow solid 
(47.3 mg, 0.082 mmol, 63%), mp 233-235 °C (decomp.). 1H NMR (600 MHz, DMSO-d6) δ 
(ppm) 13.02 (s, 1H), 10.21 (br s, 1H), 8.86 (s, 1H), 8.49 (s, 1H), 8.11 (dd, J = 1.5, 7.9 Hz, 1H), 
7.97 (m, 1H), 7.88 (d, J = 8.3 Hz, 1H), 7.74 (d, J = 7.9 Hz, 1H), 7.60 (m, 1H), 7.16 (m, 1H), 
6.99 (s, 1H), 4.99 (t, J = 6.2 Hz, 2H), 4.04-3.14 (m, 10H), 2.39 (s, 3H). 13C NMR (151 MHz, 
DMSO-d6) δ (ppm) 177.3, 158.6 (TFA), 158.4 (TFA), 158.1 (TFA), 157.9 (TFA), 157.2, 155.2, 
154.9, 146.2, 138.7, 135.2, 134.5, 127.6, 126.3, 125.9, 125.2, 123.7, 123.6, 121.5, 118.4, 117.0 
(TFA), 116.3, 115.03 (TFA), 111.0, 63.4 (2C), 54.6, 51.6 (2C), 44.3, 21.2. RP-HPLC 
(220 nm): 100% (tR = 3.6 min, k = 2.4). HRMS (ESI): m/z [M+H]
+ calcd. for C25H26N5O4
+: 
460.1979, found: 460.2015. C25H25N5O4 · C2HF3O2 (459.51 + 114.02). 
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N-(5-Methyl-2-(1-(2-(pyrrolidin-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)phenyl)-4-oxo-4H-
chromene-2-carboxamide hydrotrifluoroacetate (3.49) 
 
3.49 was prepared according to the general procedure for the click reaction. The reaction was 
carried out using N-(2-ethynyl-5-methylphenyl)-4-oxo-4H-chromene-2-carboxamide (3.47) 
(40.0 mg, 0.132 mmol, 1.0 eq), 1-(2-azidoethyl)pyrrolidine (3.35) (27.7 mg, 0.198 mmol, 
1.5 eq), CuSO4∙5H2O (4.9 mg, 0.020 mmol, 0.15 eq), sodium ascorbate (18.3 mg, 0.092 mmol, 
0.7 eq) and TBTA (10.5 mg, 0.020 mmol, 0.15 eq) in CHCl3 (9 mL). Refluxing lasted for 2 d. 
Flash column chromatography (4 g column, gradient: 0-40 min: DCM/MeOH 100:0-90:10, 
Rf = 0.4 in DCM/MeOH 90:10), followed by preparative HPLC (gradient: 0-30 min: MeCN/ 
0.1% aq TFA 32:68-68:32, tR = 11.5 min), afforded the product as a slightly yellow solid 
(33.6 mg, 0.044 mmol, 34%), mp 177-183 °C (decomp.). 1H NMR (600 MHz, DMSO-d6) δ 
(ppm) 13.00 (s, 1H), 9.95 (s, 1H), 8.87 (s, 1H), 8.49 (s, 1H), 8.11 (dd, J = 1.5, 7.9 Hz, 1H), 7.97 
(m, 1H), 7.89 (d, J = 8.3 Hz, 1H), 7.74 (d, J = 7.9 Hz, 1H), 7.60 (m, 1H), 7.16 (m, 1H), 6.99 (s, 
1H), 4.95 (t, J = 6.2 Hz, 2H), 3.85 (m, 2H), 3.61 (m, 2H), 3.12 (m, 2H), 2.39 (s, 3H), 2.08-1.80 
(m, 4H). 13C NMR (151 MHz, DMSO-d6) δ (ppm) 177.3, 158.2 (TFA), 158.0 (TFA), 157.2, 
155.2, 154.9, 146.2, 138.7, 135.2, 134.5, 127.6, 126.3, 125.9, 125.2, 123.7, 123.7, 121.5, 118.4, 
116.3, 111.0, 53.7 (2C), 52.7, 46.1, 22.6 (2C), 21.2. RP-HPLC (220 nm): 100% (tR = 3.8 min, 
k = 2.6). HRMS (ESI): m/z [M+H]+ calcd. for C25H26N5O3
+: 444.2023, found: 444.2050. 
C25H25N5O3 · C2HF3O2 (443.51 + 114.02). 
  





3.50 was prepared according to the general procedure for the click reaction. The reaction was 
carried out using N-(2-ethynyl-5-methylphenyl)-4-oxo-4H-chromene-2-carboxamide (3.47) 
(40.0 mg, 0.132 mmol, 1.0 eq), 2-azidoethan-1-ol (17.2 mg, 0.198 mmol, 1.5 eq), CuSO4∙5H2O 
(4.9 mg, 0.020 mmol, 0.15 eq), sodium ascorbate (18.3 mg, 0.092 mmol, 0.7 eq) and TBTA 
(10.5 mg, 0.020 mmol, 0.15 eq) in CHCl3 (9 mL). Refluxing lasted for 2 d. Flash column 
chromatography (4 g column, gradient: 0-30 min: DCM/MeOH 100:0-95:05, 30-35 min: 
DCM/MeOH 95:5, Rf = 0.3 in DCM/MeOH 95:5) followed by preparative HPLC (gradient: 0-
30 min: MeCN/ 0.1% aq TFA 42:58-78:22, tR = 12.0 min) afforded the product as a yellow 
solid (37.4 mg, 0.096 mmol, 73%), mp 319-321 °C (decomp.). 1H NMR (600 MHz, DMSO-
d6) δ (ppm) 13.25 (s, 1H), 8.78 (s, 1H), 8.54 (m, 1H), 8.10 (dd, J = 1.5, 7.9 Hz, 1H), 8.00 (m, 
1H), 7.91 (d, J = 8.2 Hz, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.59 (m, 1H), 7.12 (m, 1H), 6.98 (s, 
1H), 5.13 (t, J = 5.4 Hz, 1H), 4.57 (t, J = 5.4 Hz, 2H), 3.90 (m, 2H), 2.38 (s, 3H). 13C NMR 
(151 MHz, DMSO-d6) δ (ppm) 177.4, 157.1, 155.3, 154.9, 145.8, 138.3, 135.3, 134.5, 127.5, 
126.3, 125.7, 125.1, 123.7, 123.3, 121.1, 118.4, 116.3, 110.9, 59.8, 52.9, 21.2. RP-HPLC 
(220 nm): 100% (tR = 5.2 min, k = 4.0). HRMS (ESI): m/z [M+H]
+ calcd. for C21H19N4O4
+: 
391.1401, found: 491.1405. C21H18N4O4 (390.40). 
N-(5-Ethynyl-2-propionylphenyl)-2-naphthamide (3.51) 
 
3.51 was prepared according to the general procedure 2 for N-acylation of anilines. The reaction 
was carried out using 2-naphthoic acid (100 mg, 0.581 mmol, 1.0 eq), thionyl chloride (84 µL, 
1.162 mmol, 2.0 eq), pyridine (94 µL, 1.162 mmol, 2.0 eq), 1-(2-amino-4-
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ethynylphenyl)propan-1-one (3.37) (100.6 mg, 0.581 mmol, 1.0 eq), DIPEA (405 µL, 
2.323 mmol, 4.0 eq) and toluene (1 mL). After the washing steps, flash column chromatography 
(4 g column, gradient: 0-20 min: PE/EtOAc 100:0-90:10, Rf = 0.2 in DCM/MeOH 90:10) 
afforded 3.51 as a yellowish solid (135 mg, 0.412 mmol, 71%), mp 149-153 °C. 1H NMR 
(400 MHz, CDCl3) δ 12.87 (s, 1H), 9.19 (d, J = 1.5 Hz, 1H), 8.61 (d, J = 1.2 Hz, 1H), 8.12 (dd, 
J = 1.9, 8.6 Hz, 1H), 8.08-8.03 (m, 1H), 8.01-7.88 (m, 3H), 7.63-7.55 (m, 2H), 7.28-7.24 (m, 
1H, signals interfering with the solvent signal), 3.28 (s, 1H), 3.12 (q, J = 7.2 Hz, 2H), 1.28 (d, 
J = 14.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ (ppm) 205.3, 166.3, 141.4, 135.2, 132.9, 
132.0, 130.8, 129.6, 128.9 (2C), 128.7, 128.2, 127.9, 126.9, 126.0, 124.6, 123.8, 121.6, 82.9, 
80.9, 33.5, 8.8. HRMS (ESI): m/z [M+H]+ calcd. for C22H18NO2




3.52 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using 5,6,7,8-tetrahydroquinoline-2-carboxylic acid (31 mg, 0.17 mmol, 
1.5 eq), TBTU (56 mg, 0.17 mmol, 1.5 eq), DIPEA (60 µL, 0.35 mmol, 3.0 eq) and 1-(2-
amino-4-ethynylphenyl)propan-1-one (3.37) (20 mg, 0.12 mmol, 1.0 eq) and DMF (1 mL). 
Dilution with DCM preceded the washing steps. Purification by column chromatography 
(eluent: PE/EtOAc = 7:1, Rf = 0.2) afforded 3.52 as a yellow solid (33 mg, 0.10 mmol, 86%), 
mp 150-154 °C. 1H NMR (300 MHz, CDCl3) δ 13.44 (s, 1H), 9.15 (d, J = 1.6 Hz, 1H), 7.96 
(d, J = 7.8 Hz, 1H), 7.87 (d, J = 8.3 Hz, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.21 (dd, J = 1.6, 8.2 Hz, 
1H), 3.23 (s, 1H), 3.13 (t, J = 6.4 Hz, 2H), 3.04 (q, J = 7.2 Hz, 2H), 2.84 (t, J = 6.3 Hz, 2H), 
2.01-1.79 (m, 4H), 1.25 (t, J = 7.2 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ (ppm) 202.8, 163.5, 
155.8, 146.3, 139.3, 137.0, 135.2, 129.5, 127.1, 124.9, 123.6, 121.7, 119.0, 82.0, 79.3, 32.5, 
31.7, 28.0, 22.0, 21.6, 7.8. HRMS (ESI): m/z [M+H]+ calcd. for C21H21N2O3
+: 333.1598, found: 
333.1607. C21H20N2O2 (332.40). 




3.53 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using 6-methylpicolinic acid (238 mg, 1.73 mmol, 1.5 eq), TBTU (556 mg, 
1.73 mmol, 1.5 eq), DIPEA (603 µL, 3.46 mmol, 3.0 eq) and 1-(2-amino-4-
ethynylphenyl)propan-1-one (3.37) (200 mg, 1.16 mmol, 1.0 eq) and DMF (3 mL). Dilution 
with DCM preceded the washing steps. Purification by column chromatography (eluent: 
PE/EtOAc = 4:1, Rf = 0.3) afforded 3.53 as a beige-colored solid (269 mg, 0.92 mmol, 80%), 
mp 135-139 °C. 1H NMR (400 MHz, CDCl3) δ (ppm) 13.53 (s, 1H), 9.17 (d, J = 1.5 Hz, 1H), 
8.07 (d, J = 7.6 Hz, 1H), 7.90 (d, J = 8.2 Hz, 1H), 7.81-7.74 (m, 1H), 7.35 (d, J = 7.7 Hz, 1H), 
7.24 (dd, J = 1.6, 8.2 Hz, 1H), 3.24 (s, 1H), 3.06 (q, J = 7.2 Hz, 2H), 2.76 (s, 3H), 1.27 (t, J = 
7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ (ppm) 203.8, 164.3, 157.8, 149.6, 140.2, 137.7, 
130.6, 128.2, 126.4, 126.1, 124.7, 122.9, 120.0, 82.9, 80.4, 33.6, 24.5, 8.8. HRMS (ESI): m/z 
[M+H]+ calcd. for C18H17N2O2
+: 293.1285, found: 293.1285. C18H16N2O2 (292.34). 
6-Chloro-N-(5-ethynyl-2-propionylphenyl)picolinamide (3.54) 
 
3.54 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using 6-chloropicolinic acid (177 mg, 1.13 mmol, 1.5 eq), TBTU (361 mg, 
1.13 mmol, 1.5 eq), DIPEA (392 µL, 2.25 mmol, 3.0 eq) and 1-(2-amino-4-
ethynylphenyl)propan-1-one (3.37) (130 mg, 0.75 mmol, 1.0 eq) and DMF (2 mL). Dilution 
with DCM preceded the washing steps. Purification by column chromatography (eluent: 
PE/EtOAc = 4:1, Rf = 0.3) afforded 3.54 as a brownish solid (191 mg, 0.61 mmol, 81%), mp 
160-163 °C. 1H NMR (300 MHz, CDCl3) δ (ppm) 13.45 (s, 1H), 9.10 (d, J = 1.5 Hz, 1H), 8.19 
(dd, J = 0.8, 7.6 Hz, 1H), 7.95-7.82 (m, 2H), 7.53 (dd, J = 0.8, 7.9 Hz, 1H), 7.29-7.23 (m, 1H, 
signals interfering with the solvent signal), 3.25 (s, 1H), 3.07 (q, J = 7.2 Hz, 2H), 1.28 (t, J = 
7.2 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ (ppm) 204.1, 162.6, 150.9, 150.6, 140.2, 139.9, 
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130.7, 128.3, 127.5, 126.5, 124.6, 122.6, 121.5, 82.8, 80.6, 33.5, 8.8. HRMS (ESI): m/z [M+H]+ 
calcd. for C17H14ClN2O2
+: 313.0738, found: 313.0743. C17H13ClN2O2 (312.75). 
N-(5-Ethynyl-2-propionylphenyl)-6-methoxypicolinamide (3.55) 
 
3.55 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using 6-methoxypicolinic acid (265 mg, 1.73 mmol, 1.5 eq), TBTU (556 mg, 
1.73 mmol, 1.5 eq), DIPEA (603 µL, 3.46 mmol, 3.0 eq) and 1-(2-amino-4-
ethynylphenyl)propan-1-one (3.37) (200 mg, 1.16 mmol, 1.0 eq) and DMF (2 mL). Dilution 
with DCM preceded the washing steps. Purification by column chromatography (eluent: 
PE/EtOAc = 10:1, Rf = 0.2) afforded 3.55 as a yellow solid (275 mg, 0.89 mmol, 77%), mp 
170-173 °C. 1H NMR (400 MHz, CDCl3) δ (ppm) 13.45 (s, 1H), 9.18 (d, J = 1.5 Hz, 1H), 7.90-
7.83 (m, 2H), 7.78-7.72 (m, 1H), 7.24 (dd, J = 1.6, 8.2 Hz, 1H), 6.95 (dd, J = 0.7, 8.2 Hz, 1H), 
4.29 (s, 3H), 3.24 (s, 1H), 3.05 (q, J = 7.2 Hz, 2H), 1.21 (t, J = 7.2 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ (ppm) 203.6, 163.9, 163.3, 147.7, 140.1, 139.8, 130.5, 128.2, 126.1, 124.6, 
123.0, 116.1, 115.0, 82.9, 80.4, 54.5, 33.4, 8.5. HRMS (ESI): m/z [M+H]+ calcd. for 
C18H17N2O3
+: 309.1234, found: 309.1242. C18H16N2O3 (308.33). 
N-(5-Ethynyl-2-propionylphenyl)-5-methoxypicolinamide (3.56) 
 
3.56 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using 5-methoxypicolinic acid (265 mg, 1.73 mmol, 1.5 eq), TBTU (556 mg, 
1.73 mmol, 1.5 eq), DIPEA (603 µL, 3.46 mmol, 3.0 eq) and 1-(2-amino-4-
ethynylphenyl)propan-1-one (3.37) (200 mg, 1.16 mmol, 1.0 eq) and DMF (3 mL). Dilution 
with DCM preceded the washing steps. Purification by column chromatography (eluent: 
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PE/EtOAc = 4:1, Rf = 0.2) afforded 3.56 as a yellow solid (296 mg, 0.96 mmol, 83%), mp 175-
178 °C. 1H NMR (400 MHz, CDCl3) δ (ppm) 13.37 (s, 1H), 9.17 (d, J = 1.5 Hz, 1H), 8.48 (d, 
J = 2.8 Hz, 1H), 8.23 (d, J = 8.7 Hz, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.33 (dd, J = 2.8, 8.7 Hz, 
1H), 7.23 (dd, J = 1.5, 8.2 Hz, 1H), 3.94 (s, 3H), 3.24 (s, 1H), 3.08 (q, J = 7.2 Hz, 2H), 1.27 (t, 
J = 7.2 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ (ppm) 204.2, 164.0, 158.2, 143.1, 140.5, 136.9, 
130.7, 128.3, 125.9, 124.7, 124.2, 122.5, 120.9, 83.0, 80.5, 56.0, 33.6, 8.8. HRMS (ESI): m/z 
[M+H]+ calcd. for C18H17N2O3
+: 309.1234, found: 309.1236. C18H16N2O3 (308.34). 
N-(5-Ethynyl-2-propionylphenyl)-6-nitropicolinamide (3.57) 
 
3.57 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using 6-nitropicolinic acid (437 mg, 2.60 mmol, 1.5 eq), TBTU (834 mg, 
2.60 mmol, 1.5 eq), DIPEA (905 µL, 5.20 mmol, 3.0 eq) and 1-(2-amino-4-
ethynylphenyl)propan-1-one (3.37) (300 mg, 1.73 mmol, 1.0 eq) and DMF (4 mL). Dilution 
with DCM preceded the washing steps. Purification by column chromatography (eluent: 
PE/EtOAc = 3:1, Rf = 0.2) afforded 3.57 as a yellow solid (460 mg, 1.42 mmol, 82%), mp 184-
193 °C. Due to a slow rotation around the amide group on the NMR time scale, two isomers 
(ratio ca 1:0.3) were evident in the NMR spectra. 1H NMR (400 MHz, CDCl3) δ (ppm) 13.72 
(s, 0.2H), 13.67 (s, 1H), 9.31 (d, J = 1.8 Hz, 0.2H), 9.11 (d, J = 1.2 Hz, 1H), 8.69-8.61 (m, 
1.3H), 8.49-8.42 (m, 1.3H), 8.32-8.25 (m, 1.3H), 8.04-7.93 (m, 1.3H), 7.49 (dd, J = 1.9, 8.5 Hz, 
0.2H), 7.31 (dd, J = 1.4, 8.2 Hz, 1H), 3.27 (s, 1.1H), 3.12 (m, 2.6H), 1.32 (m, 3.9H). 13C NMR 
(101 MHz, CDCl3) δ (ppm) 204.4, 161.6, 155.5, 150.3, 141.8, 139.7, 130.9, 128.5, 128.1, 127.0, 
124.7, 122.7, 120.6, 82.7, 80.9, 33.5, 8.7. HRMS (ESI): m/z [M+H]+ calcd. for C17H14N3O4
+: 
324.0979, found: 324.0980. C17H13N3O4 (323.31). 
  




3.58 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using benzofuran-2-carboxylic acid (827 mg, 5.10 mmol, 1.5 eq), TBTU 
(1638 mg, 5.10 mmol, 1.5 eq), DIPEA (1777 µL, 10.20 mmol, 3.0 eq) and 1-(2-amino-4-
ethynylphenyl)propan-1-one (3.37) (589 mg, 3.40 mmol, 1.0 eq) and DMF (9 mL). Dilution 
with DCM preceded the washing steps. Purification by column chromatography (eluent: 
PE/EtOAc = 6:1, Rf = 0.3) afforded 3.58 as a brownish solid (400 mg, 1.26 mmol, 37%), mp 
144-148 °C. 1H NMR (300 MHz, CDCl3) δ (ppm) 12.91 (s, 1H), 9.10 (d, J = 1.6 Hz, 1H), 7.94 
(d, J = 8.3 Hz, 1H), 7.75-7.68 (m, 2H), 7.62 (m, 1H), 7.51-7.43 (m, 1H), 7.35-7.25 (m, 2H, 
signals interfering with the solvent signal), 3.27 (s, 1H), 3.11 (q, J = 7.2  Hz, 2H), 1.29 (t, J = 
7.3 Hz, 3H). 13C NMR (75 MHz, CDCl3) δ (ppm) 204.9, 157.8, 155.4, 148.9, 140.4, 130.8, 
128.7, 127.7, 127.4, 126.4, 124.7, 123.9, 122.8, 121.7, 112.6, 111.8, 82.7, 80.9, 33.5, 8.8. 
HRMS (ESI): m/z [M+H]+ calcd. for C20H16NO3
+: 318.1125, found: 318.1127. C20H15NO 
(317.34). 
N-(5-(1-(4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-1H-
1,2,3-triazol-4-yl)-2-propionylphenyl)-2-naphthamide hydrotrifluoroacetate (3.59) 
 
3.59 was prepared according to the general procedure for the CuAAC. The reaction was carried 
out using N-(5-ethynyl-2-propionylphenyl)-2-naphthamide (3.51) (30.0 mg, 0.092 mmol, 
1.0 eq), 2-(4-azidophenethyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (3.09) (37.2 mg, 
0.110 mmol, 1.2 eq), CuSO4∙5H2O (3.4 mg, 0.014 mmol, 0.15 eq), sodium ascorbate (12.7 mg, 
0.064 mmol, 0.7 eq) and TBTA (7.3 mg, 0.014 mmol, 0.15 eq) in CHCl3 (3 mL). Refluxing 
Water-Soluble Inhibitors of ABCG2 – A Fragment-Based and Computational Approach 
158 
lasted for 3 d. Flash column chromatography (4 g column, gradient: 0-20 min: DCM/MeOH 
100:0-95:5, Rf = 0.4 in DCM/MeOH 95:5) followed by preparative HPLC (gradient: 0-30 min: 
MeCN/ 0.1% aq TFA 51:49-87:13, tR = 14.2 min) afforded the product as a yellowish solid 
(14.2 mg, 0.018 mmol, 20%), mp 91-104 °C. 1H NMR (600 MHz, CDCl3) δ (ppm) 13.35 (br 
s, 1H), 13.06 (s, 1H), 9.42 (s, 1H), 8.60 (s, 1H), 8.44 (s, 1H), 8.12 (dd, J = 1.3, 8.6 Hz, 1H), 
8.09 (d, J = 8.3 Hz, 1H), 8.04 (d, J = 7.9 Hz, 1H), 7.99 (d, J = 8.5 Hz, 1H), 7.94 (d, J = 8.2 Hz, 
1H), 7.91 (d, J = 7.9 Hz, 1H), 7.76 (d, J = 7.9 Hz, 2H), 7.59 (m, 2H), 7.42 (d, J = 7.9 Hz, 2H), 
6.64 (s, 1H), 6.54 (s, 1H), 4.67 (d, J = 14.2 Hz, 1H), 4.08 (d, J = 14.2 Hz, 1H), 3.86 (s, 3H), 
3.84 (s, 3H), 3.79 (m, 1H), 3.44 (m, 2H), 3.35 (m, 1H), 3.27 (m, 3H), 3.15 (q, J = 7.2 Hz, 2H), 
2.98 (d, J = 15.4 Hz, 1H), 1.29 (t, J = 7.2 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ (ppm) 205.4, 
166.6, 149.5, 148.8, 147.4, 142.0, 137.1, 136.3, 136.2, 135.2, 132.9, 132.0, 131.9, 130.4 (2C), 
129.6, 129.0, 128.8, 128.2, 127.9, 127.0, 123.7, 122.4, 121.4, 121.1 (2C), 119.9, 119.4, 118.2, 
117.7, 111.3, 109.3, 56.2, 56.1, 55.6, 52.5, 49.4, 33.4, 30.5, 24.1, 8.8. RP-HPLC (220 nm): 
99% (tR = 7.7 min, k = 6.4). HRMS (ESI): m/z [M+H]
+ calcd. for C41H39N5O4
+: 666.3075, 





3.60 was prepared according to the general procedure for the CuAAC. The reaction was carried 
out using N-(5-ethynyl-2-propionylphenyl)-5,6,7,8-tetrahydroquinoline-2-carboxamide (3.52) 
(50.0 mg, 0.150 mmol, 1.0 eq), 2-(4-azidophenethyl)-6,7-dimethoxy-1,2,3,4-tetrahydro-
isoquinoline (3.09) (76.4 mg, 0.226 mmol, 1.5 eq), CuSO4∙5H2O (5.6 mg, 0.023 mmol, 
0.15 eq), sodium ascorbate (20.9 mg, 0.105 mmol, 0.7 eq) and TBTA (12.0 mg, 0.023 mmol, 
0.15 eq) in CHCl3 (3 mL). Refluxing lasted for 3 d. Column chromatography (eluent: 
DCM/MeOH 19:1, Rf = 0.3) followed by preparative HPLC (gradient: 0-30 min: MeCN/ 0.1% 
aq TFA 51:49-87:13, tR = 15.0 min) afforded the product as a beige-colored solid (46.9 mg, 
0.060 mmol, 40%), mp 83-92 °C. 1H NMR (600 MHz, CDCl3) δ (ppm) 13.63 (s, 1H), 11.80 
(br s, 1H), 9.34 (s, 1H), 8.54 (s, 1H), 8.07 (d, J = 8.0 Hz, 1H), 7.96 (d, J = 7.7 Hz, 1H), 7.91 (d, 
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J = 7.6 Hz, 1H), 7.79 (d, J = 6.7 Hz, 2H), 7.66 (d, J = 7.7 Hz, 1H), 7.40 (d, J = 5.6 Hz, 2H), 
6.64 (s, 1H), 6.55 (s, 1H), 4.71 (d, J = 12.9 Hz, 1H), 4.13 (d, J = 12.2 Hz, 1H), 3.86 (s, 3H), 
3.84 (m, 4H), 3.49 (m, 2H), 3.40 (m, 1H), 3.27 (m, 3H), 3.19 (t, J = 6.2 Hz, 2H), 3.11 (q, J = 
7.1 Hz, 2H), 3.00 (d, J = 15.9 Hz, 1H), 2.90 (t, J = 6.1 Hz, 2H), 1.99 (m, 2H), 1.89 (m, 2H), 
1.29 (t, J = 7.1 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ (ppm) 204.5, 164.0, 161.0 (TFA), 
160.8 (TFA), 157.2, 149.6, 148.9, 147.3, 146.1, 140.5, 139.4, 137.4, 136.8, 136.1, 135.7, 131.9, 
130.4 (2C), 122.5, 122.2, 121.0 (2C), 120.3, 120.1, 119.7, 118.0, 118.0, 116.6 (TFA), 114.7 
(TFA), 111.3, 109.3, 56.2, 56.1, 55.9, 52.9, 49.9, 33.5, 32.0, 30.5, 29.0, 24.1, 22.7, 22.4, 8.8. 
RP-HPLC (220 nm): 99% (tR = 7.5 min, k = 6.2). HRMS (ESI): m/z [M+H]
+ calcd. for 
C40H43N6O4





3.61 was prepared according to the general procedure for the CuAAC. The reaction was carried 
out using N-(5-ethynyl-2-propionylphenyl)-6-methylpicolinamide (3.53) (60.0 mg, 
0.205 mmol, 1.0 eq), 2-(4-azidophenethyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 
(3.09) (104.2 mg, 0.308 mmol, 1.5 eq), CuSO4∙5H2O (7.7 mg, 0.031 mmol, 0.15 eq), sodium 
ascorbate (28.5 mg, 0.114 mmol, 0.7 eq) and TBTA (16.3 mg, 0.031 mmol, 0.15 eq) in 
DMSO/isopropanol 3:1 (5 mL). Refluxing lasted for 2 d. The mixture was diluted with DCM 
(100 mL) and washed with H2O (3 x 100 mL). The organic layer was dried over Na2SO4 and 
the solvent evaporated. Column chromatography (eluent: DCM/MeOH 19:1, Rf = 0.4) followed 
by preparative HPLC (gradient: 0-30 min: MeCN/ 0.1% aq TFA 42:58-78:22, tR = 14.5 min) 
afforded the product as a yellow solid (18.56 mg, 0.025 mmol, 12%), mp 121-132 °C. 1H NMR 
(600 MHz, CDCl3) δ (ppm) 13.69 (s, 1H), 12.96 (br s, 1H), 9.40 (s, 1H), 8.44 (s, 1H), 8.04 (m, 
2H), 7.89 (d, J = 7.9 Hz, 1H), 7.76 (m, 3H), 7.41 (m, 2H), 7.35 (d, J = 7.6 Hz, 1H), 6.63 (s, 
1H), 6.54 (s, 1H), 4.67 (m, 1H), 4.10 (m, 1H), 3.85 (s, 3H), 3.84-3.74 (m, 4H), 3.54-3.18 (m, 
6H), 3.11 (q, J = 7.2 Hz, 2H), 2.99 (m, 1H), 2.77 (s, 3H), 1.29 (t, J = 7.2 Hz, 3H). 13C NMR 
(151 MHz, CDCl3) δ (ppm) 203.0, 163.7, 157.0, 148.6, 148.4, 147.8, 146.5, 139.8, 136.8, 136.0, 
135.1, 134.7, 130.8, 129.4 (2C), 125.5, 121.6, 121.4, 120.0 (2C), 119.0, 118.8, 118.3, 117.2, 
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116.9, 110.3, 108.3, 55.2, 55.1, 54.7, 51.6, 48.5, 32.5, 29.5, 23.6, 23.1, 7.8. RP-HPLC 
(220 nm): 97% (tR = 6.5 min, k = 5.2). HRMS (ESI): m/z [M+H]
+ calcd. for C37H39N6O4
+: 





3.62 was prepared according to the general procedure for the CuAAC. The reaction was carried 
out using 6-chloro-N-(5-ethynyl-2-propionylphenyl)picolinamide (3.54) (60.0 mg, 
0.192 mmol, 1.0 eq), 2-(4-azidophenethyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 
(3.09) (97.4 mg, 0.288 mmol, 1.5 eq), CuSO4∙5H2O (7.2 mg, 0.029 mmol, 0.15 eq), sodium 
ascorbate (26.6 mg, 0.134 mmol, 0.7 eq) and TBTA (15.3 mg, 0.029 mmol, 0.15 eq) in CHCl3 
(2 mL). Refluxing lasted for 1 d. Column chromatography (eluent: DCM/MeOH 19:1, Rf = 0.3) 
followed by preparative HPLC (gradient: 0-30 min: MeCN/ 0.1% aq TFA 46:54-82:18, tR = 
13.0 min) afforded the product as a yellowish solid (64.1 mg, 0.084 mmol, 44%), mp 148-
154 °C. 1H NMR (600 MHz, CDCl3) δ (ppm) 13.59 (s, 1H), 12.79 (br s, 1H), 9.34 (s, 1H), 8.41 
(s, 1H), 8.15 (d, J = 7.4 Hz, 1H), 8.07 (d, J = 8.3 Hz, 1H), 7.92-7.84 (m, 2H), 7.75 (d, J = 
7.7 Hz, 2H), 7.54 (d, J = 7.9 Hz, 1H), 7.41 (d, J = 7.6 Hz, 2H), 6.64 (s, 1H), 6.54 (s, 1H), 4.68 
(d, J = 12.3 Hz, 1H), 4.10 (d, J = 12.1 Hz, 1H), 3.86 (s, 3H), 3.83 (s, 3H), 3.80 (m, 1H), 3.54-
3.21 (m, 6H), 3.12 (q, J = 7.2 Hz, 2H), 3.00 (m, 1H), 1.30 (t, J = 7.2 Hz, 3H). 13C NMR 
(151 MHz, CDCl3) δ (ppm) 204.2, 162.9, 161.9 (TFA), 161.7 (TFA), 150.9, 150.8, 149.5, 
148.8, 147.3, 140.6, 140.2, 137.0, 136.1, 135.7, 131.9, 130.4 (2C), 127.6, 122.5, 122.4, 121.4, 
121.1 (2C), 120.4, 119.3, 118.1, 117.9, 111.3, 109.3, 56.2, 56.1, 55.7, 52.6, 49.6, 33.5, 30.5, 
24.1, 8.9. RP-HPLC (220 nm): 98% (tR = 6.6 min, k = 5.3). HRMS (ESI): m/z [M+H]
+ calcd. 
for C36H36ClN6O4
+: 651.2481, found: 651.2505. C36H35ClN6O4 · C2HF3O2 (651.15 + 114.02). 






3.63 was prepared according to the general procedure for the CuAAC. The reaction was carried 
out using N-(5-ethynyl-2-propionylphenyl)-6-methoxypicolinamide (3.55) (40.0 mg, 
0.130 mmol, 1.0 eq), 2-(4-azidophenethyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 
(3.09) (65.8 mg, 0.195 mmol, 1.5 eq), CuSO4∙5H2O (4.9 mg, 0.019 mmol, 0.15 eq), sodium 
ascorbate (18.0 mg, 0.091 mmol, 0.7 eq) and TBTA (10.3 mg, 0.019 mmol, 0.15 eq) in CHCl3 
(2 mL). Refluxing lasted for 3 d. Column chromatography (eluent: DCM/MeOH 19:1, Rf = 0.2) 
followed by preparative HPLC (gradient: 0-30 min: MeCN/ 0.1% aq TFA 46:54-82:18, tR = 
15.0 min) afforded the product as a yellowish solid (52.11 mg, 0.068 mmol, 53%), mp 127-
136 °C. 1H NMR (600 MHz, CDCl3) δ (ppm) 13.64 (s, 1H), 12.86 (br s, 1H), 9.41 (s, 1H), 8.45 
(s, 1H), 8.05 (d, J = 8.2 Hz, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.83 (d, J = 7.2 Hz, 1H), 7.80-7.73 
(m, 3H), 7.43 (d, J = 7.6 Hz, 2H), 6.96 (d, J = 8.2 Hz, 1H), 6.65 (s, 1H), 6.55 (s, 1H), 4.69 (d, 
J = 12.8 Hz, 1H), 4.32 (s, 3H), 4.10 (d, J = 12.2 Hz, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 3.81 (m, 
1H), 3.51-3.24 (m, 6H), 3.10 (q, J = 7.2 Hz, 2H), 3.00 (m, 1H), 1.24 (t, J = 7.2 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ (ppm) 203.7, 164.4, 163.4, 162.0 (TFA), 161.7 (TFA), 149.5, 
148.9, 147.7, 147.5, 140.7, 139.8, 137.0, 136.2, 135.7, 131.6, 130.4 (2C), 122.8, 122.4, 121.1 
(2C), 120.1, 119.3, 118.1, 117.8, 116.0, 115.2, 111.3, 109.4, 56.2, 56.1, 55.6, 54.6, 52.7, 49.6, 
33.4, 30.5, 24.1, 8.5. RP-HPLC (220 nm): 99% (tR = 7.1 min, k = 5.8). HRMS (ESI): m/z 
[M+H]+ calcd. for C37H39N6O5
+: 647.2976, found: 647.2970. C37H38N6O5 · C2HF3O2 (646.75 
+ 114.02). 






3.64 was prepared according to the general procedure for the CuAAC. The reaction was carried 
out using N-(5-ethynyl-2-propionylphenyl)-5-methoxypicolinamide (3.56) (25.0 mg, 
0.081 mmol, 1.0 eq), 2-(4-azidophenethyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 
(3.09) (41.2 mg, 0.122 mmol, 1.5 eq), CuSO4∙5H2O (3.0 mg, 0.012 mmol, 0.15 eq), sodium 
ascorbate (11.2 mg, 0.057 mmol, 0.7 eq) and TBTA (6.5 mg, 0.012 mmol, 0.15 eq) in 
DMSO/isopropanol 3:1 (3 mL). Refluxing lasted for 1 d. The mixture was diluted with DCM 
(50 mL) and washed with H2O (3 x 50 mL). The organic layer was dried over Na2SO4 and the 
solvent evaporated. Column chromatography (eluent: DCM/MeOH 19:1, Rf = 0.3) followed by 
preparative HPLC (gradient: 0-30 min: MeCN/ 0.1% aq TFA 42:58-78:22, tR = 13.5 min) 
afforded the product as a yellowish solid (6.86 mg, 0.009 mmol, 11%), mp 110-130 °C. 
1H NMR (600 MHz, CDCl3) δ (ppm) 13.56 (s, 1H), 12.91 (br s, 1H), 9.42 (s, 1H), 8.51 (d, J = 
2.5 Hz, 1H), 8.46 (s, 1H), 8.21 (d, J = 8.6 Hz, 1H), 8.09 (d, J = 8.3 Hz, 1H), 7.95 (d, J = 8.2 Hz, 
1H), 7.79 (d, J = 7.7 Hz, 2H), 7.44 (d, J = 7.4 Hz, 2H), 7.35 (dd, J = 2.6, 8.6 Hz, 1H), 6.66 (s, 
1H), 6.55 (s, 1H), 4.69 (d, J = 13.8 Hz, 1H), 4.09 (d, J = 11.3 Hz, 1H), 3.96 (s, 3H), 3.87 (s, 
3H), 3.85 (s, 3H), 3.80 (m, 1H), 3.53-3.25 (m, 6H), 3.14 (q, J = 7.2 Hz, 2H), 3.00 (s, 1H), 1.31 
(t, J = 7.2 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ (ppm) 204.4, 164.5, 158.3, 149.6, 148.9, 
147.6, 143.0, 141.1, 137.1, 137.0, 136.3, 135.8, 131.9, 130.4 (2C), 124.1, 122.4, 122.3, 121.2 
(2C), 120.9, 119.9, 119.3, 118.1, 117.9, 111.3, 109.4, 56.2, 56.2, 56.0, 55.6, 52.6, 49.6, 33.5, 
30.5, 24.0, 8.9. RP-HPLC (220 nm): 99% (tR = 6.1 min, k = 4.9). HRMS (ESI): m/z [M+H]
+ 
calcd. for C37H39N6O5
+: 647.2976, found: 647.2984. C37H38N6O5 · C2HF3O2 (646.75 + 
114.02). 






3.65 was prepared according to the general procedure 1 for N-acylation of anilines. The reaction 
was carried out using 1-(2-amino-4-(1-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-
yl)ethyl)phenyl)-1H-1,2,3-triazol-4-yl)phenyl)propan-1-one (3.69) (60.0 mg, 0.096 mmol, 
1.0 eq), 6-hydroxypicolinic acid (26.7 mg, 0.192 mmol, 2.0 eq), TBTU (61.6 mg, 0.192 mmol, 
2.0 eq), DIPEA (100 µL, 0.576 mmol, 6.0 eq) and DMF (2 mL). Dilution with DCM preceded 
the washing steps. The crude product was subjected to flash column chromatography (4 g 
column, gradient: 0-20 min: DCM/MeOH 100:0-95:5, Rf = 0.2 in DCM/MeOH 95:5) and for 
further purification to preparative HPLC (gradient: 0-30 min: MeCN/ 0.1% aq TFA 33:67-
69:31, tR = 17.0 min). Removal of the solvent from the eluate through evaporation and 
lyophilization afforded 3.65 as a yellow solid (3.9 mg, 0.005 mmol, 5%), mp 162-173 °C. 
1H NMR (600 MHz, DMSO-d6) δ (ppm) 12.94 (s, 1H), 11.26 (br s, 1H), 10.10 (s, 1H), 9.48 (s, 
1H), 9.40 (s, 1H), 8.29 (d, J = 8.5 Hz, 1H), 8.02 (d, J = 8.4 Hz, 2H), 7.89 (m, 1H), 7.81 (dd, J 
= 1.6, 8.3 Hz, 1H), 7.67 (m, 1H), 7.60 (d, J = 8.5 Hz, 2H), 6.97 (d, J = 7.7 Hz, 1H), 6.85 (s, 
1H), 6.81 (s, 1H), 4.56 (d, J = 15.1 Hz, 1H), 4.32 (m, 1H), 3.81* (m, 1H), 3.76* (s, 3H), 3.75* 
(s, 3H), 3.54* (m, 2H), 3.37 (m, 1H), 3.20 (m, 4H), 3.13-2.98 (m, 2H), 1.16 (t, J = 7.1 Hz, 3H) 
(*signals interfering with the water signal). 13C NMR (151 MHz, DMSO-d6) δ (ppm) 203.8, 
162.8, 158.1 (TFA), 157.8 (TFA), 148.5, 147.8, 146.3, 140.7, 139.7, 137.7, 135.4, 135.3, 132.3, 
130.3 (2C), 123.1, 122.8, 121.0, 120.4 (2C), 120.0, 119.8, 117.2, 111.5, 109.7, 55.6, 55.6, 55.5, 
51.9, 49.3, 32.9, 29.2, 24.6, 8.5 (two tertiary and two quaternary carbons not apparent). 
RP-HPLC (220 nm): 98% (tR = 5.0 min, k = 3.7). HRMS (ESI): m/z [M+H]
+ calcd. for 
C36H37N6O5
+: 633.2820, found: 633.2829. C36H36N6O5 · C2HF3O2 (632.72 + 114.02). 






3.66 was prepared according to the general procedure for the CuAAC. The reaction was carried 
out using N-(5-ethynyl-2-propionylphenyl)-6-nitropicolinamide (3.57) (70.0 mg, 0.217 mmol, 
1.0 eq), 2-(4-azidophenethyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (3.09) (109.9 mg, 
0.433 mmol, 1.5 eq), CuSO4∙5H2O (8.1 mg, 0.032 mmol, 0.15 eq), sodium ascorbate (30.0 mg, 
0.152 mmol, 0.7 eq) and TBTA (17.2 mg, 0.032 mmol, 0.15 eq) in DMSO/isopropanol 3:1 
(5 mL). Refluxing lasted for 2 d. The mixture was diluted with DCM (100 mL) and washed 
with H2O (3 x 100 mL). The organic layer was dried over Na2SO4 and the solvent evaporated. 
Column chromatography (eluent: DCM/MeOH 19:1, Rf = 0.3) followed by preparative HPLC 
(gradient: 0-30 min: MeCN/ 0.1% aq TFA 42:58-78:22, tR = 12.0 min) afforded the product as 
a light yellow solid (59.13 mg, 0.076 mmol, 35%), mp 107-117 °C. 1H NMR (600 MHz, 
CDCl3) δ (ppm) 13.79 (s, 1H), 13.38 (br s, 1H), 9.35 (s, 1H), 8.61 (d, J = 7.4 Hz, 1H), 8.45 (d, 
J = 7.9 Hz, 1H), 8.41 (m, 1H), 8.28 (s, 1H), 8.09 (d, J = 8.2 Hz, 1H), 7.91 (d, J = 8.0 Hz, 1H), 
7.76 (d, J = 7.6 Hz, 2H), 7.42 (d, J = 7.6 Hz, 2H), 6.64 (s, 1H), 6.55 (s, 1H), 4.66 (m, 1H), 4.09 
(m, 1H), 3.86 (s, 3H), 3.84 (s, 3H), 3.79 (m, 1H), 3.52-3.23 (m, 6H), 3.14 (q, J = 7.0 Hz, 2H), 
2.99 (m, 1H), 1.32 (t, J = 7.1 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ (ppm) 204.5, 161.8, 
155.5, 150.3, 149.5, 148.8, 147.2, 141.9, 140.4, 137.1, 136.1, 135.9, 131.9, 130.4 (2C), 128.0, 
122.5, 122.5, 121.1 (2C), 120.7, 120.6, 119.3, 118.2, 117.9, 111.3, 109.3, 56.2, 56.1, 55.6, 52.5, 
49.4, 33.5, 30.5, 24.1, 8.7. RP-HPLC (220 nm): 95% (tR = 5.9 min, k = 4.7). HRMS (ESI): m/z 
[M+H]+ calcd. for C36H36N7O6
+: 662.2722, found: 662.2732. C36H35N7O6 · C2HF3O2 (661.72 
+ 114.02). 







triazol-4-yl)-2-propionylphenyl)-6-nitropicolinamide (3.66) (13.0 mg, 0.017 mmol, 1.0 eq) 
was suspended in THF/MeOH 2:1 (6 mL) and ammonium formate (21.1 mg, 0.335 mmol, 
20 eq) was added, causing the starting material to go into solution. Palladium on carbon 
(10 wt. % loading; 2 mg) was added and the mixture refluxed overnight. The reflux cooler was 
equipped with a balloon to collect the nascent hydrogen. The solids were removed by filtration 
and the volatiles evaporated. Preparative HPLC (gradient: 0-30 min: MeCN/ 0.1% aq TFA 
33:67-60:40, tR = 14.0 min) afforded the product as a yellowish solid (6.5 mg, 0.009 mmol, 
52%), mp 183-190 °C. 1H NMR (600 MHz, DMSO-d6) δ (ppm) 12.99 (s, 1H), 10.17 (br s, 
1H), 9.47 (s, 1H), 9.40 (d, J = 1.4 Hz, 1H), 8.28 (d, J = 8.4 Hz, 1H), 8.03 (d, J = 8.3 Hz, 2H), 
7.79 (dd, J = 1.6, 8.3 Hz, 1H), 7.66 (m, 1H), 7.60 (d, J = 8.5 Hz, 2H), 7.36 (d, J = 7.1 Hz, 1H), 
6.85 (s, 1H), 6.81 (s, 1H), 6.78 (d, J = 8.3 Hz, 1H), 4.55 (d, J = 15.0 Hz, 1H), 4.32 (m, 1H), 
3.80 (s, 1H), 3.76 (s, 3H), 3.75 (s, 3H), 3.54 (m, 2H), 3.37 (m, 1H), 3.25-3.15 (m, 4H), 3.11-
2.98 (m, 2H), 1.17 (t, J = 7.1 Hz, 3H) (the NH2 protons appear as a very broad signal at about 
4.6-6.0 ppm interfering with the broad water signal). 13C NMR (151 MHz, DMSO-d6) δ (ppm) 
203.8, 163.6, 158.5, 158.3 (TFA), 158.0 (TFA), 148.5, 147.8, 146.3, 139.7, 138.7, 137.7, 135.4, 
135.3, 132.2, 130.3 (2C), 123.1, 122.8, 121.0, 120.4 (2C), 119.8, 119.8, 117.1, 116.8, 114.9, 
111.5, 110.9, 109.6, 55.6, 55.6, 55.5, 51.8, 49.3, 32.9, 29.2, 24.5, 8.6. RP-HPLC (220 nm): 
100% (tR = 4.3 min, k = 3.1). HRMS (ESI): m/z [M+H]
+ calcd. for C36H38N7O4
+: 632.2980, 
found: 632.2982. C36H37N7O4 · C2HF3O2 (631.74 + 114.02). 






3.68 was prepared according to the general procedure for the CuAAC. The reaction was carried 
out using N-(5-ethynyl-2-propionylphenyl)benzofuran-2-carboxamide (3.58) (300 mg, 
0.945 mmol, 1.0 eq), 2-(4-azidophenethyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 
(3.09) (480 mg, 1.418 mmol, 1.5 eq), CuSO4∙5H2O (35.4 mg, 0.142 mmol, 0.15 eq), sodium 
ascorbate (131 mg, 0.662 mmol, 0.7 eq) and TBTA (75.2 mg, 0.142 mmol, 0.15 eq) in CHCl3 
(8 mL). Refluxing lasted for 1 d. Column chromatography (eluent: DCM/MeOH 19:1, Rf = 0.3) 
followed by preparative HPLC (gradient: 0-30 min: MeCN/ 0.1% aq TFA 55:45-90:10, tR = 
12.0 min) afforded the product as a yellowish solid (318 mg, 0.413 mmol, 44%), mp 217-
219 °C. 1H NMR (600 MHz, DMSO-d6) δ (ppm) 12.83 (s, 1H), 10.11 (s, 1H), 9.50 (s, 1H), 
9.35 (d, J = 1.6 Hz, 1H), 8.32 (d, J = 8.5 Hz, 1H), 8.02 (d, J = 8.4 Hz, 2H), 7.87 (d, J = 7.7 Hz, 
1H), 7.84-7.78 (m, 3H), 7.60 (d, J = 8.5 Hz, 2H), 7.58-7.54 (m, 1H), 7.44-7.39 (m, 1H), 6.85 
(s, 1H), 6.81 (s, 1H), 4.56 (d, J = 14.1 Hz, 1H), 4.32 (d, J = 13.8 Hz, 1H), 3.80 (m, 1H), 3.76 
(s, 3H), 3.75 (s, 3H), 3.53 (m, 2H), 3.37 (s, 1H, signal interfering with the water signal 
(identified by 1H-COSY and HSQC)), 3.26-3.17 (m, 4H), 3.15-2.96 (m, 2H), 1.18 (t, J = 7.1 Hz, 
3H). 13C NMR (151 MHz, DMSO-d6) δ (ppm) 205.1, 157.9 (TFA), 157.7 (TFA), 156.7, 154.6, 
148.5, 148.4, 147.8, 146.1, 139.7, 137.8, 135.6, 135.4, 132.4, 130.3 (2C), 127.8, 127.2, 124.1, 
123.2, 122.2, 121.2, 120.4 (2C), 120.3, 119.8, 118.3, 116.8, 112.1, 111.7, 111.5, 109.7, 55.6, 
55.6, 55.5, 51.9, 49.3, 32.8, 29.2, 24.6, 8.5. RP-HPLC (220 nm): 99% (tR = 7.1 min, k = 5.8). 
HRMS (ESI): m/z [M+H]+ calcd. for C39H38N5O5
+: 656.2867, found: 656.2882. C39H37N5O5 · 
C2HF3O2 (655.74 + 114.02). 






3.69 was prepared according to the general procedure for the CuAAC. The reaction was carried 
out using 1-(2-amino-4-ethynylphenyl)propan-1-one (3.37) (150 mg, 0.866 mmol, 1.0 eq), 
2-(4-azidophenethyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (3.09) (440 mg, 
1.299 mmol, 1.5 eq), CuSO4∙5H2O (32.4 mg, 0.130 mmol, 0.15 eq), sodium ascorbate (120 mg, 
0.606 mmol, 0.7 eq) and TBTA (68.9 mg, 0.130 mmol, 0.15 eq) in CHCl3 (5 mL). Refluxing 
lasted for 3 d. Column chromatography (eluent: DCM/MeOH 19:1, Rf = 0.3) followed by 
preparative HPLC (gradient: 0-30 min: MeCN/ 0.1% aq TFA 33:67-69:31, tR = 13.0 min) 
afforded the product as a yellow solid (164 mg, 0.262 mmol, 30%), mp 121-125 °C. 1H NMR 
(400 MHz, DMSO-d6) δ (ppm) 10.56 (s, 1H), 9.32 (s, 1H), 7.97 (d, J = 8.5 Hz, 2H), 7.89 (d, J 
= 8.5 Hz, 1H), 7.58 (d, J = 8.6 Hz, 2H), 7.45 (d, J = 1.5 Hz, 1H), 7.08 (dd, J = 1.5, 8.3 Hz, 1H), 
6.84 (s, 1H), 6.80 (s, 1H), 4.57 (d, J = 14.7 Hz, 1H), 4.32 (d, J = 13.1 Hz, 1H), 3.79* (m, 1H), 
3.75* (s, 3H), 3.74* (s, 3H), 3.53* (d, J = 7.0 Hz, 2H), 3.37* (m, 1H), 3.21 (t, J = 8.3 Hz, 2H), 
3.15-2.92 (m, 4H), 1.08 (t, J = 7.2 Hz, 3H) (*signals interfering with the NH2 signal; the NH2 
protons appear as a very broad signal between 4.2 and 3.3 ppm). 13C NMR (101 MHz, DMSO-
d6) δ 202.1, 151.4, 148.5, 147.8, 146.7, 137.7, 135.5, 135.0, 132.2, 130.3 (2C), 123.2, 120.6, 
120.3 (2C), 119.8, 116.1, 112.9, 112.0, 111.5, 109.7, 55.6, 55.6, 55.5, 51.7, 49.2, 31.7, 29.2, 
24.5, 8.8. HRMS (ESI): m/z [M+H]+ calcd. for C30H34N5O3
+: 512.2656, found: 512.2664. 
C30H33N5O3 · C2HF3O2 (511.63 + 114.02). 
3.4.2 Molecular Docking 
ABCG2 transporter and ligand preparation. The cryo-EM structure of the human ABCG2 
transporter (PDB ID: 5NJ3 [30]) was used as template. To reconstitute missing N-termini and 
loops, Modeller 9.18 [91-93] was used. The ABCG2 model contained disulfide bridges within 
each monomer (Cys592 - Cys608) and between the monomers (Cys603 - Cys603). Coordinates 
of the antibody 5D3-Fab were removed. Protein and ligand preparation (Schrödinger LLC, 
Portland, OR, USA) including an assignment of protonation states were essentially performed 
as described [94,95] before. Compounds 3.27, 3.48 and 3.50 were considered in the 
unprotonated state. 
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Induced-fit docking. Compounds 3.27, 3.48, 3.50 and further potential ligands were docked 
“flexibly” to the ABCG2 transporter using the induced-fit docking module (Schrödinger LLC). 
The ligands were docked within a box of 46 × 46 × 46 Å3 around the center of mass between 
N436 of the first and the second monomer, respectively. Redocking was performed in the 
extended precision mode. From the induced-fit docking results obtained, one pose (ligand-
ABCG2 transporter complex) was selected based on low/minimal XP Gscores and reasonability 
of the ligand binding pose. Ligand-receptor interactions were analyzed using PLIP 1.4.2 [96]. 
Figures showing molecular structures of the ABCG2 transporter in complex with 3.27 or 3.48 
were generated with PyMOL Molecular Graphics system, version 2.2.0 (Schrödinger LLC). 
3.4.3 Biology 
3.4.3.1 General Experimental Conditions 
Materials. Commodity chemicals and solvents were purchased from commercial suppliers 
(Sigma Aldrich, Munich, Germany; Merck, Darmstadt, Germany; VWR, Darmstadt, Germany; 
Thermo Fisher Scientific, Waltham, MA, USA; Invitrogen, Karlsruhe, Germany). Topotecan 
and vinblastine were obtained from Sigma Aldrich. Hoechst 33342 and calcein-AM were 
procured from Biotium (Fremont, CA, USA). FTC was from Merck. Tariquidar was 
synthesized in our laboratory according to literature [97] with slight modifications [98]. 
Reversan was obtained from Tocris (Wiesbaden-Nordenstadt, Germany). Millipore water was 
used throughout for the preparation of buffers, aqueous reagent solutions and HPLC eluents. 
The pH of buffers and aqueous reagent solutions was adjusted with NaOH aq or HCl aq unless 
stated otherwise. Acetonitrile for HPLC (gradient grade) was obtained from Merck. All cell 
lines were purchased from the ATCC (American Type Culture Collection; Manassas, VA, 
USA). Tissue culture flasks were procured from Sarstedt (Nümbrecht, Germany). Dulbecco’s 
Modified Eagle’s Medium - high glucose (DMEM/High; with 4500 mg/L glucose, sodium 
pyruvate and sodium bicarbonate, without L-glutamine, liquid, sterile-filtered, suitable for cell 
culture) and L-glutamine solution (200 mM, sterile-filtered, BioXtra, suitable for cell culture) 
were from Sigma Aldrich. Fetal calf serum (FCS) and trypsin/EDTA and were from Biochrom 
(Berlin, Germany). For all assays in microplate format, 96-well plates (PS, clear, F-bottom, 
with lid, sterile) from Greiner Bio-One (Frickenhausen, Germany) were used. Human CPD 
(citrate, phosphate, dextrose) plasma was a gift from the Bavarian Red Cross (Regensburg, 
Germany). Syringe filters (Phenex-RC, 4 mm, 0.2 µm) used in the chemical stability assay (in 
blood plasma) were from Phenomenex (Aschaffenburg, Germany). 
Stock solutions. Topotecan and vinblastine were dissolved in 70% EtOH to give 100 µM stock 
solutions. Hoechst 33342 stock solution (0.8 mM) was prepared in water and calcein-AM stock 
solution (100 µM) in DMSO. The test compounds and the reference compounds 
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fumitremorgin C, tariquidar, reversan and sulfasalazine were dissolved in DMSO at 100 times 
the final concentrations in the transport assays and the ATPase assay and at 1000 times the final 
concentrations in the chemosensitivity assay. For the stability assay in blood plasma, 10 mM 
stock solutions of the test compounds were prepared in DMSO. If not stated otherwise, 
millipore water served as solvent for other assay reagents. 
Instruments. Fluorescence and absorbance measurements in microplates were carried out with 
a GENios Pro microplate reader (equipped with a Xenon arc lamp; Tecan, Grödig, Austria). 
Analytical HPLC after incubation in human blood plasma was performed on a system from 
Agilent described in Section 3.4.1.1. The HPLC conditions were as described, yet with two 
alterations. The following linear gradient was applied: 0-12 min: A/B 20:80-95:5, 12-15 min: 
A/B 95:5. The injection volume was 100 µL. 
Software. All biological data were analyzed with GraphPad Prism 5 (GraphPad Software, San 
Diego, CA, USA). 
3.4.3.2 Cell Culture 
All cells were cultured in DMEM/High supplemented with 2% (v/v) of a 200 mM L-glutamine 
solution and 10% (v/v) FCS at 37 °C in a water-saturated atmosphere containing 5% CO2. 
MCF-7/Topo cells, an ABCG2-overexpressing variant of the MCF-7 cell line (ATCC® HTB-
22), were obtained by passaging the MCF-7 cells with increasing amounts of topotecan in the 
culture medium to achieve a maximum concentration of 550 nM within a period of about 40 d; 
after 3 passages at the maximum concentration the treated cells expressed sufficient quantities 
of ABCG2 [99,100]. Cells were cultured in the presence of topotecan (550 nM) to maintain 
overexpression of the ABCG2 transporter. 
KB-V1 cells, an ABCB1-overexpressing variant of the KB cell line (ATCC® CCL-17), were 
obtained by passaging the KB cells with increasing amounts of vinblastine in the culture 
medium to achieve a maximum concentration of 330 nM within a period of about 90 d; after 3 
passages at the maximum concentration the treated cells expressed sufficient quantities of 
ABCB1 transporter [98,101]. They were cultured with 330 nM vinblastine to maintain 
overexpression of the ABCB1 transporter. 
MDCK.2-MRP1 cells were a kind gift from Prof. Dr. P. Borst from the Netherland Cancer 
Institute (Amsterdam, NL). They were obtained by transfecting MDCK.2 cells (ATCC® CRL-
2936) with human ABCC1 [102,103]. Due to the strong adherence of this cell line, 
trypsinization was performed using 2X trypsin/EDTA (0.1%./0.04%) for 30 min. 
All cells were routinely monitored for mycoplasma contamination by PCR using the 
Venor®GeM mycoplasma detection kit (Minerva Biolabs, Berlin, Germany) and were negative. 
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3.4.3.3 Inhibition of ABCG2: Hoechst 33342 Transport Assay 
The assay was performed as described in our previous report [28] (c.f. Section 2.4.2.3), applying 
the following modification: cells were seeded into 96-well plates at a density of 18,000 cells 
per well (instead of 20,000). 
3.4.3.4 Inhibition of ABCB1: Calcein-AM Transport Assay 
The assay was performed as described in our previous report [28] (c.f. Section 2.4.2.4). 
3.4.3.5 Inhibition of ABCC1: Calcein-AM Transport Assay 
The assay was performed as described in our previous report [28] (c.f. Section 2.4.2.5). 
3.4.3.6 Chemosensitivity Assay 
The assay was performed as described in our previous report [28] (c.f. Section 2.4.2.8). 









CT corr  
where T is the mean absorbance of the treated cells, C the mean absorbance of the negative 
controls and C0 the mean absorbance of the cells at the time of compound addition (t0). When 
the absorbance of treated cells T was lower than at the beginning of the experiment (C0), the 









3.4.3.7 ABCG2 ATPase Assay 
Membrane preparation. The protocol is based on the procedure of Sarkadi et al. [104] and 
our previous report [28]. MCF-7/Topo cells were harvested after trypsinization by 
centrifugation at 4 °C and 500 g for 10 min. The cell pellet was re-suspended in Tris mannitol 
buffer (50 mM Tris, 300 mM mannitol, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), pH 7; 
100 mL) and centrifuged again. Then the pellet was lysed and homogenized in TMEP buffer 
(50 mM Tris, 50 mM mannitol, 1 mM EDTA, 10 µg/mL leupeptin, 10 µg/mL benzamidine, 
0.5 mM PMSF, 2 mM DTT, pH 7; 60 mL) by a Potter Elvehjem tissue homogenizer. 
Undisrupted cells and cellular debris were pelleted by centrifugation at 4 °C and 500 g for 
10 min and the supernatant, containing the membranes, was removed carefully. After 
centrifugation at 4 °C and 100,000 g for 1 h the pellet (containing the membranes) was re-
suspended in TMEP buffer (30 mL), giving a protein concentration of 2.0-3.0 mg/mL, and 
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homogenized with a Potter Elvehjem tissue homogenizer. All procedures during the membrane 
preparation were performed at 4 °C and aliquots (500-1000 µL) were stored at - 80 °C until use. 
Protein quantification was performed by the method of Bradford using the Bio-Rad protein 
assay kit according to the manual. 
Assay procedure. The assay was performed by analogy with the ABCB1 ATPase assay 
procedure described by Sarkadi et al. [104] and the procedure described in our previous report 
[28]. The ATPase activity of the ABCG2 transporter was estimated by measuring inorganic 
phosphate liberation. It was determined as orthovanadate-sensitive ATPase activity in the 
presence of inhibitors in ABCG2 MCF-7/Topo membrane preparations. 
Membranes containing 2.0-2.5 mg of total soluble protein were thawed on ice and pelleted by 
centrifugation at 4 °C and 16,200 g for 10 min. Then they were suspended in assay buffer 
(50 mM MOPS-Tris (100 mM MOPS, pH adjusted to 7.0 with 1.7 M Tris), 50 mM KCl, 5 mM 
NaN3, 2 mM EGTA, 2 mM DTT, 1 mM ouabain; 4.2 mL), mixed with 10% (w/w) CHAPS 
(42 µL; decreases the high basal ABCG2 ATPase activity) and homogenized using a syringe 
and a needle (27G). The suspension was split into 2 portions (2.0 mL each) and one portion was 
supplemented with orthovanadate (100 mM Na3VO4, pH 10; 50 µL; final conc. 2 mM), the 
other with the same amount of purified water. The two suspensions (w. and wo. orthovanadate) 
were transferred into a 96-well plate on ice (40 µL/well; 20-25 µg protein/well) and pre-
incubated at 37 °C for 3 min. 
The ATPase reaction was started by adding the reference and test compounds in assay buffer 
containing 20 mM ATP (10 µL/well, giving a final volume of 50 µL/well; final conc. 4 mM) 
with a multichannel pipette and the plate was incubated at 37 °C in a microplate shaker for 1 h. 
For this purpose, an ATP solution (200 mM MgxATP, 400 mM MgCl2, pH adjusted to 7.0 with 
1.7 M Tris) was diluted 1:10 (v/v) with assay buffer and the test and reference compounds were 
added 5-fold concentrated. Sulfasalazine at a final concentration of 30 µM served as reference 
activator (positive control); the vehicle DMSO (1% final content) served as negative control. 
Each concentration (w. and wo. orthovanadate) was measured in duplicate, positive and 
negative control in quadruplicate each. 
The reaction was stopped by the addition of 10% (w/w) SDS (30 µL/well); background control 
(phosphate stemming from the assay buffer) (w. and wo. orthovanadate) was stopped before 
starting the reaction with MgATP and was measured in duplicate. 
Phosphate standards (0, 0.05, 0.1, 0.25, 1.5 and 2.0 mM NaH2PO4 in assay buffer; 50 µL/well; 
each concentration measured in duplicate) were included on each plate for calibration. 
The amount of phosphate was determined by adding a colorimetric reagent (1 part of reagent A 
(35 mM ammonium molybdate, 15 mM zinc acetate) mixed with 4 parts of reagent B (5% 
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(w/w) ascorbic acid, pH 5.0; freshly prepared); 200 µL/well) and by incubating at 37 °C for 
further 20 min. The absorbance (820 nm) as a parameter proportional to the phosphate amount 
was measured, using a GENios Pro microplate reader. 
The data obtained under the treatment with orthovanadate were subtracted from the data without 
orthovanadate to obtain phosphate liberation resulting from ABCG2 activity. The ensuing data 
were normalized relative to the absorbance in the absence of an ABCG2 activator (negative 
control) and the response elicited by the sulfasalazine (positive) control, which was defined as 
100% ATPase activity. IC50 values were calculated using four parameter sigmoidal fits. Errors 
were expressed as standard error of the mean (SEM). 
3.4.3.8 Chemical Stability Assay (in Blood Plasma) 
The human CPD (citrate, phosphate, dextrose) blood plasma samples were stored at - 80 °C and 
thawed before use. Stock solutions of the test compounds (10 mM in DMSO) were diluted 1:50 
with blood plasma, giving a concentration of 200 µM. The samples were vortexed briefly and 
incubated at 37 °C. After different periods of time, aliquots were taken and deproteinated by 
adding three parts of ice-cold MeCN, vortexing and storing at 4 °C for 30 min. Samples were 
centrifuged at 4 °C and 16,000 g for 5 min and the supernatants were diluted 1:1 with 0.05% 
TFA aq and stored at - 80 °C until analyzed. They were thawed at room temperature, filtered 
with syringe filters and analyzed with HPLC. 
3.4.4 Solubility 
3.4.4.1 General Experimental Conditions 
Materials. Chemicals and solvents were purchased from commercial suppliers (Sigma Aldrich, 
Munich, Germany; Merck, Darmstadt, Germany; VWR, Darmstadt, Germany; Thermo Fisher 
Scientific, Waltham, MA, USA). Millipore water was used throughout for the preparation of 
buffers and HPLC eluents. The pH of buffers was adjusted with NaOH aq and HCl aq. Buffers 
were filtered before use. Acetonitrile for HPLC (gradient grade) was obtained from Merck. 
Micro tubes were from Sarstedt (Nümbrecht, Germany). 96-Well plates (PS, clear, F-bottom, 
with lid, sterile) were acquired from Greiner Bio-One (Frickenhausen, Germany). Glass vials 
(with PE plug) were procured from Altmann Analytik (München, Germany); borosilicate glass 
centrifuge tubes (without plug) from Thermo Fisher Scientific. Sigmacote® (Sigma Aldrich) 
was used as siliconizing agent for the vials. Parafilm (Bemis, Neenah, WI, USA) was used to 
cap the centrifuge tubes. 
Stock solutions. The test compounds and the reference compound haloperidol were dissolved 
in DMSO at 1000 times the final concentrations in the thermodynamic solubility assay and for 
the calibration curve at 100 times the final concentrations. Furthermore, the test compounds 
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and the reference compound coronene were dissolved at 100 times the final concentrations in 
the kinetic solubility assay. 
Instruments. For incubating and shaking vials an MB-102 ThermoCell mixing block (BIOER, 
Hangzhou, China) was used. Analytical HPLC of the samples from the thermodynamic 
solubility assay was performed on a system from Agilent, described in Section 3.4.1.1. The 
HPLC conditions were as described with two alterations. The following linear gradient was 
applied: 0-8 min: A/B 30:70-73:27, 8-9 min: A/B 73:27-95:5, 9-12 min: A/B 95:5, 12-13 min: 
A/B 95:5-30:70. The injection volume was 100 µL. Absorbance measurements of the 
microplates were carried out with a GENios Pro microplate reader (Tecan, Männedorf, 
Switzerland). 
Software. Data were analyzed with Microsoft Excel and GraphPad Prism 5 (GraphPad 
Software, San Diego, CA, USA). ClogP values were calculated with ACD/Structure Designer, 
version 12 (Advanced Chemistry Development, Inc. (ACD/Labs), Toronto, Canada). 
3.4.4.2 Kinetic Solubility Assay 
UV-VIS Spectra of the test compounds were recorded along with the high-resolution mass 
spectrometry (HRMS) analysis, which was performed on the Agilent LC/MS system described 
in Section 3.4.1.1; the system was additionally equipped with a 1290 DAD detector (Agilent 
Technologies, Santa Clara, CA, USA). 
Assay Procedure. The kinetic solubility was determined turbidimetrically. DMSO stock 
solutions of the test compound (different concentrations) were diluted 1:100 with the respective 
buffer (pH 7.4) at 37 °C in a micro tube (10 µL stock in 1000 µL buffer), giving a final DMSO 
concentration of 1%. The sample was vortexed and transferred into a 96-well plate 
(300 µL/well, 3 replicate wells). DMSO (1% in buffer; 300 µL/well, measured 12-fold) served 
as vehicle control/ blank value, coronene served as a highly insoluble control compound. After 
incubating the plate at 37 °C for 2 h, the extinction was measured at 380 nm using a GENios 
Pro microplate reader. The data were normalized to the blank value and the kinetic solubility 
limit was estimated as the highest concentration at which more than 95% of the radiation is 
transmitted (i.e. the extinction is lower than 0.0223). 
3.4.4.3 Thermodynamic Solubility Assay 
The thermodynamic solubility of the test and reference compounds was determined by the 
saturation shake-flask method. A DMSO stock solution of the test compound was diluted 
1:1000 in PBS (pH 7.4) in a glass vial or glass centrifuge tube, both of which had been treated 
with a siliconizing agent, giving a final DMSO content of 1‰ (e.g. 0.6 µL stock in 600 µL 
PBS). According to solubility, stock solutions of different concentrations were used 
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(compounds 3.40, 3.41, 3.48 and 3.49: 50 mM, compound 3.65: 20 mM, all other compounds: 
10 mM). The vial was capped, vortexed and shaken at 25 °C for 36-40 h. Shaking was stopped 
and the precipitate was allowed to sediment at 25 °C for 24 h. In the case of poorly sedimenting 
compounds, the samples were then centrifuged at 25 °C and 2700 g for 30 min. 2 aliquots of 
supernatant (100 µL each) were taken carefully from each vial with a micropipette, anxious not 
to swirl up the sediment, and diluted with MeCN (50 µL). The micropipette tip was rinsed 
thoroughly in the mixture of supernatant and MeCN to dissolve potential residue adsorbed to 
the tip surface. The sample was analyzed with HPLC and the peak area was determined. 
Standard solutions were produced as follows. DMSO stock solutions (5 concentrations) and 
DMSO were diluted 1:100 in PBS (1% final DMSO content), vortexed and immediately an 
aliquot (100 µL) from each solution was taken and diluted with MeCN (50 µL) (plus pipette tip 
was rinsed). The standards were measured by HPLC and the peak areas were used to construct 
a calibration curve. Solubility of the test compound was determined by quantifying the 
concentration of the sample using the calibration curve. At least 6 independent experiments 
were carried out for each reported result. Errors were expressed as standard error of the mean 
(SEM). 
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3.5 Supplementary Material 
3.5.1 Figures 3.13, 3.14 and 3.15 
 
Figure 3.13. Comparison of the concentration-dependent inhibition of ABCG2-mediated Hoechst 33342 efflux and the 
concentration-dependent extinction (at 380 nm) due to scattering in a kinetic solubility assay, both caused by the inhibitor 3.01. 
 
Figure 3.14. Concentration-dependent extinction (at 380 nm) due to scattering in a kinetic solubility assay in PBS caused by 
the inhibitor 3.01 in the absence (w/o) and presence (w/) BSA. The data were normalized to the blank value. Presented are 
mean values ± SEM from two independent experiments, each performed in triplicate. 
 
Figure 3.15. Influence of the vial material on the adsorption of inhibitor 3.01 to the vial surface. Solutions of 3.01 at a 
concentration of 7 µM in PBS were prepared in vials consisting of glass (G), ‘siliconized’ glass (S G), polypropylene (PP) or 
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3.5.2 NMR Spectra 
1H NMR spectrum (600 MHz, CDCl3) of compound 3.03. 
13C NMR spectrum (151 MHz, CDCl3) of compound 3.03. 
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1H NMR spectrum (300 MHz, CDCl3) of compound 3.04. 
13C NMR spectrum (75 MHz, CDCl3) of compound 3.04. 
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1H NMR spectrum (400 MHz, CDCl3) of compound 3.12. 
13C NMR spectrum (101 MHz, CDCl3) of compound 3.12. 
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1H NMR spectrum (400 MHz, CDCl3) of compound 3.13. 
13C NMR spectrum (101 MHz, CDCl3) of compound 3.13. 
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1H NMR spectrum (300 MHz, CDCl3) of compound 3.14. 
13C NMR spectrum (75 MHz, CDCl3) of compound 3.14. 
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1H NMR spectrum (300 MHz, CDCl3) of compound 3.15. 
13C NMR spectrum (75 MHz, CDCl3) of compound 3.15. 
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1H NMR spectrum (300 MHz, CDCl3) of compound 3.16. 
13C NMR spectrum (75 MHz, CDCl3) of compound 3.16. 
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1H NMR spectrum (400 MHz, CDCl3) of compound 3.17. 
13C NMR spectrum (101 MHz, CDCl3) of compound 3.17. 
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1H NMR spectrum (300 MHz, CDCl3) of compound 3.18. 
13C NMR spectrum (75 MHz, CDCl3) of compound 3.18. 
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1H NMR spectrum (300 MHz, CDCl3) of compound 3.19. 
13C NMR spectrum (75 MHz, CDCl3) of compound 3.19. 
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1H NMR spectrum (400 MHz, DMSO-d6) of compound 3.20. 
 
13C NMR spectrum (101 MHz, DMSO-d6) of compound 3.20. 
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1H NMR spectrum (300 MHz, CDCl3) of compound 3.21. 
13C NMR spectrum (75 MHz, CDCl3) of compound 3.21. 
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1H NMR spectrum (400 MHz, CDCl3) of compound 3.22. 
13C NMR spectrum (101 MHz, CDCl3) of compound 3.22. 
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1H NMR spectrum (600 MHz, DMSO-d6) of compound 3.23. 
13C NMR spectrum (151 MHz, DMSO-d6) of compound 3.23. 
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1H NMR spectrum (300 MHz, DMSO-d6) of compound 3.24. 
13C NMR spectrum (101 MHz, DMSO-d6) of compound 3.24. 
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1H NMR spectrum (300 MHz, CDCl3) of compound 3.25. 
13C NMR spectrum (75 MHz, CDCl3) of compound 3.25. 
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1H NMR spectrum (300 MHz, CDCl3) of compound 3.26. 
13C NMR spectrum (75 MHz, CDCl3) of compound 3.26. 
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1H NMR spectrum (300 MHz, CDCl3) of compound 3.27. 
13C NMR spectrum (75 MHz, CDCl3) of compound 3.27. 
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1H NMR spectrum (300 MHz, CDCl3) of compound 3.28. 
 
13C NMR spectrum (75 MHz, CDCl3) of compound 3.28. 
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1H NMR spectrum (600 MHz, DMSO-d6) of compound 3.39. 
13C NMR spectrum (151 MHz, DMSO-d6) of compound 3.39. 
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1H NMR spectrum (600 MHz, DMSO-d6, D2O 10%) of compound 3.40. 
13C NMR spectrum (151 MHz, DMSO-d6, D2O 10%) of compound 3.40. 
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1H NMR spectrum (600 MHz, DMSO-d6) of compound 3.41. 
13C NMR spectrum (151 MHz, DMSO-d6) of compound 3.41. 
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1H NMR spectrum (600 MHz, DMSO-d6) of compound 3.42. 
13C NMR spectrum (151 MHz, DMSO-d6) of compound 3.42. 
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1H NMR spectrum (600 MHz, DMSO-d6) of compound 3.43. 
13C NMR spectrum (151 MHz, DMSO-d6) of compound 3.43. 
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1H NMR spectrum (600 MHz, DMSO-d6) of compound 3.48. 
13C NMR spectrum (151 MHz, DMSO-d6) of compound 3.48. 
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1H NMR spectrum (600 MHz, DMSO-d6) of compound 3.49. 
13C NMR spectrum (151 MHz, DMSO-d6) of compound 3.49. 
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1H NMR spectrum (600 MHz, DMSO-d6) of compound 3.50. 
13C NMR spectrum (151 MHz, DMSO-d6) of compound 3.50. 
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1H NMR spectrum (600 MHz, CDCl3) of compound 3.59. 
13C NMR spectrum (151 MHz, CDCl3) of compound 3.59. 
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1H NMR spectrum (600 MHz, CDCl3) of compound 3.60. 
13C NMR spectrum (151 MHz, CDCl3) of compound 3.60. 
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1H NMR spectrum (600 MHz, CDCl3) of compound 3.61. 
13C NMR spectrum (151 MHz, CDCl3) of compound 3.61. 
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1H NMR spectrum (600 MHz, CDCl3) of compound 3.62. 
13C NMR spectrum (151 MHz, CDCl3) of compound 3.62. 
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1H NMR spectrum (600 MHz, CDCl3) of compound 3.63. 
13C NMR spectrum (151 MHz, CDCl3) of compound 3.63. 
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1H NMR spectrum (600 MHz, CDCl3) of compound 3.64. 
13C NMR spectrum (151 MHz, CDCl3) of compound 3.64. 
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1H NMR spectrum (600 MHz, DMSO-d6) of compound 3.65. 
 
13C NMR spectrum (151 MHz, DMSO-d6) of compound 3.65. 
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1H NMR spectrum (600 MHz, CDCl3) of compound 3.66. 
13C NMR spectrum (151 MHz, CDCl3) of compound 3.66. 
Water-Soluble Inhibitors of ABCG2 – A Fragment-Based and Computational Approach 
211 
1H NMR spectrum (600 MHz, DMSO-d6) of compound 3.67. 
13C NMR spectrum (151 MHz, DMSO-d6) of compound 3.67. 
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1H NMR spectrum (600 MHz, DMSO-d6) of compound 3.68. 
13C NMR spectrum (151 MHz, DMSO-d6) of compound 3.68.  
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3.5.3 Chromatograms (Purity Control) 
 
Chromatogram (purity control) of 3.03 (RP-HPLC). 
 
Chromatogram (purity control) of 3.04 (RP-HPLC). 
 
Chromatogram (purity control) of 3.12 (RP-HPLC). 
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Chromatogram (purity control) of 3.13 (RP-HPLC). 
 
Chromatogram (purity control) of 3.14 (RP-HPLC). 
 
Chromatogram (purity control) of 3.15 (RP-HPLC). 
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Chromatogram (purity control) of 3.16 (RP-HPLC). 
 
Chromatogram (purity control) of 3.17 (RP-HPLC). 
 
Chromatogram (purity control) of 3.18 (RP-HPLC). 
Water-Soluble Inhibitors of ABCG2 – A Fragment-Based and Computational Approach 
216 
 
Chromatogram (purity control) of 3.19 (RP-HPLC). 
 
Chromatogram (purity control) of 3.20 (RP-HPLC). 
 
Chromatogram (purity control) of 3.21 (RP-HPLC). 
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Chromatogram (purity control) of 3.22 (RP-HPLC). 
 
Chromatogram (purity control) of 3.23 (RP-HPLC). 
 
Chromatogram (purity control) of 3.24 (RP-HPLC). 
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Chromatogram (purity control) of 3.25 (RP-HPLC). 
 
Chromatogram (purity control) of 3.26 (RP-HPLC). 
 
Chromatogram (purity control) of 3.27 (RP-HPLC). 
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Chromatogram (purity control) of 3.28 (RP-HPLC). 
 
Chromatogram (purity control) of 3.39 (RP-HPLC). 
 
Chromatogram (purity control) of 3.40 (RP-HPLC). 
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Chromatogram (purity control) of 3.41 (RP-HPLC). 
 
Chromatogram (purity control) of 3.42 (RP-HPLC). 
 
Chromatogram (purity control) of 3.43 (RP-HPLC). 
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Chromatogram (purity control) of 3.44 (RP-HPLC). 
 
Chromatogram (purity control) of 3.49 (RP-HPLC). 
 
Chromatogram (purity control) of 3.50 (RP-HPLC). 
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Chromatogram (purity control) of 3.59 (RP-HPLC). 
 
Chromatogram (purity control) of 3.60 (RP-HPLC). 
 
Chromatogram (purity control) of 3.61 (RP-HPLC). 
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Chromatogram (purity control) of 3.62 (RP-HPLC). 
 
Chromatogram (purity control) of 3.63 (RP-HPLC). 
 
Chromatogram (purity control) of 3.64 (RP-HPLC). 
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Chromatogram (purity control) of 3.65 (RP-HPLC). 
 
Chromatogram (purity control) of 3.66 (RP-HPLC). 
 
Chromatogram (purity control) of 3.67 (RP-HPLC). 
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Chromatogram (purity control) of 3.68 (RP-HPLC). 
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ATP-binding cassette (ABC) transporters are gatekeepers at all major physiological barriers, 
such as the intestinal barrier, the hepatic barrier or the blood-brain barrier (BBB). On one hand, 
these proteins extrude endogenous substrates like bile salts, and on the other hand, they protect 
cells against the entry of numerous xenobiotics, including a variety of drugs such as anticancer 
and anti-HIV agents or neuropharmaceuticals. The three main drug transporters are ABCB1, 
ABCC1 and ABCG2, with ABCG2 being predominant at the human BBB. They constitute a 
severe impediment for the oral bioavailability and brain penetration of drugs, and confer 
multidrug resistance (MDR) to cancer cells. Thus, inhibitors of ABCG2 are required as 
molecular tools for examinations on the patho(physiological) role of this transporter, for 
(clinical) studies on drug-drug interactions (DDIs) during drug development and as potential 
drugs to overcome tissue barriers (especially the BBB) and MDR in cancer. 
Heretofore, the discovery of ABCG2 inhibitors had largely been driven by potency, while drug-
like properties – imperative for application in vivo – had been overlooked. Moreover, the 
mechanism of transport inhibition had still been enigmatic. Therefore, the present thesis aimed 
at creating novel ABCG2 inhibitors with improved drug-like properties, in particular stability 
in blood plasma and water solubility, and at elucidating the underlying transport inhibition 
mechanism. 
Tariquidar analogs had been described as potent and selective ABCG2 inhibitors by our 
working group. However, their susceptibility to hydrolysis limited their applicability in vivo. 
Chapter 2 of this thesis comprises the synthesis (performed by Prof. König’s group) and 
characterization (performed by our group, including the author of this thesis) of new tariquidar-
related inhibitors, obtained by bioisosteric replacement of the labile moieties in the previous 
tariquidar analog UR-ME22-1. CuAAC (“click” reaction) gave convenient access to a triazole 
core as a substitute for the labile amide group and the unstable ester moiety was replaced by 
different acyl groups in a Sugasawa reaction. An HPLC assay proved the enhancement of the 
stability in murine blood plasma. Compounds UR-MB108 and UR-MB136 inhibited ABCG2 
in a Hoechst 33342 transport assay with an IC50 value of about 80 nM and thus belong to the 
most potent ABCG2 inhibitors described so far (Figure 4.1). Compound UR-MB108 was highly 
selective for ABCG2, whereas its PEGylated analog UR-MB136 showed some potency at 
ABCB1. Both UR-MB108 and UR-MB136 produced an ABCG2 ATPase-depressing effect, 
which is in agreement with a precedent cryo-EM study identifying UR-MB136 as an ATPase 
inhibitor that exerts its effect via locking the inward-facing conformation of ABCG2. 
Thermostabilization of ABCG2 by UR-MB108 and UR-MB136 (performed by Prof. Locher’s 
group) can be taken as a hint to comparable binding to ABCG2. As reference substances, 
compounds UR-MB108 and UR-MB136 allow additional mechanistic studies on ABCG2 
inhibition. Due to their stability in blood plasma, they are also applicable in vivo. The highly 
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specific inhibitor UR-MB108 is suited for PET labeling, helping to further clarify the 
(patho)physiological role of ABCG2, e.g. at the BBB. 
 
Figure 4.1. Graphical summary of Chapter 2 on tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2. 
Chapter 3 of this thesis is focused on water solubility. The latter is an indispensable prerequisite 
for all bioactive compounds – seemingly trivial, however often underestimated. Many drug 
development failures have been attributed to poor aqueous solubility. ABCG2 inhibitors are 
especially prone to be insoluble since they have to address the extremely large and hydrophobic 
multidrug binding site in ABCG2. A case in point is UR-MB108, which showed high potency 
(79 nM), but very low aqueous solubility (78 nM; determined in Chapter 3 of this thesis). To 
discover novel potent ABCG2 inhibitors with improved solubility, a fragment-based approach 
was pursued. Substructures of UR-MB108 were optimized and the fragments ‘enlarged’ to 
obtain inhibitors, in part supported by molecular docking studies. Syntheses were achieved, i.a., 
via Sonogashira coupling, click chemistry and amide coupling. A kinetic solubility assay 
revealed that UR-MB108 and most of the new inhibitors did not precipitate during the short 
time period of the applied biological assays (up to two hours). The solubility of the compounds 
in aqueous media at equilibrium was investigated in a thermodynamic solubility assay, where 
UR-Ant116, UR-Ant121, UR-Ant131 and UR-Ant132 excelled with solubilities between 1 µM 
and 1.5 µM – an up to 19-fold improvement compared to UR-MB108 (Figure 4.2). Moreover, 
these novel N-phenyl-chromone-2-carboxamides inhibited ABCG2 in a Hoechst 33342 
transport assay with potencies in the low three-digit nanomolar range, reversed MDR in 
ABCG2-overexpressing cancer cells, were non-toxic and proved stable in blood plasma. 
Altogether, the aforementioned compounds are attractive candidates especially for in vivo 
studies, but also for in vitro assays requiring long-term incubation, both needing sufficient 
solubility at equilibrium. UR-Ant121 and UR-Ant132 were highly ABCG2-selective, a 
precondition for developing PET tracers. The triple ABCB1/ABCC1/ABCG2 inhibitor 
UR-Ant116 qualifies for potential therapeutic applications, given the concerted role of the three 




Figure 4.2. Graphical summary of Chapter 3 on water-soluble inhibitors of ABCG2, obtained by a fragment-based and 
computational approach. 
Taken together, this thesis provides ABCG2 inhibitors that are both potent and effective as well 
as water-soluble, stable in blood plasma and nontoxic – important drug-like properties. These 
novel compounds may be of broad interest as molecular biological tools to scientists in 
fundamental ABCG2 research and to pharmaceutical companies assessing DDIs, and possibly 
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5.1 Introduction 
Cancer is the second leading cause of death worldwide [1]. Surgery and radiation are local 
therapies and cannot eradicate metastatic cancer, where every organ in the body needs to be 
reached [2]. By contrast, chemotherapy works systemically and is the most effective treatment 
for disseminated tumors [2,3]. The era of chemotherapy began in 1942 with the discovery of 
nitrogen mustards – originally produced as chemical warfare agents – as a remedy for cancer 
[2,4]. A basic chemical reaction underlies the mechanism of action of nitrogen mustards, 
namely the intramolecular cyclization in a polar solvent to form an aziridnium cation, which 
reacts readily with bionucleophiles (Figure 5.1), e.g. nitrogen in the DNA. This reaction leads 
to the formation of DNA interstrand crosslinks, which prevents cell replication and ultimately 
causes cell death [4,5]. 
 
Figure 5.1. Mechanism of the reaction of nitrogen mustards with nucleophiles (Nu-), here shown for mechlorethamine (5.01). 
Inspired by this success, further, improved DNA-alkylating agents of the nitrogen mustard type 
were developed as chemotherapeutics, such as chlorambucil, melphalan or bendamustine. 
Chlorambucil (5.02) (Figure 5.2) was first synthesized by Everett et al. in 1953 [6]. The nitrogen 
mustard moiety (i.e. the bis(2-chloroethyl)amino moiety, also called N-lost moiety) was 
attached to a phenyl ring, which withdraws electrons from the nitrogen atom, thereby 
disfavoring aziridinium ion formation, which renders the nitrogen mustard moiety less reactive 
towards nucleophilic attack [7]. Therefore, Chlorambucil and other aromatic analogs are 
sufficiently deactivated so that they can reach their target DNA sites before being degraded by 
reacting with collateral nucleophiles, resulting in reduced toxic side effects and allowing oral 
administration [7]. The butanoic acid side chain makes the compound hydrophilic [8]. 
Chlorambucil is sold, e.g., under the brand name of Leukeran and is indicated in the treatment 
of chronic lymphocytic leukemia (CLL), Hodgkin and non-Hodgkin lymphomas (HL and 
NHL) as well as breast and ovarian carcinomas [5,9,10]. 
Melphalan (5.03) (Figure 5.2) differs from chlorambucil in the length of the alkanoic acid side 
chain and in the amino group attached to the latter – the amino acid L-phenylalanine is the 
‘carrier’ of the N-lost moiety. Melphalan was first synthesized in 1954 by Bergel et al., aiming 
at increased tumor-selectivity [11]. Indeed melphalan is imported by amino acid transporters 
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[12], whose expression is up-regulated in cancer cells [13]. Melphalan is used for treating 
various malignancies including multiple myeloma (MM), ovarian cancer, breast cancer and 
melanoma and is sold, among others, under the trade name of Alkeran [14,15]. 
Bendamustine (5.04) (Figure 5.3) was initially synthesized in 1963 by Ozegowski et al. [16,17] 
in the former German Democratic Republic and was introduced into the market there [18,19]. 
It distinguishes itself from chlorambucil in the central benzimidazole ring, which is unique to 
bendamustine and was intended to include antimetabolite properties, which, however, have not 
yet been confirmed [17,18]. Nevertheless, bendamustine displays a unique mechanism of 
action, as it inhibits mitotic checkpoints, causes inefficient DNA repair and induces the 
expression of the protein p53, a tumor suppressor, which initiates apoptosis [20,21]. 
Bendamustine was approved in the Federal Republic of Germany after the iron curtain had 
fallen and today it is sold, e.g., under the brand name of Ribomustin for CLL, indolent NHL 
and MM [19,22]. In the USA, the drug is marketed, among others, under the brand name of 
Treanda and is approved for CLL and indolent NHL [18,19]. The assets of bendamustine are a 
favorable side-effect profile [18], the lack of cross-resistances with many other alkylating 
agents [19] and its superiority to chlorambucil in previously untreated patients with CLL [22]. 
 
Figure 5.2. Structures of the nitrogen mustard anticancer agents chlorambucil (5.02) and melphalan (5.03). 
Bendamustine is usually dosed intravenously, however there have been a couple of patent 
applications aiming at formulations for oral administration [23,24]. Esterification of the 
carboxylic acid moiety may increase the chances of oral application and, furthermore, has been 
reported to enhance the hydrolytic stability of the N-lost moiety (for different reasons) [25-27]. 
The increasing interest in esters of bendamustine prompted our working group to perform a 
study on the pharmacological properties of the latter. It was revealed that esters of bendamustine 
are by far more potent cytotoxic agents than the parent compound, in particular esters 
comprising basic moieties, which are charged under physiological conditions, e.g. the 
2-pyrrolidinoethyl ester 5.05 (Figure 5.3) [28]. The basic esters show pronounced cellular 
accumulation for reasons not yet identified, but transport proteins may be involved [28]. 
However, the basic esters turned out to be especially prone to hydrolysis at the ester bond in 
blood plasma, which was attributed to their similarity to substrates of unspecific cholinesterases 
[29]. We were able to overcome this obstacle by substituting the linear ester moiety in 5.05 by 
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a branched ester (compound 5.06), which increased the stability to an acceptable level [29], and 
so did replacement of the ester by an amide bond (compound 5.07; unpublished data). 
Bendamustine, its derivatives 5.05-5.07, as well as their respective half-lives in human blood 
plasma are depicted in Figure 5.3. As a note, the decomposition of bendamustine is due to the 
hydrolysis of the carbon-chlorine bonds of the N-lost moiety. 
The preparation of 5.07 and the cytotoxicity analysis of 5.06 and 5.07 have not yet been reported 
and are part of the present study. 
 
Figure 5.3. Structures of the nitrogen mustard anticancer agent bendamustine (5.04) and its derivatives 5.05, 5.06 and 5.07, as 
well as their corresponding half-lives in human blood plasma. 
Since other anticancer agents are structurally very similar to bendamustine, it is conceivable 
that these can be improved by the same modification. Aiming at increased cytotoxicity, the 
present study comprises the synthesis and cytotoxicity analysis of basic derivatives of further 
members of the nitrogen mustard family, in particular an isomer of bendamustine we recently 
described (6-isobendamustine) [30,31], chlorambucil and melphalan. A pyrrolidino alkyl chain 
was introduced via amide or branched ester formation, since these moieties previously proved 
superior to a linear ester group in terms of stability in blood plasma [29]. 
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5.2 Results and Discussion 
5.2.1 Synthesis 
The anticancer agents bendamustine, chlorambucil and melphalan are marketed drugs. 
6-Isobendamustine (5.09) [30,31] (here short: isobendamustine), which, by contrast with 
conventional bendamustine, bears the N-lost moiety in 6-position – instead of 5-position – of 
the benzimidazole ring, is not commercially available. The latter was prepared from 4-(1-
methyl-6-bis(2-hydroxyethyl)aminobenzimidazol-2-yl)butyric acid ethyl ester (5.08), which 
we received as a kind gift from Gemini PharmChem. Compound 5.08 was first treated with the 
chlorinating agent thionyl chloride and then with hydrochloric acid to hydrolyze the ester bond 
(Scheme 5.1). 
 
Scheme 5.1. Synthesis of 6-isobendamustine (5.09). Reagents and conditions: (I) SOCl2, DCM, reflux, 60 min; (II) 6 M 
HCl aq., 90 °C, 2 h. 
The esters and amides were prepared from their respective parent compounds and a 
pyrrolidinoalkyl alcohol or amine. The bendamustine ester 5.06 was synthesized with the help 
of the coupling reagent DCC, as we described previously [29]; for the preparation of the novel 
bendamustine amide 5.07 the coupling reagents TBTU and DIPEA were used (Scheme 5.2). 
Isobendamustine was converted to the ester 5.10 and the amide 5.11 in the same way as 
compounds 5.06 and 5.07, respectively (Scheme 5.2). The chlorambucil ester 5.12 could not be 
synthesized with DCC, but coupling with TBTU and DIPEA was successful, and the same 
reagents were used to prepare the chlorambucil amide 5.13 (which is already known in literature 
[32]) (Scheme 5.2). Melphalan was first boc-protected (to compound 5.14), then treated with 
the respective alcohol or amide and the established coupling reagents TBTU and DIPEA, and 
subsequently deprotected to the melphalan ester 5.15 or the amide 5.16 (Scheme 5.2). 
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Scheme 5.2. Synthesis of the target compounds 5.06, 5.07, 5.10-5.13, 5.15 and 5.16. Reagents and conditions: (a) 
1-(pyrrolidin-1-yl)propan-2-ol, DCC, DMF, 0 °C, 15 min → 80 °C (microwave), 30 min; (b) respective alcohol or amine, 
TBTU, DIPEA, DMF, rt, overnight or 60-80 °C (microwave), 45 –120 min; (c) Boc2O, NaHCO3, THF/H2O 1:1, rt, 30 min; (d) 
TFA, DCM, rt, 2 h. 
5.2.2 Cytotoxicity 
The cytotoxicity of the target compounds was investigated in a kinetic chemosensitivity assay, 
which allows the distinction between cytotoxic, cytostatic and cytocidal drug effects [33]. The 
effects against the following three cancer cell lines were determined: a carcinoma (colorectal 
adenocarcinoma, HT-29), a sarcoma (osteosarcoma, MG-63) and a malignant melanoma 
(SK-MEL-3). 
  
Derivatives of Nitrogen Mustard Anticancer Agents with Improved Cytotoxicity 
243 
5.2.2.1 Bendamustine and Derivatives 
In accordance with our previous report [28], bendamustine proved ineffective against HT-29 
carcinoma cells (Figure 5.4). Also the chemosensitivity of MG-63 osteosarcoma and 
SK-MEL-3 melanoma cells was very low with slight cytotoxic effects at concentrations above 
30 µM. By contrast, the branched ester 5.06 and the amide 5.07 exhibited a distinct increase in 
cytotoxicity compared to the parent compound, showing cytocidal effects against the treated 
cancer cells at concentrations of 10-30 µM. This is in good accordance with our previously 
examined, linear esters of bendamustine [28]. Thus, the replacement of the linear ester moiety 
by a branched ester or an amide group did not only increase the stability in human blood plasma, 
but also proved to be bioisosteric. 
 
Figure 5.4. Cytotoxicity of bendamustine (5.04), its ester 5.06 and its amide 5.07 against HT-29 cells (A), MG-63 cells (B) 
and SK-MEL-3 cells (C). Cytotoxic/ cytocidal effects correspond to the left y-axes. The growth curves of untreated control 
cells (open circles) correspond to the right y-axes. Data are mean values ± SEM of two to four independent experiments, each 
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5.2.2.2 Isobendamustine and Derivatives 
The comportment of isobendamustine in the chemosensitivity assay was almost identical to its 
isomer bendamustine – all three cell lines were refractory against treatment with 
isobendamustine (Figure 5.5). By contrast, the basic derivatives 5.10 and 5.11 exerted a 
pronounced effect against the three cell lines (cytocidal at concentrations between 10-30 µM), 
which is in analogy with the basic derivatives of bendamustine. Hence, the method of increasing 
the cytotoxicity by the introduction of a basic moiety was successfully applied to the 6-isomer 
of bendamustine and it became obvious that changing the position of the nitrogen mustard 
moiety at the benzimidazole ring is well-tolerated. 
 
Figure 5.5. Cytotoxicity of isobendamustine (5.09), its ester 5.10 and its amide 5.11 against HT-29 cells (A), MG-63 cells (B) 
and SK-MEL-3 cells (C). Cytotoxic/ cytocidal effects correspond to the left y-axes. The growth curves of untreated control 
cells (open circles) correspond to the right y-axes. Data are mean values ± SEM of two to four independent experiments, each 
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5.2.2.3 Chlorambucil and Derivatives 
Chlorambucil displays a pronounced structural difference from bendamustine, as it bears a 
phenyl ring instead of a benzimidazole moiety. Its effect against HT-29 carcinoma cells and 
SK-MEL-3 melanoma cells was rather weak, whereas it showed a cytocidal effect against 
MG-63 osteosarcoma cells at a concentration of 30 µM (Figure 5.6). The conversion into the 
basic ester 5.12 or amide 5.13 markedly increased the cytotoxicity compared to the parent 
compound, both derivatives showing cytocidal effects against HT-29 and MG-63 cells at 
concentrations of 1-10 µM and against SK-MEL-3 cells, which were refractory against 
treatment with chlorambucil, at concentrations of 10-30 µM. The chlorambucil amide was more 
potent than the ester; for instance the amide exhibited a cytocidal effect against MG-63 
osteosarcoma cells at a concentration as low as 1 µM, whereas a concentration of 10 µM of the 
ester was necessary to achieve the same effect. Taken together, the introduction of a basic 
moiety via an ester or amide bond turned out an effective means to increase the potency of 
chlorambucil. 
 
Figure 5.6. Cytotoxicity of chlorambucil (5.02), its ester 5.12 and its amide 5.13 against HT-29 cells (A), MG-63 cells (B) and 
SK-MEL-3 cells (C). Cytotoxic/ cytocidal effects correspond to the left y-axes. The growth curves of untreated control cells 
(open circles) correspond to the right y-axes. Data are mean values ± SEM of two to four independent experiments, each 
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5.2.2.4 Melphalan and Derivatives 
Melphalan, an L-phenylalanine-nitrogen mustard, was more effective against the three cell lines 
than bendamustine, isobendamustine or chlorambucil, which may be due to its property as an 
amino acid transporter substrate, causing increased cellular uptake. Melphalan showed a 
cytocidal effect on carcinoma HT-29 and osteosarcoma MG-63 cells at concentrations of 30 µM 
and 10 µM, respectively (Figure 5.7). The chemosensitivity of SK-MEL-3 cells was lower, with 
a cytostatic effect at a concentration of 30 µM. The basic ester 5.15 and amide 5.16 showed 
effects similar to the parent compound against MG-63 cells. However, HT-29 and SK-MEL-3 
cells exhibited a higher response upon treatment with 5.15 and 5.16 than when treated with 
melphalan (cytocidal effects at concentrations of 3-30 µM). As in the case of the chlorambucil 
derivatives, the amide was somewhat more potent than the ester. All in all, only a slight 
improvement in cytotoxicity of melphalan could be achieved by the introduction of a basic 
moiety. 
 
Figure 5.7. Cytotoxicity of melphalan (5.03), its ester 5.15 and its amide 5.16 against HT-29 cells (A), MG-63 cells (B) and 
SK-MEL-3 cells (C). Cytotoxic/ cytocidal effects correspond to the left y-axes. The growth curves of untreated control cells 
(open circles) correspond to the right y-axes. Data are mean values ± SEM of two to four independent experiments, each 
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Comparing the basic derivatives of bendamustine, isobendamustine, chlorambucil and 
melphalan, it becomes apparent that they all display similar potencies – the growth curves of 
the individual cell lines upon treatment with 5.06, 5.07, 5.10-5.13, 5.15 and 5.16 are very much 
alike. This can be taken as a hint that the enhancement of cytotoxicity is due to the same 
mechanism, for instance increased cellular uptake. Since the basic pyrrolidine ring is protonated 
under physiological conditions, the involvement of cation transporters is conceivable. This 
would also explain the smaller potency difference between melphalan and its derivatives – 
contrary to bendamustine and chlorambucil, melphalan is imported into the cell by amino acid 
transporters [12], which is why the cellular uptake does not leave much room for optimization. 
5.3 Conclusion 
Previously, we showed that esters of bendamustine are by far more cytotoxic anticancer agents 
than their parent compound, in particular ones containing a basic moiety. Since the latter were 
rapidly cleaved in human blood plasma, the labile ester moiety was substituted by a branched 
ester, resulting in compound UR-Ant26 (5.06), or an amide group, yielding UR-Ant16 (5.07), 
both of which markedly increased the stability. In the current study, the cytotoxicity of the 
compounds 5.06 and 5.07 was examined. By analogy with the previous linear esters, they 
showed cytocidal effects at concentrations between 10 µM and 30 µM – a striking increase in 
cytotoxicity compared to bendamustine, which was practically ineffective against the treated 
cells. These results verify that the replacement of the labile ester moiety by a branched ester or 
an amide was bioisosteric. 
In the hope that this approach of increasing the cytotoxicity would be applicable to other, related 
nitrogen mustard anticancer agents, basic esters and amides of 6-isobendamustine (compounds 
UR-Ant45 (5.10) and UR-Ant48 (5.11)), chlorambucil (compounds UR-Ant66 (5.12) and 
UR-Ant55 (5.13)) and melphalan (compounds UR-Ant65 (5.15) and UR-Ant39 (5.16)) were 
synthesized. The reaction of the respective parent compound with a pyrrolidino alkyl alcohol 
or amide and the coupling reagent DCC or TBTU gave access to the target compounds. 
Cytotoxicity against carcinoma, sarcoma and melanoma cells was assessed in a kinetic 
chemosensitivity assay. The novel derivatives showed cytotoxic or cytocidal effects at 
concentrations above 1 μM. This constitutes a striking enhancement over 6-isobendamustine, 
which was ineffective against the selected cancer cells. These results are very similar to 
bendamustine and its derivatives, which shows that the constitution isomerism, i.e. the change 
in the position of the N-lost moiety, is well-tolerated. Also an ample improvement over 
chlorambucil was achieved, which only showed weak potency against the sarcoma cells. 
Melphalan was almost as effective as the target compounds – derivatization provided only a 
small increase in cytotoxicity. It can be speculated that the introduction of a basic moiety 
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confers substrate properties of (cation) transporters, thereby increasing cellular uptake and 
ultimately cytotoxicity. This would explain the comparable meager enhancement achieved by 
derivatization of melphalan – the latter already exploits membrane transport systems, as it is a 
substrate of amino acid transporters [12]. 
Taken together, the novel nitrogen mustard chemotherapeutics can be considered interesting 
molecular tools for the analysis of a correlation between cytotoxicity and membrane transport 
mechanisms. Furthermore, the increased antiproliferative activity suggests higher efficacy in 
the treatment of malignancies for which the parent compound is approved, and a possible 
extension of the scope of indications. 
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5.4 Experimental Section 
5.4.1 Chemistry 
5.4.1.1 General Experimental Conditions 
Chemicals and solvents were purchased from commercial suppliers (Sigma Aldrich, Munich, 
Germany; Merck, Darmstadt, Germany; VWR, Darmstadt, Germany; Thermo Fisher Scientific, 
Karlsruhe, Germany; TCI, Eschborn, Germany) and used without further purification unless 
stated otherwise. Bendamustine was a kind gift from Arevipharma (Radebeul, Germany). 4-(1-
Methyl-6-bis(2-hydroxyethyl)aminobenzimidazol-2-yl)butyric acid ethyl ester was a kind gift 
from Gemini PharmChem (Mannheim, Germany). Reactions requiring anhydrous conditions 
were carried out in dried reaction vessels under an atmosphere of argon and anhydrous solvents 
were used. Millipore water was used throughout for the preparation of buffers and HPLC 
eluents. Acetonitrile for HPLC (gradient grade) was obtained from Merck. 
Microwave reactions were carried out in an Initiator 8 microwave reactor (Biotage, Uppsala, 
Sweden). 
Thin layer chromatography was performed on TLC Silica gel 60 F254 aluminium plates 
(Merck, Darmstadt, Germany). Visualization was accomplished by UV irradiation at 
wavelengths of 254 nm and 366 nm or by staining with ninhydrin (1.5 g ninhydrin, 5 mL acetic 
acid, 500 mL 95% ethanol). 
NMR spectra were recorded on an Avance 400 instrument (9.40 T, 1H: 400 MHz, 13C: 
101 MHz) or an Avance 600 instrument with cryogenic probe (14.1 T, 1H: 600 MHz, 13C: 
151 MHz) (Bruker, Karlsruhe, Germany) with TMS as external standard. 
High-resolution mass spectrometry (HRMS) analysis was performed on an Agilent 6540 
UHD Accurate-Mass Q-TOF LC/MS system (Agilent Technologies, Santa Clara, CA, USA) 
using an ESI source. 
Preparative HPLC was performed on a system from Knauer (Berlin, Germany) consisting of 
two K-1800 pumps and a K-2001 detector. A Nucleodur 100-5 C18 (5 µm, 110 Å, 250 mm x 
21 mm; Macherey-Nagel, Düren, Germany) (compound 5.07) or a Kinetex® XB-C18 (5 µm, 
100 Å, 250 mm x 21.2 mm; Phenomenex, Aschaffenburg, Germany) (all other compounds) 
served as RP-columns at flow-rates of 16 mL/min and 15 mL/min, respectively. Mixtures of 
acetonitrile and 0.1% aq TFA were used as mobile phase. The detection wavelength was set to 
220 nm throughout. The solvent mixtures were removed by lyophilization using an Alpha 2-4 
LD lyophilization apparatus (Christ, Osterode am Harz, Germany) equipped with an RZ 6 
rotary vane vacuum pump (Vacuubrand, Wertheim, Germany). 
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Analytical HPLC of all compounds, except for 5.12 and 5.15, was performed on a system from 
Thermo Separation Products (Dreieich, Germany), composed of an SN400 controller, a P4000 
pump, a Degassex DG-4400 degasser (Phenomenex, Aschaffenburg, Germany), an AS3000 
autosampler and a Spectra Focus UV-VIS detector. A Nucleodur 100-5 C18 (5 μm, 250 mm x 
4.0 mm; Macherey-Nagel, Düren, Germany) (compound 5.07) or a Kinetex® XB-C18 (5 µm, 
100 Å, 250 mm × 4.6 mm; Phenomenex) (all other compounds) served as RP-columns at a flow 
rate of 0.75 mL/min. Oven temperature was set to 30 °C throughout. Mixtures of acetonitrile 
(A) and 0.05% aq TFA (B) were used as mobile phase and degassed with Helium. The detection 
wavelength was set to 220 nm throughout. Solutions for injection (100 µM) were prepared in a 
mixture of A and B corresponding to the mixture at the start of the gradient. The following 
linear gradient was applied: 0-30 min: A/B 20:80-95:5, 30-35 min: A/B 95:5. Analytical HPLC 
of compounds 5.12 and 5.15 was performed on a system from Agilent Technologies (Santa 
Clara, CA, USA) (Series 1100) composed of a G1312A binary pump equipped with a G1379A 
degasser, a G1329A ALS autosampler, a G1316A COLCOM thermostated column 
compartment and a G1314A VWD detector. A Kinetex® C18 (2.6 µm, 100 Å, 100 mm × 3 mm; 
Phenomenex, Aschaffenburg, Germany) served as RP-column at a flow rate of 0.4 mL/min. 
Oven temperature was set to 30 °C throughout. Mixtures of acetonitrile (A) and 0.05% aq TFA 
(B) were used as mobile phase. The detection wavelength was set to 220 nm throughout. 
Solutions for injection (100 µM) were prepared in a mixture of A and B corresponding to the 
mixture at the start of the gradient. The following linear gradient was applied: 0-12 min: A/B 
20:80-95:5, 12-15 min: A/B 95:5. Retention (capacity) factors were calculated from retention 
times (tR) according to k = (tR - t0)/t0 (t0 = dead time of the respective HPLC-system). 
5.4.1.2 Synthesis Protocols and Analytical Data 
General Procedure 1 for Ester Bond Formation 
The respective carboxylic acid (1.0 eq) was dissolved in anhydrous DMF (0.2-0.3 M) in a 
microwave reaction vessel. 1-(Pyrrolidin-1-yl)propan-2-ol (1.5 eq) was added and the stirred 
mixture was cooled down to 0 °C using an ice bath. DCC (1.1 eq) was added and stirring was 
continued at 0 °C for 15 min and at 80 °C in a microwave reactor for 30 min. The mixture was 
subjected to preparative HPLC (eluent: MeCN/0.1% aq TFA) and the eluate lyophilized. 
General Procedure 2 for Ester Bond Formation 
Under dry conditions the respective carboxylic acid (1.0 eq) was dissolved in anhydrous DMF 
(0.2-0.3 M) in a microwave reaction vessel. DIPEA (2.0 eq) and the coupling reagent TBTU 
(1.0 eq) were added and the solution was stirred at rt for 5 min. 1-(Pyrrolidin-1-yl)propan-2-ol 
(1.5 eq) was added and stirring was continued for another 45 min at 80 °C in a microwave 
reactor. The mixture was subjected to preparative HPLC (eluent: MeCN/0.1% aq TFA) and the 
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eluate lyophilized. In the case of boc-protected compounds, work-up and deprotection preceded 
purification of the final product by preparative HPLC. 
General Procedure for Amide Bond Formation 
Under dry conditions the respective carboxylic acid (1.0 eq) was dissolved in anhydrous DMF 
(0.2-0.3 M) in a microwave reaction vessel or a round bottom flask. DIPEA (2.0-3.0 eq) and 
the coupling reagent TBTU (1.0 eq) were added and the solution was stirred at rt for 5 min. The 
according amine (1.0-1.1 eq) was added and stirring was continued for another 45-120 min at 
60-80 °C in a microwave reactor or at rt overnight. The mixture was subjected to preparative 
HPLC (eluent: MeCN/0.1% aq TFA) and the eluate lyophilized. In the case of boc-protected 
compounds, work-up and deprotection preceded purification of the final product by preparative 
HPLC. 
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)-N-(2-(pyrrolidin-
1-yl)ethyl)butanamide (isobendamustine 2-pyrrolidinooethyl amide) (5.07) 
 
Compound 5.07 was prepared according to the general procedure for amide bond formation (in 
a round bottom flask with stirring overnight). The reaction was carried out using, bendamustine 
(100 mg, 0.279 mmol, 1.0 eq), TBTU (98.6 mg, 0.307 mmol, 1.1 eq), DIPEA (52.2 µL, 
0.307 mmol, 1.1 eq), 2-(pyrrolidin-1-yl)ethan-1-amine (35.4 µL, 0.279 mmol, 1.0 eq) and 
DMF (1 mL). Preparative HPLC (0-30 min: MeCN/ 0.1% aq TFA 19:81-55:45, tR = 13.0 min) 
yielded 5.07 as a yellowish resin (97.5 mg, 0.143 mmol, 51%). 1H NMR (600 MHz, CDCl3): δ 
(ppm) = 11.43 (s, 1H), 8.24 (t, J = 4.9 Hz, 1H), 7.39 (d, J = 9.2 Hz, 1H), 6.98 (d, J = 2.3 Hz, 
1H), 6.95 (dd, J = 9.2 Hz, J = 2.3 Hz, 1H), 3.89 (s, 3H), 3.81 (t, J = 6.6 Hz, 6H), 3.67 (t, 
J = 6.6 Hz, 4H), 3.49 (q, J = 5.4 Hz, 2H), 3.24 (t, J = 5.4 Hz, 2H), 3.19 (t, J = 7.4 Hz, 2H), 2.89 
(br s, 2H), 2.39 (t, J = 6.7 Hz, 2H), 2.18 (qi, J = 7.1 Hz, 2H), 2.08 (br s, 4H). 13C NMR 
(150 MHz, CDCl3): δ (ppm) = 173.0, 162.1 (TFA), 161.9 (TFA), 161.6 (TFA), 161.4 (TFA), 
151.5, 146.1, 132.8, 125.1, 117.5 (TFA), 115.5 (TFA), 112.9, 112.3, 96.4, 55.0, 54.4 (2C), 54.1 
(2C), 40.6 (2C), 35.7, 34.3, 31.0, 24.7, 23.2 (2C), 22.5. RP-HPLC (220 nm): 99% (tR = 7.8 min, 
k = 2.3). HRMS (ESI): m/z [M+H]+ calcd. for C22H34Cl2N5O
+: 454.2135, found: 454.2135. 
C22H33Cl2N5O · C4H2F6O4  (454.44 + 228.05). 
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4-(6-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid 
(6-isobendamustine) hydrotrifluoroacetate (5.09) [30,31] 
 
4-(1-Methyl-6-bis(2-hydroxyethyl)aminobenzimidazol-2-yl)butyric acid ethyl ester (800 mg, 
2.29 mmol, 1.0 eq) was dissolved in DCM and the chlorinating agent thionyl chloride (498 µL, 
6.87 mmol, 3.0 eq) was added dropwise. The mixture was refluxed for 60 min and the volatiles 
were removed under reduced pressure. The ester bond was hydrolyzed with 6 M HCl aq (4 mL) 
90 °C for 2 h. The mixture was washed with DCM to remove lipophilic impurities and 
isobendamustine hydrochloride was precipitated by adding 10 M NaOH aq until a pH of 0-1 
was reached. Recrystallization in isopropanol yielded isobendamustine free base as a brownish 
solid (346 mg, 0.966 mmol, 42%). For further purification, 50 mg of the substance were 
subjected to preparative HPLC (gradient: 0-30 min: MeCN/ 0.1% aq TFA 25:75-55:45, 
tR = 13.0 min) and the eluate was lyophilized, yielding compound 5.09 as a brownish resin 
(61.8 mg, 0.131 mmol, 94%). Analytical and pharmacological characterization was performed 
with the HPLC-purified substance. 1H NMR (600 MHz, DMSO-d6): δ (ppm) = 14.70 (br s, 
1H), 12.26 (br s, 1H), 7.58 (d, J = 9.03 Hz, 1H), 7.11 (d, J = 2.28 Hz, 1H), 7.08 (dd, 
J = 9.03 Hz, J = 2.28 Hz, 1H), 3.90 (s, 3H), 3.86 (t, J = 6.57 Hz, 2H), 3.80 Hz (t, J = 6.66 Hz, 
4H), 3.15 (t, J = 7.74 Hz, 2H), 2.41 (t, J = 7.1 Hz, 2H), 2.00 (qi, J = 7.56 Hz, 2H). 13C NMR 
(151 MHz, DMSO-d6): δ (ppm) = 173.7, 158.5 (TFA), 158.3 (TFA), 158.1 (TFA), 157.8 (TFA), 
151.8, 145.4, 134.3, 121.9, 117.5 (TFA), 115.6 (TFA), 114.5, 112.7, 94.0, 52.4 (2C), 41.2 (2C), 
32.5, 30.8, 24.2, 21.4. RP-HPLC (220 nm): 98% (tR = 11.7 min, k = 2.9). HRMS (ESI): m/z 
[M+H]+ calcd. for C16H22Cl2N3O2
+: 358.1084, found: 358.1104. C16H21Cl2N3O2 · C2HF3O2 
(358.26 + 114.02). 
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1-(Pyrrolidin-1-yl)propan-2-yl 4-(6-(bis(2-chloroethyl)amino)-1-methyl-1H-
benzo[d]imidazol-2-yl)butanoate (isobendamustine 1-methyl-2-pyrrolidinoethyl 
ester) bis(hydrotrifluoroacetate) (5.10) 
 
Compound 5.10 was prepared according to the general procedure 1 for ester bond formation. 
The reaction was carried out using isobendamustine (75 mg, 0.209 mmol, 1.0 eq), 1-(pyrrolidin-
1-yl)propan-2-ol (40.6 mg, 0.314 mmol, 1.5 eq), DCC (47.5 mg, 0.230 mmol, 1.1 eq) and DMF 
(0.5 mL). A yellow coloration and a white precipitate could be observed. Preparative HPLC 
(0-30 min: MeCN/ 0.1% aq TFA 20:80-55:45, tR = 14.5 min) yielded 5.10 as a brownish resin 
(32.8 mg, 0.047 mmol, 22%). More than one diastereoisomer was evident in the NMR spectra. 
1H NMR (600 MHz, DMSO-d6): δ (ppm) = 15.03 (br s, 1H), 10.18 (s, 1H), 7.59 (d, J = 9.13 Hz, 
1H), 7.12 (d, J = 2.23 Hz, 1H), 7.08 (dd, J = 9.13 Hz, J = 2.23 Hz, 1H), 5.13 (m, 1H), 3.91 Hz 
(s, 3H), 3.86 (t, J = 6.58 Hz, 4H), 3.80 (t, J = 6.58 Hz, 4H), 3.54 (br s, 2H), 3.38 (m, 2H), 3.16 
(t, J = 7.56 Hz, 2H), 3.10 (br s, 2H), 2.55 (m, 2H), 2.04 (m, 2H), 1.92 (br s, 4H), 1.18 (d, 
J = 6.25 Hz, 3H). 13C NMR (151 MHz, DMSO-d6): δ (ppm) = 171.7, 158.8 (TFA), 158.5 
(TFA), 158.3 (TFA), 158.1 (TFA), 151.7, 145.4, 134.3, 122.0, 117.4 (TFA), 115.5 (TFA), 
114.6, 112.7, 94.0, 66.5, 57.4, 54.9 and 53.3 (the two carbons adjacent to the pyrrolidine 
nitrogen yielded two signals), 52.4 (2C), 41.2 (2C), 32.4, 30.8, 24.1, 22.6 (2C), 21.1, 17.7. 
RP-HPLC (220 nm): 96% (tR = 10.2 min, k = 2.4). HRMS (ESI): m/z [M+H]
+ calcd. for 
C23H35Cl2N4O2
+: 469.2132, found: 469.2137. C23H34Cl2N4O2 · C4H2F6O4 (469.45 + 228.05). 
4-(6-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)-N-(2-(pyrrolidin-
1-yl)ethyl)butanamide (isobendamustine 2-pyrrolidinooethyl amide) 
bis(hydrotrifluoroacetate) (5.11) 
 
Compound 5.11 was prepared according to the general procedure for amide bond formation (in 
the microwave). The reaction was carried out using isobendamustine (100 mg, 0.279 mmol, 
1.0 eq), TBTU (89.6 mg, 0.279 mmol, 1.0 eq), DIPEA (97.2 µL, 0.558 mmol, 2.0 eq), 
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2-(pyrrolidin-1-yl)ethan-1-amine (38.9 µL, 0.279 mmol, 1.0 eq) and DMF (1 mL). Preparative 
HPLC (0-30 min: MeCN/ 0.1% aq TFA 15:85-55:45, tR = 14.2 min) yielded 5.11 as a yellow 
resin (77.2 mg, 0.113 mmol, 41%). 1H NMR (600 MHz, DMSO-d6): δ (ppm) = 14.98 (br s, 
1H), 10.02 (s, 1H), 8.24 (t, J = 5.69 Hz, 1H), 7.58 (d, J = 9.07 Hz, 1H), 7.11 (d, J = 2.25 Hz, 
1H), 7.08 (dd, J = 9.07 Hz, J = 2.25, 1H), 3.91 (s, 3H), 3.86 (t, J = 6.51 Hz, 4H), 3.80 (t, 
J = 6.51 Hz, 4H), 3.57 (br s, 2H), 3.36 (m, 2H), 3.17 (s, 2H), 3.13 (t, J = 7.71 Hz, 2H), 2.99 (br 
s, 2H), 2.27 (t, J = 7.24 Hz, 2H), 2.01 (m, 2H), 1.92 (m, 4H). 13C NMR (151 MHz, DMSO-d6): 
δ (ppm) = 171.9, 158.8 (TFA), 158.6 (TFA), 158.4 (TFA), 158.1 (TFA), 151.9, 145.4, 134.3, 
122.0, 117.6 (TFA), 115.6 (TFA), 114.6, 112.7, 94.0, 53.3(2C), 53.1, 52.4 (2C), 41.2 (2C), 
35.0, 33.7, 30.8, 24.3, 22.5 (2C), 21.8. RP-HPLC (220 nm): 96% (tR = 9.0 min, k = 2.0). 
HRMS (ESI): m/z [M+H]+ calcd. for C22H34Cl2N5O
+: 454.2135, found: 454.2135. 
C22H33Cl2N5O · C4H2F6O4 (454.44 + 228.05). 
1-(Pyrrolidin-1-yl)propan-2-yl 4-(4-(bis(2-chloroethyl)amino)phenyl)butanoate 
(chlorambucil 1-methyl-2-pyrrolidinoethyl ester) hydrotrifluoroacetate (5.12) 
 
Compound 5.12 was prepared according to the general procedure 2 for ester bond formation. 
The reaction was carried out using chlorambucil (80 mg, 0.263 mmol, 1.0 eq), TBTU (84.4 mg, 
0.263 mmol, 1.0 eq), DIPEA (89.4 µL, 0.526 mmol, 2.0 eq), 1-(pyrrolidin-1-yl)propan-2-ol 
(51.0 µL, 0.394 mmol, 1.5 eq) and DMF (1 mL). Preparative HPLC (0-30 min: MeCN/ 0.1% 
aq TFA 33:67-69:31, tR = 15.5 min) yielded 5.12 as a brownish resin (49.2 mg, 0.093 mmol, 
35%). More than one diastereoisomer was evident in the NMR spectra. 1H NMR (600 MHz, 
DMSO-d6) δ (ppm) 9.99 (br s, 1H), 7.02 (d, J = 8.6 Hz, 2H), 6.67 (d, J = 8.8 Hz, 2H), 5.13 (m, 
1H), 3.69 (m, 8H), 3.59-3.45 (m, 2H), 3.44-3.30 (m, 2H), 3.12-3.99 (m, 2H), 2.49-2.45 (m, 2H), 
2.38-2.27 (m, 2H), 1.99 (m, 2H), 1.86 (m, 2H), 1.77 (m, 2H), 1.20 (d, J = 6.3 Hz, 3H). 13C NMR 
(151 MHz, DMSO-d6) δ (ppm) 172.3, 158.6 (TFA), 158.3 (TFA), 158.1 (TFA), 157.9 (TFA), 
144.5, 129.4, 129.3 (2C), 117.5 (TFA), 115.6 (TFA), 111.9 (2C), 66.1, 57.4, 54.9 and 53.3 (the 
two carbons adjacent to the pyrrolidine nitrogen yielded two signals), 52.2 (2C), 41.2 (2C), 
33.2, 33.0, 26.3, 22.7 and 22.5 (the two pyrrolidine carbons not adjacent to the nitrogen yielded 
two signals), 17.7. RP-HPLC (220 nm): 92% (tR = 9.2 min, k = 6.2) (the second peak in the 
chromatogram is not due to impurity but to decomposition in the aqueous HPLC eluent). 
HRMS (ESI): m/z [M+H]+ calcd. for C21H33Cl2N2O2
+: 415.1914, found: 415.1924. 
C21H32Cl2N2O2 · C2HF3O2 (414.18 + 114.02). 
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4-(4-(Bis(2-chloroethyl)amino)phenyl)-N-(2-(pyrrolidin-1-yl)ethyl)butanamide 
(chlorambucil 2-pyrrolidinooethyl amide) hydrotrifluoroacetate (5.13) [32] 
 
Compound 5.13 was prepared according to the general procedure for amide bond formation (in 
the microwave). The reaction was carried out using chlorambucil (100 mg, 0.329 mmol, 
1.0 eq), TBTU (105.5 mg, 0.329 mmol, 1.0 eq), DIPEA (111.8 µL, 0.657 mmol, 2.0 eq), 
2-(pyrrolidin-1-yl)ethan-1-amine (45.8 µL, 0.362 mmol, 1.1 eq) and DMF (1 mL). Twofold 
purification by preparative HPLC (0-30 min: MeCN/ 0.1% aq TFA 28:72-68:32, tR = 13.5 min) 
yielded 5.13 as a yellowish resin (75.5 mg, 0.147 mmol, 45%). 1H NMR (600 MHz, DMSO-
d6) δ (ppm) 9.80 (br s, 1H), 8.07 (m, 1H), 7.01 (d, J = 8.6 Hz, 2H), 6.66 (d, J = 8.6 Hz, 2H), 
3.69 (m, 8H), 3.57 (m, 2H), 3.36 (q, J = 6.1 Hz, 2H), 3.18 (q, J = 6.0 Hz, 2H), 3.00 (m, 2H), 
2.44 (t, J = 7.7 Hz, 2H), 2.10 (t, J = 7.4 Hz, 2H), 1.99 (m, 2H), 1.85 (m, 2H), 1.74 (m, 2H). 
13C NMR (151 MHz, DMSO-d6) δ (ppm) 172.8, 158.6 (TFA), 158.4 (TFA), 158.2 (TFA), 
158.0 (TFA), 144.4, 129.8, 129.3 (2C), 117. 6 (TFA), 115.6 (TFA), 111.9 (2C), 53.4 (2C), 53.3, 
52.2 (2C), 41.2 (2C), 35.0, 34.8, 33.6, 27.0, 22.5 (2C). RP-HPLC (220 nm): 92% (tR = 
14.3 min, k = 3.7) (the second peak in the chromatogram is not due to impurity but to 
decomposition in the aqueous HPLC eluent). HRMS (ESI): m/z [M+H]+ calcd. for 
C20H32Cl2N3O
+: 400.1917, found: 400.1925. C20H31Cl2N3O · C2HF3O2 (399.18 + 114.02). 
(S)-3-(4-(Bis(2-chloroethyl)amino)phenyl)-2-((tert-butoxycarbonyl)amino)propanoic 
acid (boc-melphalan) (5.14) [34,35] 
 
Melphalan (38.0 mg, 0.125 mmol, 1.0 eq) and NaHCO3 (31.4 mg, 0.374 mmol, 3.0 eq) were 
dissolved in THF/H2O 1:1 (1 mL), Boc2O (42.9 µL, 0.1787 mmol, 1.5 eq) was added and the 
mixture stirred at rt for 30 min. The suspension was diluted with EtOAc and the organic layer 
was washed with 1 M HCl aq and brine, dried over Na2SO4 and concentrated under reduced 
pressure to a brown oil which was used in subsequent reactions without further purification. 
1H NMR (400 MHz, CDCl3) δ (ppm) 9.79 (s, 1H), 7.07 (d, J = 7.8 Hz, 2H), 6.62 (d, J = 8.6 Hz, 
2H), 4.96 (d, J = 7.4 Hz, 1H), 4.55 (m, 1H), 3.70 (m, 4H), 3.61 (m, 4H), 3.13-2.96 (m, 2H), 
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1.52 (s, 9H). HRMS (ESI): m/z [M+H]+ calcd. for C22H34Cl2N5O
+: 454.2135, found: 454.2135. 
C18H26Cl2N2O4 (504.32). 
1-(Pyrrolidin-1-yl)propan-2-yl (2S)-2-amino-3-(4-(bis(2-chloroethyl)amino)phenyl)-
propanoate (melphalan 1-methyl-2-pyrrolidinoethyl ester) 
bis(hydrotrifluoroacetate) (5.15) 
 
Compound 5.15 was prepared according to the general procedure 2 for ester bond formation. 
The reaction was carried out using boc-melphalan (133 mg, 0.328 mmol, 1.0 eq), TBTU 
(105 mg, 0.328 mmol, 1.0 eq), DIPEA (111 µL, 0.655 mmol, 2.0 eq), 1-(pyrrolidin-1-
yl)propan-2-ol (63.5 µL, 0.491 mmol, 1.5 eq) and DMF (3 mL). The mixture was diluted with 
brine (50 mL) and the product extracted with EtOAc (3 x 50 mL). The combined organic layers 
were dried over Na2SO4 and concentrated under reduced pressure. For N-boc deprotection, the 
residue was dissolved in DCM (2 mL), TFA (0.5 mL) was added and the solution was stirred 
at rt for 2 h. Evaporation of the volatiles and purification by preparative HPLC (0-30 min: 
MeCN/ 0.1% aq TFA 21:79-57:43, tR = 13.5 min) yielded 5.15 as a brown resin (20.2 mg, 
0.031 mmol, 10% for protection, coupling and deprotection). More than one diastereoisomer 
was evident in the NMR spectra. 1H NMR (600 MHz, DMSO-d6) δ (ppm) 10.07 (br s, 1H), 
8.57 (m, 3H), 7.08 (m, 2H), 6.72 (m, 2H), 5.16 (m, 1H), 4.33-4.15 (m, 1H), 3.72 (m, 8H), 3.62-
3.31 (m, 4H), 3.12-2.91 (m, 4H), 2.05-1.74 (m, 4H), 1.27-1.12 (m, 3H). 13C NMR (151 MHz, 
DMSO-d6) δ (ppm) 168.7, 168.0, 158.8 (TFA), 158.6 (TFA), 158.4 (TFA), 158.2 (TFA), 145.7, 
145.7, 130.7, 130.6 (2C), 122.3, 122.0, 117.6 (TFA), 115.6 (TFA), 112.0 (2C), 68.9, 68.6, 57.1, 
57.0, 54.8, 53.7, 53.5, 53.3, 53.0, 52.0 (2C), 41.1 (2C), 34.8, 34.8, 22.6 (2C), 17.3, 17.2. 
RP-HPLC (220 nm): 98% (tR = 5.5 min, k = 3.4). HRMS (ESI): m/z [M+H]
+ calcd. for 
C20H32Cl2N3O2
+: 416.1866, found: 416.1871. C20H31Cl2N3O2 · C4H2F6O4 (416.39 + 228.05). 
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(S)-2-Amino-3-(4-(bis(2-chloroethyl)amino)phenyl)-N-(3-(pyrrolidin-1-yl)propyl)-
propanamide (melphalan 3-pyrrolidinopropyl amide) bis(hydrotrifluoroacetate) 
(5.16) 
 
Compound 5.16 was prepared according to the general procedure for amide bond formation (in 
the microwave). The reaction was carried out using boc-melphalan (64.2 mg, 0.125 mmol, 
1.0 eq), TBTU (40.0 mg, 0.125 mmol, 1.0 eq), DIPEA (65.1 µL, 0.374 mmol, 3.0 eq), 
3-(pyrrolidin-1-yl)propan-1-amine (47.3 µL, 0.374 mmol, 3.0 eq) and DMF (1 mL). The 
mixture was diluted with brine (20 mL) and the product extracted with EtOAc (3 x 20 mL). The 
combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. For 
N-boc deprotection, the residue was dissolved in DCM (0.5 mL), TFA (0.5 mL) was added and 
the solution was stirred at rt for 2 h. Evaporation of the volatiles and purification by preparative 
HPLC (0-30 min: MeCN/ 0.1% aq TFA 15:85-55:45, tR = 14.4 min) yielded 5.16 as a brownish 
resin (22.9 mg, 0.036 mmol, 29% for protection, coupling and deprotection). More than one 
diastereoisomer was evident in the NMR spectra. 1H NMR (600 MHz, DMSO-d6) δ (ppm) 
10.08 (s, 1H), 8.59 (t, J = 5.8 Hz, 1H), 8.20 (br s, 3H), 7.06 (d, J = 8.7 Hz, 2H), 6.71 (d, J = 
8.8 Hz, 2H), 3.86 (m, 1H), 3.71 (s, 8H), 3.51 (m, 2H), 3.21-3.09 (m, 2H), 3.07-2.98 (m, 2H), 
2.95-2.83 (m, 4H), 2.03-1.82 (m, 4H), 1.79-1.67 (m, 2H). 13C NMR (151 MHz, DMSO-d6) δ 
(ppm) 168.3, 158.8 (TFA), 158.6 (TFA), 158.4 (TFA), 158.2 (TFA), 145.5, 130.5 (2C), 122.8, 
117.8 (TFA), 115.9 (TFA), 112.0 (2C), 53.9, 53.3 and 53.2 (the two carbons adjacent to the 
pyrrolidine nitrogen yielded two signals), 52.1 (2C), 51.8, 41.2 (2C), 36.1, 35.9, 25.4, 22.6 (2C). 
RP-HPLC (220 nm): 97% (tR = 8.9 min, k = 1.9). HRMS (ESI): m/z [M+H]
+ calcd. for 
C20H33Cl2N4O
+: 415.2026, found: 415.2034. C20H32Cl2N4O · C4H2F6O4 (415.40 + 228.05). 
5.4.2 Biology 
5.4.2.1 General Experimental Conditions 
Materials. Commodity chemicals and solvents were purchased from commercial suppliers 
(Sigma Aldrich, Munich, Germany; Merck, Darmstadt, Germany; VWR, Darmstadt, Germany; 
Thermo Fisher Scientific, Waltham, MA, USA; Invitrogen, Karlsruhe, Germany; Serva, 
Heidelberg, Germany). Millipore water was used throughout for the preparation of buffers and 
aqueous reagent solutions. The pH of buffers was adjusted with NaOH aq or HCl aq. All cell 
lines were purchased from the ATCC (American Type Culture Collection; Manassas, VA, 
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USA). Tissue culture flasks were procured from Sarstedt (Nümbrecht, Germany). RPMI-1640 
medium was from Sigma Aldrich. Fetal calf serum (FCS) and trypsin/EDTA solution were from 
Biochrom (Berlin, Germany). 96-Well microplates (PS, clear, F-bottom, with lid, sterile) were 
purchased from Greiner Bio-One (Frickenhausen, Germany). 
Stock solutions. The test compounds were dissolved in DMSO at 1000 times the final 
concentrations in the chemosensitivity assay. 
Instruments. Absorbance measurements were carried out with a GENios Pro microplate reader 
(equipped with a Xenon arc lamp; Tecan, Grödig, Austria). 
Software. All biological data were analyzed with GraphPad Prism 5 (GraphPad Software, San 
Diego, CA, USA). 
5.4.2.2 Cell Culture 
All cell lines were cultured in RPMI-1640 medium containing 110 mg/L sodium pyruvate, 
2.4 g/L HEPES and 2.0 g/L NaHCO3 and supplemented with 10% (v/v) FCS at 37 °C in a 
water-saturated atmosphere containing 5% CO2. Cells were passaged following treatment with 
a solution containing 0.05% trypsin and 0.025% EDTA. All cells were routinely monitored for 
mycoplasma contamination by PCR using the Venor®GeM mycoplasma detection kit (Minerva 
Biolabs, Berlin, Germany) and were negative. 
5.4.2.3 Chemosensitivity Assay [33] 
Cells were seeded into 96-well plates at a density of 1500 cells per well (MG-63 and HT-29 
cells) or a density of 3000 cells per well (SK-MEL-3 cells) (100 μL/well) and allowed to attach 
to the surface of the microplates in a water-saturated atmosphere containing 5% CO2 at 37 °C 
overnight. The next day, fresh medium containing the test compounds at 2-fold final 
concentrations was added (100 µL/well; giving a final volume of 200 µL/well). On each plate, 
vinblastine at a final concentration of 300 nM served as reference cytostatic (positive control); 
the vehicle DMSO (0.1%) served as negative control to monitor cell growth in the absence of 
a drug. Each concentration was measured in octuplicate, the negative control in 16-fold 
replication. Growth of the cells was stopped after different periods of time by removal of 
medium and fixation with 2% (v/v) glutardialdehyde in PBS (100 µL/well). All the plates were 
stored at 4 °C until the end of the experiment and afterwards stained with 0.02% crystal violet 
in water (100 µL/well) for 20 min. Excess dye was removed by rinsing the plates with water 
three times. Crystal violet bound by the fixed cells was re-dissolved in 70% EtOH 
(180 µL/well) while shaking the microplates for 2-3 h. The absorbance (580 nm) as a parameter 
proportional to the cell mass was measured using a GENios Pro microplate reader. 
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where T is the mean absorbance of the treated cells, C the mean absorbance of the negative 
controls and C0 the mean absorbance of the cells at the time of compound addition (t0). When 
the absorbance of treated cells T was lower than at the beginning of the experiment (C0), the 
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5.5 Supplementary Material 
5.5.1 NMR Spectra 
 
1H NMR spectrum (600 MHz, CDCl3) of compound 5.07. 
 
13C NMR spectrum (151 MHz, CDCl3) of compound 5.07. 
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1H NMR spectrum (600 MHz, DMSO-d6) of compound 5.09. 
13C NMR spectrum (151 MHz, DMSO-d6) of compound 5.09. 
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1H NMR spectrum (600 MHz, DMSO-d6) of compound 5.10. 
13C NMR spectrum (151 MHz, DMSO-d6) of compound 5.10. 
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1H NMR spectrum (600 MHz, DMSO-d6) of compound 5.11. 
13C NMR spectrum (151 MHz, DMSO-d6) of compound 5.11. 
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1H NMR spectrum (600 MHz, DMSO-d6) of compound 5.12. 
13C NMR spectrum (151 MHz, DMSO-d6) of compound 5.12. 
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1H NMR spectrum (600 MHz, DMSO-d6) of compound 5.13. 
13C NMR spectrum (151 MHz, DMSO-d6) of compound 5.13. 
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1H NMR spectrum (600 MHz, DMSO-d6) of compound 5.15. 
13C NMR spectrum (151 MHz, DMSO-d6) of compound 5.15. 
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1H NMR spectrum (600 MHz, DMSO-d6) of compound 5.16. 
13C NMR spectrum (151 MHz, DMSO-d6) of compound 5.16. 
Derivatives of Nitrogen Mustard Anticancer Agents with Improved Cytotoxicity 
268 
5.5.2 Chromatograms (Purity Control) 
 
Chromatogram (purity control) of 5.07 (RP-HPLC). 
 
Chromatogram (purity control) of 5.09 (RP-HPLC). 
 
Chromatogram (purity control) of 5.10 (RP-HPLC). 
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Chromatogram (purity control) of 5.11 (RP-HPLC). 
 
Chromatogram (purity control) of 5.12 (RP-HPLC). 
 
Chromatogram (purity control) of 5.13 (RP-HPLC). 
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Chromatogram (purity control) of 5.15 (RP-HPLC). 
 
Chromatogram (purity control) of 5.16 (RP-HPLC). 
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ABC ATP-binding cassette transporter 
ABCB1 ATP-binding cassette transporter, subfamily B, member 1 
ABCC1 ATP-binding cassette transporter, subfamily C, member 1 
ABCG2 ATP-binding cassette transporter, subfamily G, member 2 
ABCP placenta-specific ATP-binding cassette transporter 
ADME-Tox absorption, distribution, metabolism, excretion and toxicity 
ADP adenosine diphosphate 
AML acute myeloid leukemia 
ATP adenosine triphosphate 
BBB blood-brain barrier 
BCRP breast cancer resistance protein 
boc tert-butyloxycarbonyl 
boc2O di-tert-butyl dicarbonate 
calcein-AM calcein acetoxymethyl ester 
CHAPS 3-((3-cholamidopropyl)dimethylammonio)-1-propanesulfonate 
CLL chronic lymphocytic leukemia 
clogP calculated logP value 
cryo-EM cryogenic electron microscopy 
CuAAC copper-catalyzed azide-alkyne cycloaddition 
DCC N,N′-Dicyclohexylcarbodiimide 
DCM dichloromethane 
DDI drug-drug interaction 
DHEAS dehydroepiandrosterone sulfate 
DIPEA N,N-diisopropylethylamine 
DMEM Dulbecco's modified Eagle's medium 
DMF dimethyformamide 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
DTT dithiothreitol 
E1S estrone 3-sulfate 
EC50 concentration of compound required to give 50% maximal effect on activity 
EDTA ethylenediaminetetraacetic acid 
EL extracellular loop 
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EMA European Medicines Agency 
EtOH ethanol 
FCS fetal calf serum 
FDA US Food and Drug Administration 
FTC fumitremorgin C 
GBB gut-blood barrier 
HBTU hexafluorophosphate benzotriazole tetramethyl uronium 
HIV human immunodeficiency virus 
HL Hodgkin lymphoma 
HPLC high pressure liquid chromatography 
HRMS high-resolution mass spectrometry 
HTS high-throughput screening 
HUGO Human Genome Organization 




mAU milli-absorbance units 
MDR multidrug resistance 
MeCN acetonitrile 
MeOH methanol 
MM multiple myeloma 
MRP1 multidrug resistance associated protein 1 
MS (low resolution) mass spectrometry 
MWT molecular weight 
NBD nucleotide binding domain 
NHL non-Hodgkin lymphoma 
NMR nuclear magnetic resonance 
NMRI Naval Medical Research Institute 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
Pd/C palladium on activated charcoal 
PEG polyethylene glycol 
PET positron emission tomography 




Pi inorganic phosphate 
PMSF phenylmethylsulfonyl fluoride 
PP polypropylene 
RAMEB randomly methylated β-cyclodextrins 
RNA ribonucleic acid 
Ro5 rule of five 
RP-HPLC reversed-phase high pressure liquid chromatography 
SDS sodium dodecyl sulfate 
SEC-TS size-exclusion chromatography-based thermostability assay 
SEM standard error of the mean 
SPECT single-photon emission computed tomography 
t1/2 half-life 
TBAF tetra-n-butylammonium fluoride 
TBTA tris((1-benzyl-4-triazolyl)methyl)amine 
TBTU 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TLC thin layer chromatography 
TM transmembrane helix 
TMD transmembrane domain 
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